Table 283: Incidence of Adverse Events by System Organ Class and Preferred Term - by Prior MS Treatment: Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 1 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	374 (100)	371 (100)	368 (100)	739 (100)	139 (100)
Number of subjects with an event	359 (96)	356 (96)	351 (95)	707 (96)	120 (86)
感染症および寄生虫症	232 (62)	230 (62)	241 (65)	471 (64)	67 (48)
鼻咽頭炎	86 (23)	87 (23)	82 (22)	169 (23)	21 (15)
尿路感染	50 (13)	51 (14)	51 (14)	102 (14)	17 (12)
上気道感染	43 (11)	48 (13)	52 (14)	100 (14)	8 (6)
インフルエンザ	35 (9)	31 (8)	43 (12)	74 (10)	8 (6)
副鼻腔炎	20 (5)	21 (6)	34 (9)	55 (7)	4 (3)
気管支炎	21 (6)	25 (7)	28 (8)	53 (7)	8 (6)
胃腸炎	15 (4)	27 (7)	15 (4)	42 (6)	3 (2)
咽頭炎	17 (5)	18 (5)	11 (3)	29 (4)	4 (3)
膀胱炎	11 (3)	9 (2)	13 (4)	22 (3)	3 (2)
鼻炎	12 (3)	8 (2)	13 (4)	21 (3)	1 (<1)
ウイルス性胃腸炎	10 (3)	9 (2)	10 (3)	19 (3)	5 (4)
ウイルス感染	7 (2)	10 (3)	8 (2)	18 (2)	1 (<1)
耳感染	7 (2)	3 (<1)	10 (3)	13 (2)	2 (1)
喉頭炎	2 (<1)	6 (2)	7 (2)	13 (2)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 2 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
口腔ヘルペス	6 (2)	9 (2)	4 (1)	13 (2)	1 (<1)
気道感染	4 (1)	7 (2)	5 (1)	12 (2)	3 (2)
消化管感染	3 (<1)	4 (1)	6 (2)	10 (1)	1 (<1)
中耳炎	0	5 (1)	5 (1)	10 (1)	1 (<1)
扁桃炎	6 (2)	5 (1)	5 (1)	10 (1)	0
外陰腟真菌感染	4 (1)	3 (<1)	7 (2)	10 (1)	3 (2)
帯状疱疹	5 (1)	1 (<1)	8 (2)	9 (1)	1 (<1)
腟感染	2 (<1)	4 (1)	4 (1)	8 (1)	2 (1)
ウイルス性上気道感染	5 (1)	5 (1)	3 (<1)	8 (1)	2 (1)
ウイルス性消化管感染	3 (<1)	3 (<1)	4 (1)	7 (<1)	0
麦粒腫	2 (<1)	4 (1)	3 (<1)	7 (<1)	0
感染性結膜炎	2 (<1)	4 (1)	2 (<1)	6 (<1)	0
ウイルス性気道感染	3 (<1)	5 (1)	1 (<1)	6 (<1)	0
気管炎	2 (<1)	4 (1)	2 (<1)	6 (<1)	1 (<1)
レンサ球菌性咽頭炎	6 (2)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
咽頭扁桃炎	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0
歯膿瘍	6 (2)	2 (<1)	3 (<1)	5 (<1)	2 (1)
蜂巣炎	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
爪真菌症	1 (<1)	4 (1)	0	4 (<1)	0
口腔カンジダ症	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
外耳炎	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 3 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯感染	3 (<1)	2 (<1)	2 (<1)	4 (<1)	5 (4)
急性扁桃炎	1 (<1)	3 (<1)	0	3 (<1)	0
細菌尿	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
せつ	1 (<1)	3 (<1)	0	3 (<1)	0
毛包炎	3 (<1)	2 (<1)	0	2 (<1)	0
ヘリコバクター性胃炎	0	1 (<1)	1 (<1)	2 (<1)	0
単純ヘルペス	1 (<1)	0	2 (<1)	2 (<1)	0
咬傷感染	0	1 (<1)	1 (<1)	2 (<1)	0
シラミ寄生	0	2 (<1)	0	2 (<1)	0
口腔真菌感染	0	1 (<1)	1 (<1)	2 (<1)	0
肺炎	2 (<1)	1 (<1)	1 (<1)	2 (<1)	4 (3)
ブドウ球菌感染	0	0	2 (<1)	2 (<1)	0
皮下組織膿瘍	0	1 (<1)	1 (<1)	2 (<1)	0
気管気管支炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
細菌性上気道感染	0	2 (<1)	0	2 (<1)	0
外陰部腟カンジダ症	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
腹壁膿瘍	0	0	1 (<1)	1 (<1)	0
虫垂炎	0	1 (<1)	0	1 (<1)	0
無症候性細菌尿	0	1 (<1)	0	1 (<1)	0
乳房膿瘍	0	0	1 (<1)	1 (<1)	0
気管支肺炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 4 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
カンジダ症	0	1 (<1)	0	1 (<1)	1 (<1)
細菌性結膜炎	0	1 (<1)	0	1 (<1)	0
憩室炎	0	0	1 (<1)	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
感染性湿疹	0	0	1 (<1)	1 (<1)	0
エプスタイン・バーウイルス感染	0	0	1 (<1)	1 (<1)	0
眼感染	2 (<1)	1 (<1)	0	1 (<1)	0
熱性感染症	1 (<1)	0	1 (<1)	1 (<1)	0
真菌感染	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ノロウイルス性胃腸炎	1 (<1)	1 (<1)	0	1 (<1)	0
ロタウイルス胃腸炎	0	1 (<1)	0	1 (<1)	0
細菌性性器感染	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
Ｈ１Ｎ１インフルエンザ	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
切開部位感染	0	1 (<1)	0	1 (<1)	0
感染性皮脂嚢腫	0	0	1 (<1)	1 (<1)	0
感染	0	0	1 (<1)	1 (<1)	1 (<1)
限局性感染	0	1 (<1)	0	1 (<1)	0
下気道感染	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ライム病	0	0	1 (<1)	1 (<1)	0
乳腺炎	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 5 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
マイコプラズマ感染	0	0	1 (<1)	1 (<1)	0
爪感染	0	0	1 (<1)	1 (<1)	0
精巣炎	0	0	1 (<1)	1 (<1)	0
爪囲炎	0	1 (<1)	0	1 (<1)	0
歯周感染	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ウイルス感染後疲労症候群	1 (<1)	1 (<1)	0	1 (<1)	0
術後創感染	0	1 (<1)	0	1 (<1)	0
歯髄炎	1 (<1)	1 (<1)	0	1 (<1)	0
腎盂腎炎	2 (<1)	1 (<1)	0	1 (<1)	0
急性腎盂腎炎	0	0	1 (<1)	1 (<1)	0
膿皮症	0	1 (<1)	0	1 (<1)	0
卵管卵巣炎	1 (<1)	1 (<1)	0	1 (<1)	0
細菌性副鼻腔炎	0	0	1 (<1)	1 (<1)	0
皮膚感染	0	1 (<1)	0	1 (<1)	0
癜風	1 (<1)	0	1 (<1)	1 (<1)	0
細菌性尿路感染	2 (<1)	0	1 (<1)	1 (<1)	0
ガードネレラ菌性腟炎	0	1 (<1)	0	1 (<1)	0
水痘	0	1 (<1)	0	1 (<1)	1 (<1)
ウイルス性咽頭炎	0	1 (<1)	0	1 (<1)	0
ウイルス性鼻炎	0	0	1 (<1)	1 (<1)	0
外陰部膿瘍	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 6 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
膿瘍	1 (<1)	0	0	0	0
急性副鼻腔炎	1 (<1)	0	0	0	0
肛門膿瘍	1 (<1)	0	0	0	0
細菌感染	1 (<1)	0	0	0	0
ボレリア感染	1 (<1)	0	0	0	0
ウイルス性気管支炎	0	0	0	0	1 (<1)
熱傷部感染	1 (<1)	0	0	0	0
ウイルス性結膜炎	1 (<1)	0	0	0	0
デング熱	0	0	0	0	1 (<1)
医療機器関連感染	1 (<1)	0	0	0	0
皮膚真菌感染	0	0	0	0	1 (<1)
陰部ヘルペス	3 (<1)	0	0	0	0
泌尿生殖器感染	1 (<1)	0	0	0	0
歯肉感染	1 (<1)	0	0	0	1 (<1)
ヘルペスウイルス感染	1 (<1)	0	0	0	1 (<1)
感染性嚢腫	1 (<1)	0	0	0	0
寄生虫感染	0	0	0	0	1 (<1)
迷路炎	2 (<1)	0	0	0	1 (<1)
乳様突起炎	0	0	0	0	1 (<1)
パラインフルエンザウイルス感染	1 (<1)	0	0	0	0
細菌性咽頭炎	2 (<1)	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 7 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
毛巣嚢胞	1 (<1)	0	0	0	0
術後膿瘍	1 (<1)	0	0	0	0
猩紅熱	1 (<1)	0	0	0	0
敗血症	2 (<1)	0	0	0	0
足部白癬	3 (<1)	0	0	0	0
尿路性敗血症	1 (<1)	0	0	0	0
腟膿瘍	1 (<1)	0	0	0	0
細菌性腟炎	0	0	0	0	1 (<1)
創傷感染	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	9 (2)	14 (4)	11 (3)	25 (3)	5 (4)
皮膚乳頭腫	1 (<1)	3 (<1)	3 (<1)	6 (<1)	0
脂肪腫	0	3 (<1)	2 (<1)	5 (<1)	1 (<1)
線維腫	0	2 (<1)	1 (<1)	3 (<1)	0
子宮平滑筋腫	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
甲状腺新生物	1 (<1)	2 (<1)	0	2 (<1)	0
基底細胞癌	1 (<1)	1 (<1)	0	1 (<1)	0
子宮頚部癌	0	0	1 (<1)	1 (<1)	1 (<1)
乳腺線維腺腫	0	0	1 (<1)	1 (<1)	0
血管腫	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 8 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝臓血管腫	0	0	1 (<1)	1 (<1)	0
メラノサイト性母斑	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
腎新生物	0	1 (<1)	0	1 (<1)	0
移行上皮癌	0	1 (<1)	0	1 (<1)	0
外陰腟ヒト乳頭腫ウイルス感染	0	1 (<1)	0	1 (<1)	0
リンパ節の良性新生物	1 (<1)	0	0	0	0
甲状腺の良性新生物	1 (<1)	0	0	0	0
線維性組織球腫	0	0	0	0	1 (<1)
モートン神経腫	1 (<1)	0	0	0	0
口腔新生物	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	19 (5)	22 (6)	26 (7)	48 (6)	5 (4)
貧血	5 (1)	4 (1)	11 (3)	15 (2)	1 (<1)
リンパ球減少症	1 (<1)	9 (2)	6 (2)	15 (2)	0
白血球減少症	0	3 (<1)	5 (1)	8 (1)	0
好酸球増加症	0	3 (<1)	2 (<1)	5 (<1)	0
リンパ節症	4 (1)	2 (<1)	2 (<1)	4 (<1)	2 (1)
鉄欠乏性貧血	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
白血球増加症	2 (<1)	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 9 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
好中球減少症	0	1 (<1)	1 (<1)	2 (<1)	0
好中球増加症	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
血小板減少症	0	2 (<1)	0	2 (<1)	0
正色素性正球性貧血	0	0	1 (<1)	1 (<1)	0
脾腫	0	0	1 (<1)	1 (<1)	0
妊娠貧血	1 (<1)	0	0	0	0
低色素性貧血	1 (<1)	0	0	0	1 (<1)
リンパ節炎	1 (<1)	0	0	0	0
小球性貧血	1 (<1)	0	0	0	0
免疫系障害	12 (3)	12 (3)	12 (3)	24 (3)	2 (1)
過敏症	1 (<1)	6 (2)	4 (1)	10 (1)	0
季節性アレルギー	8 (2)	4 (1)	5 (1)	9 (1)	1 (<1)
食物アレルギー	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
造影剤アレルギー	0	1 (<1)	1 (<1)	2 (<1)	0
薬物過敏症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
家塵アレルギー	2 (<1)	0	0	0	0
内分泌障害	4 (1)	5 (1)	7 (2)	12 (2)	2 (1)
甲状腺腫	0	2 (<1)	1 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 10 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
HY PERPARAT HYROIDISM	0	1 (<1)	1 (<1)	2 (<1)	0
甲状腺機能低下症	3 (<1)	0	2 (<1)	2 (<1)	1 (<1)
自己免疫性甲状腺炎	0	1 (<1)	0	1 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
続発性副甲状腺機能亢進症	0	1 (<1)	0	1 (<1)	0
エストロゲン欠乏症	0	0	1 (<1)	1 (<1)	0
甲状腺腫瘤	0	0	1 (<1)	1 (<1)	0
副腎腫瘤	1 (<1)	0	0	0	0
代謝および栄養障害	29 (8)	32 (9)	27 (7)	59 (8)	10 (7)
食欲減退	7 (2)	12 (3)	9 (2)	21 (3)	1 (<1)
高コレステロール血症	2 (<1)	5 (1)	3 (<1)	8 (1)	0
ビタミンＤ欠乏	7 (2)	3 (<1)	5 (1)	8 (1)	3 (2)
高血糖	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
脱水	0	2 (<1)	1 (<1)	3 (<1)	0
糖尿病	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
低カリウム血症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
食欲亢進	0	2 (<1)	0	2 (<1)	0
鉄欠乏	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミンＢ１２欠乏	0	0	2 (<1)	2 (<1)	0
耐糖能障害	0	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 11 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
高脂血症	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
高トリグリセリド血症	2 (<1)	1 (<1)	0	1 (<1)	2 (1)
高尿酸血症	0	1 (<1)	0	1 (<1)	2 (1)
過小食	0	0	1 (<1)	1 (<1)	0
低リン酸血症	0	0	1 (<1)	1 (<1)	0
ビタミン欠乏症	0	1 (<1)	0	1 (<1)	0
ケトーシス	0	0	1 (<1)	1 (<1)	0
１型糖尿病	0	1 (<1)	0	1 (<1)	0
亜鉛欠乏	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	2 (<1)	0	0	0	0
葉酸欠乏	1 (<1)	0	0	0	0
妊娠糖尿病	1 (<1)	0	0	0	0
高カルシウム血症	1 (<1)	0	0	0	0
低ナトリウム血症	1 (<1)	0	0	0	0
肥満	1 (<1)	0	0	0	1 (<1)
精神障害	87 (23)	77 (21)	79 (21)	156 (21)	29 (21)
うつ病	35 (9)	31 (8)	30 (8)	61 (8)	14 (10)
不眠症	22 (6)	22 (6)	20 (5)	42 (6)	7 (5)
不安	16 (4)	20 (5)	18 (5)	38 (5)	2 (1)
睡眠障害	7 (2)	7 (2)	5 (1)	12 (2)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 12 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
抑うつ気分	8 (2)	4 (1)	2 (<1)	6 (<1)	2 (1)
気分動揺	1 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
感情障害	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
リビドー減退	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
気分変化	0	1 (<1)	2 (<1)	3 (<1)	0
ストレス	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
抑うつ症状	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
大うつ病	0	0	2 (<1)	2 (<1)	0
神経症	0	1 (<1)	1 (<1)	2 (<1)	0
パニック発作	1 (<1)	0	2 (<1)	2 (<1)	0
自殺念慮	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
異常行動	0	1 (<1)	0	1 (<1)	0
異常な夢	1 (<1)	0	1 (<1)	1 (<1)	0
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
不安障害	1 (<1)	1 (<1)	0	1 (<1)	0
歯ぎしり	0	0	1 (<1)	1 (<1)	0
燃え尽き症候群	0	1 (<1)	0	1 (<1)	0
転換性障害	0	0	1 (<1)	1 (<1)	0
情動障害	0	0	1 (<1)	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	1 (<1)	0
全般性不安障害	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 13 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
幻聴	0	1 (<1)	0	1 (<1)	0
初期不眠症	0	0	1 (<1)	1 (<1)	0
リビド消失	0	1 (<1)	0	1 (<1)	0
躁病	0	1 (<1)	0	1 (<1)	0
自己愛性人格障害	0	1 (<1)	0	1 (<1)	0
神経過敏	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
パニック障害	0	1 (<1)	0	1 (<1)	0
人格障害	0	1 (<1)	0	1 (<1)	0
精神症状	0	1 (<1)	0	1 (<1)	0
落ち着きのなさ	0	1 (<1)	0	1 (<1)	0
睡眠発作	0	0	1 (<1)	1 (<1)	0
自殺企図	0	0	1 (<1)	1 (<1)	0
感情不安定	4 (1)	0	0	0	0
激越	1 (<1)	0	0	0	0
気晴らし食い	1 (<1)	0	0	0	0
精神緩慢	1 (<1)	0	0	0	0
閉所恐怖症	0	0	0	0	1 (<1)
不快気分	1 (<1)	0	0	0	0
幻覚	1 (<1)	0	0	0	0
中期不眠症	1 (<1)	0	0	0	0
悪夢	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 14 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
身体表現性障害	2 (<1)	0	0	0	1 (<1)
緊張	1 (<1)	0	0	0	0
神経系障害	262 (70)	214 (58)	215 (58)	429 (58)	76 (55)
多発性硬化症再発	184 (4 9)	121 (33)	115 (31)	236 (32)	51 (37)
頭痛	73 (20)	57 (15)	72 (20)	129 (17)	22 (16)
錯感覚	24 (6)	27 (7)	33 (9)	60 (8)	3 (2)
感覚鈍麻	21 (6)	14 (4)	28 (8)	42 (6)	9 (6)
浮動性めまい	17 (5)	15 (4)	21 (6)	36 (5)	4 (3)
灼熱感	5 (1)	11 (3)	15 (4)	26 (4)	0
片頭痛	15 (4)	11 (3)	14 (4)	25 (3)	2 (1)
筋痙直	17 (5)	11 (3)	10 (3)	21 (3)	4 (3)
平衡障害	6 (2)	7 (2)	8 (2)	15 (2)	2 (1)
感覚障害	7 (2)	7 (2)	6 (2)	13 (2)	1 (<1)
多発性硬化症	8 (2)	6 (2)	5 (1)	11 (1)	4 (3)
坐骨神経痛	3 (<1)	5 (1)	4 (1)	9 (1)	1 (<1)
振戦	6 (2)	6 (2)	3 (<1)	9 (1)	4 (3)
緊張性頭痛	4 (1)	3 (<1)	5 (1)	8 (1)	0
構語障害	0	2 (<1)	5 (1)	7 (<1)	0
レルミット徴候	5 (1)	2 (<1)	5 (1)	7 (<1)	0
神経痛	1 (<1)	3 (<1)	4 (1)	7 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 15 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
異常感覚	2 (<1)	4 (1)	2 (<1)	6 (<1)	0
傾眠	3 (<1)	3 (<1)	3 (<1)	6 (<1)	0
健忘	2 (<1)	3 (<1)	2 (<1)	5 (<1)	0
味覚異常	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
副鼻腔炎に伴う頭痛	1 (<1)	1 (<1)	4 (1)	5 (<1)	0
知覚過敏	4 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
記憶障害	2 (<1)	3 (<1)	1 (<1)	4 (<1)	2 (1)
前兆を伴う片頭痛	2 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
失神	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
三叉神経痛	5 (1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
運動失調	0	0	3 (<1)	3 (<1)	0
手根管症候群	3 (<1)	3 (<1)	0	3 (<1)	2 (1)
認知障害	0	0	3 (<1)	3 (<1)	1 (<1)
注意力障害	0	2 (<1)	1 (<1)	3 (<1)	0
過眠症	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
下肢静止不能症候群	4 (1)	1 (<1)	2 (<1)	3 (<1)	4 (3)
味覚消失	0	1 (<1)	1 (<1)	2 (<1)	0
帯状感	0	1 (<1)	1 (<1)	2 (<1)	0
頚髄神経根痛	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
協調運動異常	0	1 (<1)	1 (<1)	2 (<1)	0
てんかん	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 16 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
頭部動揺	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
不全片麻痺	1 (<1)	0	2 (<1)	2 (<1)	0
意識消失	2 (<1)	0	2 (<1)	2 (<1)	0
感覚異常性大腿神経痛	0	1 (<1)	1 (<1)	2 (<1)	0
運動機能障害	0	1 (<1)	1 (<1)	2 (<1)	0
不随意性筋収縮	0	2 (<1)	0	2 (<1)	1 (<1)
眼振	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ウートホフ現象	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0
良性頭蓋内圧亢進	0	0	1 (<1)	1 (<1)	0
小脳症候群	0	0	1 (<1)	1 (<1)	0
頚原性頭痛	0	0	1 (<1)	1 (<1)	0
不器用	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
痙攣	2 (<1)	1 (<1)	0	1 (<1)	0
振動覚低下	1 (<1)	1 (<1)	0	1 (<1)	0
よだれ	1 (<1)	0	1 (<1)	1 (<1)	0
ジスキネジー	0	1 (<1)	0	1 (<1)	0
ジストニー	0	1 (<1)	0	1 (<1)	1 (<1)
てんかんの前兆	0	1 (<1)	0	1 (<1)	0
顔面部神経痛	0	1 (<1)	0	1 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 17 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
舌咽神経痛	0	1 (<1)	0	1 (<1)	0
大発作痙攣	0	0	1 (<1)	1 (<1)	1 (<1)
思考散乱	0	0	1 (<1)	1 (<1)	0
肋間神経痛	0	0	1 (<1)	1 (<1)	0
脳圧低下	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
嗜眠	0	0	1 (<1)	1 (<1)	0
腰髄神経根障害	0	1 (<1)	0	1 (<1)	0
神経学的症状	0	1 (<1)	0	1 (<1)	0
後頭神経痛	0	0	1 (<1)	1 (<1)	0
腓骨神経麻痺	0	1 (<1)	0	1 (<1)	1 (<1)
睡眠の質低下	0	1 (<1)	0	1 (<1)	1 (<1)
失神寸前の状態	3 (<1)	0	1 (<1)	1 (<1)	0
神経根痛	0	1 (<1)	0	1 (<1)	0
頚髄神経根炎	0	1 (<1)	0	1 (<1)	0
鎮静	0	0	1 (<1)	1 (<1)	0
感覚消失	0	1 (<1)	0	1 (<1)	1 (<1)
舌の麻痺	0	1 (<1)	0	1 (<1)	0
一過性全健忘	0	0	1 (<1)	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
第７脳神経麻痺	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 18 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
視野欠損	1 (<1)	1 (<1)	0	1 (<1)	0
異痛症	1 (<1)	0	0	0	0
失語症	1 (<1)	0	0	0	0
中枢神経系病変	1 (<1)	0	0	0	0
中枢痛症候群	1 (<1)	0	0	0	0
頚腕症候群	2 (<1)	0	0	0	0
顔面不全麻痺	1 (<1)	0	0	0	1 (<1)
顔面痙攣	1 (<1)	0	0	0	1 (<1)
痙性歩行	1 (<1)	0	0	0	0
片側頭痛	4 (1)	0	0	0	1 (<1)
反射亢進	4 (1)	0	0	0	1 (<1)
不全単麻痺	1 (<1)	0	0	0	1 (<1)
単麻痺	1 (<1)	0	0	0	0
末梢性ニューロパチー	2 (<1)	0	0	0	1 (<1)
起立不耐性	0	0	0	0	1 (<1)
周期性四肢運動障害	0	0	0	0	1 (<1)
片頭痛発作重積	1 (<1)	0	0	0	0
足根管症候群	0	0	0	0	1 (<1)
温度覚鈍麻	1 (<1)	0	0	0	0
振動覚亢進	2 (<1)	0	0	0	0
第６脳神経麻痺	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 19 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼障害	47 (13)	38 (10)	47 (13)	85 (12)	15 (11)
霧視	12 (3)	7 (2)	11 (3)	18 (2)	3 (2)
眼痛	9 (2)	6 (2)	10 (3)	16 (2)	1 (<1)
結膜炎	3 (<1)	5 (1)	3 (<1)	8 (1)	1 (<1)
視力障害	4 (1)	3 (<1)	5 (1)	8 (1)	1 (<1)
眼瞼痙攣	4 (1)	2 (<1)	5 (1)	7 (<1)	0
複視	5 (1)	3 (<1)	4 (1)	7 (<1)	1 (<1)
視力低下	4 (1)	4 (1)	2 (<1)	6 (<1)	4 (3)
アレルギー性結膜炎	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
眼乾燥	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
眼の異常感	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
霰粒腫	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
緑内障	0	0	2 (<1)	2 (<1)	0
眼筋麻痺	0	1 (<1)	1 (<1)	2 (<1)	0
眼精疲労	0	0	1 (<1)	1 (<1)	0
眼瞼炎	0	1 (<1)	0	1 (<1)	0
アレルギー性眼瞼炎	0	0	1 (<1)	1 (<1)	0
失明	0	1 (<1)	0	1 (<1)	0
白内障	1 (<1)	0	1 (<1)	1 (<1)	0
眼瞼湿疹	0	1 (<1)	0	1 (<1)	0
眼運動障害	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 20 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼そう痒症	1 (<1)	0	1 (<1)	1 (<1)	0
眼瞼浮腫	0	0	1 (<1)	1 (<1)	0
眼瞼下垂	0	0	1 (<1)	1 (<1)	0
遠視	0	1 (<1)	0	1 (<1)	0
角膜炎	0	0	1 (<1)	1 (<1)	0
瞼板腺炎	0	0	1 (<1)	1 (<1)	0
夜盲	0	0	1 (<1)	1 (<1)	0
眼球運動失調	0	1 (<1)	0	1 (<1)	0
眼充血	0	1 (<1)	0	1 (<1)	0
開放隅角緑内障	0	0	1 (<1)	1 (<1)	0
羞明	0	0	1 (<1)	1 (<1)	0
老視	0	1 (<1)	0	1 (<1)	0
強膜炎	0	1 (<1)	0	1 (<1)	0
ブドウ膜炎	0	0	1 (<1)	1 (<1)	2 (1)
硝子体浮遊物	0	0	1 (<1)	1 (<1)	0
一過性失明	1 (<1)	0	0	0	0
結膜出血	1 (<1)	0	0	0	1 (<1)
結膜刺激	1 (<1)	0	0	0	0
眼瞼紅斑	1 (<1)	0	0	0	0
眼のアレルギー	0	0	0	0	1 (<1)
眼の障害	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 21 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼部腫脹	0	0	0	0	1 (<1)
眼瞼刺激	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
虹彩毛様体炎	0	0	0	0	1 (<1)
流涙増加	2 (<1)	0	0	0	1 (<1)
黄斑浮腫	1 (<1)	0	0	0	0
近視	1 (<1)	0	0	0	1 (<1)
翼状片	1 (<1)	0	0	0	0
閃輝暗点	1 (<1)	0	0	0	0
耳および迷路障害	22 (6)	27 (7)	40 (11)	67 (9)	9 (6)
回転性めまい	14 (4)	13 (4)	27 (7)	40 (5)	5 (4)
耳鳴	1 (<1)	4 (1)	5 (1)	9 (1)	0
耳痛	3 (<1)	4 (1)	4 (1)	8 (1)	1 (<1)
耳閉	0	0	3 (<1)	3 (<1)	0
乗物酔い	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
耳不快感	0	0	2 (<1)	2 (<1)	1 (<1)
聴覚過敏	0	1 (<1)	1 (<1)	2 (<1)	0
頭位性回転性めまい	1 (<1)	0	2 (<1)	2 (<1)	0
耳垢栓塞	0	1 (<1)	0	1 (<1)	1 (<1)
感音性難聴	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 22 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
耳出血	0	1 (<1)	0	1 (<1)	0
耳管機能障害	0	0	1 (<1)	1 (<1)	0
外耳痛	0	1 (<1)	0	1 (<1)	0
難聴	1 (<1)	0	0	0	0
聴力低下	2 (<1)	0	0	0	0
中耳の炎症	1 (<1)	0	0	0	0
前庭性運動失調	0	0	0	0	1 (<1)
心臓障害	14 (4)	19 (5)	24 (7)	43 (6)	11 (8)
心室性期外収縮	3 (<1)	2 (<1)	5 (1)	7 (<1)	0
動悸	6 (2)	5 (1)	1 (<1)	6 (<1)	3 (2)
上室性期外収縮	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
頻脈	2 (<1)	3 (<1)	2 (<1)	5 (<1)	3 (2)
第一度房室ブロック	0	3 (<1)	1 (<1)	4 (<1)	0
期外収縮	0	3 (<1)	1 (<1)	4 (<1)	0
狭心症	0	2 (<1)	1 (<1)	3 (<1)	0
徐脈	0	0	3 (<1)	3 (<1)	2 (1)
洞性徐脈	0	1 (<1)	2 (<1)	3 (<1)	0
左脚ブロック	1 (<1)	0	2 (<1)	2 (<1)	0
洞性頻脈	0	0	2 (<1)	2 (<1)	0
右脚ブロック	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 23 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓瘤	0	0	1 (<1)	1 (<1)	0
心不全	0	0	1 (<1)	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	1 (<1)	0
心筋症	0	0	1 (<1)	1 (<1)	0
僧帽弁逸脱	0	0	1 (<1)	1 (<1)	0
結節性調律	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	0	1 (<1)
伝導障害	1 (<1)	0	0	0	0
心筋炎	0	0	0	0	1 (<1)
発作性頻脈	0	0	0	0	1 (<1)
血管障害	44 (12)	170 (46)	149 (40)	319 (43)	13 (9)
潮紅	16 (4)	141 (38)	121 (33)	262 (35)	2 (1)
ほてり	8 (2)	26 (7)	23 (6)	49 (7)	2 (1)
高血圧	10 (3)	6 (2)	7 (2)	13 (2)	8 (6)
充血	0	0	5 (1)	5 (<1)	0
静脈瘤	0	4 (1)	1 (<1)	5 (<1)	0
低血圧	2 (<1)	3 (<1)	1 (<1)	4 (<1)	0
血腫	4 (1)	1 (<1)	2 (<1)	3 (<1)	2 (1)
静脈不全	0	1 (<1)	1 (<1)	2 (<1)	0
動脈障害	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 24 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
高血圧クリーゼ	1 (<1)	0	1 (<1)	1 (<1)	0
末梢冷感	2 (<1)	1 (<1)	0	1 (<1)	0
静脈痛	0	1 (<1)	0	1 (<1)	0
起立性低血圧	1 (<1)	0	0	0	0
蒼白	1 (<1)	0	0	0	0
末梢性虚血	1 (<1)	0	0	0	0
静脈炎	2 (<1)	0	0	0	0
レイノー現象	2 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	64 (17)	61 (16)	66 (18)	127 (17)	18 (13)
口腔咽頭痛	15 (4)	18 (5)	23 (6)	41 (6)	5 (4)
咳嗽	19 (5)	16 (4)	13 (4)	29 (4)	5 (4)
呼吸困難	6 (2)	5 (1)	4 (1)	9 (1)	2 (1)
鼻閉	4 (1)	7 (2)	2 (<1)	9 (1)	0
鼻漏	4 (1)	7 (2)	2 (<1)	9 (1)	1 (<1)
鼻出血	2 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
アレルギー性鼻炎	4 (1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
喘息	0	3 (<1)	1 (<1)	4 (<1)	2 (1)
副鼻腔うっ血	1 (<1)	0	4 (1)	4 (<1)	0
気道うっ血	5 (1)	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 25 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
息詰まり	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
しゃっくり	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
湿性咳嗽	2 (<1)	2 (<1)	0	2 (<1)	0
咽喉刺激感	3 (<1)	2 (<1)	0	2 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	2 (<1)	0
上気道うっ血	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
上気道咳症候群	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	1 (<1)	0
アレルギー性咽頭炎	2 (<1)	0	1 (<1)	1 (<1)	0
息詰まり感	0	1 (<1)	0	1 (<1)	0
発声障害	2 (<1)	0	1 (<1)	1 (<1)	0
労作性呼吸困難	1 (<1)	1 (<1)	0	1 (<1)	0
過換気	1 (<1)	0	1 (<1)	1 (<1)	0
鼻乾燥	1 (<1)	0	1 (<1)	1 (<1)	0
鼻浮腫	0	0	1 (<1)	1 (<1)	0
鼻中隔弯曲	0	1 (<1)	0	1 (<1)	0
口腔咽頭不快感	1 (<1)	1 (<1)	0	1 (<1)	0
呼吸時疼痛	0	0	1 (<1)	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	1 (<1)	0
咽頭紅斑	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 26 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
咽頭腫瘤	0	0	1 (<1)	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	1 (<1)	0
気胸	0	0	1 (<1)	1 (<1)	0
ラ音	1 (<1)	0	1 (<1)	1 (<1)	0
呼吸障害	0	0	1 (<1)	1 (<1)	0
気道の炎症	1 (<1)	0	1 (<1)	1 (<1)	0
睡眠時無呼吸症候群	0	0	1 (<1)	1 (<1)	1 (<1)
声帯ポリープ	0	0	1 (<1)	1 (<1)	0
喘鳴	1 (<1)	1 (<1)	0	1 (<1)	0
アレルギー性咳嗽	1 (<1)	0	0	0	0
アレルギー性呼吸器疾患	1 (<1)	0	0	0	0
アレルギー性呼吸器症状	1 (<1)	0	0	0	0
アレルギー性副鼻腔炎	1 (<1)	0	0	0	0
慢性気管支炎	1 (<1)	0	0	0	0
咽喉乾燥	1 (<1)	0	0	0	0
喀血	1 (<1)	0	0	0	0
低換気	0	0	0	0	1 (<1)
上気道分泌増加	1 (<1)	0	0	0	0
口腔咽頭水疱形成	1 (<1)	0	0	0	0
副鼻腔障害	1 (<1)	0	0	0	0
くしゃみ	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 27 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
扁桃障害	1 (<1)	0	0	0	0
声帯の炎症	1 (<1)	0	0	0	0
胃腸障害	156 (42)	173 (47)	203 (55)	376 (51)	25 (18)
下痢	50 (13)	60 (16)	61 (17)	121 (16)	5 (4)
悪心	40 (11)	44 (12)	57 (15)	101 (14)	9 (6)
上腹部痛	27 (7)	43 (12)	47 (13)	90 (12)	1 (<1)
腹痛	21 (6)	29 (8)	31 (8)	60 (8)	3 (2)
嘔吐	24 (6)	33 (9)	23 (6)	56 (8)	7 (5)
消化不良	10 (3)	17 (5)	22 (6)	39 (5)	0
胃腸障害	4 (1)	9 (2)	19 (5)	28 (4)	0
便秘	19 (5)	7 (2)	17 (5)	24 (3)	4 (3)
歯痛	13 (3)	8 (2)	16 (4)	24 (3)	2 (1)
胃食道逆流性疾患	9 (2)	9 (2)	14 (4)	23 (3)	2 (1)
腹部不快感	10 (3)	9 (2)	9 (2)	18 (2)	0
胃炎	5 (1)	8 (2)	8 (2)	16 (2)	1 (<1)
口内乾燥	4 (1)	6 (2)	6 (2)	12 (2)	1 (<1)
痔核	5 (1)	3 (<1)	7 (2)	10 (1)	0
腹部膨満	4 (1)	1 (<1)	6 (2)	7 (<1)	0
嚥下障害	3 (<1)	2 (<1)	5 (1)	7 (<1)	2 (1)
鼓腸	5 (1)	4 (1)	3 (<1)	7 (<1)	2 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 28 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
便意切迫	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
齲歯	0	3 (<1)	1 (<1)	4 (<1)	2 (1)
裂孔ヘルニア	0	3 (<1)	1 (<1)	4 (<1)	0
歯周炎	3 (<1)	0	4 (1)	4 (<1)	0
大腸炎	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
心窩部不快感	0	1 (<1)	2 (<1)	3 (<1)	0
便失禁	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
食中毒	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
歯肉炎	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
腹部ヘルニア	0	2 (<1)	0	2 (<1)	0
下腹部痛	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
腸憩室	0	0	2 (<1)	2 (<1)	0
小腸炎	0	0	2 (<1)	2 (<1)	0
吐血	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口の感覚鈍麻	0	0	2 (<1)	2 (<1)	0
食道炎	0	2 (<1)	0	2 (<1)	0
逆流性食道炎	1 (<1)	0	2 (<1)	2 (<1)	0
口内炎	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
埋伏歯	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
腹部硬直	1 (<1)	1 (<1)	0	1 (<1)	0
腹部圧痛	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 29 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
アフタ性口内炎	1 (<1)	0	1 (<1)	1 (<1)	0
便通不規則	1 (<1)	0	1 (<1)	1 (<1)	0
口腔灼熱感症候群	0	0	1 (<1)	1 (<1)	0
口唇炎	0	1 (<1)	0	1 (<1)	0
結腸ポリープ	0	0	1 (<1)	1 (<1)	0
クローン病	0	1 (<1)	0	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)	0
排便回数増加	0	1 (<1)	0	1 (<1)	0
胃潰瘍	0	0	1 (<1)	1 (<1)	0
出血性胃炎	0	1 (<1)	0	1 (<1)	0
歯肉嚢胞	0	0	1 (<1)	1 (<1)	0
舌炎	0	1 (<1)	0	1 (<1)	0
血便排泄	1 (<1)	0	1 (<1)	1 (<1)	0
胃酸過多	2 (<1)	1 (<1)	0	1 (<1)	0
炎症性腸疾患	0	0	1 (<1)	1 (<1)	0
弛緩歯	0	1 (<1)	0	1 (<1)	0
腰ヘルニア	0	0	1 (<1)	1 (<1)	0
マロリー・ワイス症候群	0	1 (<1)	0	1 (<1)	0
神経因性腸	0	0	1 (<1)	1 (<1)	0
嚥下痛	0	1 (<1)	0	1 (<1)	0
食道出血	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 30 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
食道痙攣	0	0	1 (<1)	1 (<1)	0
食道潰瘍	0	0	1 (<1)	1 (<1)	0
口腔内痛	0	0	1 (<1)	1 (<1)	0
膵脂肪腫症	0	1 (<1)	0	1 (<1)	0
膵機能不全	0	0	1 (<1)	1 (<1)	0
膵炎	1 (<1)	1 (<1)	0	1 (<1)	0
口の錯感覚	0	1 (<1)	0	1 (<1)	0
消化性潰瘍	0	0	1 (<1)	1 (<1)	0
歯周病	0	1 (<1)	0	1 (<1)	0
肛門周囲痛	1 (<1)	1 (<1)	0	1 (<1)	0
流涎過多	0	1 (<1)	0	1 (<1)	0
舌腫脹	0	1 (<1)	0	1 (<1)	0
舌苔	0	0	1 (<1)	1 (<1)	0
舌障害	1 (<1)	0	1 (<1)	1 (<1)	0
歯の磨耗	0	1 (<1)	0	1 (<1)	0
歯の脱落	0	1 (<1)	0	1 (<1)	0
臍ヘルニア	0	0	1 (<1)	1 (<1)	0
異常便	1 (<1)	0	0	0	0
裂肛	1 (<1)	0	0	0	0
根尖肉芽腫	0	0	0	0	1 (<1)
口唇のひび割れ	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 31 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
十二指腸胃逆流	1 (<1)	0	0	0	0
胃障害	2 (<1)	0	0	0	0
胃ポリープ	1 (<1)	0	0	0	0
胃腸出血	1 (<1)	0	0	0	0
消化器痛	3 (<1)	0	0	0	1 (<1)
歯肉出血	0	0	0	0	1 (<1)
歯肉腫脹	1 (<1)	0	0	0	0
過敏性腸症候群	1 (<1)	0	0	0	0
口腔内潰瘍形成	2 (<1)	0	0	0	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
直腸出血	1 (<1)	0	0	0	0
逆流性胃炎	1 (<1)	0	0	0	0
脆弱歯	1 (<1)	0	0	0	0
舌乾燥	1 (<1)	0	0	0	0
肝胆道系障害	4 (1)	4 (1)	5 (1)	9 (1)	2 (1)
脂肪肝	1 (<1)	2 (<1)	0	2 (<1)	0
肝障害	0	0	2 (<1)	2 (<1)	1 (<1)
胆石症	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
肝細胞融解性肝炎	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 32 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胆嚢浮腫	0	0	1 (<1)	1 (<1)	0
肝嚢胞	0	1 (<1)	0	1 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
高ビリルビン血症	1 (<1)	0	0	0	0
皮膚および皮下組織障害	84 (22)	129 (35)	133 (36)	262 (35)	30 (22)
そう痒症	15 (4)	35 (9)	32 (9)	67 (9)	4 (3)
発疹	12 (3)	30 (8)	26 (7)	56 (8)	4 (3)
紅斑	3 (<1)	15 (4)	28 (8)	43 (6)	4 (3)
多汗症	4 (1)	9 (2)	14 (4)	23 (3)	2 (1)
蕁麻疹	6 (2)	9 (2)	7 (2)	16 (2)	1 (<1)
脱毛症	13 (3)	9 (2)	6 (2)	15 (2)	0
寝汗	5 (1)	7 (2)	8 (2)	15 (2)	1 (<1)
全身性そう痒症	1 (<1)	6 (2)	5 (1)	11 (1)	1 (<1)
アレルギー性皮膚炎	1 (<1)	5 (1)	5 (1)	10 (1)	1 (<1)
ざ瘡	9 (2)	5 (1)	3 (<1)	8 (1)	2 (1)
皮膚乾燥	4 (1)	2 (<1)	5 (1)	7 (<1)	1 (<1)
全身性皮疹	0	4 (1)	3 (<1)	7 (<1)	0
そう痒性皮疹	0	4 (1)	3 (<1)	7 (<1)	0
光線過敏性反応	1 (<1)	3 (<1)	3 (<1)	6 (<1)	0
皮膚灼熱感	0	1 (<1)	5 (1)	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 33 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
斑状皮疹	0	0	5 (1)	5 (<1)	0
皮膚炎	4 (1)	1 (<1)	3 (<1)	4 (<1)	0
湿疹	2 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
顔面感覚鈍麻	4 (1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
紅斑性皮疹	0	2 (<1)	2 (<1)	4 (<1)	0
全身紅斑	0	3 (<1)	0	3 (<1)	0
過角化	0	1 (<1)	2 (<1)	3 (<1)	0
丘疹性皮疹	0	1 (<1)	2 (<1)	3 (<1)	0
酒さ	2 (<1)	3 (<1)	0	3 (<1)	0
皮膚色素過剰	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
皮膚刺激	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
皮膚反応	0	1 (<1)	2 (<1)	3 (<1)	2 (1)
水疱	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚嚢腫	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
ざ瘡様皮膚炎	1 (<1)	2 (<1)	0	2 (<1)	0
接触性皮膚炎	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
爪破損	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚疼痛	0	0	2 (<1)	2 (<1)	0
痒疹	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性そう痒症	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚硬結	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 34 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚のつっぱり感	0	1 (<1)	1 (<1)	2 (<1)	0
日光性角化症	0	0	1 (<1)	1 (<1)	0
冷汗	1 (<1)	0	1 (<1)	1 (<1)	0
薬疹	0	0	1 (<1)	1 (<1)	0
斑状出血	2 (<1)	0	1 (<1)	1 (<1)	0
紅色症	0	0	1 (<1)	1 (<1)	0
紅色汗疹	0	1 (<1)	0	1 (<1)	0
掌蹠角化症	0	1 (<1)	0	1 (<1)	0
内出血発生の増加傾向	0	0	1 (<1)	1 (<1)	1 (<1)
乾癬	2 (<1)	0	1 (<1)	1 (<1)	0
瘢痕	0	1 (<1)	0	1 (<1)	0
皮膚剥脱	0	1 (<1)	0	1 (<1)	0
皮膚病変	2 (<1)	1 (<1)	0	1 (<1)	0
皮膚潰瘍	0	0	1 (<1)	1 (<1)	0
皮膚熱感	0	1 (<1)	0	1 (<1)	0
スティーブンス・ジョンソン症候群	0	1 (<1)	0	1 (<1)	0
顔面腫脹	0	1 (<1)	0	1 (<1)	3 (2)
毛細血管拡張症	1 (<1)	1 (<1)	0	1 (<1)	0
乾皮症	0	0	1 (<1)	1 (<1)	0
血管浮腫	0	0	0	0	1 (<1)
頭部粃糠疹	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 35 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
発汗障害	1 (<1)	0	0	0	0
嵌入爪	1 (<1)	0	0	0	1 (<1)
後天性リポジストロフィー	0	0	0	0	1 (<1)
網状皮斑	0	0	0	0	1 (<1)
爪床障害	1 (<1)	0	0	0	0
点状出血	2 (<1)	0	0	0	0
色素沈着障害	2 (<1)	0	0	0	0
ばら色粃糠疹	1 (<1)	0	0	0	0
小水疱性皮疹	1 (<1)	0	0	0	0
皮膚変色	1 (<1)	0	0	0	0
皮膚障害	1 (<1)	0	0	0	0
皮膚小結節	0	0	0	0	1 (<1)
筋骨格系および結合組織障害	134 (36)	136 (37)	130 (35)	266 (36)	37 (27)
背部痛	42 (11)	56 (15)	39 (11)	95 (13)	13 (9)
関節痛	33 (9)	41 (11)	33 (9)	74 (10)	8 (6)
四肢痛	28 (7)	32 (9)	32 (9)	64 (9)	10 (7)
筋痙縮	20 (5)	15 (4)	28 (8)	43 (6)	2 (1)
筋力低下	16 (4)	10 (3)	17 (5)	27 (4)	5 (4)
筋骨格痛	10 (3)	6 (2)	10 (3)	16 (2)	5 (4)
頚部痛	7 (2)	10 (3)	6 (2)	16 (2)	4 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 36 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋肉痛	13 (3)	7 (2)	8 (2)	15 (2)	3 (2)
滑液包炎	3 (<1)	4 (1)	5 (1)	9 (1)	0
変形性関節症	4 (1)	3 (<1)	3 (<1)	6 (<1)	0
筋緊張	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
筋骨格系胸痛	4 (1)	3 (<1)	2 (<1)	5 (<1)	0
筋骨格硬直	5 (1)	3 (<1)	2 (<1)	5 (<1)	7 (5)
重感	1 (<1)	3 (<1)	2 (<1)	5 (<1)	2 (1)
骨痛	3 (<1)	1 (<1)	3 (<1)	4 (<1)	0
椎間板突出	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
関節腫脹	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
関節周囲炎	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
腱炎	6 (2)	2 (<1)	2 (<1)	4 (<1)	0
筋骨格不快感	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
骨減少症	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
骨粗鬆症	4 (1)	2 (<1)	1 (<1)	3 (<1)	0
尾骨痛	2 (<1)	0	2 (<1)	2 (<1)	0
椎間板障害	0	2 (<1)	0	2 (<1)	0
関節硬直	0	0	2 (<1)	2 (<1)	1 (<1)
筋拘縮	0	0	2 (<1)	2 (<1)	1 (<1)
筋攣縮	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ミオキミア	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 37 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
膝蓋大腿部痛症候群	0	1 (<1)	1 (<1)	2 (<1)	0
シェーグレン症候群	0	2 (<1)	0	2 (<1)	0
変形性脊椎症	1 (<1)	0	2 (<1)	2 (<1)	0
滑液嚢腫	2 (<1)	2 (<1)	0	2 (<1)	0
腱鞘炎	2 (<1)	0	2 (<1)	2 (<1)	0
関節炎	0	0	1 (<1)	1 (<1)	0
関節障害	0	0	1 (<1)	1 (<1)	0
腋窩腫瘤	1 (<1)	1 (<1)	0	1 (<1)	0
腱付着部症	0	1 (<1)	0	1 (<1)	0
外骨腫	0	0	1 (<1)	1 (<1)	2 (1)
側腹部痛	0	0	1 (<1)	1 (<1)	2 (1)
鼠径部痛	1 (<1)	1 (<1)	0	1 (<1)	0
椎間板圧迫	0	1 (<1)	0	1 (<1)	0
椎間板変性症	0	0	1 (<1)	1 (<1)	0
関節滲出液	0	0	1 (<1)	1 (<1)	0
下肢腫瘤	0	0	1 (<1)	1 (<1)	0
筋腫脹	0	1 (<1)	0	1 (<1)	0
筋硬化症	1 (<1)	1 (<1)	0	1 (<1)	0
筋炎	1 (<1)	0	1 (<1)	1 (<1)	0
骨端症	0	0	1 (<1)	1 (<1)	0
骨壊死	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 38 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肩回旋筋腱板症候群	2 (<1)	0	1 (<1)	1 (<1)	0
脊椎障害	0	1 (<1)	0	1 (<1)	0
脊椎分離	0	1 (<1)	0	1 (<1)	0
滑膜障害	0	1 (<1)	0	1 (<1)	0
腱障害	1 (<1)	1 (<1)	0	1 (<1)	0
線維筋痛	1 (<1)	0	0	0	0
運動性低下	0	0	0	0	1 (<1)
顎痛	2 (<1)	0	0	0	0
回帰性リウマチ	1 (<1)	0	0	0	0
足底筋膜炎	1 (<1)	0	0	0	0
関節リウマチ	2 (<1)	0	0	0	0
脊柱変形	1 (<1)	0	0	0	0
腱痛	1 (<1)	0	0	0	0
斜頚	1 (<1)	0	0	0	0
腎および尿路障害	72 (19)	65 (18)	86 (23)	151 (20)	29 (21)
蛋白尿	30 (8)	28 (8)	34 (9)	62 (8)	13 (9)
血尿	9 (2)	16 (4)	19 (5)	35 (5)	4 (3)
ミクロアルブミン尿	13 (3)	16 (4)	15 (4)	31 (4)	5 (4)
排尿困難	4 (1)	4 (1)	8 (2)	12 (2)	1 (<1)
ケトン尿	2 (<1)	5 (1)	6 (2)	11 (1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 39 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
頻尿	6 (2)	5 (1)	3 (<1)	8 (1)	3 (2)
尿意切迫	7 (2)	4 (1)	3 (<1)	7 (<1)	5 (4)
腎結石症	6 (2)	2 (<1)	5 (1)	7 (<1)	1 (<1)
尿失禁	3 (<1)	3 (<1)	3 (<1)	6 (<1)	2 (1)
尿閉	3 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
糖尿	5 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
アルブミン尿	0	1 (<1)	2 (<1)	3 (<1)	2 (1)
膀胱機能障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
神経因性膀胱	0	2 (<1)	1 (<1)	3 (<1)	0
排尿躊躇	4 (1)	0	3 (<1)	3 (<1)	1 (<1)
白血球尿	0	0	2 (<1)	2 (<1)	1 (<1)
腎仙痛	0	0	2 (<1)	2 (<1)	0
腎臓痛	0	0	2 (<1)	2 (<1)	0
切迫性尿失禁	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
尿臭異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
膀胱刺激症状	0	0	1 (<1)	1 (<1)	0
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
出血性膀胱炎	0	1 (<1)	0	1 (<1)	0
非感染性膀胱炎	1 (<1)	0	1 (<1)	1 (<1)	0
グロブリン尿	0	1 (<1)	0	1 (<1)	0
緊張性膀胱	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 40 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
失禁	0	0	1 (<1)	1 (<1)	1 (<1)
起立性蛋白尿症	0	0	1 (<1)	1 (<1)	0
腎嚢胞	0	1 (<1)	0	1 (<1)	0
慢性腎不全	0	0	1 (<1)	1 (<1)	0
有痛性排尿困難	0	1 (<1)	0	1 (<1)	0
膀胱痙縮	1 (<1)	0	0	0	0
高血圧性腎症	0	0	0	0	1 (<1)
ネフローゼ症候群	0	0	0	0	1 (<1)
膿尿	0	0	0	0	1 (<1)
腹圧性尿失禁	1 (<1)	0	0	0	0
尿路の炎症	1 (<1)	0	0	0	0
尿路痛	1 (<1)	0	0	0	1 (<1)
妊娠、産褥および周産期の状態	3 (<1)	0	0	0	0
自然流産	2 (<1)	0	0	0	0
妊娠浮腫	1 (<1)	0	0	0	0
生殖系および乳房障害	40 (11)	42 (11)	49 (13)	91 (12)	6 (4)
不正子宮出血	3 (<1)	5 (1)	7 (2)	12 (2)	3 (2)
月経困難症	4 (1)	5 (1)	6 (2)	11 (1)	1 (<1)
卵巣嚢胞	5 (1)	6 (2)	3 (<1)	9 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 41 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
勃起不全	3 (<1)	4 (1)	4 (1)	8 (1)	0
不規則月経	7 (2)	2 (<1)	5 (1)	7 (<1)	0
無月経	3 (<1)	2 (<1)	3 (<1)	5 (<1)	0
子宮出血	0	1 (<1)	3 (<1)	4 (<1)	0
腟出血	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
乳房痛	0	0	3 (<1)	3 (<1)	0
月経過多	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
骨盤痛	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
頻発月経	0	2 (<1)	1 (<1)	3 (<1)	0
性機能不全	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
萎縮性外陰腟炎	0	0	2 (<1)	2 (<1)	0
乳房嚢胞	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
閉経期症状	0	1 (<1)	1 (<1)	2 (<1)	0
月経障害	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
月経遅延	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
外陰腟乾燥	0	1 (<1)	1 (<1)	2 (<1)	0
外陰腟そう痒症	0	1 (<1)	1 (<1)	2 (<1)	0
腺筋症	0	0	1 (<1)	1 (<1)	0
バルトリン腺炎	0	0	1 (<1)	1 (<1)	0
良性前立腺肥大症	0	1 (<1)	0	1 (<1)	0
乳房出血	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 42 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乳房腫瘤	0	0	1 (<1)	1 (<1)	0
乳房圧痛	0	0	1 (<1)	1 (<1)	0
子宮頚部上皮異形成	0	1 (<1)	0	1 (<1)	0
射精障害	0	1 (<1)	0	1 (<1)	0
子宮内膜増殖症	0	1 (<1)	0	1 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
線維嚢胞性乳腺疾患	1 (<1)	0	1 (<1)	1 (<1)	0
希発月経	1 (<1)	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	1 (<1)	1 (<1)	0	1 (<1)	0
多嚢胞性卵巣	0	1 (<1)	0	1 (<1)	0
閉経後出血	0	0	1 (<1)	1 (<1)	0
早発閉経	0	1 (<1)	0	1 (<1)	0
前立腺炎	0	1 (<1)	0	1 (<1)	0
前立腺腫大	0	0	1 (<1)	1 (<1)	0
精巣障害	0	0	1 (<1)	1 (<1)	0
子宮の炎症	0	1 (<1)	0	1 (<1)	0
子宮ポリープ	1 (<1)	1 (<1)	0	1 (<1)	0
子宮脱	0	1 (<1)	0	1 (<1)	0
膣分泌物	0	0	1 (<1)	1 (<1)	0
乳房硬結	1 (<1)	0	0	0	0
生殖器病変	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 43 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
機能性子宮出血	1 (<1)	0	0	0	1 (<1)
精巣痛	1 (<1)	0	0	0	0
子宮頚部びらん	1 (<1)	0	0	0	0
外陰腟痛	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (<1)	1 (<1)	1 (<1)
異形成母斑症候群	0	0	1 (<1)	1 (<1)	0
過誤腫	0	0	0	0	1 (<1)
一般・全身障害および投与部位の状態	109 (29)	106 (29)	109 (30)	215 (29)	64 (4 6)
疲労	51 (14)	59 (16)	59 (16)	118 (16)	18 (13)
発熱	17 (5)	12 (3)	15 (4)	27 (4)	6 (4)
無力症	8 (2)	14 (4)	11 (3)	25 (3)	9 (6)
インフルエンザ様疾患	8 (2)	9 (2)	10 (3)	19 (3)	1 (<1)
疼痛	6 (2)	10 (3)	8 (2)	18 (2)	1 (<1)
胸痛	8 (2)	7 (2)	10 (3)	17 (2)	2 (1)
熱感	1 (<1)	8 (2)	3 (<1)	11 (1)	0
歩行障害	5 (1)	4 (1)	7 (2)	11 (1)	5 (4)
末梢性浮腫	10 (3)	5 (1)	6 (2)	11 (1)	2 (1)
非心臓性胸痛	1 (<1)	3 (<1)	5 (1)	8 (1)	2 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 44 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胸部不快感	3 (<1)	4 (1)	2 (<1)	6 (<1)	1 (<1)
倦怠感	1 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
悪寒	5 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
高熱	0	2 (<1)	1 (<1)	3 (<1)	0
易刺激性	4 (1)	2 (<1)	1 (<1)	3 (<1)	2 (1)
粘膜乾燥	0	1 (<1)	1 (<1)	2 (<1)	0
浮腫	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
嚢胞	0	0	1 (<1)	1 (<1)	0
医療機器不具合	0	1 (<1)	0	1 (<1)	0
不快感	0	0	1 (<1)	1 (<1)	0
顔面痛	1 (<1)	1 (<1)	0	1 (<1)	2 (1)
脂肪壊死	0	1 (<1)	0	1 (<1)	0
異常感	0	0	1 (<1)	1 (<1)	0
冷感	0	0	1 (<1)	1 (<1)	0
全身性浮腫	0	1 (<1)	0	1 (<1)	0
閉塞性ヘルニア	0	0	1 (<1)	1 (<1)	0
炎症	0	0	1 (<1)	1 (<1)	0
注入部位血腫	0	1 (<1)	0	1 (<1)	0
注射部位硬結	0	0	1 (<1)	1 (<1)	2 (1)
局所腫脹	0	1 (<1)	0	1 (<1)	0
医療機器による疼痛	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 45 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
粘膜の炎症	0	0	1 (<1)	1 (<1)	0
軟部組織の炎症	0	1 (<1)	0	1 (<1)	0
腫脹	0	1 (<1)	0	1 (<1)	0
温度変化不耐症	0	1 (<1)	0	1 (<1)	0
圧痛	0	0	1 (<1)	1 (<1)	0
血管穿刺部位血腫	0	0	1 (<1)	1 (<1)	0
適用部位浮腫	0	0	0	0	1 (<1)
嚢胞破裂	0	0	0	0	1 (<1)
医療機器関連眼合併症	1 (<1)	0	0	0	0
ヘルニア痛	1 (<1)	0	0	0	0
空腹	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	3 (2)
注射部位乾燥	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	15 (11)
注射部位血管外漏出	0	0	0	0	1 (<1)
注射部位血腫	0	0	0	0	2 (1)
注射部位出血	0	0	0	0	1 (<1)
注射部位過敏反応	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	6 (4)
注射部位結節	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 46 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位浮腫	0	0	0	0	1 (<1)
注射部位疼痛	0	0	0	0	14 (10)
注射部位そう痒感	0	0	0	0	7 (5)
注射部位発疹	0	0	0	0	1 (<1)
注射部位反応	0	0	0	0	3 (2)
注射部位腫脹	0	0	0	0	7 (5)
注射部位蕁麻疹	0	0	0	0	2 (1)
注射部位熱感	0	0	0	0	2 (1)
口渇	1 (<1)	0	0	0	0
ワクチン接種部位疼痛	1 (<1)	0	0	0	0
臨床検査	92 (25)	93 (25)	101 (27)	194 (26)	37 (27)
アラニン・アミノトランスフェラーゼ増加	16 (4)	23 (6)	22 (6)	45 (6)	6 (4)
アスパラギン酸アミノトランスフェラーゼ増加	8 (2)	16 (4)	16 (4)	32 (4)	4 (3)
尿中蛋白陽性	18 (5)	17 (5)	10 (3)	27 (4)	7 (5)
尿中アルブミン陽性	17 (5)	15 (4)	11 (3)	26 (4)	8 (6)
γ－グルタミルトランスフェラーゼ増加	9 (2)	11 (3)	7 (2)	18 (2)	4 (3)
血中ブドウ糖増加	3 (<1)	6 (2)	9 (2)	15 (2)	2 (1)
尿中白血球陽性	8 (2)	8 (2)	7 (2)	15 (2)	5 (4)
体重減少	2 (<1)	6 (2)	7 (2)	13 (2)	0
リンパ球数減少	0	7 (2)	5 (1)	12 (2)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 47 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球数減少	0	6 (2)	6 (2)	12 (2)	0
尿中血陽性	2 (<1)	6 (2)	5 (1)	11 (1)	1 (<1)
体重増加	6 (2)	4 (1)	6 (2)	10 (1)	1 (<1)
血中副甲状腺ホルモン増加	4 (1)	2 (<1)	7 (2)	9 (1)	1 (<1)
尿中β２ミクログロブリン増加	7 (2)	3 (<1)	5 (1)	8 (1)	3 (2)
尿中ケトン体陽性	1 (<1)	4 (1)	4 (1)	8 (1)	1 (<1)
ヘモグロビン減少	3 (<1)	2 (<1)	4 (1)	6 (<1)	0
肝酵素上昇	3 (<1)	2 (<1)	4 (1)	6 (<1)	2 (1)
血中カリウム増加	0	3 (<1)	2 (<1)	5 (<1)	0
尿中ブドウ糖陽性	1 (<1)	3 (<1)	2 (<1)	5 (<1)	2 (1)
好中球数減少	0	4 (1)	1 (<1)	5 (<1)	0
好中球数増加	9 (2)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
β２ミクログロブリン増加	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
血中アルカリホスファターゼ増加	4 (1)	3 (<1)	1 (<1)	4 (<1)	0
血中クレアチニン増加	0	1 (<1)	3 (<1)	4 (<1)	2 (1)
心電図ＱＴ延長	4 (1)	0	4 (1)	4 (<1)	2 (1)
ヘマトクリット減少	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
尿中赤血球陽性	2 (<1)	4 (1)	0	4 (<1)	1 (<1)
血中コレステロール増加	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
血中ナトリウム増加	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
血中トリグリセリド増加	4 (1)	2 (<1)	1 (<1)	3 (<1)	2 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 48 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ビタミンD増加	1 (<1)	0	3 (<1)	3 (<1)	0
血中クロール増加	0	0	2 (<1)	2 (<1)	0
血圧上昇	0	0	2 (<1)	2 (<1)	1 (<1)
血中尿素増加	0	0	2 (<1)	2 (<1)	1 (<1)
血中尿酸増加	0	0	2 (<1)	2 (<1)	0
体温上昇	0	0	2 (<1)	2 (<1)	0
心電図ＳＴ部分下降	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
血液学的検査異常	1 (<1)	0	2 (<1)	2 (<1)	0
リンパ球形態異常	0	1 (<1)	1 (<1)	2 (<1)	0
血小板数減少	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
赤血球数減少	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミンD減少	2 (<1)	2 (<1)	0	2 (<1)	0
アレルギー検査	0	0	1 (<1)	1 (<1)	0
抗ＳＳＡ抗体陽性	0	1 (<1)	0	1 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	1 (<1)	0
血中重炭酸塩減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中重炭酸塩増加	0	1 (<1)	0	1 (<1)	0
血中ビリルビン増加	3 (<1)	0	1 (<1)	1 (<1)	0
血中カルシウム減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中カルシウム増加	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
血中クレアチン増加	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 49 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中クレアチニン異常	0	1 (<1)	0	1 (<1)	0
血中葉酸減少	0	0	1 (<1)	1 (<1)	0
血中ケトン体増加	0	0	1 (<1)	1 (<1)	1 (<1)
血中乳酸脱水素酵素増加	3 (<1)	1 (<1)	0	1 (<1)	0
血中副甲状腺ホルモン異常	0	0	1 (<1)	1 (<1)	0
血中カリウム減少	1 (<1)	0	1 (<1)	1 (<1)	0
拡張期血圧上昇	0	0	1 (<1)	1 (<1)	0
呼吸音異常	0	1 (<1)	0	1 (<1)	0
尿中結晶陽性	3 (<1)	0	1 (<1)	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	1 (<1)	0
心電図異常	1 (<1)	0	1 (<1)	1 (<1)	0
好酸球数増加	0	0	1 (<1)	1 (<1)	0
エプスタイン・バーウイルス抗体陽性	0	0	1 (<1)	1 (<1)	0
胃内ｐＨ上昇	0	0	1 (<1)	1 (<1)	0
心拍数減少	0	0	1 (<1)	1 (<1)	0
心拍数増加	1 (<1)	1 (<1)	0	1 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	1 (<1)	0
肝機能検査異常	2 (<1)	1 (<1)	0	1 (<1)	0
低比重リポ蛋白増加	0	0	1 (<1)	1 (<1)	0
リンパ節触知	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 50 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
リンパ球百分率減少	1 (<1)	1 (<1)	0	1 (<1)	0
単球数減少	0	0	1 (<1)	1 (<1)	1 (<1)
神経学的検査異常	0	1 (<1)	0	1 (<1)	0
好中球百分率増加	1 (<1)	1 (<1)	0	1 (<1)	0
脳核磁気共鳴画像異常	0	1 (<1)	0	1 (<1)	0
血小板数	0	1 (<1)	0	1 (<1)	0
血小板数増加	0	0	1 (<1)	1 (<1)	1 (<1)
ロンベルグ徴候陽性	0	1 (<1)	0	1 (<1)	0
腎機能検査異常	0	1 (<1)	0	1 (<1)	0
残尿量増加	0	1 (<1)	0	1 (<1)	0
呼吸数増加	0	0	1 (<1)	1 (<1)	0
子宮頚部スミア異常	0	0	1 (<1)	1 (<1)	0
尿円柱	0	0	1 (<1)	1 (<1)	0
ビタミンＢ１２減少	2 (<1)	1 (<1)	0	1 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	0	0	0	1 (<1)
動脈雑音	1 (<1)	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	0	0	0	1 (<1)
細菌検査	1 (<1)	0	0	0	0
細菌検査陽性	1 (<1)	0	0	0	1 (<1)
血中アルカリホスファターゼ異常	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 51 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中クロール減少	1 (<1)	0	0	0	0
血中ブドウ糖減少	0	0	0	0	1 (<1)
血中乳酸脱水素酵素異常	0	0	0	0	1 (<1)
血中副甲状腺ホルモン減少	1 (<1)	0	0	0	0
血中リン増加	1 (<1)	0	0	0	0
血圧低下	1 (<1)	0	0	0	0
収縮期血圧上昇	1 (<1)	0	0	0	0
心電図Ｔ波振幅減少	0	0	0	0	1 (<1)
全血球数異常	1 (<1)	0	0	0	0
握力低下	0	0	0	0	2 (1)
リンパ球数増加	1 (<1)	0	0	0	0
後骨髄球百分率増加	1 (<1)	0	0	0	0
骨髄球数増加	1 (<1)	0	0	0	0
骨髄球百分率増加	1 (<1)	0	0	0	0
ＱＲＳ軸異常	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	1 (<1)
尿細胞診異常	1 (<1)	0	0	0	0
白血球数増加	9 (2)	0	0	0	4 (3)
傷害、中毒および処置合併症	80 (21)	59 (16)	59 (16)	118 (16)	22 (16)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 52 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
挫傷	13 (3)	13 (4)	16 (4)	29 (4)	4 (3)
転倒	9 (2)	15 (4)	11 (3)	26 (4)	8 (6)
関節捻挫	10 (3)	9 (2)	5 (1)	14 (2)	1 (<1)
節足動物咬傷	5 (1)	2 (<1)	4 (1)	6 (<1)	0
足骨折	3 (<1)	2 (<1)	4 (1)	6 (<1)	2 (1)
交通事故	5 (1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
擦過傷	4 (1)	2 (<1)	3 (<1)	5 (<1)	2 (1)
四肢損傷	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
半月板障害	2 (<1)	4 (1)	1 (<1)	5 (<1)	0
肉離れ	3 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
処置による疼痛	1 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
皮膚裂傷	5 (1)	5 (1)	0	5 (<1)	1 (<1)
足関節部骨折	0	1 (<1)	2 (<1)	3 (<1)	0
靭帯断裂	3 (<1)	0	3 (<1)	3 (<1)	0
サンバーン	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
熱傷	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
節足動物刺傷	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
顔面損傷	0	1 (<1)	1 (<1)	2 (<1)	0
術後発熱	0	2 (<1)	0	2 (<1)	0
骨格損傷	5 (1)	2 (<1)	0	2 (<1)	0
脊椎圧迫骨折	0	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 53 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯牙破折	2 (<1)	2 (<1)	0	2 (<1)	0
創傷	1 (<1)	2 (<1)	0	2 (<1)	0
動物咬傷	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
凍瘡	1 (<1)	1 (<1)	0	1 (<1)	0
鎖骨骨折	0	1 (<1)	0	1 (<1)	0
脳振盪	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
造影剤反応	0	0	1 (<1)	1 (<1)	0
眼瞼損傷	0	1 (<1)	0	1 (<1)	0
顔面骨骨折	0	1 (<1)	0	1 (<1)	0
大腿骨骨折	0	0	1 (<1)	1 (<1)	0
頭部損傷	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
腸脛靭帯症候群	0	0	1 (<1)	1 (<1)	0
切開部位痛	0	1 (<1)	0	1 (<1)	0
瘢痕ヘルニア	0	1 (<1)	0	1 (<1)	0
閉塞性瘢痕ヘルニア	0	0	1 (<1)	1 (<1)	0
損傷	0	0	1 (<1)	1 (<1)	1 (<1)
関節脱臼	0	1 (<1)	0	1 (<1)	0
関節損傷	4 (1)	1 (<1)	0	1 (<1)	0
頚部損傷	0	0	1 (<1)	1 (<1)	1 (<1)
神経損傷	0	0	1 (<1)	1 (<1)	0
過量投与	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 54 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
処置後出血	1 (<1)	1 (<1)	0	1 (<1)	0
処置後浮腫	0	0	1 (<1)	1 (<1)	0
処置による低血圧	0	1 (<1)	0	1 (<1)	0
橈骨骨折	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
反復性挫傷	0	1 (<1)	0	1 (<1)	0
肋骨骨折	0	0	1 (<1)	1 (<1)	0
引っかき傷	0	0	1 (<1)	1 (<1)	0
滑膜断裂	0	0	1 (<1)	1 (<1)	0
舌損傷	0	1 (<1)	0	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
外傷性骨折	0	0	1 (<1)	1 (<1)	0
外傷性血腫	0	1 (<1)	0	1 (<1)	0
むち打ち損傷	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
手首関節骨折	1 (<1)	0	1 (<1)	1 (<1)	0
労働災害	1 (<1)	0	0	0	0
動物による引っかき傷	0	0	0	0	1 (<1)
眼部化学的損傷	1 (<1)	0	0	0	0
角膜擦過傷	1 (<1)	0	0	0	0
上顆炎	2 (<1)	0	0	0	0
眼外傷	2 (<1)	0	0	0	1 (<1)
大腿骨頚部骨折	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 55 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腓骨骨折	1 (<1)	0	0	0	0
前腕骨折	0	0	0	0	1 (<1)
眼内異物	1 (<1)	0	0	0	0
尾骨骨折	1 (<1)	0	0	0	0
手骨折	2 (<1)	0	0	0	1 (<1)
口唇損傷	0	0	0	0	1 (<1)
処置後合併症	0	0	0	0	1 (<1)
外傷後疼痛	1 (<1)	0	0	0	1 (<1)
ストレス骨折	0	0	0	0	1 (<1)
腱損傷	1 (<1)	0	0	0	0
脛骨骨折	1 (<1)	0	0	0	0
歯の完全脱臼	1 (<1)	0	0	0	0
上肢骨折	0	0	0	0	1 (<1)
有毒性刺傷	1 (<1)	0	0	0	0
第７神経損傷	0	0	0	0	1 (<1)
創傷出血	1 (<1)	0	0	0	0
外科および内科処置	3 (<1)	5 (1)	4 (1)	9 (1)	2 (1)
抜歯	2 (<1)	2 (<1)	0	2 (<1)	2 (1)
乳房腫瘤摘除	0	1 (<1)	0	1 (<1)	0
デンタルケア	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 56 of 108
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
女性不妊手術	0	1 (<1)	0	1 (<1)	0
子宮摘出	0	0	1 (<1)	1 (<1)	0
椎間板手術	0	0	1 (<1)	1 (<1)	0
治療食	0	1 (<1)	0	1 (<1)	0
静脈ステント挿入	0	0	1 (<1)	1 (<1)	0
嚢胞ドレナージ	1 (<1)	0	0	0	0
社会環境	2 (<1)	0	0	0	0
元タバコ使用者	1 (<1)	0	0	0	0
職場でのストレス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 57 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	397 (100)	398 (100)	392 (100)	790 (100)	212 (100)
Number of subjects with an event	361 (91)	377 (95)	361 (92)	738 (93)	184 (87)
感染症および寄生虫症	215 (54)	233 (59)	231 (59)	464 (59)	108 (51)
鼻咽頭炎	73 (18)	83 (21)	90 (23)	173 (22)	30 (14)
尿路感染	45 (11)	56 (14)	44 (11)	100 (13)	29 (14)
上気道感染	44 (11)	51 (13)	46 (12)	97 (12)	19 (9)
インフルエンザ	26 (7)	23 (6)	30 (8)	53 (7)	7 (3)
胃腸炎	13 (3)	15 (4)	19 (5)	34 (4)	2 (<1)
副鼻腔炎	11 (3)	14 (4)	18 (5)	32 (4)	7 (3)
気管支炎	11 (3)	10 (3)	20 (5)	30 (4)	8 (4)
咽頭炎	14 (4)	13 (3)	16 (4)	29 (4)	10 (5)
鼻炎	14 (4)	18 (5)	10 (3)	28 (4)	7 (3)
気道感染	10 (3)	10 (3)	15 (4)	25 (3)	6 (3)
口腔ヘルペス	20 (5)	14 (4)	9 (2)	23 (3)	5 (2)
ウイルス性胃腸炎	6 (2)	6 (2)	10 (3)	16 (2)	1 (<1)
ウイルス性上気道感染	7 (2)	8 (2)	6 (2)	14 (2)	5 (2)
ウイルス感染	8 (2)	8 (2)	5 (1)	13 (2)	4 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 58 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
帯状疱疹	5 (1)	7 (2)	4 (1)	11 (1)	1 (<1)
歯膿瘍	5 (1)	7 (2)	4 (1)	11 (1)	2 (<1)
耳感染	5 (1)	2 (<1)	8 (2)	10 (1)	0
喉頭炎	3 (<1)	5 (1)	5 (1)	10 (1)	1 (<1)
外陰腟真菌感染	7 (2)	5 (1)	5 (1)	10 (1)	2 (<1)
感染性結膜炎	0	3 (<1)	6 (2)	9 (1)	0
中耳炎	1 (<1)	5 (1)	4 (1)	9 (1)	0
腟感染	1 (<1)	6 (2)	3 (<1)	9 (1)	3 (1)
膀胱炎	10 (3)	2 (<1)	6 (2)	8 (1)	2 (<1)
下気道感染	3 (<1)	1 (<1)	7 (2)	8 (1)	0
扁桃炎	3 (<1)	4 (1)	4 (1)	8 (1)	2 (<1)
消化管感染	5 (1)	1 (<1)	5 (1)	6 (<1)	1 (<1)
肺炎	1 (<1)	3 (<1)	3 (<1)	6 (<1)	2 (<1)
外陰部腟カンジダ症	2 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
歯感染	1 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
蜂巣炎	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)
せつ	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
陰部ヘルペス	0	4 (1)	0	4 (<1)	1 (<1)
Ｈ１Ｎ１インフルエンザ	1 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
麦粒腫	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
細菌性腟炎	2 (<1)	4 (1)	0	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 59 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
急性副鼻腔炎	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
遊走性紅斑	0	1 (<1)	2 (<1)	3 (<1)	0
ウイルス性消化管感染	1 (<1)	3 (<1)	0	3 (<1)	1 (<1)
爪真菌症	1 (<1)	3 (<1)	0	3 (<1)	0
レンサ球菌性咽頭炎	4 (1)	1 (<1)	2 (<1)	3 (<1)	0
細菌性副鼻腔炎	0	3 (<1)	0	3 (<1)	0
癜風	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
細菌感染	0	2 (<1)	0	2 (<1)	0
細菌尿	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
細菌性結膜炎	0	0	2 (<1)	2 (<1)	0
毛包炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
性器カンジダ症	0	2 (<1)	0	2 (<1)	0
ヘリコバクター感染	0	1 (<1)	1 (<1)	2 (<1)	0
単純ヘルペス	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
伝染性単核症	0	1 (<1)	1 (<1)	2 (<1)	0
骨盤内炎症性疾患	1 (<1)	0	2 (<1)	2 (<1)	0
歯周感染	1 (<1)	0	2 (<1)	2 (<1)	0
ウイルス性気道感染	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
陰嚢膿瘍	0	0	2 (<1)	2 (<1)	0
皮下組織膿瘍	0	1 (<1)	1 (<1)	2 (<1)	0
気管炎	0	2 (<1)	0	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 60 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腸チフス熱	0	0	2 (<1)	2 (<1)	0
外陰部炎	0	2 (<1)	0	2 (<1)	0
ダニ症	0	0	1 (<1)	1 (<1)	0
急性扁桃炎	3 (<1)	0	1 (<1)	1 (<1)	2 (<1)
無症候性細菌尿	1 (<1)	0	1 (<1)	1 (<1)	0
ボレリア感染	2 (<1)	1 (<1)	0	1 (<1)	0
乳房蜂巣炎	0	0	1 (<1)	1 (<1)	0
ウイルス性気管支炎	0	0	1 (<1)	1 (<1)	0
子宮頚管炎	0	1 (<1)	0	1 (<1)	1 (<1)
ウイルス性結膜炎	0	0	1 (<1)	1 (<1)	0
デング熱	0	1 (<1)	0	1 (<1)	0
感染性皮膚炎	0	0	1 (<1)	1 (<1)	0
大腸菌性尿路感染	0	1 (<1)	0	1 (<1)	0
眼感染	1 (<1)	1 (<1)	0	1 (<1)	0
真菌感染	0	1 (<1)	0	1 (<1)	0
泌尿生殖器感染	0	1 (<1)	0	1 (<1)	0
ジアルジア症	0	1 (<1)	0	1 (<1)	0
歯肉感染	1 (<1)	0	1 (<1)	1 (<1)	0
ヘリコバクター性胃炎	0	0	1 (<1)	1 (<1)	1 (<1)
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	1 (<1)	0
膿痂疹	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 61 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
切開部位感染	0	1 (<1)	0	1 (<1)	0
咬傷感染	1 (<1)	1 (<1)	0	1 (<1)	0
感染性嚢腫	0	1 (<1)	0	1 (<1)	0
カンジダ性間擦疹	0	0	1 (<1)	1 (<1)	0
迷路炎	0	1 (<1)	0	1 (<1)	0
シラミ寄生	0	0	1 (<1)	1 (<1)	0
限局性感染	3 (<1)	1 (<1)	0	1 (<1)	0
口腔カンジダ症	1 (<1)	0	1 (<1)	1 (<1)	0
急性中耳炎	0	0	1 (<1)	1 (<1)	0
爪囲炎	1 (<1)	1 (<1)	0	1 (<1)	0
扁桃周囲膿瘍	0	0	1 (<1)	1 (<1)	0
咽頭扁桃炎	0	1 (<1)	0	1 (<1)	1 (<1)
術後創感染	1 (<1)	0	1 (<1)	1 (<1)	0
歯髄炎	0	0	1 (<1)	1 (<1)	0
膿疱性皮疹	0	1 (<1)	0	1 (<1)	1 (<1)
皮膚細菌感染	0	0	1 (<1)	1 (<1)	0
軟部組織感染	0	1 (<1)	0	1 (<1)	0
足部白癬	1 (<1)	0	1 (<1)	1 (<1)	0
真菌性尿路感染	0	1 (<1)	0	1 (<1)	0
泌尿生殖器真菌感染	0	0	1 (<1)	1 (<1)	0
顎膿瘍	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 62 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
四肢膿瘍	1 (<1)	0	0	0	0
虫垂炎	0	0	0	0	1 (<1)
慢性副鼻腔炎	0	0	0	0	1 (<1)
感染性下痢	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0
皮膚真菌感染	1 (<1)	0	0	0	0
真菌性消化管感染	1 (<1)	0	0	0	0
感染性皮脂嚢腫	1 (<1)	0	0	0	0
ライム病	0	0	0	0	1 (<1)
ムンプス	1 (<1)	0	0	0	0
口腔真菌感染	1 (<1)	0	0	0	0
外耳炎	1 (<1)	0	0	0	0
子宮傍組織炎	0	0	0	0	1 (<1)
耳下腺炎	0	0	0	0	1 (<1)
細菌性咽頭炎	1 (<1)	0	0	0	0
腎盂腎炎	0	0	0	0	1 (<1)
膿胸	0	0	0	0	1 (<1)
ライター症候群	1 (<1)	0	0	0	0
卵管卵巣炎	1 (<1)	0	0	0	0
レンサ球菌感染	1 (<1)	0	0	0	0
白癬感染	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 63 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
気管気管支炎	0	0	0	0	1 (<1)
消化器結核	1 (<1)	0	0	0	0
細菌性上気道感染	1 (<1)	0	0	0	0
細菌性尿路感染	1 (<1)	0	0	0	0
尿路性敗血症	1 (<1)	0	0	0	0
ウイルス性咽頭炎	1 (<1)	0	0	0	0
外陰部膿瘍	1 (<1)	0	0	0	0
創傷感染	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	8 (2)	7 (2)	13 (3)	20 (3)	4 (2)
メラノサイト性母斑	2 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
皮膚乳頭腫	0	2 (<1)	1 (<1)	3 (<1)	0
子宮平滑筋腫	0	0	3 (<1)	3 (<1)	1 (<1)
脂肪腫	0	0	2 (<1)	2 (<1)	0
肺新生物	0	1 (<1)	1 (<1)	2 (<1)	0
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
乳癌	1 (<1)	0	1 (<1)	1 (<1)	0
乳腺線維腺腫	0	1 (<1)	0	1 (<1)	0
泌尿生殖器新生物	0	0	1 (<1)	1 (<1)	0
神経鞘腫	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 64 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乳頭腫	0	0	1 (<1)	1 (<1)	0
脂漏性角化症	0	0	1 (<1)	1 (<1)	0
アクロコルドン	1 (<1)	0	0	0	0
基底細胞癌	0	0	0	0	1 (<1)
乳房新生物	1 (<1)	0	0	0	0
子宮内膜癌	0	0	0	0	1 (<1)
線維腫	1 (<1)	0	0	0	0
血管腫	1 (<1)	0	0	0	0
皮膚の新生物	1 (<1)	0	0	0	0
良性副甲状腺腫瘍	1 (<1)	0	0	0	0
血液およびリンパ系障害	18 (5)	29 (7)	30 (8)	59 (7)	6 (3)
リンパ球減少症	1 (<1)	9 (2)	11 (3)	20 (3)	0
貧血	10 (3)	9 (2)	10 (3)	19 (2)	3 (1)
白血球減少症	1 (<1)	4 (1)	6 (2)	10 (1)	0
好中球増加症	3 (<1)	3 (<1)	5 (1)	8 (1)	0
白血球増加症	2 (<1)	6 (2)	1 (<1)	7 (<1)	0
リンパ節症	2 (<1)	2 (<1)	4 (1)	6 (<1)	2 (<1)
好酸球増加症	1 (<1)	0	3 (<1)	3 (<1)	0
鉄欠乏性貧血	1 (<1)	2 (<1)	0	2 (<1)	0
好中球減少症	1 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 65 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血小板減少症	0	0	0	0	1 (<1)
血小板増加症	1 (<1)	0	0	0	0
免疫系障害	5 (1)	11 (3)	10 (3)	21 (3)	6 (3)
過敏症	1 (<1)	5 (1)	5 (1)	10 (1)	1 (<1)
食物アレルギー	0	4 (1)	0	4 (<1)	1 (<1)
季節性アレルギー	1 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
薬物過敏症	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
家塵アレルギー	0	0	1 (<1)	1 (<1)	0
免疫不全症	0	0	1 (<1)	1 (<1)	0
続発性免疫不全症	0	0	1 (<1)	1 (<1)	0
化学物質アレルギー	1 (<1)	0	0	0	0
アナフィラキシー反応	0	0	0	0	2 (<1)
内分泌障害	4 (1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
甲状腺機能低下症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
甲状腺腫	0	1 (<1)	0	1 (<1)	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	1 (<1)	0
甲状腺機能亢進症	2 (<1)	0	1 (<1)	1 (<1)	0
副甲状腺機能亢進症	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 66 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
代謝および栄養障害	31 (8)	18 (5)	24 (6)	42 (5)	10 (5)
食欲減退	7 (2)	5 (1)	5 (1)	10 (1)	3 (1)
高コレステロール血症	2 (<1)	2 (<1)	4 (1)	6 (<1)	2 (<1)
ビタミンD欠乏	0	2 (<1)	3 (<1)	5 (<1)	0
高血糖	5 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
高脂血症	4 (1)	2 (<1)	2 (<1)	4 (<1)	0
脱水	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
脂質異常症	0	0	3 (<1)	3 (<1)	0
耐糖能障害	0	0	3 (<1)	3 (<1)	0
２型糖尿病	0	2 (<1)	0	2 (<1)	0
異常体重減少	0	0	1 (<1)	1 (<1)	0
糖尿病	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
糖尿病性ケトアシドーシス	0	0	1 (<1)	1 (<1)	0
痛風	1 (<1)	1 (<1)	0	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	1 (<1)	0
高トリグリセリド血症	2 (<1)	0	1 (<1)	1 (<1)	2 (<1)
低血糖症	0	0	1 (<1)	1 (<1)	0
ビタミン欠乏症	2 (<1)	1 (<1)	0	1 (<1)	0
鉄欠乏	0	1 (<1)	0	1 (<1)	0
ビタミンＢ１２欠乏	0	0	1 (<1)	1 (<1)	0
電解質失調	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 67 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
高カリウム血症	1 (<1)	0	0	0	1 (<1)
高尿酸血症	0	0	0	0	1 (<1)
ビタミンD過剰症	1 (<1)	0	0	0	0
食欲亢進	3 (<1)	0	0	0	0
多飲症	1 (<1)	0	0	0	0
精神障害	76 (19)	54 (14)	52 (13)	106 (13)	31 (15)
うつ病	33 (8)	22 (6)	18 (5)	40 (5)	16 (8)
不眠症	16 (4)	13 (3)	10 (3)	23 (3)	6 (3)
不安	11 (3)	11 (3)	8 (2)	19 (2)	5 (2)
抑うつ気分	9 (2)	8 (2)	5 (1)	13 (2)	2 (<1)
パニック発作	0	0	3 (<1)	3 (<1)	0
睡眠障害	5 (1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
ストレス	1 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (1)
感情不安定	1 (<1)	0	2 (<1)	2 (<1)	2 (<1)
感情障害	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
初期不眠症	0	0	2 (<1)	2 (<1)	0
気分変化	0	1 (<1)	1 (<1)	2 (<1)	0
気分動揺	4 (1)	0	2 (<1)	2 (<1)	0
神経過敏	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
身体表現性障害	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 68 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
双極１型障害	0	1 (<1)	0	1 (<1)	0
抑うつ症状	2 (<1)	0	1 (<1)	1 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	1 (<1)	0
リビドー減退	0	1 (<1)	0	1 (<1)	0
神経症	0	1 (<1)	0	1 (<1)	0
人格変化	0	1 (<1)	0	1 (<1)	0
精神病性障害	0	0	1 (<1)	1 (<1)	0
落ち着きのなさ	0	1 (<1)	0	1 (<1)	0
自殺念慮	0	1 (<1)	0	1 (<1)	1 (<1)
適応障害	0	0	0	0	1 (<1)
攻撃性	1 (<1)	0	0	0	0
怒り	1 (<1)	0	0	0	0
不安障害	1 (<1)	0	0	0	0
歯ぎしり	1 (<1)	0	0	0	0
自殺既遂	0	0	0	0	1 (<1)
錯乱状態	1 (<1)	0	0	0	0
故意の自傷行為	0	0	0	0	1 (<1)
躁病	1 (<1)	0	0	0	0
精神障害	0	0	0	0	1 (<1)
強迫性障害	1 (<1)	0	0	0	0
自殺企図	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 69 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
タバコ乱用	1 (<1)	0	0	0	0
神経系障害	249 (63)	200 (50)	174 (44)	374 (47)	102 (48)
多発性硬化症再発	160 (40)	100 (25)	84 (21)	184 (23)	68 (32)
頭痛	57 (14)	76 (19)	54 (14)	130 (16)	24 (11)
錯感覚	45 (11)	29 (7)	26 (7)	55 (7)	12 (6)
感覚鈍麻	27 (7)	17 (4)	15 (4)	32 (4)	7 (3)
浮動性めまい	21 (5)	18 (5)	10 (3)	28 (4)	5 (2)
灼熱感	8 (2)	10 (3)	10 (3)	20 (3)	0
片頭痛	6 (2)	10 (3)	8 (2)	18 (2)	4 (2)
筋痙直	10 (3)	6 (2)	6 (2)	12 (2)	3 (1)
異常感覚	3 (<1)	8 (2)	2 (<1)	10 (1)	0
傾眠	5 (1)	3 (<1)	5 (1)	8 (1)	2 (<1)
坐骨神経痛	5 (1)	4 (1)	3 (<1)	7 (<1)	1 (<1)
振戦	5 (1)	5 (1)	2 (<1)	7 (<1)	0
平衡障害	3 (<1)	3 (<1)	3 (<1)	6 (<1)	0
ウートホフ現象	1 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
レルミット徴候	3 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
多発性硬化症	7 (2)	2 (<1)	3 (<1)	5 (<1)	3 (1)
神経圧迫	1 (<1)	0	5 (1)	5 (<1)	0
感覚障害	3 (<1)	2 (<1)	3 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 70 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
失神	1 (<1)	0	5 (1)	5 (<1)	1 (<1)
緊張性頭痛	3 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
味覚異常	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
前兆を伴う片頭痛	0	4 (1)	0	4 (<1)	0
神経痛	5 (1)	4 (1)	0	4 (<1)	1 (<1)
失神寸前の状態	1 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
三叉神経痛	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
認知障害	0	1 (<1)	2 (<1)	3 (<1)	0
注意力障害	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)
反射亢進	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
視神経炎	0	2 (<1)	1 (<1)	3 (<1)	0
下肢静止不能症候群	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
健忘	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
運動失調	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
帯状感	0	0	2 (<1)	2 (<1)	0
構語障害	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
顔面不全麻痺	0	1 (<1)	1 (<1)	2 (<1)	0
不随意性筋収縮	0	1 (<1)	1 (<1)	2 (<1)	0
一過性脳虚血発作	0	1 (<1)	1 (<1)	2 (<1)	0
失認症	0	1 (<1)	0	1 (<1)	0
自律神経失調	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 71 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
手根管症候群	3 (<1)	0	1 (<1)	1 (<1)	0
頚原性頭痛	0	1 (<1)	0	1 (<1)	0
概日リズム睡眠障害	0	1 (<1)	0	1 (<1)	0
不器用	0	1 (<1)	0	1 (<1)	0
痙攣	2 (<1)	0	1 (<1)	1 (<1)	0
泣き	0	0	1 (<1)	1 (<1)	0
振動覚低下	1 (<1)	1 (<1)	0	1 (<1)	0
体位性めまい	0	1 (<1)	0	1 (<1)	0
てんかん	1 (<1)	0	1 (<1)	1 (<1)	0
顔面神経障害	0	0	1 (<1)	1 (<1)	0
大発作痙攣	2 (<1)	0	1 (<1)	1 (<1)	0
片側頭痛	1 (<1)	1 (<1)	0	1 (<1)	0
知覚過敏	1 (<1)	1 (<1)	0	1 (<1)	0
過眠症	1 (<1)	0	1 (<1)	1 (<1)	0
肋間神経痛	2 (<1)	1 (<1)	0	1 (<1)	0
腰髄神経根障害	1 (<1)	1 (<1)	0	1 (<1)	0
記憶障害	4 (1)	1 (<1)	0	1 (<1)	3 (1)
神経学的症状	0	0	1 (<1)	1 (<1)	0
末梢性ニューロパチー	1 (<1)	0	1 (<1)	1 (<1)	0
眼振	0	0	1 (<1)	1 (<1)	0
後頭神経痛	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 72 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
部分発作	0	1 (<1)	0	1 (<1)	1 (<1)
逆行性健忘	0	1 (<1)	0	1 (<1)	0
二次性進行型多発性硬化症	0	0	1 (<1)	1 (<1)	0
副鼻腔炎に伴う頭痛	2 (<1)	1 (<1)	0	1 (<1)	2 (<1)
会話障害	0	1 (<1)	0	1 (<1)	0
尺骨神経管症候群	0	1 (<1)	0	1 (<1)	0
血管性頭痛	0	0	1 (<1)	1 (<1)	0
失語症	0	0	0	0	2 (<1)
中枢神経系病変	1 (<1)	0	0	0	0
小脳症候群	1 (<1)	0	0	0	0
脳血管発作	1 (<1)	0	0	0	0
脳血管障害	0	0	0	0	1 (<1)
頚髄神経根痛	0	0	0	0	1 (<1)
複雑部分発作	1 (<1)	0	0	0	0
協調運動異常	1 (<1)	0	0	0	0
脳症	1 (<1)	0	0	0	0
顔面痙攣	1 (<1)	0	0	0	1 (<1)
不全片麻痺	1 (<1)	0	0	0	1 (<1)
ホルネル症候群	1 (<1)	0	0	0	0
筋緊張亢進	1 (<1)	0	0	0	0
筋緊張低下	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 73 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
意識消失	0	0	0	0	1 (<1)
仮面状顔貌	0	0	0	0	1 (<1)
嗅覚錯誤	1 (<1)	0	0	0	0
錐体路症候群	1 (<1)	0	0	0	0
振動覚亢進	0	0	0	0	1 (<1)
眼障害	48 (12)	34 (9)	33 (8)	67 (8)	14 (7)
眼痛	5 (1)	7 (2)	6 (2)	13 (2)	5 (2)
霧視	10 (3)	6 (2)	7 (2)	13 (2)	3 (1)
結膜炎	3 (<1)	3 (<1)	4 (1)	7 (<1)	2 (<1)
複視	7 (2)	2 (<1)	4 (1)	6 (<1)	3 (1)
眼乾燥	3 (<1)	6 (2)	0	6 (<1)	0
視力障害	2 (<1)	4 (1)	1 (<1)	5 (<1)	0
眼充血	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
眼瞼炎	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
眼瞼痙攣	3 (<1)	2 (<1)	1 (<1)	3 (<1)	0
流涙増加	0	1 (<1)	2 (<1)	3 (<1)	0
光視症	0	2 (<1)	1 (<1)	3 (<1)	0
失明	0	0	2 (<1)	2 (<1)	0
白内障	0	1 (<1)	1 (<1)	2 (<1)	0
眼出血	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 74 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼刺激	1 (<1)	0	2 (<1)	2 (<1)	0
眼瞼下垂	0	1 (<1)	1 (<1)	2 (<1)	0
屈折障害	1 (<1)	2 (<1)	0	2 (<1)	0
ブドウ膜炎	0	1 (<1)	1 (<1)	2 (<1)	0
視力低下	7 (2)	0	2 (<1)	2 (<1)	0
硝子体浮遊物	0	2 (<1)	0	2 (<1)	0
眼の異常感	0	1 (<1)	0	1 (<1)	0
黒内障	0	1 (<1)	0	1 (<1)	0
両眼球運動障害	0	0	1 (<1)	1 (<1)	0
霰粒腫	0	1 (<1)	0	1 (<1)	0
アレルギー性結膜炎	0	0	1 (<1)	1 (<1)	1 (<1)
眼部腫脹	0	0	1 (<1)	1 (<1)	0
眼瞼嚢胞	0	1 (<1)	0	1 (<1)	0
眼瞼障害	0	0	1 (<1)	1 (<1)	0
視神経萎縮	0	0	1 (<1)	1 (<1)	0
動揺視	0	1 (<1)	0	1 (<1)	0
全眼球炎	0	1 (<1)	0	1 (<1)	0
羞明	2 (<1)	1 (<1)	0	1 (<1)	0
乾燥症候群	0	1 (<1)	0	1 (<1)	0
眼精疲労	1 (<1)	0	0	0	0
一過性失明	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 75 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
片側失明	0	0	0	0	1 (<1)
嚢下白内障	1 (<1)	0	0	0	0
眼瞼紅斑	1 (<1)	0	0	0	0
眼そう痒症	1 (<1)	0	0	0	0
眼瞼そう痒症	1 (<1)	0	0	0	0
緑内障	1 (<1)	0	0	0	0
遠視	2 (<1)	0	0	0	0
硝子体出血	1 (<1)	0	0	0	0
耳および迷路障害	34 (9)	18 (5)	25 (6)	43 (5)	15 (7)
回転性めまい	23 (6)	9 (2)	15 (4)	24 (3)	10 (5)
耳痛	1 (<1)	2 (<1)	4 (1)	6 (<1)	0
耳鳴	5 (1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
頭位性回転性めまい	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
聴力低下	1 (<1)	0	3 (<1)	3 (<1)	1 (<1)
難聴	1 (<1)	1 (<1)	0	1 (<1)	0
耳不快感	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
耳そう痒症	0	1 (<1)	0	1 (<1)	0
耳管障害	0	0	1 (<1)	1 (<1)	0
外耳障害	0	0	1 (<1)	1 (<1)	0
鼓膜充血	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 76 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
耳垢栓塞	1 (<1)	0	0	0	0
外耳道紅斑	1 (<1)	0	0	0	0
耳閉	1 (<1)	0	0	0	0
耳管機能障害	0	0	0	0	1 (<1)
乗物酔い	1 (<1)	0	0	0	0
前庭障害	1 (<1)	0	0	0	0
心臓障害	23 (6)	21 (5)	23 (6)	44 (6)	8 (4)
頻脈	4 (1)	5 (1)	6 (2)	11 (1)	3 (1)
動悸	4 (1)	4 (1)	5 (1)	9 (1)	0
第一度房室ブロック	1 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
上室性期外収縮	1 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
狭心症	0	1 (<1)	1 (<1)	2 (<1)	0
徐脈	1 (<1)	0	2 (<1)	2 (<1)	0
洞性徐脈	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
洞性頻脈	3 (<1)	0	2 (<1)	2 (<1)	0
心室性期外収縮	4 (1)	0	2 (<1)	2 (<1)	0
ウォルフ・パーキンソン・ホワイト症候群	0	2 (<1)	0	2 (<1)	0
急性冠動脈症候群	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	1 (<1)	1 (<1)	0
右脚ブロック	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 77 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓瘤	0	1 (<1)	0	1 (<1)	0
心筋症	0	1 (<1)	0	1 (<1)	0
伝導障害	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
僧帽弁逸脱	0	1 (<1)	0	1 (<1)	0
頻脈性不整脈	0	0	1 (<1)	1 (<1)	0
上室性不整脈	1 (<1)	0	0	0	0
左脚ブロック	0	0	0	0	1 (<1)
期外収縮	1 (<1)	0	0	0	0
心筋虚血	1 (<1)	0	0	0	0
上室性頻脈	1 (<1)	0	0	0	0
発作性頻脈	1 (<1)	0	0	0	0
血管障害	40 (10)	152 (38)	128 (33)	280 (35)	12 (6)
潮紅	17 (4)	124 (31)	94 (24)	218 (28)	4 (2)
ほてり	8 (2)	26 (7)	26 (7)	52 (7)	3 (1)
高血圧	14 (4)	6 (2)	13 (3)	19 (2)	5 (2)
充血	0	2 (<1)	2 (<1)	4 (<1)	0
低血圧	1 (<1)	3 (<1)	0	3 (<1)	0
起立性低血圧	1 (<1)	0	2 (<1)	2 (<1)	0
静脈炎	0	0	2 (<1)	2 (<1)	0
レイノー現象	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 78 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血管障害	0	0	1 (<1)	1 (<1)	0
動脈硬化症	0	0	1 (<1)	1 (<1)	0
血腫	1 (<1)	1 (<1)	0	1 (<1)	0
微小血管症	0	1 (<1)	0	1 (<1)	0
末梢性虚血	0	1 (<1)	0	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0	0
深部静脈血栓症	0	0	0	0	1 (<1)
腹腔内血腫	0	0	0	0	1 (<1)
末梢冷感	1 (<1)	0	0	0	0
静脈狭窄	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	56 (14)	56 (14)	59 (15)	115 (15)	23 (11)
咳嗽	17 (4)	22 (6)	24 (6)	46 (6)	4 (2)
口腔咽頭痛	18 (5)	19 (5)	19 (5)	38 (5)	10 (5)
鼻漏	4 (1)	8 (2)	9 (2)	17 (2)	0
副鼻腔うっ血	1 (<1)	1 (<1)	4 (1)	5 (<1)	0
喘息	2 (<1)	3 (<1)	1 (<1)	4 (<1)	0
鼻閉	4 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
アレルギー性鼻炎	3 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
上気道咳症候群	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
鼻出血	5 (1)	3 (<1)	0	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 79 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
喘鳴	0	2 (<1)	1 (<1)	3 (<1)	0
咽喉乾燥	1 (<1)	2 (<1)	0	2 (<1)	0
呼吸困難	1 (<1)	1 (<1)	1 (<1)	2 (<1)	5 (2)
口腔咽頭不快感	0	0	2 (<1)	2 (<1)	1 (<1)
湿性咳嗽	1 (<1)	0	2 (<1)	2 (<1)	0
上気道うっ血	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
アレルギー性咽頭炎	0	1 (<1)	0	1 (<1)	0
アレルギー性副鼻腔炎	0	1 (<1)	0	1 (<1)	0
息詰まり	1 (<1)	0	1 (<1)	1 (<1)	0
発声障害	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
口腔咽頭プラーク	1 (<1)	1 (<1)	0	1 (<1)	0
口腔咽頭腫脹	0	0	1 (<1)	1 (<1)	0
咽頭嚢腫	0	1 (<1)	0	1 (<1)	0
咽頭紅斑	1 (<1)	1 (<1)	0	1 (<1)	0
胸水	0	1 (<1)	0	1 (<1)	0
胸膜炎	0	0	1 (<1)	1 (<1)	0
呼吸抑制	0	1 (<1)	0	1 (<1)	0
低音性連続性ラ音	3 (<1)	1 (<1)	0	1 (<1)	0
副鼻腔障害	0	0	1 (<1)	1 (<1)	0
咽喉刺激感	0	1 (<1)	0	1 (<1)	0
声帯の炎症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 80 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
しゃっくり	1 (<1)	0	0	0	0
鼻部不快感	1 (<1)	0	0	0	0
鼻乾燥	1 (<1)	0	0	0	0
鼻茸	1 (<1)	0	0	0	0
鼻中隔穿孔	0	0	0	0	1 (<1)
咽頭の炎症	1 (<1)	0	0	0	0
ラ音	1 (<1)	0	0	0	0
気道うっ血	0	0	0	0	1 (<1)
季節性鼻炎	0	0	0	0	1 (<1)
睡眠時無呼吸症候群	0	0	0	0	1 (<1)
くしゃみ	1 (<1)	0	0	0	0
上気道の炎症	1 (<1)	0	0	0	0
胃腸障害	133 (34)	193 (48)	195 (50)	388 (49)	40 (19)
下痢	33 (8)	47 (12)	67 (17)	114 (14)	9 (4)
悪心	27 (7)	49 (12)	48 (12)	97 (12)	7 (3)
腹痛	16 (4)	44 (11)	32 (8)	76 (10)	2 (<1)
上腹部痛	18 (5)	33 (8)	38 (10)	71 (9)	3 (1)
嘔吐	13 (3)	32 (8)	30 (8)	62 (8)	2 (<1)
消化不良	10 (3)	18 (5)	18 (5)	36 (5)	6 (3)
便秘	14 (4)	16 (4)	12 (3)	28 (4)	5 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 81 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胃炎	6 (2)	14 (4)	12 (3)	26 (3)	3 (1)
胃腸障害	4 (1)	9 (2)	15 (4)	24 (3)	2 (<1)
歯痛	6 (2)	10 (3)	10 (3)	20 (3)	2 (<1)
腹部不快感	1 (<1)	10 (3)	5 (1)	15 (2)	1 (<1)
口内乾燥	2 (<1)	10 (3)	4 (1)	14 (2)	0
鼓腸	8 (2)	7 (2)	6 (2)	13 (2)	0
腹部膨満	7 (2)	3 (<1)	8 (2)	11 (1)	0
胃食道逆流性疾患	6 (2)	6 (2)	4 (1)	10 (1)	0
下腹部痛	1 (<1)	2 (<1)	6 (2)	8 (1)	0
歯周炎	0	2 (<1)	6 (2)	8 (1)	0
食中毒	1 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
痔核	2 (<1)	5 (1)	1 (<1)	6 (<1)	1 (<1)
齲歯	2 (<1)	1 (<1)	4 (1)	5 (<1)	1 (<1)
おくび	0	2 (<1)	3 (<1)	5 (<1)	0
便失禁	0	2 (<1)	2 (<1)	4 (<1)	0
胃酸過多	0	4 (1)	0	4 (<1)	0
十二指腸潰瘍	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
嚥下障害	3 (<1)	3 (<1)	0	3 (<1)	0
胃障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
腹部硬直	0	0	2 (<1)	2 (<1)	0
腹部圧痛	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 82 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
異常便	0	2 (<1)	0	2 (<1)	0
小腸炎	0	1 (<1)	1 (<1)	2 (<1)	0
心窩部不快感	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
排便回数増加	0	0	2 (<1)	2 (<1)	0
歯肉出血	1 (<1)	2 (<1)	0	2 (<1)	0
歯肉痛	1 (<1)	0	2 (<1)	2 (<1)	0
歯肉炎	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
舌痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口の感覚鈍麻	1 (<1)	2 (<1)	0	2 (<1)	0
過敏性腸症候群	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口腔内潰瘍形成	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
逆流性食道炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
流涎過多	0	2 (<1)	0	2 (<1)	0
唾液欠乏	0	1 (<1)	0	1 (<1)	0
便習慣変化	0	0	1 (<1)	1 (<1)	0
結腸ポリープ	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
憩室穿孔	0	1 (<1)	0	1 (<1)	0
十二指腸ポリープ	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
腸炎	1 (<1)	0	1 (<1)	1 (<1)	0
胃十二指腸炎	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 83 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胃腸出血	0	0	1 (<1)	1 (<1)	0
消化器痛	0	1 (<1)	0	1 (<1)	0
歯肉障害	0	0	1 (<1)	1 (<1)	0
歯肉腫脹	0	1 (<1)	0	1 (<1)	0
裂孔ヘルニア	2 (<1)	1 (<1)	0	1 (<1)	0
胃排出不全	0	1 (<1)	0	1 (<1)	0
腸閉塞	0	0	1 (<1)	1 (<1)	0
腸管ポリープ	0	1 (<1)	0	1 (<1)	0
口唇水疱	0	1 (<1)	0	1 (<1)	0
嚥下痛	0	0	1 (<1)	1 (<1)	0
口腔内痛	0	1 (<1)	0	1 (<1)	0
膵臓障害	0	0	1 (<1)	1 (<1)	0
口の錯感覚	2 (<1)	1 (<1)	0	1 (<1)	0
直腸出血	0	1 (<1)	0	1 (<1)	0
逆流性胃炎	0	0	1 (<1)	1 (<1)	0
唾液管閉塞	0	0	1 (<1)	1 (<1)	0
口内炎	1 (<1)	1 (<1)	0	1 (<1)	0
地図状舌	0	1 (<1)	0	1 (<1)	0
歯の障害	1 (<1)	1 (<1)	0	1 (<1)	0
埋伏歯	0	0	1 (<1)	1 (<1)	0
呼気臭	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 84 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
大腸炎	1 (<1)	0	0	0	0
潰瘍性大腸炎	1 (<1)	0	0	0	0
便意切迫	0	0	0	0	1 (<1)
腸憩室	0	0	0	0	1 (<1)
変色便	0	0	0	0	1 (<1)
出血性胃炎	0	0	0	0	1 (<1)
歯肉紅斑	0	0	0	0	1 (<1)
血便排泄	1 (<1)	0	0	0	0
痔出血	0	0	0	0	1 (<1)
口唇乾燥	1 (<1)	0	0	0	0
肛門周囲痛	1 (<1)	0	0	0	0
直腸攣縮	0	0	0	0	1 (<1)
歯の発育障害	1 (<1)	0	0	0	0
歯の脱落	1 (<1)	0	0	0	0
臍ヘルニア	1 (<1)	0	0	0	0
肝胆道系障害	7 (2)	6 (2)	10 (3)	16 (2)	4 (2)
肝障害	1 (<1)	2 (<1)	4 (1)	6 (<1)	1 (<1)
胆道ジスキネジー	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
胆石症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)
肝細胞融解性肝炎	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 85 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胆管結石	2 (<1)	0	1 (<1)	1 (<1)	0
肝嚢胞	1 (<1)	0	1 (<1)	1 (<1)	0
肝炎	1 (<1)	0	1 (<1)	1 (<1)	0
高ビリルビン血症	1 (<1)	0	1 (<1)	1 (<1)	0
高トランスアミナーゼ血症	0	1 (<1)	0	1 (<1)	0
中毒性肝炎	1 (<1)	0	0	0	0
皮膚および皮下組織障害	73 (18)	116 (29)	114 (29)	230 (29)	30 (14)
発疹	14 (4)	28 (7)	29 (7)	57 (7)	5 (2)
そう痒症	15 (4)	27 (7)	26 (7)	53 (7)	3 (1)
紅斑	7 (2)	21 (5)	26 (7)	47 (6)	2 (<1)
多汗症	6 (2)	8 (2)	12 (3)	20 (3)	3 (1)
脱毛症	6 (2)	8 (2)	5 (1)	13 (2)	7 (3)
寝汗	3 (<1)	6 (2)	6 (2)	12 (2)	1 (<1)
アレルギー性皮膚炎	4 (1)	8 (2)	3 (<1)	11 (1)	0
湿疹	2 (<1)	5 (1)	3 (<1)	8 (1)	1 (<1)
全身性そう痒症	2 (<1)	4 (1)	4 (1)	8 (1)	2 (<1)
蕁麻疹	3 (<1)	2 (<1)	6 (2)	8 (1)	1 (<1)
ざ瘡	4 (1)	2 (<1)	5 (1)	7 (<1)	2 (<1)
皮膚乾燥	2 (<1)	5 (1)	2 (<1)	7 (<1)	0
皮膚灼熱感	0	5 (1)	2 (<1)	7 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 86 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚炎	0	3 (<1)	3 (<1)	6 (<1)	1 (<1)
そう痒性皮疹	2 (<1)	4 (1)	2 (<1)	6 (<1)	0
全身紅斑	0	1 (<1)	4 (1)	5 (<1)	0
斑状皮疹	1 (<1)	1 (<1)	4 (1)	5 (<1)	0
乾癬	3 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
酒さ	1 (<1)	3 (<1)	0	3 (<1)	0
薬疹	0	1 (<1)	1 (<1)	2 (<1)	0
斑状出血	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
顔面感覚鈍麻	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
網状皮斑	0	1 (<1)	1 (<1)	2 (<1)	0
光線過敏性反応	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
痒疹	0	2 (<1)	0	2 (<1)	0
紅斑性皮疹	0	0	2 (<1)	2 (<1)	0
皮膚剥脱	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
皮膚病変	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚のつっぱり感	0	0	2 (<1)	2 (<1)	0
顔面腫脹	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
水疱	0	1 (<1)	0	1 (<1)	0
皮膚弛緩症	0	1 (<1)	0	1 (<1)	0
アトピー性皮膚炎	1 (<1)	1 (<1)	0	1 (<1)	0
接触性皮膚炎	0	1 (<1)	0	1 (<1)	3 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 87 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
剥脱性発疹	1 (<1)	1 (<1)	0	1 (<1)	0
過角化	0	1 (<1)	0	1 (<1)	0
特発性蕁麻疹	0	1 (<1)	0	1 (<1)	0
嵌入爪	0	0	1 (<1)	1 (<1)	0
毛孔性角化症	0	0	1 (<1)	1 (<1)	0
睫毛眉毛脱落症	0	1 (<1)	0	1 (<1)	0
爪変色	1 (<1)	1 (<1)	0	1 (<1)	0
爪の障害	0	0	1 (<1)	1 (<1)	0
色素沈着障害	1 (<1)	1 (<1)	0	1 (<1)	0
アレルギー性そう痒症	1 (<1)	0	1 (<1)	1 (<1)	0
全身性皮疹	0	0	1 (<1)	1 (<1)	0
丘疹性皮疹	0	0	1 (<1)	1 (<1)	0
脂腺障害	0	0	1 (<1)	1 (<1)	0
脂漏	0	1 (<1)	0	1 (<1)	0
皮膚色素脱失	0	0	1 (<1)	1 (<1)	0
皮膚変色	0	0	1 (<1)	1 (<1)	0
皮膚色素過剰	1 (<1)	1 (<1)	0	1 (<1)	2 (<1)
皮膚色素減少	0	1 (<1)	0	1 (<1)	0
皮膚刺激	0	1 (<1)	0	1 (<1)	0
皮膚熱感	0	0	1 (<1)	1 (<1)	0
皮下結節	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 88 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
一過性棘融解性皮膚症	0	0	1 (<1)	1 (<1)	0
冷汗	1 (<1)	0	0	0	0
皮膚嚢腫	1 (<1)	0	0	0	0
多形紅斑	1 (<1)	0	0	0	0
皮膚肉芽腫	1 (<1)	0	0	0	0
皮下出血	0	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0	0
紅色汗疹	1 (<1)	0	0	0	0
黒子	1 (<1)	0	0	0	0
脂肪組織萎縮症	0	0	0	0	1 (<1)
爪床の炎症	1 (<1)	0	0	0	0
神経皮膚炎	0	0	0	0	1 (<1)
点状出血	1 (<1)	0	0	0	0
光線性皮膚症	1 (<1)	0	0	0	0
ばら色粃糠疹	2 (<1)	0	0	0	0
前癌性皮膚病変	1 (<1)	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0	0
猩紅熱様発疹	1 (<1)	0	0	0	0
瘢痕	1 (<1)	0	0	0	1 (<1)
脂漏性皮膚炎	0	0	0	0	1 (<1)
裂毛	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 89 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乾皮症	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	127 (32)	110 (28)	116 (30)	226 (29)	45 (21)
背部痛	48 (12)	38 (10)	43 (11)	81 (10)	19 (9)
関節痛	32 (8)	25 (6)	31 (8)	56 (7)	9 (4)
四肢痛	30 (8)	26 (7)	23 (6)	49 (6)	11 (5)
筋痙縮	14 (4)	12 (3)	22 (6)	34 (4)	6 (3)
頚部痛	15 (4)	17 (4)	14 (4)	31 (4)	1 (<1)
筋骨格痛	16 (4)	8 (2)	11 (3)	19 (2)	3 (1)
筋力低下	20 (5)	8 (2)	7 (2)	15 (2)	1 (<1)
筋肉痛	13 (3)	6 (2)	5 (1)	11 (1)	1 (<1)
関節炎	1 (<1)	4 (1)	5 (1)	9 (1)	2 (<1)
筋骨格硬直	6 (2)	4 (1)	2 (<1)	6 (<1)	2 (<1)
関節硬直	0	2 (<1)	3 (<1)	5 (<1)	0
関節腫脹	2 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
筋骨格系胸痛	2 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
重感	3 (<1)	4 (1)	0	4 (<1)	0
骨痛	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
側腹部痛	1 (<1)	0	3 (<1)	3 (<1)	0
関節障害	0	1 (<1)	1 (<1)	2 (<1)	0
滑液包炎	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 90 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
四肢の結節	0	0	2 (<1)	2 (<1)	0
変形性関節症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
骨壊死	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
変形性脊椎症	1 (<1)	2 (<1)	0	2 (<1)	0
滑液嚢腫	0	0	2 (<1)	2 (<1)	0
腱炎	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
腱鞘炎	0	2 (<1)	0	2 (<1)	0
弾発指	0	1 (<1)	1 (<1)	2 (<1)	0
軟骨炎	0	1 (<1)	0	1 (<1)	0
尾骨痛	0	0	1 (<1)	1 (<1)	0
四肢拘縮	0	1 (<1)	0	1 (<1)	0
凧径部痛	0	1 (<1)	0	1 (<1)	0
成長痛	0	0	1 (<1)	1 (<1)	1 (<1)
椎間板障害	0	0	1 (<1)	1 (<1)	0
椎間板突出	1 (<1)	0	1 (<1)	1 (<1)	0
関節滲出液	0	0	1 (<1)	1 (<1)	0
四肢不快感	1 (<1)	0	1 (<1)	1 (<1)	0
中足骨痛	0	1 (<1)	0	1 (<1)	0
筋肉内出血	0	0	1 (<1)	1 (<1)	0
骨減少症	0	1 (<1)	0	1 (<1)	1 (<1)
骨粗鬆症	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 91 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
顎痛	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
乾癬性関節症	0	0	1 (<1)	1 (<1)	0
肩回旋筋腱板症候群	0	0	1 (<1)	1 (<1)	0
足根洞症候群	0	1 (<1)	0	1 (<1)	0
斜頚	0	0	1 (<1)	1 (<1)	0
線維筋痛	1 (<1)	0	0	0	0
運動性低下	1 (<1)	0	0	0	0
筋拘縮	1 (<1)	0	0	0	0
筋肉疲労	1 (<1)	0	0	0	0
筋固縮	0	0	0	0	1 (<1)
筋緊張	1 (<1)	0	0	0	0
筋攣縮	2 (<1)	0	0	0	0
筋骨格不快感	1 (<1)	0	0	0	0
結節性変形性関節症	1 (<1)	0	0	0	0
関節周囲炎	2 (<1)	0	0	0	0
多発性関節炎	1 (<1)	0	0	0	0
滑膜炎	1 (<1)	0	0	0	0
腎および尿路障害	79 (20)	81 (20)	90 (23)	171 (22)	29 (14)
蛋白尿	29 (7)	39 (10)	51 (13)	90 (11)	17 (8)
ミクロアルブミン尿	11 (3)	19 (5)	21 (5)	40 (5)	10 (5)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 92 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血尿	25 (6)	17 (4)	22 (6)	39 (5)	6 (3)
尿意切迫	4 (1)	6 (2)	6 (2)	12 (2)	0
ケトン尿	4 (1)	2 (<1)	9 (2)	11 (1)	1 (<1)
排尿困難	7 (2)	3 (<1)	5 (1)	8 (1)	0
尿失禁	4 (1)	5 (1)	2 (<1)	7 (<1)	1 (<1)
腎結石症	2 (<1)	3 (<1)	3 (<1)	6 (<1)	0
頻尿	6 (2)	2 (<1)	3 (<1)	5 (<1)	0
切迫性尿失禁	0	1 (<1)	3 (<1)	4 (<1)	0
糖尿	4 (1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
排尿躊躇	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
尿閉	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
腎臓痛	1 (<1)	2 (<1)	0	2 (<1)	0
尿臭異常	0	0	2 (<1)	2 (<1)	0
アルブミン尿	0	1 (<1)	0	1 (<1)	0
膀胱刺激症状	0	1 (<1)	0	1 (<1)	0
膀胱痛	0	1 (<1)	0	1 (<1)	0
着色尿	0	0	1 (<1)	1 (<1)	0
非感染性膀胱炎	2 (<1)	1 (<1)	0	1 (<1)	0
グロブリン尿	0	1 (<1)	0	1 (<1)	0
緊張性膀胱	0	0	1 (<1)	1 (<1)	0
白血球尿	2 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 93 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
排尿異常	0	1 (<1)	0	1 (<1)	0
腎下垂症	1 (<1)	1 (<1)	0	1 (<1)	0
起立性蛋白尿症	0	1 (<1)	0	1 (<1)	0
腎仙痛	1 (<1)	1 (<1)	0	1 (<1)	0
腎嚢胞	1 (<1)	1 (<1)	0	1 (<1)	0
腎障害	0	1 (<1)	0	1 (<1)	0
腎機能障害	0	0	1 (<1)	1 (<1)	0
腎尿細管性アシドーシス	0	0	1 (<1)	1 (<1)	0
尿管瘤	0	1 (<1)	0	1 (<1)	0
尿路痛	0	1 (<1)	0	1 (<1)	0
膀胱憩室	1 (<1)	0	0	0	0
尿路結石	1 (<1)	0	0	0	0
肋骨脊柱角圧痛	1 (<1)	0	0	0	0
慢性糸球体腎炎	1 (<1)	0	0	0	0
神経因性膀胱	2 (<1)	0	0	0	0
夜間頻尿	1 (<1)	0	0	0	1 (<1)
妊娠、産褥および周産期の状態	0	1 (<1)	0	1 (<1)	0
妊娠	0	1 (<1)	0	1 (<1)	0
生殖系および乳房障害	36 (9)	34 (9)	27 (7)	61 (8)	20 (9)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 94 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
月経困難症	5 (1)	7 (2)	5 (1)	12 (2)	2 (<1)
月経過多	3 (<1)	4 (1)	4 (1)	8 (1)	3 (1)
不規則月経	2 (<1)	3 (<1)	5 (1)	8 (1)	5 (2)
乳房痛	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
卵巣嚢胞	0	3 (<1)	1 (<1)	4 (<1)	2 (<1)
無月経	3 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (1)
不正子宮出血	3 (<1)	3 (<1)	0	3 (<1)	2 (<1)
骨盤痛	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
腟出血	0	2 (<1)	1 (<1)	3 (<1)	0
勃起不全	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
月経障害	0	0	2 (<1)	2 (<1)	1 (<1)
頻発月経	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
乳房嚢胞	0	1 (<1)	0	1 (<1)	1 (<1)
乳房分泌	0	0	1 (<1)	1 (<1)	0
乳房不快感	0	1 (<1)	0	1 (<1)	0
乳房障害	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
乳房腫瘤	1 (<1)	1 (<1)	0	1 (<1)	0
乳房圧痛	0	0	1 (<1)	1 (<1)	0
子宮頚部上皮異形成	1 (<1)	1 (<1)	0	1 (<1)	0
子宮頚部の炎症	0	1 (<1)	0	1 (<1)	0
性交困難	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 95 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乳汁漏出症	0	1 (<1)	0	1 (<1)	0
月経遅延	0	1 (<1)	0	1 (<1)	1 (<1)
乳頭障害	0	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
多嚢胞性卵巣	0	0	1 (<1)	1 (<1)	0
前立腺炎	0	0	1 (<1)	1 (<1)	0
精巣痛	2 (<1)	1 (<1)	0	1 (<1)	0
バルトリン嚢腫	2 (<1)	0	0	0	0
良性前立腺肥大症	1 (<1)	0	0	0	0
乳房腫大	0	0	0	0	1 (<1)
子宮頚管ポリープ	0	0	0	0	1 (<1)
線維嚢胞性乳腺疾患	2 (<1)	0	0	0	0
閉経期症状	1 (<1)	0	0	0	0
閉経後出血	2 (<1)	0	0	0	0
前立腺腫大	0	0	0	0	1 (<1)
性機能不全	1 (<1)	0	0	0	0
子宮出血	2 (<1)	0	0	0	1 (<1)
腟分泌物	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
角膜ジストロフィー	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 96 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
異形成母斑症候群	0	1 (<1)	0	1 (<1)	0
先天性心臓疾患	0	1 (<1)	0	1 (<1)	0
陰嚢水瘤	0	0	1 (<1)	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	1 (<1)	0
ジルベール症候群	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	85 (21)	72 (18)	107 (27)	179 (23)	69 (33)
疲労	36 (9)	35 (9)	39 (10)	74 (9)	12 (6)
発熱	23 (6)	15 (4)	29 (7)	44 (6)	11 (5)
無力症	12 (3)	10 (3)	6 (2)	16 (2)	6 (3)
熱感	1 (<1)	7 (2)	9 (2)	16 (2)	4 (2)
末梢性浮腫	9 (2)	2 (<1)	10 (3)	12 (2)	2 (<1)
疼痛	5 (1)	5 (1)	7 (2)	12 (2)	4 (2)
歩行障害	5 (1)	4 (1)	4 (1)	8 (1)	1 (<1)
胸痛	2 (<1)	2 (<1)	4 (1)	6 (<1)	1 (<1)
インフルエンザ様疾患	3 (<1)	1 (<1)	5 (1)	6 (<1)	2 (<1)
顔面痛	2 (<1)	1 (<1)	4 (1)	5 (<1)	0
悪寒	2 (<1)	2 (<1)	2 (<1)	4 (<1)	3 (1)
易刺激性	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
嚢胞	1 (<1)	0	3 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 97 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胸部不快感	2 (<1)	0	2 (<1)	2 (<1)	0
倦怠感	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
非心臓性胸痛	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
腫脹	0	1 (<1)	1 (<1)	2 (<1)	0
圧痛	0	0	2 (<1)	2 (<1)	0
腋窩痛	0	0	1 (<1)	1 (<1)	0
医療機器関連眼合併症	0	1 (<1)	0	1 (<1)	0
冷感	1 (<1)	0	1 (<1)	1 (<1)	0
びくびく感	0	0	1 (<1)	1 (<1)	0
重力性浮腫	0	0	1 (<1)	1 (<1)	0
炎症	0	0	1 (<1)	1 (<1)	0
注射部位血腫	0	0	1 (<1)	1 (<1)	3 (1)
足のもつれ	1 (<1)	1 (<1)	0	1 (<1)	0
腫瘤	0	1 (<1)	0	1 (<1)	0
医療機器による疼痛	0	0	1 (<1)	1 (<1)	0
浮腫	0	1 (<1)	0	1 (<1)	0
不活発	0	0	1 (<1)	1 (<1)	0
口渇	0	0	1 (<1)	1 (<1)	0
血管穿刺部位出血	0	1 (<1)	0	1 (<1)	0
血管穿刺部位疼痛	0	1 (<1)	0	1 (<1)	0
血管穿刺部位反応	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 98 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
異常感	1 (<1)	0	0	0	1 (<1)
体温変動感	1 (<1)	0	0	0	0
全身症状	1 (<1)	0	0	0	0
高熱	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	1 (<1)
注射部位変色	0	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	16 (8)
注射部位出血	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	2 (<1)
注射部位硬結	0	0	0	0	5 (2)
注射部位炎症	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	1 (<1)
注射部位浮腫	0	0	0	0	2 (<1)
注射部位疼痛	0	0	0	0	15 (7)
注射部位そう痒感	0	0	0	0	6 (3)
注射部位発疹	0	0	0	0	2 (<1)
注射部位反応	0	0	0	0	2 (<1)
注射部位瘢痕	0	0	0	0	1 (<1)
注射部位腫脹	0	0	0	0	3 (1)
注射部位蕁麻疹	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 99 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位熱感	0	0	0	0	1 (<1)
微石症	0	0	0	0	1 (<1)
壊死	0	0	0	0	1 (<1)
骨盤腔内腫瘤	1 (<1)	0	0	0	0
臨床検査	108 (27)	119 (30)	115 (29)	234 (30)	69 (33)
尿中アルブミン陽性	10 (3)	31 (8)	25 (6)	56 (7)	10 (5)
アラニン・アミノトランスフェラーゼ増加	22 (6)	22 (6)	27 (7)	49 (6)	14 (7)
アスパラギン酸アミノトランスフェラーゼ増加	10 (3)	17 (4)	13 (3)	30 (4)	10 (5)
血中副甲状腺ホルモン増加	2 (<1)	13 (3)	10 (3)	23 (3)	1 (<1)
尿中血陽性	5 (1)	10 (3)	13 (3)	23 (3)	3 (1)
尿中蛋白陽性	4 (1)	11 (3)	10 (3)	21 (3)	8 (4)
尿中β２ミクログロブリン増加	7 (2)	9 (2)	10 (3)	19 (2)	2 (<1)
γ－グルタミルトランスフェラーゼ増加	10 (3)	9 (2)	5 (1)	14 (2)	4 (2)
白血球数増加	5 (1)	8 (2)	6 (2)	14 (2)	1 (<1)
尿中白血球陽性	5 (1)	6 (2)	8 (2)	14 (2)	4 (2)
血中ブドウ糖増加	4 (1)	4 (1)	9 (2)	13 (2)	5 (2)
白血球数減少	1 (<1)	7 (2)	6 (2)	13 (2)	1 (<1)
尿中赤血球陽性	4 (1)	4 (1)	5 (1)	9 (1)	1 (<1)
尿中ケトン体陽性	1 (<1)	3 (<1)	6 (2)	9 (1)	1 (<1)
ヘモグロビン減少	2 (<1)	6 (2)	2 (<1)	8 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 100 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝酵素上昇	7 (2)	5 (1)	3 (<1)	8 (1)	5 (2)
好中球数増加	3 (<1)	4 (1)	4 (1)	8 (1)	1 (<1)
体重減少	1 (<1)	5 (1)	3 (<1)	8 (1)	3 (1)
β２ミクログロブリン増加	1 (<1)	3 (<1)	4 (1)	7 (<1)	0
血中クレアチニン増加	5 (1)	5 (1)	2 (<1)	7 (<1)	4 (2)
血中トリグリセリド増加	1 (<1)	4 (1)	2 (<1)	6 (<1)	4 (2)
体重増加	5 (1)	1 (<1)	5 (1)	6 (<1)	3 (1)
ヘマトクリット減少	1 (<1)	4 (1)	1 (<1)	5 (<1)	1 (<1)
肝機能検査異常	0	2 (<1)	3 (<1)	5 (<1)	0
リンパ球数減少	1 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
ビタミンＤ減少	0	3 (<1)	2 (<1)	5 (<1)	1 (<1)
血中ビリルビン増加	6 (2)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
血中乳酸脱水素酵素増加	1 (<1)	4 (1)	0	4 (<1)	0
赤血球数減少	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
血中コレステロール増加	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
体温上昇	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
好酸球数増加	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
リンパ球数増加	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
細菌検査陽性	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 101 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中アルカリホスファターゼ増加	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
血中クレアチン増加	0	2 (<1)	0	2 (<1)	0
血中カリウム増加	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
血圧上昇	1 (<1)	2 (<1)	0	2 (<1)	0
血中尿素増加	2 (<1)	0	2 (<1)	2 (<1)	0
心電図異常	3 (<1)	0	2 (<1)	2 (<1)	0
心電図ＱＴ延長	3 (<1)	1 (<1)	1 (<1)	2 (<1)	3 (1)
γ－グルタミルトランスフェラーゼ異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
血液学的検査異常	0	2 (<1)	0	2 (<1)	0
高比重リポ蛋白増加	0	0	2 (<1)	2 (<1)	0
リンパ球形態異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
好中球数減少	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
血小板数減少	0	2 (<1)	0	2 (<1)	2 (<1)
赤血球数増加	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
アスパラギン酸アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)	0
血中アルカリホスファターゼ異常	0	1 (<1)	0	1 (<1)	0
血中葉酸減少	0	1 (<1)	0	1 (<1)	0
血中ブドウ糖減少	1 (<1)	0	1 (<1)	1 (<1)	0
血中免疫グロブリンM増加	0	0	1 (<1)	1 (<1)	0
血中鉄減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中ケトン体増加	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 102 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血圧低下	0	1 (<1)	0	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	1 (<1)	0
血中甲状腺刺激ホルモン増加	0	0	1 (<1)	1 (<1)	0
体温低下	0	1 (<1)	0	1 (<1)	0
心雑音	2 (<1)	1 (<1)	0	1 (<1)	0
結腸内視鏡検査	0	1 (<1)	0	1 (<1)	0
尿中結晶陽性	3 (<1)	1 (<1)	0	1 (<1)	0
心筋虚血の心電図所見	0	1 (<1)	0	1 (<1)	0
心電図ＳＴ部分下降	0	1 (<1)	0	1 (<1)	2 (<1)
心電図Ｔ波振幅減少	1 (<1)	0	1 (<1)	1 (<1)	0
心電図Ｔ波逆転	1 (<1)	1 (<1)	0	1 (<1)	2 (<1)
好酸球数異常	1 (<1)	0	1 (<1)	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	1 (<1)	0
大腸菌検査陽性	0	1 (<1)	0	1 (<1)	0
γ－グルタミルトランスフェラーゼ減少	0	1 (<1)	0	1 (<1)	0
尿中ブドウ糖陽性	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
心拍数増加	1 (<1)	1 (<1)	0	1 (<1)	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	1 (<1)	0
ヒステロスコピー	0	1 (<1)	0	1 (<1)	0
眼圧上昇	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 103 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
検査	0	0	1 (<1)	1 (<1)	0
医学的観察	0	0	1 (<1)	1 (<1)	0
単球数増加	0	0	1 (<1)	1 (<1)	0
血小板数増加	3 (<1)	1 (<1)	0	1 (<1)	0
血清フェリチン減少	0	0	1 (<1)	1 (<1)	0
つぎ足歩行検査異常	0	1 (<1)	0	1 (<1)	0
ビタミンＢ１２減少	0	1 (<1)	0	1 (<1)	0
ビタミンD増加	1 (<1)	0	1 (<1)	1 (<1)	0
抗甲状腺抗体陽性	1 (<1)	0	0	0	0
抗核抗体増加	1 (<1)	0	0	0	0
細菌検査	1 (<1)	0	0	0	0
血中ビリルビン異常	0	0	0	0	1 (<1)
血中ビリルビン減少	1 (<1)	0	0	0	0
血中カルシウム減少	0	0	0	0	1 (<1)
血中カルシウム増加	1 (<1)	0	0	0	0
血中クレアチン異常	1 (<1)	0	0	0	0
血中マグネシウム減少	1 (<1)	0	0	0	0
血中リン減少	1 (<1)	0	0	0	0
血中カリウム減少	1 (<1)	0	0	0	0
血中ナトリウム増加	0	0	0	0	1 (<1)
血中尿酸増加	2 (<1)	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 104 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
中枢神経系機能検査異常	1 (<1)	0	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0	0
心電図異常ＱＲＳ群	1 (<1)	0	0	0	0
心電図ＱＲＳ群延長	1 (<1)	0	0	0	0
心電図２相性Ｔ波	0	0	0	0	1 (<1)
心音異常	1 (<1)	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	1 (<1)	0	0	0	0
リンパ球数異常	0	0	0	0	1 (<1)
好中球数異常	0	0	0	0	1 (<1)
好中球百分率異常	1 (<1)	0	0	0	0
脳核磁気共鳴画像異常	1 (<1)	0	0	0	0
便潜血陽性	0	0	0	0	1 (<1)
ＱＲＳ軸異常	1 (<1)	0	0	0	0
子宮頚部スミア異常	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	2 (<1)	0	0	0	0
膀胱超音波検査異常	1 (<1)	0	0	0	0
前庭機能検査異常	0	0	0	0	1 (<1)
白血球数異常	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 105 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
傷害、中毒および処置合併症	60 (15)	44 (11)	60 (15)	104 (13)	19 (9)
転倒	13 (3)	7 (2)	11 (3)	18 (2)	6 (3)
挫傷	6 (2)	8 (2)	9 (2)	17 (2)	1 (<1)
関節捻挫	6 (2)	4 (1)	8 (2)	12 (2)	2 (<1)
肉離れ	2 (<1)	3 (<1)	5 (1)	8 (1)	0
足骨折	1 (<1)	5 (1)	2 (<1)	7 (<1)	0
四肢損傷	4 (1)	2 (<1)	4 (1)	6 (<1)	2 (<1)
節足動物咬傷	4 (1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
処置による疼痛	2 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
上顆炎	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
擦過傷	0	0	3 (<1)	3 (<1)	0
皮膚裂傷	2 (<1)	0	3 (<1)	3 (<1)	0
熱傷	5 (1)	0	3 (<1)	3 (<1)	0
歯牙破折	0	1 (<1)	2 (<1)	3 (<1)	0
外傷性血腫	0	2 (<1)	1 (<1)	3 (<1)	1 (<1)
むち打ち損傷	0	3 (<1)	0	3 (<1)	2 (<1)
足関節部骨折	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
節足動物刺傷	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
眼外傷	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
関節脱臼	1 (<1)	2 (<1)	0	2 (<1)	0
関節損傷	2 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 106 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
靭帯断裂	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
半月板障害	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
筋断裂	0	2 (<1)	0	2 (<1)	0
橈骨骨折	0	0	2 (<1)	2 (<1)	1 (<1)
交通事故	0	0	2 (<1)	2 (<1)	2 (<1)
骨格損傷	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
サンバーン	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
偶発的過量投与	0	1 (<1)	0	1 (<1)	0
アルコール中毒	0	0	1 (<1)	1 (<1)	0
動物咬傷	1 (<1)	1 (<1)	0	1 (<1)	0
鎖骨骨折	0	0	1 (<1)	1 (<1)	0
脳振盪	0	1 (<1)	0	1 (<1)	1 (<1)
大腿骨骨折	0	1 (<1)	0	1 (<1)	1 (<1)
尾骨骨折	0	0	1 (<1)	1 (<1)	0
手骨折	0	1 (<1)	0	1 (<1)	3 (1)
損傷	0	0	1 (<1)	1 (<1)	0
靭帯損傷	1 (<1)	0	1 (<1)	1 (<1)	0
靭帯捻挫	0	0	1 (<1)	1 (<1)	0
下肢骨折	0	0	1 (<1)	1 (<1)	0
頚部損傷	0	1 (<1)	0	1 (<1)	0
処置による悪心	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 107 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
処置による嘔吐	0	1 (<1)	0	1 (<1)	0
放射線皮膚損傷	0	0	1 (<1)	1 (<1)	0
網膜損傷	1 (<1)	1 (<1)	0	1 (<1)	0
軟部組織損傷	0	1 (<1)	0	1 (<1)	0
上肢骨折	1 (<1)	0	1 (<1)	1 (<1)	0
ワクチン接種合併症	1 (<1)	0	1 (<1)	1 (<1)	0
創傷	2 (<1)	0	1 (<1)	1 (<1)	0
創し開	0	0	1 (<1)	1 (<1)	0
手首関節骨折	1 (<1)	0	1 (<1)	1 (<1)	0
気圧性中耳炎	0	0	0	0	1 (<1)
第２度熱傷	1 (<1)	0	0	0	0
顔面損傷	0	0	0	0	1 (<1)
頭部損傷	1 (<1)	0	0	0	0
瘢痕ヘルニア	1 (<1)	0	0	0	0
筋損傷	2 (<1)	0	0	0	0
処置後合併症	2 (<1)	0	0	0	0
外傷後疼痛	1 (<1)	0	0	0	1 (<1)
術後創合併症	0	0	0	0	1 (<1)
反復性挫傷	1 (<1)	0	0	0	0
腱断裂	3 (<1)	0	0	0	1 (<1)
治療薬毒性	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 108 of 108
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脛骨骨折	1 (<1)	0	0	0	0
有毒性刺傷	1 (<1)	0	0	0	0
外科および内科処置	4 (1)	4 (1)	0	4 (<1)	2 (<1)
抜歯	1 (<1)	2 (<1)	0	2 (<1)	0
ヘルニア修復	0	1 (<1)	0	1 (<1)	0
子宮摘出	0	1 (<1)	0	1 (<1)	0
子宮頚部円錐切除	1 (<1)	0	0	0	0
入院	0	0	0	0	1 (<1)
色素性母斑切除	1 (<1)	0	0	0	0
不妊手術	0	0	0	0	1 (<1)
鼻甲介切除	1 (<1)	0	0	0	0
社会環境	1 (<1)	1 (<1)	0	1 (<1)	0
閉経	0	1 (<1)	0	1 (<1)	0
社会問題	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG0

0012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-PRMSTRT-A.SAS DATE: 02DEC2015

Table 285: Incidence of Serious Adverse Events by System Organ Class and Preferred Term - by Prior MS Treatment: Studies 109MS301 and 109MS302

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 1 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	374 (100)	371 (100)	368 (100)	739 (100)	139 (100)
Number of subjects with an event	84 (22)	73 (20)	64 (17)	137 (19)	21 (15)
感染症および寄生虫症	6 (2)	12 (3)	7 (2)	19 (3)	2 (1)
胃腸炎	0	5 (1)	2 (<1)	7 (<1)	0
蜂巣炎	0	1 (<1)	1 (<1)	2 (<1)	0
ウイルス感染	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
虫垂炎	0	1 (<1)	0	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
Ｈ１Ｎ１インフルエンザ	0	1 (<1)	0	1 (<1)	0
インフルエンザ	0	0	1 (<1)	1 (<1)	0
肺炎	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ウイルス感染後疲労症候群	0	1 (<1)	0	1 (<1)	0
急性腎盂腎炎	0	0	1 (<1)	1 (<1)	0
副鼻腔炎	0	0	1 (<1)	1 (<1)	0
尿路感染	0	1 (<1)	0	1 (<1)	0
外陰部膿瘍	0	0	1 (<1)	1 (<1)	0
肛門膿瘍	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 2 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
鼻咽頭炎	1 (<1)	0	0	0	0
敗血症	2 (<1)	0	0	0	0
気管炎	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	2 (<1)	2 (<1)	2 (<1)	4 (<1)	3 (2)
子宮平滑筋腫	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
子宮頚部癌	0	0	1 (<1)	1 (<1)	1 (<1)
移行上皮癌	0	1 (<1)	0	1 (<1)	0
基底細胞癌	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	2 (<1)	0	0	0	0
貧血	1 (<1)	0	0	0	0
小球性貧血	1 (<1)	0	0	0	0
免疫系障害	0	0	2 (<1)	2 (<1)	0
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
過敏症	0	0	1 (<1)	1 (<1)	0
内分泌障害	0	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 3 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
甲状腺腫	0	1 (<1)	1 (<1)	2 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
代謝および栄養障害	1 (<1)	0	0	0	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0
精神障害	2 (<1)	4 (1)	2 (<1)	6 (<1)	1 (<1)
うつ病	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
全般性不安障害	0	1 (<1)	0	1 (<1)	0
躁病	0	1 (<1)	0	1 (<1)	0
自己愛性人格障害	0	1 (<1)	0	1 (<1)	0
自殺念慮	1 (<1)	1 (<1)	0	1 (<1)	0
自殺企図	0	0	1 (<1)	1 (<1)	0
神経系障害	62 (17)	42 (11)	38 (10)	80 (11)	15 (11)
多発性硬化症再発	57 (15)	39 (11)	32 (9)	71 (10)	14 (10)
頭痛	0	0	3 (<1)	3 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0
良性頭蓋内圧亢進	0	0	1 (<1)	1 (<1)	0
構語障害	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 4 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
てんかん	1 (<1)	1 (<1)	0	1 (<1)	0
舌咽神経痛	0	1 (<1)	0	1 (<1)	0
大発作痙攣	0	0	1 (<1)	1 (<1)	1 (<1)
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
片頭痛	1 (<1)	0	1 (<1)	1 (<1)	0
多発性硬化症	1 (<1)	0	1 (<1)	1 (<1)	0
神経学的症状	0	1 (<1)	0	1 (<1)	0
後頭神経痛	0	0	1 (<1)	1 (<1)	0
一過性全健忘	0	0	1 (<1)	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
第７脳神経麻痺	0	1 (<1)	0	1 (<1)	0
痙攣	2 (<1)	0	0	0	0
意識消失	1 (<1)	0	0	0	0
下肢静止不能症候群	1 (<1)	0	0	0	0
眼障害	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
耳および迷路障害	0	0	1 (<1)	1 (<1)	1 (<1)
頭位性回転性めまい	0	0	1 (<1)	1 (<1)	0
前庭性運動失調	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 5 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓障害	0	0	3 (<1)	3 (<1)	1 (<1)
徐脈	0	0	1 (<1)	1 (<1)	0
心不全	0	0	1 (<1)	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	1 (<1)	0
心筋炎	0	0	0	0	1 (<1)
血管障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
静脈瘤	0	1 (<1)	1 (<1)	2 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
末梢性虚血	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	0	1 (<1)	0	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	1 (<1)	0
胃腸障害	3 (<1)	2 (<1)	4 (1)	6 (<1)	0
胃炎	0	0	2 (<1)	2 (<1)	0
腹部ヘルニア	0	1 (<1)	0	1 (<1)	0
裂孔ヘルニア	0	1 (<1)	0	1 (<1)	0
臍ヘルニア	0	0	1 (<1)	1 (<1)	0
嘔吐	0	0	1 (<1)	1 (<1)	0
胃腸出血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 6 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
肝胆道系障害	0	1 (<1)	0	1 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
皮膚および皮下組織障害	0	1 (<1)	0	1 (<1)	0
スティーブンス・ジョンソン症候群	0	1 (<1)	0	1 (<1)	0
筋骨格系および結合組織障害	1 (<1)	5 (1)	2 (<1)	7 (<1)	0
背部痛	0	2 (<1)	1 (<1)	3 (<1)	0
関節痛	0	1 (<1)	0	1 (<1)	0
滑液包炎	0	1 (<1)	0	1 (<1)	0
シェーグレン症候群	0	1 (<1)	0	1 (<1)	0
変形性脊椎症	0	0	1 (<1)	1 (<1)	0
滑液嚢腫	1 (<1)	0	0	0	0
腎および尿路障害	0	1 (<1)	3 (<1)	4 (<1)	0
膀胱機能障害	0	1 (<1)	0	1 (<1)	0
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
腎仙痛	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 7 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿失禁	0	0	1 (<1)	1 (<1)	0
妊娠、産褥および周産期の状態	3 (<1)	0	0	0	0
自然流産	2 (<1)	0	0	0	0
妊娠浮腫	1 (<1)	0	0	0	0
生殖系および乳房障害	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
卵巣嚢胞	1 (<1)	0	2 (<1)	2 (<1)	0
腺筋症	0	0	1 (<1)	1 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
不正子宮出血	0	0	1 (<1)	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
月経障害	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	2 (<1)	0	5 (1)	5 (<1)	0
無力症	1 (<1)	0	1 (<1)	1 (<1)	0
閉塞性ヘルニア	0	0	1 (<1)	1 (<1)	0
非心臓性胸痛	0	0	1 (<1)	1 (<1)	0
末梢性浮腫	0	0	1 (<1)	1 (<1)	0
発熱	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 8 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
インフルエンザ様疾患	1 (<1)	0	0	0	0
臨床検査	2 (<1)	0	2 (<1)	2 (<1)	0
アレルギー検査	0	0	1 (<1)	1 (<1)	0
血中ブドウ糖増加	0	0	1 (<1)	1 (<1)	0
肝酵素上昇	2 (<1)	0	0	0	0
傷害、中毒および処置合併症	2 (<1)	7 (2)	3 (<1)	10 (1)	0
交通事故	0	1 (<1)	1 (<1)	2 (<1)	0
脳振盪	0	1 (<1)	0	1 (<1)	0
顔面骨骨折	0	1 (<1)	0	1 (<1)	0
大腿骨骨折	0	0	1 (<1)	1 (<1)	0
半月板障害	0	1 (<1)	0	1 (<1)	0
肉離れ	0	0	1 (<1)	1 (<1)	0
過量投与	0	1 (<1)	0	1 (<1)	0
術後発熱	0	1 (<1)	0	1 (<1)	0
処置による低血圧	0	1 (<1)	0	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
外傷性血腫	0	1 (<1)	0	1 (<1)	0
手首関節骨折	0	0	1 (<1)	1 (<1)	0
大腿骨頚部骨折	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 9 of 17
(Yes)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
手骨折	1 (<1)	0	0	0	0
外科および内科処置	0	3 (<1)	2 (<1)	5 (<1)	0
乳房腫瘤摘除	0	1 (<1)	0	1 (<1)	0
女性不妊手術	0	1 (<1)	0	1 (<1)	0
椎間板手術	0	0	1 (<1)	1 (<1)	0
治療食	0	1 (<1)	0	1 (<1)	0
静脈ステント挿入	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 10 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	397 (100)	398 (100)	392 (100)	790 (100)	212 (100)
Number of subjects with an event	81 (20)	62 (16)	55 (14)	117 (15)	39 (18)
感染症および寄生虫症	6 (2)	5 (1)	8 (2)	13 (2)	2 (<1)
蜂巣炎	0	1 (<1)	1 (<1)	2 (<1)	0
胃腸炎	0	1 (<1)	1 (<1)	2 (<1)	0
尿路感染	0	0	2 (<1)	2 (<1)	0
ウイルス性胃腸炎	0	0	1 (<1)	1 (<1)	0
Ｈ１Ｎ１インフルエンザ	1 (<1)	0	1 (<1)	1 (<1)	0
骨盤内炎症性疾患	1 (<1)	0	1 (<1)	1 (<1)	0
扁桃周囲膿瘍	0	0	1 (<1)	1 (<1)	0
肺炎	0	1 (<1)	0	1 (<1)	1 (<1)
副鼻腔炎	0	1 (<1)	0	1 (<1)	0
ウイルス感染	0	1 (<1)	0	1 (<1)	0
虫垂炎	0	0	0	0	1 (<1)
ボレリア感染	1 (<1)	0	0	0	0
感染性下痢	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 11 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
インフルエンザ	1 (<1)	0	0	0	0
膿胸	0	0	0	0	1 (<1)
ライター症候群	1 (<1)	0	0	0	0
消化器結核	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	4 (1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
乳癌	1 (<1)	0	1 (<1)	1 (<1)	0
神経鞘腫	0	1 (<1)	0	1 (<1)	0
基底細胞癌	0	0	0	0	1 (<1)
乳房新生物	1 (<1)	0	0	0	0
子宮内膜癌	0	0	0	0	1 (<1)
線維腫	1 (<1)	0	0	0	0
血管腫	1 (<1)	0	0	0	0
免疫系障害	0	1 (<1)	0	1 (<1)	3 (1)
過敏症	0	1 (<1)	0	1 (<1)	1 (<1)
アナフィラキシー反応	0	0	0	0	2 (<1)
代謝および栄養障害	0	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 12 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脱水	0	0	1 (<1)	1 (<1)	0
低血糖症	0	0	1 (<1)	1 (<1)	0
精神障害	2 (<1)	1 (<1)	0	1 (<1)	3 (1)
双極１型障害	0	1 (<1)	0	1 (<1)	0
不安	1 (<1)	0	0	0	0
自殺既遂	0	0	0	0	1 (<1)
うつ病	1 (<1)	0	0	0	1 (<1)
自殺念慮	0	0	0	0	1 (<1)
自殺企図	0	0	0	0	1 (<1)
神経系障害	56 (14)	39 (10)	31 (8)	70 (9)	25 (12)
多発性硬化症再発	54 (14)	39 (10)	30 (8)	69 (9)	22 (10)
神経学的症状	0	0	1 (<1)	1 (<1)	0
部分発作	0	1 (<1)	0	1 (<1)	1 (<1)
下肢静止不能症候群	0	0	1 (<1)	1 (<1)	0
一過性脳虚血発作	0	1 (<1)	0	1 (<1)	0
失語症	0	0	0	0	1 (<1)
脳血管発作	1 (<1)	0	0	0	0
脳血管障害	0	0	0	0	1 (<1)
痙攣	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 13 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脳症	1 (<1)	0	0	0	0
大発作痙攣	2 (<1)	0	0	0	0
意識消失	0	0	0	0	1 (<1)
片頭痛	1 (<1)	0	0	0	0
眼障害	2 (<1)	0	0	0	0
眼痛	1 (<1)	0	0	0	0
視力低下	1 (<1)	0	0	0	0
心臓障害	0	0	1 (<1)	1 (<1)	0
急性冠動脈症候群	0	0	1 (<1)	1 (<1)	0
血管障害	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
潮紅	0	1 (<1)	1 (<1)	2 (<1)	0
深部静脈血栓症	0	0	0	0	1 (<1)
呼吸器、胸郭および縦隔障害	1 (<1)	2 (<1)	0	2 (<1)	0
喘息	0	1 (<1)	0	1 (<1)	0
胸水	0	1 (<1)	0	1 (<1)	0
鼻茸	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 14 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胃腸障害	2 (<1)	6 (2)	6 (2)	12 (2)	0
嘔吐	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
腹痛	0	2 (<1)	0	2 (<1)	0
下腹部痛	0	0	1 (<1)	1 (<1)	0
便秘	0	1 (<1)	0	1 (<1)	0
憩室穿孔	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
胃炎	0	0	1 (<1)	1 (<1)	0
胃腸障害	0	1 (<1)	0	1 (<1)	0
胃腸出血	0	0	1 (<1)	1 (<1)	0
腸閉塞	0	0	1 (<1)	1 (<1)	0
悪心	1 (<1)	1 (<1)	0	1 (<1)	0
大腸炎	1 (<1)	0	0	0	0
潰瘍性大腸炎	1 (<1)	0	0	0	0
肝胆道系障害	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
胆石症	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
胆管結石	0	0	1 (<1)	1 (<1)	0
皮膚および皮下組織障害	1 (<1)	0	1 (<1)	1 (<1)	0
そう痒症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 15 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
アレルギー性皮膚炎	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	2 (<1)	0	1 (<1)	1 (<1)	0
変形性関節症	1 (<1)	0	1 (<1)	1 (<1)	0
多発性関節炎	1 (<1)	0	0	0	0
腎および尿路障害	2 (<1)	1 (<1)	0	1 (<1)	0
尿管瘤	0	1 (<1)	0	1 (<1)	0
膀胱憩室	1 (<1)	0	0	0	0
腎下垂症	1 (<1)	0	0	0	0
生殖系および乳房障害	4 (1)	2 (<1)	0	2 (<1)	2 (<1)
月経過多	0	1 (<1)	0	1 (<1)	0
卵巣嚢胞	0	1 (<1)	0	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0	0
不正子宮出血	0	0	0	0	1 (<1)
骨盤痛	1 (<1)	0	0	0	0
子宮出血	2 (<1)	0	0	0	1 (<1)
先天性、家族性および遺伝性障害	0	0	1 (<1)	1 (<1)	0
陰嚢水瘤	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 16 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
一般・全身障害および投与部位の状態	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
発熱	0	1 (<1)	1 (<1)	2 (<1)	0
末梢性浮腫	0	0	0	0	1 (<1)
骨盤腔内腫瘤	1 (<1)	0	0	0	0
臨床検査	0	1 (<1)	3 (<1)	4 (<1)	0
尿中β２ミクログロブリン増加	0	0	1 (<1)	1 (<1)	0
結腸内視鏡検査	0	1 (<1)	0	1 (<1)	0
検査	0	0	1 (<1)	1 (<1)	0
医学的観察	0	0	1 (<1)	1 (<1)	0
傷害、中毒および処置合併症	7 (2)	3 (<1)	6 (2)	9 (1)	3 (1)
アルコール中毒	0	0	1 (<1)	1 (<1)	0
足関節部骨折	0	0	1 (<1)	1 (<1)	0
転倒	0	1 (<1)	0	1 (<1)	0
大腿骨骨折	0	1 (<1)	0	1 (<1)	1 (<1)
足骨折	0	1 (<1)	0	1 (<1)	0
靭帯断裂	0	1 (<1)	0	1 (<1)	0
肉離れ	0	0	1 (<1)	1 (<1)	0
橈骨骨折	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term - by prior MS treatment:
Studies 109MS301 and 109MS302
Page 17 of 17
(No)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
交通事故	0	0	1 (<1)	1 (<1)	1 (<1)
手首関節骨折	0	0	1 (<1)	1 (<1)	0
眼外傷	1 (<1)	0	0	0	0
靭帯損傷	1 (<1)	0	0	0	0
半月板障害	1 (<1)	0	0	0	0
腱断裂	3 (<1)	0	0	0	0
治療薬毒性	1 (<1)	0	0	0	0
脛骨骨折	1 (<1)	0	0	0	0
むち打ち損傷	0	0	0	0	1 (<1)
外科および内科処置	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
子宮摘出	0	1 (<1)	0	1 (<1)	0
子宮頚部円錐切除	1 (<1)	0	0	0	0
不妊手術	0	0	0	0	1 (<1)
鼻甲介切除	1 (<1)	0	0	0	0
社会環境	1 (<1)	0	0	0	0
社会問題	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-PRMSTRT-A.SAS DATE: 02DEC2015

Table 287: Incidence of Adverse Events in Subjects Treated With IV Corticosteroids by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 1 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Number of subjects treated with IV corticosteroids	319 (100)	205 (100)	184 (100)	389 (100)	113 (100)
Number of subjects with an event	319 (100)	205 (100)	184 (100)	389 (100)	113 (100)
感染症および寄生虫症	193 (61)	130 (63)	127 (69)	257 (66)	62 (55)
鼻咽頭炎	71 (22)	42 (20)	47 (26)	89 (23)	17 (15)
尿路感染	37 (12)	36 (18)	25 (14)	61 (16)	18 (16)
上気道感染	37 (12)	34 (17)	21 (11)	55 (14)	10 (9)
インフルエンザ	24 (8)	11 (5)	20 (11)	31 (8)	4 (4)
副鼻腔炎	12 (4)	13 (6)	16 (9)	29 (7)	4 (4)
気管支炎	15 (5)	14 (7)	13 (7)	27 (7)	5 (4)
胃腸炎	14 (4)	15 (7)	11 (6)	26 (7)	3 (3)
口腔ヘルペス	15 (5)	11 (5)	6 (3)	17 (4)	2 (2)
鼻炎	14 (4)	9 (4)	8 (4)	17 (4)	1 (<1)
咽頭炎	17 (5)	11 (5)	5 (3)	16 (4)	4 (4)
膀胱炎	11 (3)	3 (1)	9 (5)	12 (3)	2 (2)
気道感染	6 (2)	7 (3)	5 (3)	12 (3)	4 (4)
ウイルス感染	11 (3)	4 (2)	5 (3)	9 (2)	1 (<1)
耳感染	8 (3)	3 (1)	5 (3)	8 (2)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 2 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
消化管感染	3 (<1)	1 (<1)	6 (3)	7 (2)	0
ウイルス性胃腸炎	4 (1)	1 (<1)	5 (3)	6 (2)	4 (4)
帯状疱疹	3 (<1)	1 (<1)	5 (3)	6 (2)	2 (2)
喉頭炎	2 (<1)	3 (1)	2 (1)	5 (1)	0
中耳炎	1 (<1)	2 (<1)	3 (2)	5 (1)	1 (<1)
肺炎	1 (<1)	1 (<1)	4 (2)	5 (1)	4 (4)
扁桃炎	3 (<1)	2 (<1)	3 (2)	5 (1)	1 (<1)
ウイルス性上気道感染	4 (1)	4 (2)	1 (<1)	5 (1)	0
外陰腟真菌感染	5 (2)	2 (<1)	3 (2)	5 (1)	2 (2)
感染性結膜炎	0	2 (<1)	2 (1)	4 (1)	0
麦粒腫	1 (<1)	2 (<1)	2 (1)	4 (1)	0
腟感染	1 (<1)	2 (<1)	2 (1)	4 (1)	1 (<1)
蜂巣炎	1 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
せつ	1 (<1)	2 (<1)	0	2 (<1)	0
ウイルス性消化管感染	1 (<1)	0	2 (1)	2 (<1)	1 (<1)
Ｈ１Ｎ１インフルエンザ	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ヘリコバクター性胃炎	0	0	2 (1)	2 (<1)	0
口腔カンジダ症	0	1 (<1)	1 (<1)	2 (<1)	0
外耳炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
レンサ球菌性咽頭炎	5 (2)	2 (<1)	0	2 (<1)	1 (<1)
術後創感染	0	1 (<1)	1 (<1)	2 (<1)	0
ブドウ球菌感染	0	0	2 (1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 3 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯膿瘍	4 (1)	1 (<1)	1 (<1)	2 (<1)	3 (3)
気管炎	1 (<1)	2 (<1)	0	2 (<1)	2 (2)
気管気管支炎	0	1 (<1)	1 (<1)	2 (<1)	0
細菌性膣炎	1 (<1)	2 (<1)	0	2 (<1)	0
外陰部膣カンジダ症	4 (1)	1 (<1)	1 (<1)	2 (<1)	0
ダニ症	0	0	1 (<1)	1 (<1)	0
急性扁桃炎	2 (<1)	1 (<1)	0	1 (<1)	0
無症候性細菌尿	1 (<1)	0	1 (<1)	1 (<1)	0
細菌感染	0	1 (<1)	0	1 (<1)	0
細菌尿	0	0	1 (<1)	1 (<1)	0
カンジダ症	0	1 (<1)	0	1 (<1)	0
細菌性結膜炎	0	1 (<1)	0	1 (<1)	0
ウイルス性結膜炎	0	0	1 (<1)	1 (<1)	0
感染性皮膚炎	0	0	1 (<1)	1 (<1)	0
感染性湿疹	0	0	1 (<1)	1 (<1)	0
エプスタイン・バーウイルス感染	0	0	1 (<1)	1 (<1)	0
大腸菌性尿路感染	0	1 (<1)	0	1 (<1)	0
眼感染	1 (<1)	1 (<1)	0	1 (<1)	0
熱性感染症	1 (<1)	0	1 (<1)	1 (<1)	0
毛包炎	1 (<1)	1 (<1)	0	1 (<1)	0
性器カンジダ症	0	1 (<1)	0	1 (<1)	0
単純ヘルペス	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 4 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
切開部位感染	0	1 (<1)	0	1 (<1)	0
咬傷感染	0	0	1 (<1)	1 (<1)	0
迷路炎	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
限局性感染	0	1 (<1)	0	1 (<1)	0
下気道感染	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
ライム病	0	0	1 (<1)	1 (<1)	0
乳腺炎	0	1 (<1)	0	1 (<1)	0
爪感染	0	0	1 (<1)	1 (<1)	0
爪真菌症	0	1 (<1)	0	1 (<1)	0
精巣炎	0	0	1 (<1)	1 (<1)	0
咽頭扁桃炎	0	1 (<1)	0	1 (<1)	0
ウイルス感染後疲労症候群	1 (<1)	1 (<1)	0	1 (<1)	0
歯髄炎	1 (<1)	1 (<1)	0	1 (<1)	0
膿疱性皮疹	0	1 (<1)	0	1 (<1)	1 (<1)
細菌性副鼻腔炎	0	1 (<1)	0	1 (<1)	0
皮下組織膿瘍	0	1 (<1)	0	1 (<1)	0
足部白癬	3 (<1)	0	1 (<1)	1 (<1)	0
歯感染	2 (<1)	0	1 (<1)	1 (<1)	4 (4)
細菌性上気道感染	0	1 (<1)	0	1 (<1)	0
細菌性尿路感染	0	0	1 (<1)	1 (<1)	0
ガードネレラ菌性腟炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 5 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
外陰部炎	0	1 (<1)	0	1 (<1)	0
顎膿瘍	1 (<1)	0	0	0	0
四肢膿瘍	1 (<1)	0	0	0	0
肛門膿瘍	1 (<1)	0	0	0	0
虫垂炎	0	0	0	0	1 (<1)
ボレリア感染	2 (<1)	0	0	0	0
熱傷部感染	1 (<1)	0	0	0	0
子宮頚管炎	0	0	0	0	1 (<1)
感染性下痢	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0
皮膚真菌感染	1 (<1)	0	0	0	0
真菌性消化管感染	1 (<1)	0	0	0	0
陰部ヘルペス	1 (<1)	0	0	0	0
細菌性性器感染	1 (<1)	0	0	0	0
泌尿生殖器感染	1 (<1)	0	0	0	0
歯肉感染	1 (<1)	0	0	0	1 (<1)
ヘルペスウイルス感染	0	0	0	0	1 (<1)
感染性皮脂嚢腫	1 (<1)	0	0	0	0
寄生虫感染	0	0	0	0	1 (<1)
ムンプス	1 (<1)	0	0	0	0
子宮傍組織炎	0	0	0	0	1 (<1)
骨盤内炎症性疾患	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 6 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯周感染	1 (<1)	0	0	0	0
細菌性咽頭炎	0	0	0	0	1 (<1)
毛巣嚢胞	1 (<1)	0	0	0	0
腎盂腎炎	1 (<1)	0	0	0	0
ライター症候群	1 (<1)	0	0	0	0
ウイルス性気道感染	3 (<1)	0	0	0	0
卵管卵巣炎	2 (<1)	0	0	0	0
白癬感染	1 (<1)	0	0	0	0
癜風	2 (<1)	0	0	0	0
消化器結核	1 (<1)	0	0	0	0
尿路性敗血症	2 (<1)	0	0	0	0
水痘	0	0	0	0	1 (<1)
創傷感染	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	8 (3)	7 (3)	6 (3)	13 (3)	3 (3)
子宮平滑筋腫	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
メラノサイト性母斑	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
皮膚乳頭腫	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
子宮頚部癌	0	0	1 (<1)	1 (<1)	1 (<1)
乳腺線維腺腫	0	1 (<1)	0	1 (<1)	0
肺新生物	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 7 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
神経鞘腫	0	1 (<1)	0	1 (<1)	0
脂漏性角化症	0	0	1 (<1)	1 (<1)	0
外陰腟ヒト乳頭腫ウイルス感染	0	1 (<1)	0	1 (<1)	0
アクロコルドン	1 (<1)	0	0	0	0
リンパ節の良性新生物	1 (<1)	0	0	0	0
子宮内膜癌	0	0	0	0	1 (<1)
線維性組織球腫	0	0	0	0	1 (<1)
脂肪腫	0	0	0	0	1 (<1)
口腔新生物	1 (<1)	0	0	0	0
甲状腺新生物	1 (<1)	0	0	0	0
血液およびリンパ系障害	15 (5)	17 (8)	17 (9)	34 (9)	4 (4)
貧血	5 (2)	5 (2)	8 (4)	13 (3)	1 (<1)
白血球減少症	0	3 (1)	3 (2)	6 (2)	0
リンパ節症	2 (<1)	3 (1)	2 (1)	5 (1)	1 (<1)
リンパ球減少症	0	4 (2)	1 (<1)	5 (1)	0
好酸球増加症	0	2 (<1)	2 (1)	4 (1)	0
好中球増加症	4 (1)	2 (<1)	2 (1)	4 (1)	1 (<1)
白血球増加症	1 (<1)	3 (1)	0	3 (<1)	0
好中球減少症	0	1 (<1)	0	1 (<1)	0
脾腫	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 8 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
妊娠貧血	1 (<1)	0	0	0	0
鉄欠乏性貧血	2 (<1)	0	0	0	0
小球性貧血	1 (<1)	0	0	0	0
血小板減少症	0	0	0	0	1 (<1)
免疫系障害	5 (2)	9 (4)	9 (5)	18 (5)	4 (4)
過敏症	1 (<1)	5 (2)	3 (2)	8 (2)	1 (<1)
薬物過敏症	2 (<1)	1 (<1)	2 (1)	3 (<1)	2 (2)
食物アレルギー	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
季節性アレルギー	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
造影剤アレルギー	0	0	1 (<1)	1 (<1)	0
家塵アレルギー	0	0	1 (<1)	1 (<1)	0
免疫不全症	0	0	1 (<1)	1 (<1)	0
続発性免疫不全症	0	0	1 (<1)	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)
内分泌障害	3 (<1)	2 (<1)	7 (4)	9 (2)	0
甲状腺機能低下症	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
副甲状腺機能亢進症	0	0	1 (<1)	1 (<1)	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 9 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
続発性副甲状腺機能亢進症	0	1 (<1)	0	1 (<1)	0
甲状腺機能亢進症	1 (<1)	0	1 (<1)	1 (<1)	0
エストロゲン欠乏症	0	0	1 (<1)	1 (<1)	0
副腎腫瘤	1 (<1)	0	0	0	0
代謝および栄養障害	22 (7)	18 (9)	16 (9)	34 (9)	8 (7)
食欲減退	7 (2)	5 (2)	5 (3)	10 (3)	2 (2)
高コレステロール血症	0	2 (<1)	3 (2)	5 (1)	1 (<1)
ビタミンＤ欠乏	3 (<1)	2 (<1)	3 (2)	5 (1)	3 (3)
脱水	0	1 (<1)	2 (1)	3 (<1)	0
脂質異常症	0	0	2 (1)	2 (<1)	0
ビタミン欠乏症	0	2 (<1)	0	2 (<1)	0
鉄欠乏	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミンＢ１２欠乏	0	0	2 (1)	2 (<1)	0
糖尿病	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
耐糖能障害	0	1 (<1)	0	1 (<1)	1 (<1)
高血糖	3 (<1)	1 (<1)	0	1 (<1)	0
高脂血症	2 (<1)	1 (<1)	0	1 (<1)	0
低カリウム血症	0	1 (<1)	0	1 (<1)	0
過小食	0	0	1 (<1)	1 (<1)	0
ケトーシス	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 10 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
葉酸欠乏	1 (<1)	0	0	0	0
高カリウム血症	1 (<1)	0	0	0	0
高トリグリセリド血症	1 (<1)	0	0	0	0
ビタミンD過剰症	1 (<1)	0	0	0	0
肥満	1 (<1)	0	0	0	1 (<1)
多飲症	1 (<1)	0	0	0	0
精神障害	74 (23)	45 (22)	45 (24)	90 (23)	25 (22)
うつ病	30 (9)	18 (9)	15 (8)	33 (8)	10 (9)
不眠症	20 (6)	13 (6)	17 (9)	30 (8)	6 (5)
不安	12 (4)	11 (5)	10 (5)	21 (5)	3 (3)
抑うつ気分	5 (2)	4 (2)	2 (1)	6 (2)	1 (<1)
睡眠障害	7 (2)	4 (2)	0	4 (1)	0
感情障害	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
抑うつ症状	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
パニック発作	0	0	2 (1)	2 (<1)	0
ストレス	4 (1)	1 (<1)	1 (<1)	2 (<1)	2 (2)
異常行動	0	1 (<1)	0	1 (<1)	0
燃え尽き症候群	0	1 (<1)	0	1 (<1)	0
幻聴	0	1 (<1)	0	1 (<1)	0
リビドー減退	1 (<1)	1 (<1)	0	1 (<1)	0
リビド消失	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 11 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
大うつ病	0	0	1 (<1)	1 (<1)	0
躁病	1 (<1)	1 (<1)	0	1 (<1)	0
気分変化	0	0	1 (<1)	1 (<1)	0
気分動揺	1 (<1)	1 (<1)	0	1 (<1)	0
神経過敏	0	1 (<1)	0	1 (<1)	1 (<1)
神経症	0	1 (<1)	0	1 (<1)	0
精神症状	0	1 (<1)	0	1 (<1)	0
精神病性障害	0	0	1 (<1)	1 (<1)	0
睡眠発作	0	0	1 (<1)	1 (<1)	0
身体表現性障害	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
自殺企図	0	0	1 (<1)	1 (<1)	0
感情不安定	2 (<1)	0	0	0	1 (<1)
激越	1 (<1)	0	0	0	0
不安障害	1 (<1)	0	0	0	0
精神緩慢	1 (<1)	0	0	0	0
歯ぎしり	1 (<1)	0	0	0	0
閉所恐怖症	0	0	0	0	1 (<1)
自殺既遂	0	0	0	0	1 (<1)
不快気分	1 (<1)	0	0	0	0
強迫性障害	1 (<1)	0	0	0	0
緊張	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 12 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
神経系障害	315 (99)	198 (97)	179 (97)	377 (97)	109 (96)
多発性硬化症再発	308 (97)	190 (93)	174 (95)	364 (94)	107 (95)
頭痛	55 (17)	43 (21)	32 (17)	75 (19)	16 (14)
錯感覚	32 (10)	18 (9)	18 (10)	36 (9)	7 (6)
感覚鈍麻	21 (7)	11 (5)	17 (9)	28 (7)	9 (8)
浮動性めまい	13 (4)	9 (4)	14 (8)	23 (6)	3 (3)
片頭痛	11 (3)	4 (2)	11 (6)	15 (4)	4 (4)
灼熱感	6 (2)	7 (3)	7 (4)	14 (4)	0
筋痙直	13 (4)	5 (2)	6 (3)	11 (3)	5 (4)
多発性硬化症	10 (3)	3 (1)	5 (3)	8 (2)	5 (4)
坐骨神経痛	3 (<1)	3 (1)	3 (2)	6 (2)	0
振戦	2 (<1)	4 (2)	2 (1)	6 (2)	2 (2)
平衡障害	4 (1)	2 (<1)	3 (2)	5 (1)	2 (2)
構語障害	0	1 (<1)	4 (2)	5 (1)	0
感覚障害	7 (2)	3 (1)	2 (1)	5 (1)	0
ウートホフ現象	1 (<1)	2 (<1)	3 (2)	5 (1)	1 (<1)
レルミット徴候	4 (1)	1 (<1)	3 (2)	4 (1)	0
前兆を伴う片頭痛	1 (<1)	3 (1)	1 (<1)	4 (1)	0
神経痛	4 (1)	2 (<1)	2 (1)	4 (1)	0
三叉神経痛	4 (1)	3 (1)	1 (<1)	4 (1)	1 (<1)
注意力障害	0	1 (<1)	2 (1)	3 (<1)	0
異常感覚	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 13 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
過眠症	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
傾眠	4 (1)	2 (<1)	1 (<1)	3 (<1)	2 (2)
運動失調	1 (<1)	0	2 (1)	2 (<1)	0
帯状感	0	1 (<1)	1 (<1)	2 (<1)	0
てんかん	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
大発作痙攣	1 (<1)	0	2 (1)	2 (<1)	0
不全片麻痺	1 (<1)	0	2 (1)	2 (<1)	0
記憶障害	3 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (2)
不随意性筋収縮	0	2 (<1)	0	2 (<1)	1 (<1)
神経学的症状	0	1 (<1)	1 (<1)	2 (<1)	0
視神経炎	0	1 (<1)	1 (<1)	2 (<1)	0
失神	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
緊張性頭痛	4 (1)	0	2 (1)	2 (<1)	0
失認症	0	1 (<1)	0	1 (<1)	0
健忘	1 (<1)	0	1 (<1)	1 (<1)	0
良性頭蓋内圧亢進	0	0	1 (<1)	1 (<1)	0
手根管症候群	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
小脳症候群	1 (<1)	0	1 (<1)	1 (<1)	0
頚髄神経根痛	0	0	1 (<1)	1 (<1)	1 (<1)
認知障害	0	0	1 (<1)	1 (<1)	0
痙攣	2 (<1)	0	1 (<1)	1 (<1)	0
協調運動異常	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 14 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
体位性めまい	0	1 (<1)	0	1 (<1)	0
味覚異常	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ジストニー	0	1 (<1)	0	1 (<1)	0
頭部動揺	0	0	1 (<1)	1 (<1)	1 (<1)
知覚過敏	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
思考散乱	0	0	1 (<1)	1 (<1)	0
肋間神経痛	1 (<1)	0	1 (<1)	1 (<1)	0
意識消失	0	0	1 (<1)	1 (<1)	1 (<1)
感覚異常性大腿神経痛	0	0	1 (<1)	1 (<1)	0
運動機能障害	0	0	1 (<1)	1 (<1)	0
神経圧迫	0	0	1 (<1)	1 (<1)	0
末梢性ニューロパチー	0	0	1 (<1)	1 (<1)	0
眼振	1 (<1)	0	1 (<1)	1 (<1)	0
後頭神経痛	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
部分発作	0	1 (<1)	0	1 (<1)	0
失神寸前の状態	2 (<1)	1 (<1)	0	1 (<1)	0
下肢静止不能症候群	3 (<1)	0	1 (<1)	1 (<1)	2 (2)
二次性進行型多発性硬化症	0	0	1 (<1)	1 (<1)	0
感覚消失	0	1 (<1)	0	1 (<1)	1 (<1)
副鼻腔炎に伴う頭痛	0	0	1 (<1)	1 (<1)	0
舌の麻痺	0	1 (<1)	0	1 (<1)	0
一過性全健忘	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 15 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
一過性脳虚血発作	0	1 (<1)	0	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
血管性頭痛	0	0	1 (<1)	1 (<1)	0
第７脳神経麻痺	0	1 (<1)	0	1 (<1)	0
異痛症	1 (<1)	0	0	0	0
失語症	0	0	0	0	2 (2)
中枢神経系病変	1 (<1)	0	0	0	0
中枢痛症候群	1 (<1)	0	0	0	0
頚腕症候群	1 (<1)	0	0	0	0
不器用	1 (<1)	0	0	0	1 (<1)
複雑部分発作	1 (<1)	0	0	0	0
振動覚低下	1 (<1)	0	0	0	0
よだれ	1 (<1)	0	0	0	0
脳症	1 (<1)	0	0	0	0
顔面痙攣	1 (<1)	0	0	0	1 (<1)
片側頭痛	3 (<1)	0	0	0	0
ホルネル症候群	1 (<1)	0	0	0	0
反射亢進	2 (<1)	0	0	0	0
仮面状顔貌	0	0	0	0	1 (<1)
単麻痺	1 (<1)	0	0	0	0
腓骨神経麻痺	0	0	0	0	1 (<1)
睡眠の質低下	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 16 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
片頭痛発作重積	1 (<1)	0	0	0	0
足根管症候群	0	0	0	0	1 (<1)
温度覚鈍麻	1 (<1)	0	0	0	0
振動覚亢進	1 (<1)	0	0	0	0
視野欠損	1 (<1)	0	0	0	0
眼障害	41 (13)	21 (10)	27 (15)	48 (12)	11 (10)
眼痛	10 (3)	5 (2)	6 (3)	11 (3)	3 (3)
霧視	8 (3)	4 (2)	6 (3)	10 (3)	1 (<1)
結膜炎	2 (<1)	1 (<1)	5 (3)	6 (2)	0
複視	5 (2)	3 (1)	3 (2)	6 (2)	3 (3)
視力低下	3 (<1)	2 (<1)	3 (2)	5 (1)	3 (3)
眼瞼痙攣	4 (1)	2 (<1)	2 (1)	4 (1)	0
アレルギー性結膜炎	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
眼乾燥	0	1 (<1)	2 (1)	3 (<1)	0
霰粒腫	0	1 (<1)	1 (<1)	2 (<1)	0
眼瞼下垂	0	1 (<1)	1 (<1)	2 (<1)	0
ブドウ膜炎	0	1 (<1)	1 (<1)	2 (<1)	0
視力障害	2 (<1)	0	2 (1)	2 (<1)	0
黒内障	0	1 (<1)	0	1 (<1)	0
眼精疲労	1 (<1)	0	1 (<1)	1 (<1)	0
眼瞼炎	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 17 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
アレルギー性眼瞼炎	0	0	1 (<1)	1 (<1)	0
眼瞼湿疹	0	1 (<1)	0	1 (<1)	0
眼刺激	0	0	1 (<1)	1 (<1)	0
眼運動障害	0	0	1 (<1)	1 (<1)	0
眼そう痒症	2 (<1)	0	1 (<1)	1 (<1)	0
眼瞼嚢胞	0	1 (<1)	0	1 (<1)	0
緑内障	1 (<1)	0	1 (<1)	1 (<1)	0
角膜炎	0	0	1 (<1)	1 (<1)	0
夜盲	0	0	1 (<1)	1 (<1)	0
眼球運動失調	0	1 (<1)	0	1 (<1)	0
羞明	1 (<1)	1 (<1)	0	1 (<1)	0
強膜炎	0	1 (<1)	0	1 (<1)	0
硝子体浮遊物	0	0	1 (<1)	1 (<1)	0
眼の異常感	1 (<1)	0	0	0	0
片側失明	0	0	0	0	1 (<1)
白内障	1 (<1)	0	0	0	0
結膜刺激	1 (<1)	0	0	0	0
眼瞼紅斑	1 (<1)	0	0	0	0
眼のアレルギー	0	0	0	0	1 (<1)
眼の障害	1 (<1)	0	0	0	0
眼部腫脹	0	0	0	0	1 (<1)
眼瞼そう痒症	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 18 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
遠視	1 (<1)	0	0	0	0
流涙増加	2 (<1)	0	0	0	0
黄斑浮腫	1 (<1)	0	0	0	0
近視	1 (<1)	0	0	0	0
眼充血	0	0	0	0	1 (<1)
翼状片	1 (<1)	0	0	0	0
閃輝暗点	1 (<1)	0	0	0	0
耳および迷路障害	22 (7)	10 (5)	25 (14)	35 (9)	9 (8)
回転性めまい	14 (4)	8 (4)	13 (7)	21 (5)	8 (7)
耳痛	2 (<1)	1 (<1)	6 (3)	7 (2)	0
耳鳴	2 (<1)	2 (<1)	2 (1)	4 (1)	0
耳閉	0	0	2 (1)	2 (<1)	0
頭位性回転性めまい	2 (<1)	0	2 (1)	2 (<1)	0
聴覚過敏	0	0	1 (<1)	1 (<1)	0
聴力低下	2 (<1)	0	1 (<1)	1 (<1)	0
乗物酔い	1 (<1)	0	1 (<1)	1 (<1)	0
耳垢栓塞	0	0	0	0	1 (<1)
難聴	1 (<1)	0	0	0	0
前庭障害	1 (<1)	0	0	0	0
心臓障害	20 (6)	9 (4)	12 (7)	21 (5)	7 (6)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 19 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
上室性期外収縮	1 (<1)	2 (<1)	2 (1)	4 (1)	0
頻脈	2 (<1)	3 (1)	1 (<1)	4 (1)	2 (2)
動悸	5 (2)	2 (<1)	1 (<1)	3 (<1)	2 (2)
心室性期外収縮	3 (<1)	1 (<1)	2 (1)	3 (<1)	0
徐脈	1 (<1)	0	2 (1)	2 (<1)	1 (<1)
右脚ブロック	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
洞性頻脈	2 (<1)	0	2 (1)	2 (<1)	0
狭心症	0	1 (<1)	0	1 (<1)	0
心房細動	0	0	1 (<1)	1 (<1)	1 (<1)
左脚ブロック	1 (<1)	0	1 (<1)	1 (<1)	0
期外収縮	1 (<1)	1 (<1)	0	1 (<1)	0
僧帽弁逸脱	0	0	1 (<1)	1 (<1)	0
伝導障害	2 (<1)	0	0	0	0
心筋炎	0	0	0	0	1 (<1)
洞性徐脈	1 (<1)	0	0	0	0
発作性頻脈	1 (<1)	0	0	0	0
血管障害	51 (16)	69 (34)	68 (37)	137 (35)	7 (6)
潮紅	24 (8)	56 (27)	54 (29)	110 (28)	1 (<1)
ほてり	8 (3)	8 (4)	13 (7)	21 (5)	2 (2)
高血圧	11 (3)	3 (1)	2 (1)	5 (1)	2 (2)
低血圧	3 (<1)	3 (1)	1 (<1)	4 (1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 20 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
静脈瘤	0	3 (1)	1 (<1)	4 (1)	0
充血	0	1 (<1)	1 (<1)	2 (<1)	0
動脈障害	0	1 (<1)	0	1 (<1)	0
動脈硬化症	0	0	1 (<1)	1 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	1 (<1)
血腫	3 (<1)	0	1 (<1)	1 (<1)	2 (2)
高血圧クリーゼ	1 (<1)	0	1 (<1)	1 (<1)	0
起立性低血圧	2 (<1)	0	1 (<1)	1 (<1)	0
レイノー現象	0	0	1 (<1)	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0	0
静脈炎	2 (<1)	0	0	0	0
静脈狭窄	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	48 (15)	29 (14)	33 (18)	62 (16)	13 (12)
咳嗽	16 (5)	12 (6)	11 (6)	23 (6)	2 (2)
口腔咽頭痛	15 (5)	6 (3)	12 (7)	18 (5)	4 (4)
喘息	1 (<1)	4 (2)	0	4 (1)	1 (<1)
鼻漏	2 (<1)	3 (1)	1 (<1)	4 (1)	1 (<1)
鼻出血	4 (1)	1 (<1)	1 (<1)	2 (<1)	0
しゃっくり	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	1 (<1)	0
アレルギー性咽頭炎	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 21 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
息詰まり	1 (<1)	0	1 (<1)	1 (<1)	0
咽喉乾燥	0	1 (<1)	0	1 (<1)	0
発声障害	1 (<1)	0	1 (<1)	1 (<1)	0
呼吸困難	6 (2)	1 (<1)	0	1 (<1)	2 (2)
鼻中隔彎曲	0	1 (<1)	0	1 (<1)	0
口腔咽頭不快感	0	1 (<1)	0	1 (<1)	1 (<1)
呼吸時疼痛	0	0	1 (<1)	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	1 (<1)	0
咽頭紅斑	0	0	1 (<1)	1 (<1)	0
気胸	0	0	1 (<1)	1 (<1)	0
ラ音	1 (<1)	0	1 (<1)	1 (<1)	0
呼吸抑制	0	1 (<1)	0	1 (<1)	0
呼吸障害	0	0	1 (<1)	1 (<1)	0
気道うっ血	3 (<1)	0	1 (<1)	1 (<1)	0
気道の炎症	0	0	1 (<1)	1 (<1)	0
副鼻腔うっ血	0	0	1 (<1)	1 (<1)	0
声帯の炎症	0	0	1 (<1)	1 (<1)	0
喘鳴	0	1 (<1)	0	1 (<1)	0
喀血	1 (<1)	0	0	0	0
過換気	1 (<1)	0	0	0	0
低換気	0	0	0	0	1 (<1)
鼻閉	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 22 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
鼻部不快感	1 (<1)	0	0	0	0
鼻茸	1 (<1)	0	0	0	0
鼻中隔穿孔	0	0	0	0	1 (<1)
アレルギー性鼻炎	6 (2)	0	0	0	0
低音性連続性ラ音	1 (<1)	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	2 (2)
咽喉刺激感	2 (<1)	0	0	0	0
扁桃障害	1 (<1)	0	0	0	0
上気道うっ血	0	0	0	0	1 (<1)
上気道の炎症	1 (<1)	0	0	0	0
胃腸障害	116 (36)	96 (47)	97 (53)	193 (50)	25 (22)
下痢	41 (13)	36 (18)	24 (13)	60 (15)	8 (7)
悪心	34 (11)	24 (12)	27 (15)	51 (13)	8 (7)
上腹部痛	19 (6)	22 (11)	24 (13)	46 (12)	1 (<1)
嘔吐	18 (6)	18 (9)	17 (9)	35 (9)	5 (4)
腹痛	18 (6)	11 (5)	17 (9)	28 (7)	3 (3)
消化不良	3 (<1)	10 (5)	12 (7)	22 (6)	1 (<1)
便秘	13 (4)	11 (5)	7 (4)	18 (5)	5 (4)
胃炎	4 (1)	6 (3)	9 (5)	15 (4)	0
歯痛	4 (1)	6 (3)	9 (5)	15 (4)	2 (2)
胃腸障害	3 (<1)	4 (2)	8 (4)	12 (3)	2 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 23 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胃食道逆流性疾患	5 (2)	2 (<1)	5 (3)	7 (2)	1 (<1)
口内乾燥	2 (<1)	3 (1)	2 (1)	5 (1)	1 (<1)
痔核	2 (<1)	2 (<1)	3 (2)	5 (1)	0
歯周炎	1 (<1)	0	5 (3)	5 (1)	0
鼓腸	6 (2)	2 (<1)	2 (1)	4 (1)	1 (<1)
腹部不快感	5 (2)	2 (<1)	1 (<1)	3 (<1)	0
腹部膨満	6 (2)	1 (<1)	2 (1)	3 (<1)	0
大腸炎	0	1 (<1)	2 (1)	3 (<1)	1 (<1)
齲歯	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
小腸炎	0	0	3 (2)	3 (<1)	0
便失禁	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
下腹部痛	0	1 (<1)	1 (<1)	2 (<1)	0
嚥下障害	4 (1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
食中毒	0	0	2 (1)	2 (<1)	0
歯肉痛	0	0	2 (1)	2 (<1)	0
歯肉炎	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
裂孔ヘルニア	0	2 (<1)	0	2 (<1)	0
口の感覚鈍麻	1 (<1)	0	2 (1)	2 (<1)	0
腹部ヘルニア	0	1 (<1)	0	1 (<1)	0
腹部硬直	1 (<1)	0	1 (<1)	1 (<1)	0
便通不規則	0	0	1 (<1)	1 (<1)	0
便習慣変化	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 24 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
口唇炎	0	1 (<1)	0	1 (<1)	0
結腸ポリープ	0	0	1 (<1)	1 (<1)	0
便意切迫	0	0	1 (<1)	1 (<1)	2 (2)
腸憩室	0	0	1 (<1)	1 (<1)	0
おくび	0	1 (<1)	0	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)	0
排便回数増加	0	1 (<1)	0	1 (<1)	0
胃潰瘍	0	0	1 (<1)	1 (<1)	0
胃腸出血	0	0	1 (<1)	1 (<1)	0
舌炎	0	1 (<1)	0	1 (<1)	0
舌痛	1 (<1)	0	1 (<1)	1 (<1)	0
胃酸過多	1 (<1)	1 (<1)	0	1 (<1)	0
神経因性腸	0	0	1 (<1)	1 (<1)	0
嚥下痛	0	0	1 (<1)	1 (<1)	0
食道出血	0	1 (<1)	0	1 (<1)	0
食道潰瘍	0	0	1 (<1)	1 (<1)	0
食道炎	0	1 (<1)	0	1 (<1)	0
口腔内痛	0	0	1 (<1)	1 (<1)	0
膵脂肪腫症	0	1 (<1)	0	1 (<1)	0
膵臓障害	0	0	1 (<1)	1 (<1)	0
膵機能不全	0	0	1 (<1)	1 (<1)	0
肛門周囲痛	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 25 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
直腸出血	0	1 (<1)	0	1 (<1)	0
流涎過多	0	1 (<1)	0	1 (<1)	0
口内炎	3 (<1)	0	1 (<1)	1 (<1)	0
舌腫脹	0	1 (<1)	0	1 (<1)	0
舌障害	0	0	1 (<1)	1 (<1)	0
歯の障害	0	1 (<1)	0	1 (<1)	0
臍ヘルニア	1 (<1)	0	1 (<1)	1 (<1)	0
腹部圧痛	1 (<1)	0	0	0	0
異常便	1 (<1)	0	0	0	0
裂肛	1 (<1)	0	0	0	0
アフタ性口内炎	1 (<1)	0	0	0	0
口唇のひび割れ	1 (<1)	0	0	0	0
十二指腸胃逆流	1 (<1)	0	0	0	0
心窩部不快感	1 (<1)	0	0	0	0
胃障害	2 (<1)	0	0	0	0
消化器痛	1 (<1)	0	0	0	1 (<1)
歯肉出血	0	0	0	0	1 (<1)
歯肉腫脹	1 (<1)	0	0	0	0
血便排泄	1 (<1)	0	0	0	0
過敏性腸症候群	1 (<1)	0	0	0	0
口腔内潰瘍形成	3 (<1)	0	0	0	0
膵炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 26 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
急性膵炎	1 (<1)	0	0	0	0
口の錯感覚	2 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
直腸攣縮	0	0	0	0	1 (<1)
逆流性胃炎	1 (<1)	0	0	0	0
逆流性食道炎	1 (<1)	0	0	0	0
肝胆道系障害	5 (2)	5 (2)	5 (3)	10 (3)	2 (2)
肝障害	0	1 (<1)	3 (2)	4 (1)	0
肝嚢胞	0	1 (<1)	1 (<1)	2 (<1)	0
脂肪肝	1 (<1)	2 (<1)	0	2 (<1)	0
肝炎	1 (<1)	0	1 (<1)	1 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
胆石症	1 (<1)	0	0	0	2 (2)
中毒性肝炎	1 (<1)	0	0	0	0
高ビリルビン血症	1 (<1)	0	0	0	0
皮膚および皮下組織障害	56 (18)	67 (33)	69 (38)	136 (35)	22 (19)
発疹	9 (3)	17 (8)	15 (8)	32 (8)	5 (4)
そう痒症	11 (3)	14 (7)	15 (8)	29 (7)	2 (2)
紅斑	3 (<1)	9 (4)	19 (10)	28 (7)	2 (2)
蕁麻疹	4 (1)	6 (3)	5 (3)	11 (3)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 27 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
多汗症	3 (<1)	4 (2)	6 (3)	10 (3)	1 (<1)
脱毛症	8 (3)	5 (2)	2 (1)	7 (2)	3 (3)
皮膚乾燥	3 (<1)	3 (1)	2 (1)	5 (1)	0
全身性そう痒症	0	3 (1)	2 (1)	5 (1)	0
アレルギー性皮膚炎	2 (<1)	3 (1)	1 (<1)	4 (1)	0
湿疹	2 (<1)	1 (<1)	3 (2)	4 (1)	0
全身紅斑	0	2 (<1)	2 (1)	4 (1)	0
顔面感覚鈍麻	3 (<1)	1 (<1)	3 (2)	4 (1)	1 (<1)
紅斑性皮疹	0	1 (<1)	3 (2)	4 (1)	0
ざ瘡	7 (2)	2 (<1)	1 (<1)	3 (<1)	3 (3)
薬疹	0	1 (<1)	2 (1)	3 (<1)	0
寝汗	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
そう痒性皮疹	0	1 (<1)	2 (1)	3 (<1)	0
皮膚灼熱感	0	0	3 (2)	3 (<1)	0
光線過敏性反応	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
酒さ	3 (<1)	2 (<1)	0	2 (<1)	0
皮膚剥脱	0	2 (<1)	0	2 (<1)	0
皮膚のつっぱり感	0	1 (<1)	1 (<1)	2 (<1)	0
日光性角化症	0	0	1 (<1)	1 (<1)	0
水疱	0	1 (<1)	0	1 (<1)	0
皮膚炎	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
ざ瘡様皮膚炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 28 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
接触性皮膚炎	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
斑状出血	0	1 (<1)	0	1 (<1)	0
過角化	0	1 (<1)	0	1 (<1)	0
掌蹠角化症	0	1 (<1)	0	1 (<1)	0
爪破損	0	1 (<1)	0	1 (<1)	0
皮膚疼痛	0	0	1 (<1)	1 (<1)	0
痒疹	0	1 (<1)	0	1 (<1)	0
アレルギー性そう痒症	0	0	1 (<1)	1 (<1)	0
乾癬	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
全身性皮疹	0	0	1 (<1)	1 (<1)	0
斑状皮疹	0	0	1 (<1)	1 (<1)	0
丘疹性皮疹	0	0	1 (<1)	1 (<1)	0
瘢痕	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
脂腺障害	0	0	1 (<1)	1 (<1)	0
皮膚色素過剰	1 (<1)	1 (<1)	0	1 (<1)	2 (2)
皮膚刺激	0	1 (<1)	0	1 (<1)	0
皮膚病変	0	1 (<1)	0	1 (<1)	0
皮膚反応	0	0	1 (<1)	1 (<1)	0
皮膚潰瘍	0	0	1 (<1)	1 (<1)	0
皮膚熱感	0	0	1 (<1)	1 (<1)	0
スティーブンス・ジョンソン症候群	0	1 (<1)	0	1 (<1)	0
皮下結節	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 29 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
頭部粃糠疹	0	0	0	0	1 (<1)
皮膚嚢腫	1 (<1)	0	0	0	0
発汗障害	1 (<1)	0	0	0	0
皮膚肉芽腫	1 (<1)	0	0	0	0
内出血発生の増加傾向	0	0	0	0	1 (<1)
黒子	1 (<1)	0	0	0	0
網状皮斑	0	0	0	0	1 (<1)
爪床障害	1 (<1)	0	0	0	0
爪変色	1 (<1)	0	0	0	0
神経皮膚炎	0	0	0	0	1 (<1)
点状出血	1 (<1)	0	0	0	0
光線性皮膚症	1 (<1)	0	0	0	0
ばら色粃糠疹	1 (<1)	0	0	0	0
前癌性皮膚病変	1 (<1)	0	0	0	0
皮膚変色	1 (<1)	0	0	0	0
皮膚障害	1 (<1)	0	0	0	0
皮膚小結節	0	0	0	0	1 (<1)
顔面腫脹	0	0	0	0	1 (<1)
毛細血管拡張症	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	88 (28)	71 (35)	62 (34)	133 (34)	36 (32)
背部痛	27 (8)	25 (12)	19 (10)	44 (11)	17 (15)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 30 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
関節痛	24 (8)	21 (10)	15 (8)	36 (9)	8 (7)
四肢痛	20 (6)	15 (7)	15 (8)	30 (8)	8 (7)
筋痙縮	12 (4)	12 (6)	14 (8)	26 (7)	3 (3)
筋力低下	16 (5)	8 (4)	6 (3)	14 (4)	2 (2)
筋骨格痛	13 (4)	3 (1)	9 (5)	12 (3)	4 (4)
頚部痛	7 (2)	6 (3)	4 (2)	10 (3)	2 (2)
筋肉痛	10 (3)	3 (1)	2 (1)	5 (1)	2 (2)
重感	0	4 (2)	1 (<1)	5 (1)	2 (2)
滑液包炎	0	2 (<1)	2 (1)	4 (1)	0
変形性関節症	1 (<1)	2 (<1)	2 (1)	4 (1)	0
椎間板障害	0	2 (<1)	1 (<1)	3 (<1)	0
関節腫脹	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
筋緊張	0	0	3 (2)	3 (<1)	0
筋骨格不快感	2 (<1)	1 (<1)	2 (1)	3 (<1)	0
関節周囲炎	3 (<1)	1 (<1)	2 (1)	3 (<1)	0
尾骨痛	0	0	2 (1)	2 (<1)	0
椎間板突出	0	2 (<1)	0	2 (<1)	0
筋骨格硬直	3 (<1)	0	2 (1)	2 (<1)	4 (4)
シェーグレン症候群	0	2 (<1)	0	2 (<1)	0
腱炎	4 (1)	1 (<1)	1 (<1)	2 (<1)	0
関節炎	0	1 (<1)	0	1 (<1)	0
骨痛	2 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 31 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
軟骨炎	0	1 (<1)	0	1 (<1)	0
外骨腫	0	0	1 (<1)	1 (<1)	2 (2)
四肢拘縮	0	1 (<1)	0	1 (<1)	0
側腹部痛	0	0	1 (<1)	1 (<1)	1 (<1)
尿径部痛	1 (<1)	1 (<1)	0	1 (<1)	0
成長痛	0	0	1 (<1)	1 (<1)	0
椎間板圧迫	0	1 (<1)	0	1 (<1)	0
骨端症	0	0	1 (<1)	1 (<1)	0
骨壊死	0	0	1 (<1)	1 (<1)	1 (<1)
骨減少症	1 (<1)	1 (<1)	0	1 (<1)	0
骨粗鬆症	2 (<1)	1 (<1)	0	1 (<1)	0
膝蓋大腿部痛症候群	0	1 (<1)	0	1 (<1)	0
脊椎障害	0	1 (<1)	0	1 (<1)	0
変形性脊椎症	1 (<1)	0	1 (<1)	1 (<1)	0
脊椎分離	0	1 (<1)	0	1 (<1)	0
滑液嚢腫	0	1 (<1)	0	1 (<1)	0
滑膜障害	0	1 (<1)	0	1 (<1)	0
腱鞘炎	0	0	1 (<1)	1 (<1)	0
弾発指	0	1 (<1)	0	1 (<1)	0
線維筋痛	2 (<1)	0	0	0	0
関節硬直	0	0	0	0	1 (<1)
四肢不快感	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 32 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
運動性低下	0	0	0	0	1 (<1)
筋拘縮	1 (<1)	0	0	0	0
筋肉疲労	1 (<1)	0	0	0	0
筋攣縮	2 (<1)	0	0	0	0
筋骨格系胸痛	4 (1)	0	0	0	0
顎痛	0	0	0	0	1 (<1)
回帰性リウマチ	1 (<1)	0	0	0	0
脊柱変形	1 (<1)	0	0	0	0
滑膜炎	1 (<1)	0	0	0	0
腱痛	1 (<1)	0	0	0	0
腎および尿路障害	58 (18)	37 (18)	51 (28)	88 (23)	24 (21)
蛋白尿	27 (8)	18 (9)	24 (13)	42 (11)	12 (11)
血尿	11 (3)	11 (5)	14 (8)	25 (6)	4 (4)
ミクロアルブミン尿	12 (4)	8 (4)	11 (6)	19 (5)	7 (6)
排尿困難	6 (2)	4 (2)	6 (3)	10 (3)	1 (<1)
ケトン尿	4 (1)	1 (<1)	7 (4)	8 (2)	0
腎結石症	3 (<1)	3 (1)	2 (1)	5 (1)	0
尿意切迫	2 (<1)	3 (1)	1 (<1)	4 (1)	3 (3)
尿失禁	3 (<1)	1 (<1)	3 (2)	4 (1)	1 (<1)
糖尿	6 (2)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
切迫性尿失禁	0	1 (<1)	2 (1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 33 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿閉	1 (<1)	0	3 (2)	3 (<1)	1 (<1)
アルブミン尿	0	1 (<1)	1 (<1)	2 (<1)	0
緊張性膀胱	0	1 (<1)	1 (<1)	2 (<1)	0
白血球尿	1 (<1)	0	2 (1)	2 (<1)	1 (<1)
頻尿	3 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (2)
尿臭異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
膀胱機能障害	1 (<1)	1 (<1)	0	1 (<1)	0
非感染性膀胱炎	1 (<1)	0	1 (<1)	1 (<1)	0
起立性蛋白尿症	0	0	1 (<1)	1 (<1)	0
腎嚢胞	1 (<1)	1 (<1)	0	1 (<1)	0
有痛性排尿困難	0	1 (<1)	0	1 (<1)	0
排尿躊躇	2 (<1)	0	1 (<1)	1 (<1)	0
神経因性膀胱	1 (<1)	0	0	0	0
夜間頻尿	0	0	0	0	1 (<1)
腎仙痛	1 (<1)	0	0	0	0
腹圧性尿失禁	1 (<1)	0	0	0	0
妊娠、産褥および周産期の状態	3 (<1)	0	0	0	0
自然流産	2 (<1)	0	0	0	0
妊娠浮腫	1 (<1)	0	0	0	0
生殖系および乳房障害	35 (11)	22 (11)	22 (12)	44 (11)	10 (9)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 34 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
月経困難症	4 (1)	3 (1)	3 (2)	6 (2)	2 (2)
不正子宮出血	3 (<1)	3 (1)	2 (1)	5 (1)	2 (2)
骨盤痛	2 (<1)	2 (<1)	3 (2)	5 (1)	0
無月経	2 (<1)	1 (<1)	3 (2)	4 (1)	1 (<1)
不規則月経	4 (1)	2 (<1)	2 (1)	4 (1)	2 (2)
卵巣嚢胞	3 (<1)	2 (<1)	1 (<1)	3 (<1)	0
子宮出血	0	1 (<1)	2 (1)	3 (<1)	0
腟出血	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
勃起不全	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
閉経期症状	0	1 (<1)	1 (<1)	2 (<1)	0
月経過多	3 (<1)	0	2 (1)	2 (<1)	0
頻発月経	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
腺筋症	0	0	1 (<1)	1 (<1)	0
萎縮性外陰腟炎	0	0	1 (<1)	1 (<1)	0
乳房不快感	0	1 (<1)	0	1 (<1)	0
乳房障害	0	1 (<1)	0	1 (<1)	1 (<1)
乳房出血	0	1 (<1)	0	1 (<1)	0
乳房圧痛	0	0	1 (<1)	1 (<1)	0
子宮内膜増殖症	0	1 (<1)	0	1 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
月経障害	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
希発月経	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 35 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
卵巣嚢胞破裂	1 (<i)	1 (<1)	0	1 (<1)	0
多嚢胞性卵巣	0	1 (<1)	0	1 (<1)	0
子宮ポリープ	1 (<1)	1 (<1)	0	1 (<1)	0
腟分泌物	0	0	1 (<1)	1 (<1)	0
外陰腟乾燥	0	1 (<1)	0	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0	0
線維嚢胞性乳腺疾患	2 (<1)	0	0	0	0
機能性子宮出血	1 (<1)	0	0	0	1 (<1)
月経遅延	2 (<1)	0	0	0	1 (<1)
性機能不全	2 (<1)	0	0	0	0
精巣痛	1 (<1)	0	0	0	0
子宮頚部びらん	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	0	0	2 (1)	2 (<1)	0
異形成母斑症候群	0	0	1 (<1)	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	1 (<1)	0
一般・全身障害および投与部位の状態	75 (24)	52 (25)	54 (29)	106 (27)	52 (46)
疲労	29 (9)	27 (13)	27 (15)	54 (14)	13 (12)
無力症	9 (3)	10 (5)	7 (4)	17 (4)	4 (4)
発熱	16 (5)	5 (2)	9 (5)	14 (4)	8 (7)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 36 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
末梢性浮腫	8 (3)	5 (2)	6 (3)	11 (3)	1 (<1)
インフルエンザ様疾患	4 (1)	4 (2)	5 (3)	9 (2)	2 (2)
疼痛	4 (1)	3 (1)	4 (2)	7 (2)	2 (2)
胸痛	5 (2)	1 (<1)	4 (2)	5 (1)	1 (<1)
熱感	1 (<1)	4 (2)	1 (<1)	5 (1)	2 (2)
歩行障害	5 (2)	2 (<1)	3 (2)	5 (1)	4 (4)
胸部不快感	1 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
顔面痛	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
非心臓性胸痛	0	0	3 (2)	3 (<1)	2 (2)
倦怠感	0	1 (<1)	1 (<1)	2 (<1)	0
腋窩痛	0	0	1 (<1)	1 (<1)	0
悪寒	3 (<1)	1 (<1)	0	1 (<1)	3 (3)
医療機器不具合	0	1 (<1)	0	1 (<1)	0
医療機器関連眼合併症	1 (<1)	1 (<1)	0	1 (<1)	0
異常感	1 (<1)	0	1 (<1)	1 (<1)	0
びくびく感	0	0	1 (<1)	1 (<1)	0
注射部位硬結	0	0	1 (<1)	1 (<1)	3 (3)
易刺激性	3 (<1)	1 (<1)	0	1 (<1)	2 (2)
腫瘤	0	1 (<1)	0	1 (<1)	0
粘膜乾燥	0	1 (<1)	0	1 (<1)	0
軟部組織の炎症	0	1 (<1)	0	1 (<1)	0
腫脹	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 37 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
温度変化不耐症	0	1 (<1)	0	1 (<1)	0
適用部位浮腫	0	0	0	0	1 (<1)
嚢胞破裂	0	0	0	0	1 (<1)
ヘルニア痛	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	1 (<1)
注射部位乾燥	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	10 (9)
注射部位血腫	0	0	0	0	2 (2)
注射部位出血	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	2 (2)
注射部位炎症	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	4 (4)
注射部位疼痛	0	0	0	0	16 (14)
注射部位そう痒感	0	0	0	0	7 (6)
注射部位発疹	0	0	0	0	2 (2)
注射部位反応	0	0	0	0	2 (2)
注射部位瘢痕	0	0	0	0	1 (<1)
注射部位腫脹	0	0	0	0	4 (4)
注射部位蕁麻疹	0	0	0	0	2 (2)
注射部位熱感	0	0	0	0	2 (2)
壊死	0	0	0	0	1 (<1)
浮腫	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 38 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
骨盤腔内腫瘤	1 (<1)	0	0	0	0
ワクチン接種部位疼痛	1 (<1)	0	0	0	0
臨床検査	81 (25)	53 (26)	64 (35)	117 (30)	46 (41)
アラニン・アミノトランスフェラーゼ増加	17 (5)	10 (5)	13 (7)	23 (6)	6 (5)
尿中アルブミン陽性	10 (3)	10 (5)	9 (5)	19 (5)	10 (9)
アスパラギン酸アミノトランスフェラーゼ増加	7 (2)	8 (4)	7 (4)	15 (4)	4 (4)
血中副甲状腺ホルモン増加	4 (1)	7 (3)	5 (3)	12 (3)	1 (<1)
尿中蛋白陽性	8 (3)	8 (4)	3 (2)	11 (3)	6 (5)
尿中血陽性	2 (<1)	4 (2)	6 (3)	10 (3)	3 (3)
γ－グルタミルトランスフェラーゼ増加	7 (2)	5 (2)	4 (2)	9 (2)	3 (3)
体重増加	4 (1)	3 (1)	5 (3)	8 (2)	2 (2)
尿中白血球陽性	5 (2)	2 (<1)	6 (3)	8 (2)	3 (3)
血中ブドウ糖増加	2 (<1)	4 (2)	3 (2)	7 (2)	2 (2)
尿中β２ミクログロブリン増加	8 (3)	3 (1)	3 (2)	6 (2)	0
体重減少	2 (<1)	2 (<1)	4 (2)	6 (2)	0
白血球数増加	4 (1)	4 (2)	2 (1)	6 (2)	2 (2)
肝酵素上昇	4 (1)	3 (1)	2 (1)	5 (1)	5 (4)
好中球数増加	5 (2)	3 (1)	2 (1)	5 (1)	1 (<1)
血中クレアチニン増加	1 (<1)	3 (1)	1 (<1)	4 (1)	2 (2)
心電図ＱＴ延長	2 (<1)	1 (<1)	3 (2)	4 (1)	3 (3)
尿中赤血球陽性	2 (<1)	2 (<1)	2 (1)	4 (1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 39 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球数減少	1 (<1)	2 (<1)	2 (1)	4 (1)	1 (<1)
血中アルカリホスファターゼ増加	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
肝機能検査異常	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
リンパ球数減少	1 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
リンパ球数増加	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
尿中ケトン体陽性	0	3 (1)	0	3 (<1)	0
血中尿酸増加	0	0	2 (1)	2 (<1)	0
好酸球数増加	0	0	2 (1)	2 (<1)	0
ヘマトクリット減少	3 (<1)	2 (<1)	0	2 (<1)	0
ヘモグロビン減少	2 (<1)	2 (<1)	0	2 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
リンパ球形態異常	0	1 (<1)	1 (<1)	2 (<1)	0
好中球数減少	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
アラニン・アミノトランスフェラーゼ異常	0	0	1 (<1)	1 (<1)	2 (2)
アレルギー検査	0	0	1 (<1)	1 (<1)	0
抗ＳＳＡ抗体陽性	0	1 (<1)	0	1 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	1 (<1)	0
β２ミクログロブリン増加	1 (<1)	1 (<1)	0	1 (<1)	0
血中ビリルビン増加	4 (1)	0	1 (<1)	1 (<1)	0
血中カルシウム増加	0	0	1 (<1)	1 (<1)	1 (<1)
血中コレステロール増加	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
血中ブドウ糖減少	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 40 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中免疫グロブリンM増加	0	0	1 (<1)	1 (<1)	0
血中ケトン体増加	0	0	1 (<1)	1 (<1)	1 (<1)
血中乳酸脱水素酵素増加	1 (<1)	1 (<1)	0	1 (<1)	0
血中カリウム減少	1 (<1)	0	1 (<1)	1 (<1)	0
血圧上昇	0	0	1 (<1)	1 (<1)	0
血中トリグリセリド増加	3 (<1)	1 (<1)	0	1 (<1)	5 (4)
血中尿素増加	0	0	1 (<1)	1 (<1)	1 (<1)
結腸内視鏡検査	0	1 (<1)	0	1 (<1)	0
心電図異常	2 (<1)	0	1 (<1)	1 (<1)	0
心電図ＳＴ部分下降	1 (<1)	1 (<1)	0	1 (<1)	0
心電図Ｔ波振幅減少	0	0	1 (<1)	1 (<1)	1 (<1)
エプスタイン・バーウイルス抗体陽性	0	0	1 (<1)	1 (<1)	0
γ－グルタミルトランスフェラーゼ異常	1 (<1)	0	1 (<1)	1 (<1)	0
胃内ｐＨ上昇	0	0	1 (<1)	1 (<1)	0
尿中ブドウ糖陽性	1 (<1)	1 (<1)	0	1 (<1)	2 (2)
血液学的検査異常	1 (<1)	0	1 (<1)	1 (<1)	0
心拍数減少	0	0	1 (<1)	1 (<1)	0
心拍数増加	1 (<1)	1 (<1)	0	1 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	1 (<1)	0
眼圧上昇	0	1 (<1)	0	1 (<1)	0
検査	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 41 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
医学的観察	0	0	1 (<1)	1 (<1)	0
単球数増加	0	0	1 (<1)	1 (<1)	0
脳核磁気共鳴画像異常	0	1 (<1)	0	1 (<1)	0
血小板数減少	0	1 (<1)	0	1 (<1)	2 (2)
腎機能検査異常	0	1 (<1)	0	1 (<1)	0
呼吸数増加	0	0	1 (<1)	1 (<1)	0
血清フェリチン減少	0	0	1 (<1)	1 (<1)	0
子宮頚部スミア異常	0	0	1 (<1)	1 (<1)	0
ビタミンＤ減少	0	1 (<1)	0	1 (<1)	1 (<1)
ビタミンＤ増加	0	0	1 (<1)	1 (<1)	0
アスパラギン酸アミノトランスフェラーゼ異常	0	0	0	0	1 (<1)
細菌検査	1 (<1)	0	0	0	0
細菌検査陽性	0	0	0	0	2 (2)
血中アルカリホスファターゼ異常	0	0	0	0	1 (<1)
血中重炭酸塩減少	1 (<1)	0	0	0	0
血中ビリルビン異常	0	0	0	0	1 (<1)
血中ビリルビン減少	1 (<1)	0	0	0	0
血中カルシウム減少	1 (<1)	0	0	0	0
血中クレアチン異常	1 (<1)	0	0	0	0
血中乳酸脱水素酵素異常	0	0	0	0	1 (<1)
血中リン減少	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 42 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中カリウム増加	0	0	0	0	1 (<1)
血中ナトリウム増加	0	0	0	0	1 (<1)
体温上昇	0	0	0	0	1 (<1)
心雑音	1 (<1)	0	0	0	0
中枢神経系機能検査異常	1 (<1)	0	0	0	0
尿中結晶陽性	1 (<1)	0	0	0	0
心電図Ｔ波逆転	1 (<1)	0	0	0	0
好酸球数異常	1 (<1)	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	1 (<1)	0	0	0	0
リンパ球数異常	0	0	0	0	1 (<1)
リンパ球百分率減少	1 (<1)	0	0	0	0
骨髄球数増加	1 (<1)	0	0	0	0
好中球数異常	0	0	0	0	1 (<1)
好中球百分率異常	1 (<1)	0	0	0	0
好中球百分率増加	1 (<1)	0	0	0	0
血小板数増加	2 (<1)	0	0	0	1 (<1)
ＱＲＳ軸異常	1 (<1)	0	0	0	0
赤血球数減少	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	2 (<1)	0	0	0	1 (<1)
尿細胞診異常	1 (<1)	0	0	0	0
ビタミンＢ１２減少	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 43 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球数異常	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	55 (17)	28 (14)	37 (20)	65 (17)	21 (19)
挫傷	10 (3)	9 (4)	8 (4)	17 (4)	3 (3)
転倒	9 (3)	9 (4)	7 (4)	16 (4)	7 (6)
関節捻挫	7 (2)	5 (2)	5 (3)	10 (3)	1 (<1)
足骨折	1 (<1)	2 (<1)	3 (2)	5 (1)	2 (2)
節足動物咬傷	2 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
関節脱臼	0	3 (1)	0	3 (<1)	0
鎖骨骨折	0	1 (<1)	1 (<1)	2 (<1)	0
擦過傷	3 (<1)	0	2 (1)	2 (<1)	0
術後発熱	0	2 (<1)	0	2 (<1)	0
橈骨骨折	0	1 (<1)	1 (<1)	2 (<1)	0
交通事故	3 (<1)	0	2 (1)	2 (<1)	1 (<1)
サンバーン	2 (<1)	0	2 (1)	2 (<1)	1 (<1)
熱傷	6 (2)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
動物咬傷	0	1 (<1)	0	1 (<1)	0
足関節部骨折	0	0	1 (<1)	1 (<1)	0
節足動物刺傷	1 (<1)	0	1 (<1)	1 (<1)	0
造影剤反応	0	0	1 (<1)	1 (<1)	0
上顆炎	1 (<1)	0	1 (<1)	1 (<1)	0
顔面損傷	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 44 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
大腿骨骨折	0	0	1 (<1)	1 (<1)	1 (<1)
頭部損傷	3 (<1)	1 (<1)	0	1 (<1)	0
靭帯損傷	0	0	1 (<1)	1 (<1)	0
四肢損傷	1 (<1)	0	1 (<1)	1 (<1)	3 (3)
半月板障害	2 (<1)	1 (<1)	0	1 (<1)	0
肉離れ	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
頚部損傷	0	0	1 (<1)	1 (<1)	0
神経損傷	0	0	1 (<1)	1 (<1)	0
過量投与	0	1 (<1)	0	1 (<1)	0
処置による低血圧	0	1 (<1)	0	1 (<1)	0
脊椎圧迫骨折	0	1 (<1)	0	1 (<1)	0
舌損傷	0	1 (<1)	0	1 (<1)	0
上肢骨折	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
むち打ち損傷	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
創傷	0	1 (<1)	0	1 (<1)	0
労働災害	1 (<1)	0	0	0	0
動物による引っかき傷	0	0	0	0	1 (<1)
第２度熱傷	1 (<1)	0	0	0	0
脳振盪	1 (<1)	0	0	0	1 (<1)
眼外傷	0	0	0	0	1 (<1)
大腿骨頚部骨折	1 (<1)	0	0	0	0
前腕骨折	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 45 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尾骨骨折	1 (<1)	0	0	0	0
手骨折	2 (<1)	0	0	0	2 (2)
瘢痕ヘルニア	1 (<1)	0	0	0	0
損傷	0	0	0	0	1 (<1)
関節損傷	3 (<1)	0	0	0	0
靭帯断裂	1 (<1)	0	0	0	0
処置後合併症	1 (<1)	0	0	0	0
処置後出血	1 (<1)	0	0	0	0
外傷後疼痛	0	0	0	0	2 (2)
術後創合併症	0	0	0	0	1 (<1)
処置による疼痛	0	0	0	0	2 (2)
反復性挫傷	1 (<1)	0	0	0	0
骨格損傷	3 (<1)	0	0	0	0
皮膚裂傷	2 (<1)	0	0	0	1 (<1)
ストレス骨折	0	0	0	0	1 (<1)
腱断裂	1 (<1)	0	0	0	0
脛骨骨折	1 (<1)	0	0	0	0
歯の完全脱臼	1 (<1)	0	0	0	0
外傷性血腫	0	0	0	0	1 (<1)
手首関節骨折	2 (<1)	0	0	0	0
外科および内科処置	6 (2)	1 (<1)	1 (<1)	2 (<1)	3 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects treated with IV corticosteroids by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 46 of 46

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
デンタルケア	0	0	1 (<1)	1 (<1)	0
抜歯	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
子宮頚部円錐切除	1 (<1)	0	0	0	0
嚢胞ドレナージ	1 (<1)	0	0	0	0
入院	0	0	0	0	1 (<1)
不妊手術	0	0	0	0	1 (<1)
鼻甲介切除	1 (<1)	0	0	0	0
社会環境	1 (<1)	0	0	0	0
社会問題	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST-A.SAS DATE: 02DEC2015

Table 288: Incidence of Adverse Events in Subjects Not Treated With IV Corticosteroids by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302

Page 1 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Number of subjects not treated with IV corticosteroids	452 (100)	564 (100)	576 (100)	1140 (100)	238 (100)
Number of subjects with an event	401 (89)	528 (94)	528 (92)	1056 (93)	191 (80)
感染症および寄生虫症	254 (56)	333 (59)	345 (60)	678 (59)	113 (47)
鼻咽頭炎	88 (19)	128 (23)	125 (22)	253 (22)	34 (14)
上気道感染	50 (11)	65 (12)	77 (13)	142 (12)	17 (7)
尿路感染	58 (13)	71 (13)	70 (12)	141 (12)	28 (12)
インフルエンザ	37 (8)	43 (8)	53 (9)	96 (8)	11 (5)
副鼻腔炎	19 (4)	22 (4)	36 (6)	58 (5)	7 (3)
気管支炎	17 (4)	21 (4)	35 (6)	56 (5)	11 (5)
胃腸炎	14 (3)	27 (5)	23 (4)	50 (4)	2 (<1)
咽頭炎	14 (3)	20 (4)	22 (4)	42 (4)	10 (4)
鼻炎	12 (3)	17 (3)	15 (3)	32 (3)	7 (3)
ウイルス性胃腸炎	12 (3)	14 (2)	15 (3)	29 (3)	2 (<1)
気道感染	8 (2)	10 (2)	15 (3)	25 (2)	5 (2)
ウイルス感染	4 (<1)	14 (2)	8 (1)	22 (2)	4 (2)
口腔ヘルペス	11 (2)	12 (2)	7 (1)	19 (2)	4 (2)
膀胱炎	10 (2)	8 (1)	10 (2)	18 (2)	3 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 2 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
喉頭炎	3 (<1)	8 (1)	10 (2)	18 (2)	1 (<1)
ウイルス性上気道感染	8 (2)	9 (2)	8 (1)	17 (1)	7 (3)
耳感染	4 (<1)	2 (<1)	13 (2)	15 (1)	1 (<1)
外陰腟真菌感染	6 (1)	6 (1)	9 (2)	15 (1)	3 (1)
帯状疱疹	7 (2)	7 (1)	7 (1)	14 (1)	0
中耳炎	0	8 (1)	6 (1)	14 (1)	0
歯膿瘍	7 (2)	8 (1)	6 (1)	14 (1)	1 (<1)
扁桃炎	6 (1)	7 (1)	6 (1)	13 (1)	1 (<1)
腟感染	2 (<1)	8 (1)	5 (<1)	13 (1)	4 (2)
感染性結膜炎	2 (<1)	5 (<1)	6 (1)	11 (<1)	0
消化管感染	5 (1)	4 (<1)	5 (<1)	9 (<1)	2 (<1)
ウイルス性消化管感染	3 (<1)	6 (1)	2 (<1)	8 (<1)	0
下気道感染	3 (<1)	2 (<1)	6 (1)	8 (<1)	0
ウイルス性気道感染	1 (<1)	6 (1)	2 (<1)	8 (<1)	0
歯感染	2 (<1)	3 (<1)	5 (<1)	8 (<1)	2 (<1)
麦粒腫	3 (<1)	4 (<1)	3 (<1)	7 (<1)	0
爪真菌症	2 (<1)	6 (1)	0	6 (<1)	0
レンサ球菌性咽頭炎	5 (1)	1 (<1)	5 (<1)	6 (<1)	0
気管炎	1 (<1)	4 (<1)	2 (<1)	6 (<1)	0
外陰部腟カンジダ症	1 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
蜂巣炎	1 (<1)	4 (<1)	1 (<1)	5 (<1)	0
せつ	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 3 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
咽頭扁桃炎	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
細菌尿	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
陰部ヘルペス	2 (<1)	4 (<1)	0	4 (<1)	1 (<1)
癜風	0	2 (<1)	2 (<1)	4 (<1)	0
急性副鼻腔炎	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
急性扁桃炎	2 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
遊走性紅斑	0	1 (<1)	2 (<1)	3 (<1)	0
毛包炎	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
Ｈ１Ｎ１インフルエンザ	0	0	3 (<1)	3 (<1)	1 (<1)
単純ヘルペス	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
シラミ寄生	0	2 (<1)	1 (<1)	3 (<1)	0
口腔カンジダ症	2 (<1)	0	3 (<1)	3 (<1)	0
歯周感染	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
肺炎	2 (<1)	3 (<1)	0	3 (<1)	2 (<1)
細菌性副鼻腔炎	0	2 (<1)	1 (<1)	3 (<1)	0
皮下組織膿瘍	0	1 (<1)	2 (<1)	3 (<1)	0
細菌性結膜炎	0	0	2 (<1)	2 (<1)	0
真菌感染	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ヘリコバクター感染	0	1 (<1)	1 (<1)	2 (<1)	0
咬傷感染	1 (<1)	2 (<1)	0	2 (<1)	0
伝染性単核症	0	1 (<1)	1 (<1)	2 (<1)	0
口腔真菌感染	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 4 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
外耳炎	0	2 (<1)	0	2 (<1)	1 (<1)
爪囲炎	1 (<1)	2 (<1)	0	2 (<1)	0
骨盤内炎症性疾患	0	0	2 (<1)	2 (<1)	0
陰嚢膿瘍	0	0	2 (<1)	2 (<1)	0
腸チフス熱	0	0	2 (<1)	2 (<1)	0
細菌性腟炎	1 (<1)	2 (<1)	0	2 (<1)	2 (<1)
腹壁膿瘍	0	0	1 (<1)	1 (<1)	0
虫垂炎	0	1 (<1)	0	1 (<1)	0
無症候性細菌尿	0	1 (<1)	0	1 (<1)	0
細菌感染	1 (<1)	1 (<1)	0	1 (<1)	0
ボレリア感染	1 (<1)	1 (<1)	0	1 (<1)	0
乳房膿瘍	0	0	1 (<1)	1 (<1)	0
乳房蜂巣炎	0	0	1 (<1)	1 (<1)	0
ウイルス性気管支炎	0	0	1 (<1)	1 (<1)	1 (<1)
気管支肺炎	0	1 (<1)	0	1 (<1)	0
子宮頚管炎	0	1 (<1)	0	1 (<1)	0
デング熱	0	1 (<1)	0	1 (<1)	1 (<1)
憩室炎	0	0	1 (<1)	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
眼感染	2 (<1)	1 (<1)	0	1 (<1)	0
ノロウイルス性胃腸炎	1 (<1)	1 (<1)	0	1 (<1)	0
ロタウイルス胃腸炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 5 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
性器カンジダ症	0	1 (<1)	0	1 (<1)	0
細菌性性器感染	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
泌尿生殖器感染	0	1 (<1)	0	1 (<1)	0
ジアルジア症	0	1 (<1)	0	1 (<1)	0
歯肉感染	1 (<1)	0	1 (<1)	1 (<1)	0
ヘリコバクター性胃炎	0	1 (<1)	0	1 (<1)	1 (<1)
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	1 (<1)	0
膿痂疹	0	0	1 (<1)	1 (<1)	0
切開部位感染	0	1 (<1)	0	1 (<1)	0
感染性嚢腫	1 (<1)	1 (<1)	0	1 (<1)	0
感染性皮脂嚢腫	0	0	1 (<1)	1 (<1)	0
感染	0	0	1 (<1)	1 (<1)	1 (<1)
カンジダ性間擦疹	0	0	1 (<1)	1 (<1)	0
限局性感染	3 (<1)	1 (<1)	0	1 (<1)	0
マイコプラズマ感染	0	0	1 (<1)	1 (<1)	0
急性中耳炎	0	0	1 (<1)	1 (<1)	0
扁桃周囲膿瘍	0	0	1 (<1)	1 (<1)	0
歯髄炎	0	0	1 (<1)	1 (<1)	0
腎盂腎炎	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
急性腎盂腎炎	0	0	1 (<1)	1 (<1)	0
膿皮症	0	1 (<1)	0	1 (<1)	0
卵管卵巣炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 6 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚細菌感染	0	0	1 (<1)	1 (<1)	0
皮膚感染	0	1 (<1)	0	1 (<1)	0
軟部組織感染	0	1 (<1)	0	1 (<1)	0
細菌性上気道感染	1 (<1)	1 (<1)	0	1 (<1)	0
真菌性尿路感染	0	1 (<1)	0	1 (<1)	0
泌尿生殖器真菌感染	0	0	1 (<1)	1 (<1)	0
水痘	0	1 (<1)	0	1 (<1)	0
ウイルス性咽頭炎	1 (<1)	1 (<1)	0	1 (<1)	0
ウイルス性鼻炎	0	0	1 (<1)	1 (<1)	0
外陰部膿瘍	1 (<1)	0	1 (<1)	1 (<1)	0
外陰部炎	0	1 (<1)	0	1 (<1)	0
膿瘍	1 (<1)	0	0	0	0
カンジダ症	0	0	0	0	1 (<1)
慢性副鼻腔炎	0	0	0	0	1 (<1)
ウイルス性結膜炎	1 (<1)	0	0	0	0
医療機器関連感染	1 (<1)	0	0	0	0
皮膚真菌感染	0	0	0	0	1 (<1)
ヘルペスウイルス感染	1 (<1)	0	0	0	0
迷路炎	1 (<1)	0	0	0	0
ライム病	0	0	0	0	1 (<1)
乳腺炎	1 (<1)	0	0	0	0
乳様突起炎	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 7 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
パラインフルエンザウイルス感染	1 (<1)	0	0	0	0
耳下腺炎	0	0	0	0	1 (<1)
細菌性咽頭炎	3 (<1)	0	0	0	0
術後膿瘍	1 (<1)	0	0	0	0
術後創感染	1 (<1)	0	0	0	0
膿胸	0	0	0	0	1 (<1)
猩紅熱	1 (<1)	0	0	0	0
敗血症	2 (<1)	0	0	0	0
レンサ球菌感染	1 (<1)	0	0	0	0
足部白癬	1 (<1)	0	0	0	0
気管気管支炎	1 (<1)	0	0	0	1 (<1)
細菌性尿路感染	3 (<1)	0	0	0	0
膣膿瘍	1 (<1)	0	0	0	0
創傷感染	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	9 (2)	14 (2)	18 (3)	32 (3)	6 (3)
脂肪腫	0	3 (<1)	4 (<1)	7 (<1)	0
皮膚乳頭腫	0	4 (<1)	3 (<1)	7 (<1)	0
メラノサイト性母斑	1 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
線維腫	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
子宮平滑筋腫	1 (<1)	0	3 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 8 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
甲状腺新生物	0	2 (<1)	0	2 (<1)	0
基底細胞癌	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
乳癌	1 (<1)	0	1 (<1)	1 (<1)	0
乳腺線維腺腫	0	0	1 (<1)	1 (<1)	0
泌尿生殖器新生物	0	0	1 (<1)	1 (<1)	0
血管腫	1 (<1)	0	1 (<1)	1 (<1)	0
肝臓血管腫	0	0	1 (<1)	1 (<1)	0
肺新生物	0	1 (<1)	0	1 (<1)	0
乳頭腫	0	0	1 (<1)	1 (<1)	0
腎新生物	0	1 (<1)	0	1 (<1)	0
移行上皮癌	0	1 (<1)	0	1 (<1)	0
甲状腺の良性新生物	1 (<1)	0	0	0	0
乳房新生物	1 (<1)	0	0	0	0
モートン神経腫	1 (<1)	0	0	0	0
皮膚の新生物	1 (<1)	0	0	0	0
良性副甲状腺腫瘍	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	22 (5)	34 (6)	39 (7)	73 (6)	7 (3)
リンパ球減少症	2 (<1)	14 (2)	16 (3)	30 (3)	0
貧血	10 (2)	8 (1)	13 (2)	21 (2)	3 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 9 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球減少症	1 (<1)	4 (<1)	8 (1)	12 (1)	0
白血球増加症	3 (<1)	5 (<1)	1 (<1)	6 (<1)	0
好中球増加症	1 (<1)	2 (<1)	4 (<1)	6 (<1)	0
鉄欠乏性貧血	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0
リンパ節症	4 (<1)	1 (<1)	4 (<1)	5 (<1)	3 (1)
好酸球増加症	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
好中球減少症	1 (<1)	0	3 (<1)	3 (<1)	0
血小板減少症	0	2 (<1)	0	2 (<1)	0
正色素性正球性貧血	0	0	1 (<1)	1 (<1)	0
低色素性貧血	1 (<1)	0	0	0	1 (<1)
リンパ節炎	1 (<1)	0	0	0	0
血小板増加症	1 (<1)	0	0	0	0
免疫系障害	12 (3)	14 (2)	13 (2)	27 (2)	4 (2)
過敏症	1 (<1)	6 (1)	6 (1)	12 (1)	0
季節性アレルギー	7 (2)	4 (<1)	6 (1)	10 (<1)	2 (<1)
食物アレルギー	0	4 (<1)	0	4 (<1)	1 (<1)
薬物過敏症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
造影剤アレルギー	0	1 (<1)	0	1 (<1)	0
化学物質アレルギー	1 (<1)	0	0	0	0
アナフィラキシー反応	0	0	0	0	1 (<1)
家塵アレルギー	2 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 10 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
内分泌障害	5 (1)	5 (<1)	3 (<1)	8 (<1)	3 (1)
甲状腺腫	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)
自己免疫性甲状腺炎	0	1 (<1)	0	1 (<1)	0
副甲状腺機能亢進症	1 (<1)	1 (<1)	0	1 (<1)	0
甲状腺機能低下症	3 (<1)	0	1 (<1)	1 (<1)	2 (<1)
甲状腺腫瘤	0	0	1 (<1)	1 (<1)	0
甲状腺機能亢進症	1 (<1)	0	0	0	0
代謝および栄養障害	38 (8)	32 (6)	35 (6)	67 (6)	12 (5)
食欲減退	7 (2)	12 (2)	9 (2)	21 (2)	2 (<1)
高コレステロール血症	4 (<1)	5 (<1)	4 (<1)	9 (<1)	1 (<1)
ビタミンD欠乏	4 (<1)	3 (<1)	5 (<1)	8 (<1)	0
高血糖	4 (<1)	2 (<1)	5 (<1)	7 (<1)	1 (<1)
高脂血症	3 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
脱水	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
耐糖能障害	0	0	3 (<1)	3 (<1)	0
糖尿病	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
高トリグリセリド血症	3 (<1)	1 (<1)	1 (<1)	2 (<1)	4 (2)
食欲亢進	3 (<1)	2 (<1)	0	2 (<1)	0
２型糖尿病	0	2 (<1)	0	2 (<1)	0
異常体重減少	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 11 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脂質異常症	0	0	1 (<1)	1 (<1)	0
痛風	1 (<1)	1 (<1)	0	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	1 (<1)	0
高尿酸血症	0	1 (<1)	0	1 (<1)	3 (1)
低血糖症	0	0	1 (<1)	1 (<1)	0
低カリウム血症	1 (<1)	0	1 (<1)	1 (<1)	0
低リン酸血症	0	0	1 (<1)	1 (<1)	0
鉄欠乏	0	1 (<1)	0	1 (<1)	0
１型糖尿病	0	1 (<1)	0	1 (<1)	0
ビタミンＢ１２欠乏	0	0	1 (<1)	1 (<1)	0
亜鉛欠乏	0	0	1 (<1)	1 (<1)	0
電解質失調	1 (<1)	0	0	0	0
妊娠糖尿病	1 (<1)	0	0	0	0
高カルシウム血症	1 (<1)	0	0	0	0
高カリウム血症	0	0	0	0	1 (<1)
低ナトリウム血症	1 (<1)	0	0	0	0
ビタミン欠乏症	2 (<1)	0	0	0	0
精神障害	89 (20)	86 (15)	86 (15)	172 (15)	35 (15)
うつ病	38 (8)	35 (6)	33 (6)	68 (6)	20 (8)
不安	15 (3)	20 (4)	16 (3)	36 (3)	4 (2)
不眠症	18 (4)	22 (4)	13 (2)	35 (3)	7 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 12 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
抑うつ気分	12 (3)	8 (1)	5 (<1)	13 (1)	3 (1)
睡眠障害	5 (1)	4 (<1)	7 (1)	11 (<1)	2 (<1)
気分動揺	4 (<1)	1 (<1)	5 (<1)	6 (<1)	1 (<1)
感情障害	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
気分変化	0	2 (<1)	2 (<1)	4 (<1)	0
ストレス	0	2 (<1)	2 (<1)	4 (<1)	2 (<1)
初期不眠症	0	0	3 (<1)	3 (<1)	0
リビドー減退	0	2 (<1)	1 (<1)	3 (<1)	0
パニック発作	1 (<1)	0	3 (<1)	3 (<1)	0
自殺念慮	1 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
感情不安定	3 (<1)	0	2 (<1)	2 (<1)	1 (<1)
神経過敏	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
神経症	0	1 (<1)	1 (<1)	2 (<1)	0
落ち着きのなさ	0	2 (<1)	0	2 (<1)	0
異常な夢	1 (<1)	0	1 (<1)	1 (<1)	0
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
不安障害	1 (<1)	1 (<1)	0	1 (<1)	0
双極１型障害	0	1 (<1)	0	1 (<1)	0
歯ぎしり	0	0	1 (<1)	1 (<1)	0
転換性障害	0	0	1 (<1)	1 (<1)	0
抑うつ症状	1 (<1)	0	1 (<1)	1 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 13 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
情動障害	0	0	1 (<1)	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	1 (<1)	0
全般性不安障害	0	1 (<1)	0	1 (<1)	0
大うつ病	0	0	1 (<1)	1 (<1)	0
自己愛性人格障害	0	1 (<1)	0	1 (<1)	0
パニック障害	0	1 (<1)	0	1 (<1)	0
人格変化	0	1 (<1)	0	1 (<1)	0
人格障害	0	1 (<1)	0	1 (<1)	0
身体表現性障害	1 (<1)	1 (<1)	0	1 (<1)	0
適応障害	0	0	0	0	1 (<1)
攻撃性	1 (<1)	0	0	0	0
怒り	1 (<1)	0	0	0	0
気晴らし食い	1 (<1)	0	0	0	0
錯乱状態	1 (<1)	0	0	0	0
幻覚	1 (<1)	0	0	0	0
故意の自傷行為	0	0	0	0	1 (<1)
精神障害	0	0	0	0	1 (<1)
中期不眠症	1 (<1)	0	0	0	0
悪夢	1 (<1)	0	0	0	0
自殺企図	0	0	0	0	1 (<1)
タバコ乱用	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 14 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
神経系障害	196 (43)	216 (38)	210 (36)	426 (37)	69 (29)
頭痛	75 (17)	90 (16)	94 (16)	184 (16)	30 (13)
錯感覚	37 (8)	38 (7)	41 (7)	79 (7)	8 (3)
多発性硬化症再発	36 (8)	31 (5)	25 (4)	56 (5)	12 (5)
感覚鈍麻	27 (6)	20 (4)	26 (5)	46 (4)	7 (3)
浮動性めまい	25 (6)	24 (4)	17 (3)	41 (4)	6 (3)
灼熱感	7 (2)	14 (2)	18 (3)	32 (3)	0
片頭痛	10 (2)	17 (3)	11 (2)	28 (2)	2 (<1)
筋痙直	14 (3)	12 (2)	10 (2)	22 (2)	2 (<1)
平衡障害	5 (1)	8 (1)	8 (1)	16 (1)	0
異常感覚	4 (<1)	10 (2)	3 (<1)	13 (1)	0
感覚障害	3 (<1)	6 (1)	7 (1)	13 (1)	1 (<1)
傾眠	4 (<1)	4 (<1)	7 (1)	11 (<1)	0
緊張性頭痛	3 (<1)	5 (<1)	6 (1)	11 (<1)	2 (<1)
坐骨神経痛	5 (1)	6 (1)	4 (<1)	10 (<1)	2 (<1)
振戦	9 (2)	7 (1)	3 (<1)	10 (<1)	2 (<1)
味覚異常	0	3 (<1)	5 (<1)	8 (<1)	1 (<1)
レルミット徴候	4 (<1)	2 (<1)	6 (1)	8 (<1)	1 (<1)
多発性硬化症	5 (1)	5 (<1)	3 (<1)	8 (<1)	2 (<1)
神経痛	2 (<1)	5 (<1)	2 (<1)	7 (<1)	1 (<1)
失神	3 (<1)	1 (<1)	6 (1)	7 (<1)	2 (<1)
健忘	4 (<1)	4 (<1)	2 (<1)	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 15 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
認知障害	0	1 (<1)	4 (<1)	5 (<1)	1 (<1)
下肢静止不能症候群	3 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
副鼻腔炎に伴う頭痛	3 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
構語障害	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
知覚過敏	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
前兆を伴う片頭痛	1 (<1)	4 (<1)	0	4 (<1)	1 (<1)
神経圧迫	1 (<1)	0	4 (<1)	4 (<1)	0
失神寸前の状態	2 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
三叉神経痛	4 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
運動失調	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
手根管症候群	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
注意力障害	0	2 (<1)	1 (<1)	3 (<1)	2 (<1)
反射亢進	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
記憶障害	3 (<1)	3 (<1)	0	3 (<1)	3 (1)
ウートホフ現象	3 (<1)	2 (<1)	1 (<1)	3 (<1)	0
味覚消失	0	1 (<1)	1 (<1)	2 (<1)	0
帯状感	0	0	2 (<1)	2 (<1)	0
頚原性頭痛	0	1 (<1)	1 (<1)	2 (<1)	0
不器用	0	2 (<1)	0	2 (<1)	0
振動覚低下	1 (<1)	2 (<1)	0	2 (<1)	0
顔面不全麻痺	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
腰髄神経根障害	1 (<1)	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 16 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
不随意性筋収縮	0	1 (<1)	1 (<1)	2 (<1)	0
眼振	0	1 (<1)	1 (<1)	2 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0
自律神経失調	0	0	1 (<1)	1 (<1)	0
頚髄神経根痛	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
概日リズム睡眠障害	0	1 (<1)	0	1 (<1)	0
痙攣	2 (<1)	1 (<1)	0	1 (<1)	0
協調運動異常	1 (<1)	0	1 (<1)	1 (<1)	0
泣き	0	0	1 (<1)	1 (<1)	0
よだれ	0	0	1 (<1)	1 (<1)	0
ジスキネジー	0	1 (<1)	0	1 (<1)	0
てんかん	0	1 (<1)	0	1 (<1)	0
てんかんの前兆	0	1 (<1)	0	1 (<1)	0
顔面神経障害	0	0	1 (<1)	1 (<1)	0
顔面部神経痛	0	1 (<1)	0	1 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)	1 (<1)
舌咽神経痛	0	1 (<1)	0	1 (<1)	0
頭部動揺	0	1 (<1)	0	1 (<1)	0
片側頭痛	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
過眠症	2 (<1)	1 (<1)	0	1 (<1)	0
肋間神経痛	1 (<1)	1 (<1)	0	1 (<1)	0
脳圧低下	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 17 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
嗜眠	0	0	1 (<1)	1 (<1)	0
意識消失	2 (<1)	0	1 (<1)	1 (<1)	0
感覚異常性大腿神経痛	0	1 (<1)	0	1 (<1)	0
運動機能障害	0	1 (<1)	0	1 (<1)	0
後頭神経痛	0	0	1 (<1)	1 (<1)	0
視神経炎	0	1 (<1)	0	1 (<1)	0
腓骨神経麻痺	0	1 (<1)	0	1 (<1)	0
睡眠の質低下	0	1 (<1)	0	1 (<1)	0
神経根痛	0	1 (<1)	0	1 (<1)	0
頚髄神経根炎	0	1 (<1)	0	1 (<1)	0
逆行性健忘	0	1 (<1)	0	1 (<1)	0
鎮静	0	0	1 (<1)	1 (<1)	0
会話障害	0	1 (<1)	0	1 (<1)	0
一過性脳虚血発作	0	0	1 (<1)	1 (<1)	0
尺骨神経管症候群	0	1 (<1)	0	1 (<1)	0
視野欠損	0	1 (<1)	0	1 (<1)	0
失語症	1 (<1)	0	0	0	0
中枢神経系病変	1 (<1)	0	0	0	0
脳血管発作	1 (<1)	0	0	0	0
脳血管障害	0	0	0	0	1 (<1)
頚腕症候群	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 18 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ジストニー	0	0	0	0	1 (<1)
顔面痙攣	1 (<1)	0	0	0	1 (<1)
痙性歩行	1 (<1)	0	0	0	0
大発作痙攣	1 (<1)	0	0	0	1 (<1)
不全片麻痺	1 (<1)	0	0	0	1 (<1)
筋緊張亢進	1 (<1)	0	0	0	0
筋緊張低下	1 (<1)	0	0	0	0
不全単麻痺	1 (<1)	0	0	0	1 (<1)
末梢性ニューロパチー	3 (<1)	0	0	0	1 (<1)
起立不耐性	0	0	0	0	1 (<1)
嗅覚錯誤	1 (<1)	0	0	0	0
部分発作	0	0	0	0	1 (<1)
周期性四肢運動障害	0	0	0	0	1 (<1)
錐体路症候群	1 (<1)	0	0	0	0
振動覚亢進	1 (<1)	0	0	0	1 (<1)
第７脳神経麻痺	1 (<1)	0	0	0	0
第６脳神経麻痺	0	0	0	0	1 (<1)
眼障害	54 (12)	51 (9)	53 (9)	104 (9)	18 (8)
霧視	14 (3)	9 (2)	12 (2)	21 (2)	5 (2)
眼痛	4 (<1)	8 (1)	10 (2)	18 (2)	3 (1)
視力障害	4 (<1)	7 (1)	4 (<1)	11 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 19 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
結膜炎	4 (<1)	7 (1)	2 (<1)	9 (<1)	3 (1)
複視	7 (2)	2 (<1)	5 (<1)	7 (<1)	1 (<1)
眼瞼痙攣	3 (<1)	2 (<1)	4 (<1)	6 (<1)	0
眼乾燥	4 (<1)	6 (1)	0	6 (<1)	1 (<1)
眼充血	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0
眼の異常感	0	2 (<1)	1 (<1)	3 (<1)	0
眼瞼炎	0	2 (<1)	1 (<1)	3 (<1)	0
失明	0	1 (<1)	2 (<1)	3 (<1)	0
白内障	0	1 (<1)	2 (<1)	3 (<1)	0
流涙増加	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
光視症	0	2 (<1)	1 (<1)	3 (<1)	0
視力低下	8 (2)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
アレルギー性結膜炎	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
眼出血	0	1 (<1)	1 (<1)	2 (<1)	0
眼筋麻痺	0	1 (<1)	1 (<1)	2 (<1)	0
屈折障害	1 (<1)	2 (<1)	0	2 (<1)	0
硝子体浮遊物	0	2 (<1)	0	2 (<1)	0
両眼球運動障害	0	0	1 (<1)	1 (<1)	0
霰粒腫	1 (<1)	1 (<1)	0	1 (<1)	0
眼刺激	1 (<1)	0	1 (<1)	1 (<1)	0
眼部腫脹	0	0	1 (<1)	1 (<1)	0
眼瞼障害	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 20 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼瞼浮腫	0	0	1 (<1)	1 (<1)	0
眼瞼下垂	0	0	1 (<1)	1 (<1)	0
緑内障	0	0	1 (<1)	1 (<1)	0
遠視	1 (<1)	1 (<1)	0	1 (<1)	0
瞼板腺炎	0	0	1 (<1)	1 (<1)	0
開放隅角緑内障	0	0	1 (<1)	1 (<1)	0
視神経萎縮	0	0	1 (<1)	1 (<1)	0
動揺視	0	1 (<1)	0	1 (<1)	0
全眼球炎	0	1 (<1)	0	1 (<1)	0
羞明	1 (<1)	0	1 (<1)	1 (<1)	0
老視	0	1 (<1)	0	1 (<1)	0
乾燥症候群	0	1 (<1)	0	1 (<1)	0
ブドウ膜炎	0	0	1 (<1)	1 (<1)	2 (<1)
一過性失明	1 (<1)	0	0	0	1 (<1)
嚢下白内障	1 (<1)	0	0	0	0
結膜出血	1 (<1)	0	0	0	1 (<1)
眼瞼紅斑	1 (<1)	0	0	0	0
眼瞼刺激	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
虹彩毛様体炎	0	0	0	0	1 (<1)
近視	0	0	0	0	1 (<1)
硝子体出血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 21 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
耳および迷路障害	34 (8)	35 (6)	40 (7)	75 (7)	15 (6)
回転性めまい	23 (5)	14 (2)	29 (5)	43 (4)	7 (3)
耳鳴	4 (<1)	4 (<1)	5 (<1)	9 (<1)	2 (<1)
耳痛	2 (<1)	5 (<1)	2 (<1)	7 (<1)	1 (<1)
頭位性回転性めまい	2 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
耳不快感	1 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
聴力低下	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
乗物酔い	1 (<1)	2 (<1)	0	2 (<1)	0
耳垢栓塞	1 (<1)	1 (<1)	0	1 (<1)	0
難聴	1 (<1)	1 (<1)	0	1 (<1)	0
感音性難聴	0	1 (<1)	0	1 (<1)	0
耳閉	1 (<1)	0	1 (<1)	1 (<1)	0
耳出血	0	1 (<1)	0	1 (<1)	0
耳そう痒症	0	1 (<1)	0	1 (<1)	0
耳管障害	0	0	1 (<1)	1 (<1)	0
耳管機能障害	0	0	1 (<1)	1 (<1)	1 (<1)
外耳障害	0	0	1 (<1)	1 (<1)	0
外耳痛	0	1 (<1)	0	1 (<1)	0
聴覚過敏	0	1 (<1)	0	1 (<1)	0
鼓膜充血	0	1 (<1)	0	1 (<1)	0
外耳道紅斑	1 (<1)	0	0	0	0
中耳の炎症	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 22 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
前庭性運動失調	0	0	0	0	1 (<1)
心臓障害	17 (4)	31 (5)	35 (6)	66 (6)	12 (5)
動悸	5 (1)	7 (1)	5 (<1)	12 (1)	1 (<1)
頻脈	4 (<1)	5 (<1)	7 (1)	12 (1)	4 (2)
第一度房室ブロック	1 (<1)	5 (<1)	3 (<1)	8 (<1)	2 (<1)
心室性期外収縮	4 (<1)	1 (<1)	5 (<1)	6 (<1)	0
洞性徐脈	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
上室性期外収縮	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
狭心症	0	2 (<1)	2 (<1)	4 (<1)	0
徐脈	0	0	3 (<1)	3 (<1)	1 (<1)
期外収縮	0	2 (<1)	1 (<1)	3 (<1)	0
心臓瘤	0	1 (<1)	1 (<1)	2 (<1)	0
心筋症	0	1 (<1)	1 (<1)	2 (<1)	0
洞性頻脈	1 (<1)	0	2 (<1)	2 (<1)	0
ウォルフ・パーキンソン・ホワイト症候群	0	2 (<1)	0	2 (<1)	0
急性冠動脈症候群	0	0	1 (<1)	1 (<1)	0
左脚ブロック	0	0	1 (<1)	1 (<1)	1 (<1)
心不全	0	0	1 (<1)	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	1 (<1)	0
伝導障害	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
僧帽弁逸脱	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 23 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
結節性調律	0	0	1 (<1)	1 (<1)	0
頻脈性不整脈	0	0	1 (<1)	1 (<1)	0
上室性不整脈	1 (<1)	0	0	0	0
心筋虚血	1 (<1)	0	0	0	0
上室性頻脈	1 (<1)	0	0	0	0
発作性頻脈	0	0	0	0	1 (<1)
血管障害	33 (7)	253 (45)	209 (36)	462 (41)	18 (8)
潮紅	9 (2)	209 (37)	161 (28)	370 (32)	5 (2)
ほてり	8 (2)	44 (8)	36 (6)	80 (7)	3 (1)
高血圧	13 (3)	9 (2)	18 (3)	27 (2)	11 (5)
充血	0	1 (<1)	6 (1)	7 (<1)	0
血腫	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
低血圧	0	3 (<1)	0	3 (<1)	0
静脈炎	0	0	2 (<1)	2 (<1)	0
静脈不全	0	1 (<1)	1 (<1)	2 (<1)	0
血管障害	0	0	1 (<1)	1 (<1)	0
微小血管症	0	1 (<1)	0	1 (<1)	0
起立性低血圧	0	0	1 (<1)	1 (<1)	0
末梢冷感	3 (<1)	1 (<1)	0	1 (<1)	0
末梢性虚血	1 (<1)	1 (<1)	0	1 (<1)	0
レイノー現象	2 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 24 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
静脈瘤	0	1 (<1)	0	1 (<1)	0
静脈痛	0	1 (<1)	0	1 (<1)	0
腹腔内血腫	0	0	0	0	1 (<1)
蒼白	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	72 (16)	88 (16)	92 (16)	180 (16)	28 (12)
口腔咽頭痛	18 (4)	31 (5)	30 (5)	61 (5)	11 (5)
咳嗽	20 (4)	26 (5)	26 (5)	52 (5)	7 (3)
鼻漏	6 (1)	12 (2)	10 (2)	22 (2)	0
鼻閉	7 (2)	9 (2)	4 (<1)	13 (1)	1 (<1)
呼吸困難	1 (<1)	5 (<1)	5 (<1)	10 (<1)	5 (2)
アレルギー性鼻炎	1 (<1)	3 (<1)	6 (1)	9 (<1)	2 (<1)
副鼻腔うっ血	2 (<1)	1 (<1)	7 (1)	8 (<1)	0
鼻出血	3 (<1)	3 (<1)	3 (<1)	6 (<1)	2 (<1)
上気道咳症候群	3 (<1)	2 (<1)	4 (<1)	6 (<1)	0
喘息	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
湿性咳嗽	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
上気道うっ血	3 (<1)	0	4 (<1)	4 (<1)	1 (<1)
咽喉刺激感	1 (<1)	3 (<1)	0	3 (<1)	0
喘鳴	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
息詰まり	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
口腔咽頭不快感	1 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 25 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
気道うっ血	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
咽喉絞扼感	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性咽頭炎	1 (<1)	1 (<1)	0	1 (<1)	0
アレルギー性副鼻腔炎	1 (<1)	1 (<1)	0	1 (<1)	0
息詰まり感	0	1 (<1)	0	1 (<1)	0
咽喉乾燥	2 (<1)	1 (<1)	0	1 (<1)	0
発声障害	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
労作性呼吸困難	1 (<1)	1 (<1)	0	1 (<1)	0
過換気	0	0	1 (<1)	1 (<1)	0
鼻乾燥	2 (<1)	0	1 (<1)	1 (<1)	0
鼻浮腫	0	0	1 (<1)	1 (<1)	0
口腔咽頭プラーク	1 (<1)	1 (<1)	0	1 (<1)	0
口腔咽頭腫脹	0	0	1 (<1)	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	1 (<1)	0
咽頭嚢腫	0	1 (<1)	0	1 (<1)	0
咽頭紅斑	1 (<1)	1 (<1)	0	1 (<1)	0
咽頭腫瘤	0	0	1 (<1)	1 (<1)	0
胸水	0	1 (<1)	0	1 (<1)	0
胸膜炎	0	0	1 (<1)	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	1 (<1)	0
低音性連続性ラ音	2 (<1)	1 (<1)	0	1 (<1)	0
副鼻腔障害	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 26 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
睡眠時無呼吸症候群	0	0	1 (<1)	1 (<1)	0
声帯ポリープ	0	0	1 (<1)	1 (<1)	0
アレルギー性咳嗽	1 (<1)	0	0	0	0
アレルギー性呼吸器疾患	1 (<1)	0	0	0	0
アレルギー性呼吸器症状	1 (<1)	0	0	0	0
慢性気管支炎	1 (<1)	0	0	0	0
しゃっくり	2 (<1)	0	0	0	0
上気道分泌増加	1 (<1)	0	0	0	0
口腔咽頭水疱形成	1 (<1)	0	0	0	0
咽頭の炎症	1 (<1)	0	0	0	0
ラ音	1 (<1)	0	0	0	0
気道の炎症	1 (<1)	0	0	0	0
季節性鼻炎	0	0	0	0	1 (<1)
くしゃみ	1 (<1)	0	0	0	1 (<1)
声帯の炎症	1 (<1)	0	0	0	0
胃腸障害	173 (38)	270 (48)	301 (52)	571 (50)	40 (17)
下痢	42 (9)	71 (13)	104 (18)	175 (15)	6 (3)
悪心	33 (7)	69 (12)	78 (14)	147 (13)	8 (3)
上腹部痛	26 (6)	54 (10)	61 (11)	115 (10)	3 (1)
腹痛	19 (4)	62 (11)	46 (8)	108 (9)	2 (<1)
嘔吐	19 (4)	47 (8)	36 (6)	83 (7)	4 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 27 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
消化不良	17 (4)	25 (4)	28 (5)	53 (5)	5 (2)
胃腸障害	5 (1)	14 (2)	26 (5)	40 (4)	0
便秘	20 (4)	12 (2)	22 (4)	34 (3)	4 (2)
腹部不快感	6 (1)	17 (3)	13 (2)	30 (3)	1 (<1)
歯痛	15 (3)	12 (2)	17 (3)	29 (3)	2 (<1)
胃炎	7 (2)	16 (3)	11 (2)	27 (2)	4 (2)
胃食道逆流性疾患	10 (2)	13 (2)	13 (2)	26 (2)	1 (<1)
口内乾燥	4 (<1)	13 (2)	8 (1)	21 (2)	0
鼓腸	7 (2)	9 (2)	7 (1)	16 (1)	1 (<1)
腹部膨満	5 (1)	3 (<1)	12 (2)	15 (1)	0
痔核	5 (1)	6 (1)	5 (<1)	11 (<1)	1 (<1)
下腹部痛	3 (<1)	2 (<1)	6 (1)	8 (<1)	0
嚥下障害	2 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
食中毒	2 (<1)	4 (<1)	3 (<1)	7 (<1)	1 (<1)
歯周炎	2 (<1)	2 (<1)	5 (<1)	7 (<1)	0
齲歯	1 (<1)	2 (<1)	4 (<1)	6 (<1)	3 (1)
心窩部不快感	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
おくび	0	1 (<1)	3 (<1)	4 (<1)	0
便失禁	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
胃酸過多	1 (<1)	4 (<1)	0	4 (<1)	0
逆流性食道炎	1 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
腹部圧痛	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 28 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
便意切迫	0	1 (<1)	2 (<1)	3 (<1)	0
十二指腸潰瘍	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
胃障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
歯肉炎	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
裂孔ヘルニア	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
埋伏歯	1 (<1)	0	3 (<1)	3 (<1)	1 (<1)
腹部硬直	0	1 (<1)	1 (<1)	2 (<1)	0
異常便	0	2 (<1)	0	2 (<1)	0
排便回数増加	0	0	2 (<1)	2 (<1)	0
歯肉出血	1 (<1)	2 (<1)	0	2 (<1)	0
吐血	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口の感覚鈍麻	0	2 (<1)	0	2 (<1)	0
過敏性腸症候群	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口腔内潰瘍形成	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口の錯感覚	0	2 (<1)	0	2 (<1)	0
流涎過多	0	2 (<1)	0	2 (<1)	0
口内炎	0	2 (<1)	0	2 (<1)	1 (<1)
腹部ヘルニア	0	1 (<1)	0	1 (<1)	0
アフタ性口内炎	0	0	1 (<1)	1 (<1)	0
唾液欠乏	0	1 (<1)	0	1 (<1)	0
口腔灼熱感症候群	0	0	1 (<1)	1 (<1)	0
結腸ポリープ	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 29 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
クローン病	0	1 (<1)	0	1 (<1)	0
憩室穿孔	0	1 (<1)	0	1 (<1)	0
腸憩室	0	0	1 (<1)	1 (<1)	1 (<1)
十二指腸ポリープ	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
小腸炎	0	1 (<1)	0	1 (<1)	0
腸炎	1 (<1)	0	1 (<1)	1 (<1)	0
出血性胃炎	0	1 (<1)	0	1 (<1)	1 (<1)
胃十二指腸炎	0	0	1 (<1)	1 (<1)	0
消化器痛	2 (<1)	1 (<1)	0	1 (<1)	0
歯肉嚢胞	0	0	1 (<1)	1 (<1)	0
歯肉障害	0	0	1 (<1)	1 (<1)	0
歯肉腫脹	0	1 (<1)	0	1 (<1)	0
舌痛	0	1 (<1)	0	1 (<1)	0
血便排泄	1 (<1)	0	1 (<1)	1 (<1)	0
胃排出不全	0	1 (<1)	0	1 (<1)	0
炎症性腸疾患	0	0	1 (<1)	1 (<1)	0
腸閉塞	0	0	1 (<1)	1 (<1)	0
腸管ポリープ	0	1 (<1)	0	1 (<1)	0
口唇水疱	0	1 (<1)	0	1 (<1)	0
弛緩歯	0	1 (<1)	0	1 (<1)	0
腰ヘルニア	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 30 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
マロリー・ワイス症候群	0	1 (<1)	0	1 (<1)	0
嚥下痛	0	1 (<1)	0	1 (<1)	0
食道痙攣	0	0	1 (<1)	1 (<1)	0
食道炎	0	1 (<1)	0	1 (<1)	0
口腔内痛	0	1 (<1)	0	1 (<1)	0
膵炎	0	1 (<1)	0	1 (<1)	0
消化性潰瘍	0	0	1 (<1)	1 (<1)	0
歯周病	0	1 (<1)	0	1 (<1)	0
逆流性胃炎	0	0	1 (<1)	1 (<1)	0
唾液管閉塞	0	0	1 (<1)	1 (<1)	0
舌苔	0	0	1 (<1)	1 (<1)	0
地図状舌	0	1 (<1)	0	1 (<1)	0
歯の磨耗	0	1 (<1)	0	1 (<1)	0
歯の脱落	1 (<1)	1 (<1)	0	1 (<1)	0
根尖肉芽腫	0	0	0	0	1 (<1)
便通不規則	1 (<1)	0	0	0	0
呼気臭	1 (<1)	0	0	0	0
大腸炎	2 (<1)	0	0	0	0
潰瘍性大腸炎	1 (<1)	0	0	0	0
変色便	0	0	0	0	1 (<1)
胃ポリープ	1 (<1)	0	0	0	0
胃腸出血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 31 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯肉紅斑	0	0	0	0	1 (<1)
歯肉痛	1 (<1)	0	0	0	0
痔出血	0	0	0	0	1 (<1)
口唇乾燥	1 (<1)	0	0	0	0
肛門周囲痛	1 (<1)	0	0	0	0
直腸出血	1 (<1)	0	0	0	0
脆弱歯	1 (<1)	0	0	0	0
舌障害	1 (<1)	0	0	0	0
舌乾燥	1 (<1)	0	0	0	0
歯の発育障害	1 (<1)	0	0	0	0
歯の障害	1 (<1)	0	0	0	0
肝胆道系障害	6 (1)	5 (<1)	10 (2)	15 (1)	4 (2)
肝障害	1 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
胆石症	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
肝細胞融解性肝炎	0	1 (<1)	2 (<1)	3 (<1)	0
胆道ジスキネジー	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
胆管結石	2 (<1)	0	1 (<1)	1 (<1)	0
胆嚢浮腫	0	0	1 (<1)	1 (<1)	0
高ビリルビン血症	1 (<1)	0	1 (<1)	1 (<1)	0
高トランスアミナーゼ血症	0	1 (<1)	0	1 (<1)	0
肝嚢胞	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 32 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚および皮下組織障害	101 (22)	178 (32)	178 (31)	356 (31)	38 (16)
そう痒症	19 (4)	48 (9)	43 (7)	91 (8)	5 (2)
発疹	17 (4)	41 (7)	40 (7)	81 (7)	4 (2)
紅斑	7 (2)	27 (5)	35 (6)	62 (5)	4 (2)
多汗症	7 (2)	13 (2)	20 (3)	33 (3)	4 (2)
寝汗	6 (1)	11 (2)	13 (2)	24 (2)	1 (<1)
脱毛症	11 (2)	12 (2)	9 (2)	21 (2)	4 (2)
アレルギー性皮膚炎	3 (<1)	10 (2)	7 (1)	17 (1)	1 (<1)
全身性そう痒症	3 (<1)	7 (1)	7 (1)	14 (1)	3 (1)
蕁麻疹	5 (1)	5 (<1)	8 (1)	13 (1)	1 (<1)
ざ瘡	6 (1)	5 (<1)	7 (1)	12 (1)	1 (<1)
そう痒性皮疹	2 (<1)	7 (1)	3 (<1)	10 (<1)	0
皮膚灼熱感	0	6 (1)	4 (<1)	10 (<1)	0
皮膚炎	1 (<1)	4 (<1)	5 (<1)	9 (<1)	0
皮膚乾燥	3 (<1)	4 (<1)	5 (<1)	9 (<1)	1 (<1)
斑状皮疹	1 (<1)	1 (<1)	8 (1)	9 (<1)	0
湿疹	2 (<1)	6 (1)	2 (<1)	8 (<1)	2 (<1)
全身性皮疹	0	4 (<1)	3 (<1)	7 (<1)	0
光線過敏性反応	0	3 (<1)	3 (<1)	6 (<1)	1 (<1)
全身紅斑	0	2 (<1)	2 (<1)	4 (<1)	0
酒さ	0	4 (<1)	0	4 (<1)	0
過角化	0	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 33 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
痒疹	0	2 (<1)	1 (<1)	3 (<1)	0
乾癬	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
丘疹性皮疹	0	1 (<1)	2 (<1)	3 (<1)	0
皮膚色素過剰	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
皮膚刺激	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
顔面腫脹	1 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (1)
水疱	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚嚢腫	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
接触性皮膚炎	2 (<1)	2 (<1)	0	2 (<1)	2 (<1)
斑状出血	4 (<1)	0	2 (<1)	2 (<1)	1 (<1)
顔面感覚鈍麻	4 (<1)	1 (<1)	1 (<1)	2 (<1)	0
網状皮斑	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性そう痒症	2 (<1)	2 (<1)	0	2 (<1)	0
紅斑性皮疹	0	1 (<1)	1 (<1)	2 (<1)	0
皮膚硬結	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)
皮膚病変	3 (<1)	2 (<1)	0	2 (<1)	0
皮膚反応	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
皮膚のつっぱり感	0	0	2 (<1)	2 (<1)	0
冷汗	2 (<1)	0	1 (<1)	1 (<1)	0
皮膚弛緩症	0	1 (<1)	0	1 (<1)	0
ざ瘡様皮膚炎	1 (<1)	1 (<1)	0	1 (<1)	0
アトピー性皮膚炎	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 34 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
紅色症	0	0	1 (<1)	1 (<1)	0
剥脱性発疹	1 (<1)	1 (<1)	0	1 (<1)	0
紅色汗疹	1 (<1)	1 (<1)	0	1 (<1)	0
特発性蕁麻疹	0	1 (<1)	0	1 (<1)	0
内出血発生の増加傾向	0	0	1 (<1)	1 (<1)	0
嵌入爪	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
毛孔性角化症	0	0	1 (<1)	1 (<1)	0
睫毛眉毛脱落症	0	1 (<1)	0	1 (<1)	0
爪変色	0	1 (<1)	0	1 (<1)	0
爪の障害	0	0	1 (<1)	1 (<1)	0
爪破損	1 (<1)	1 (<1)	0	1 (<1)	0
皮膚疼痛	0	0	1 (<1)	1 (<1)	0
色素沈着障害	3 (<1)	1 (<1)	0	1 (<1)	0
脂漏	0	1 (<1)	0	1 (<1)	0
皮膚色素脱失	0	0	1 (<1)	1 (<1)	0
皮膚変色	0	0	1 (<1)	1 (<1)	0
皮膚剥脱	1 (<1)	0	1 (<1)	1 (<1)	0
皮膚色素減少	0	1 (<1)	0	1 (<1)	0
皮膚熱感	0	1 (<1)	0	1 (<1)	0
毛細血管拡張症	0	1 (<1)	0	1 (<1)	0
一過性棘融解性皮膚症	0	0	1 (<1)	1 (<1)	0
乾皮症	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 35 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血管浮腫	0	0	0	0	1 (<1)
多形紅斑	1 (<1)	0	0	0	0
皮下出血	0	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0	0
脂肪組織萎縮症	0	0	0	0	1 (<1)
後天性リポジストロフィー	0	0	0	0	1 (<1)
爪床の炎症	1 (<1)	0	0	0	0
点状出血	2 (<1)	0	0	0	0
ばら色粃糠疹	2 (<1)	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0	0
猩紅熱様発疹	1 (<1)	0	0	0	0
小水疱性皮疹	1 (<1)	0	0	0	0
脂漏性皮膚炎	0	0	0	0	1 (<1)
皮下結節	0	0	0	0	1 (<1)
裂毛	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	173 (38)	175 (31)	184 (32)	359 (31)	46 (19)
背部痛	63 (14)	69 (12)	63 (11)	132 (12)	15 (6)
関節痛	41 (9)	45 (8)	49 (9)	94 (8)	9 (4)
四肢痛	38 (8)	43 (8)	40 (7)	83 (7)	13 (5)
筋痙縮	22 (5)	15 (3)	36 (6)	51 (4)	5 (2)
頚部痛	15 (3)	21 (4)	16 (3)	37 (3)	3 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 36 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋力低下	20 (4)	10 (2)	18 (3)	28 (2)	4 (2)
筋骨格痛	13 (3)	11 (2)	12 (2)	23 (2)	4 (2)
筋肉痛	16 (4)	10 (2)	11 (2)	21 (2)	2 (<1)
関節炎	1 (<1)	3 (<1)	6 (1)	9 (<1)	2 (<1)
筋骨格系胸痛	2 (<1)	4 (<1)	5 (<1)	9 (<1)	1 (<1)
筋骨格硬直	8 (2)	7 (1)	2 (<1)	9 (<1)	5 (2)
滑液包炎	3 (<1)	3 (<1)	4 (<1)	7 (<1)	0
関節硬直	0	2 (<1)	5 (<1)	7 (<1)	0
骨痛	2 (<1)	2 (<1)	4 (<1)	6 (<1)	0
関節腫脹	2 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
変形性関節症	4 (<1)	2 (<1)	2 (<1)	4 (<1)	0
重感	4 (<1)	3 (<1)	1 (<1)	4 (<1)	0
腱炎	5 (1)	2 (<1)	2 (<1)	4 (<1)	0
関節障害	0	1 (<1)	2 (<1)	3 (<1)	0
側腹部痛	1 (<1)	0	3 (<1)	3 (<1)	1 (<1)
椎間板突出	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
骨減少症	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
骨粗鬆症	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
変形性脊椎症	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
滑液嚢腫	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
腱鞘炎	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
関節滲出液	0	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 37 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋拘縮	0	0	2 (<1)	2 (<1)	1 (<1)
筋緊張	2 (<1)	2 (<1)	0	2 (<1)	0
筋攣縮	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ミオキミア	0	1 (<1)	1 (<1)	2 (<1)	0
四肢の結節	0	0	2 (<1)	2 (<1)	0
骨壊死	1 (<1)	2 (<1)	0	2 (<1)	0
肩回旋筋腱板症候群	2 (<1)	0	2 (<1)	2 (<1)	0
腋窩腫瘤	1 (<1)	1 (<1)	0	1 (<1)	0
尾骨痛	2 (<1)	0	1 (<1)	1 (<1)	0
腱付着部症	0	1 (<1)	0	1 (<1)	0
凧径部痛	0	1 (<1)	0	1 (<1)	0
椎間板変性症	0	0	1 (<1)	1 (<1)	0
四肢不快感	0	0	1 (<1)	1 (<1)	0
下肢腫瘤	0	0	1 (<1)	1 (<1)	0
中足骨痛	0	1 (<1)	0	1 (<1)	0
筋肉内出血	0	0	1 (<1)	1 (<1)	0
筋腫脹	0	1 (<1)	0	1 (<1)	0
筋硬化症	1 (<1)	1 (<1)	0	1 (<1)	0
筋炎	1 (<1)	0	1 (<1)	1 (<1)	0
顎痛	4 (<1)	1 (<1)	0	1 (<1)	0
膝蓋大腿部痛症候群	0	0	1 (<1)	1 (<1)	0
関節周囲炎	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 38 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乾癬性関節症	0	0	1 (<1)	1 (<1)	0
足根洞症候群	0	1 (<1)	0	1 (<1)	0
腱障害	1 (<1)	1 (<1)	0	1 (<1)	0
斜頚	1 (<1)	0	1 (<1)	1 (<1)	0
弾発指	0	0	1 (<1)	1 (<1)	0
成長痛	0	0	0	0	1 (<1)
運動性低下	1 (<1)	0	0	0	0
筋固縮	0	0	0	0	1 (<1)
筋骨格不快感	1 (<1)	0	0	0	0
結節性変形性関節症	1 (<1)	0	0	0	0
足底筋膜炎	1 (<1)	0	0	0	0
多発性関節炎	1 (<1)	0	0	0	0
関節リウマチ	2 (<1)	0	0	0	0
腎および尿路障害	93 (21)	109 (19)	125 (22)	234 (21)	34 (14)
蛋白尿	32 (7)	49 (9)	61 (11)	110 (10)	18 (8)
ミクロアルブミン尿	12 (3)	27 (5)	25 (4)	52 (5)	8 (3)
血尿	23 (5)	22 (4)	27 (5)	49 (4)	6 (3)
尿意切迫	9 (2)	7 (1)	8 (1)	15 (1)	2 (<1)
ケトン尿	2 (<1)	6 (1)	8 (1)	14 (1)	1 (<1)
頻尿	9 (2)	6 (1)	5 (<1)	11 (<1)	1 (<1)
排尿困難	5 (1)	3 (<1)	7 (1)	10 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 39 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿失禁	4 (<1)	7 (1)	2 (<1)	9 (<1)	2 (<1)
腎結石症	5 (1)	2 (<1)	6 (1)	8 (<1)	1 (<1)
排尿躊躇	3 (<1)	1 (<1)	4 (<1)	5 (<1)	1 (<1)
尿閉	3 (<1)	4 (<1)	1 (<1)	5 (<1)	0
糖尿	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
腎臓痛	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
神経因性膀胱	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
腎仙痛	0	1 (<1)	2 (<1)	3 (<1)	0
切迫性尿失禁	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
アルブミン尿	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
膀胱機能障害	0	1 (<1)	1 (<1)	2 (<1)	0
膀胱刺激症状	0	1 (<1)	1 (<1)	2 (<1)	0
グロブリン尿	0	2 (<1)	0	2 (<1)	0
尿臭異常	0	0	2 (<1)	2 (<1)	0
膀胱痛	0	1 (<1)	0	1 (<1)	0
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
着色尿	0	0	1 (<1)	1 (<1)	0
出血性膀胱炎	0	1 (<1)	0	1 (<1)	0
非感染性膀胱炎	2 (<1)	1 (<1)	0	1 (<1)	0
失禁	0	0	1 (<1)	1 (<1)	1 (<1)
白血球尿	1 (<1)	0	1 (<1)	1 (<1)	0
排尿異常	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 40 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腎下垂症	1 (<1)	1 (<1)	0	1 (<1)	0
起立性蛋白尿症	0	1 (<1)	0	1 (<1)	0
腎嚢胞	0	1 (<1)	0	1 (<1)	0
腎障害	0	1 (<1)	0	1 (<1)	0
慢性腎不全	0	0	1 (<1)	1 (<1)	0
腎機能障害	0	0	1 (<1)	1 (<1)	0
腎尿細管性アシドーシス	0	0	1 (<1)	1 (<1)	0
尿管瘤	0	1 (<1)	0	1 (<1)	0
尿路痛	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
膀胱憩室	1 (<1)	0	0	0	0
膀胱痙縮	1 (<1)	0	0	0	0
尿路結石	1 (<1)	0	0	0	0
肋骨脊柱角圧痛	1 (<1)	0	0	0	0
慢性糸球体腎炎	1 (<1)	0	0	0	0
高血圧性腎症	0	0	0	0	1 (<1)
ネフローゼ症候群	0	0	0	0	1 (<1)
夜間頻尿	1 (<1)	0	0	0	0
膿尿	0	0	0	0	1 (<1)
尿路の炎症	1 (<1)	0	0	0	0
妊娠、産褥および周産期の状態	0	1 (<1)	0	1 (<1)	0
妊娠	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 41 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
生殖系および乳房障害	41 (9)	54 (10)	54 (9)	108 (9)	16 (7)
月経困難症	5 (1)	9 (2)	8 (1)	17 (1)	1 (<1)
不規則月経	5 (1)	3 (<1)	8 (1)	11 (<1)	3 (1)
不正子宮出血	3 (<1)	5 (<1)	5 (<1)	10 (<1)	3 (1)
卵巣嚢胞	2 (<1)	7 (1)	3 (<1)	10 (<1)	3 (1)
月経過多	3 (<1)	5 (<1)	4 (<1)	9 (<1)	3 (1)
乳房痛	1 (<1)	2 (<1)	6 (1)	8 (<1)	0
勃起不全	2 (<1)	4 (<1)	4 (<1)	8 (<1)	0
無月経	4 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
腟出血	2 (<1)	3 (<1)	1 (<1)	4 (<1)	0
乳房嚢胞	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
月経障害	0	0	3 (<1)	3 (<1)	0
月経遅延	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
頻発月経	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
性機能不全	0	1 (<1)	2 (<1)	3 (<1)	0
乳房腫瘤	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
子宮頚部上皮異形成	1 (<1)	2 (<1)	0	2 (<1)	0
前立腺炎	0	1 (<1)	1 (<1)	2 (<1)	0
外陰腟そう痒症	0	1 (<1)	1 (<1)	2 (<1)	0
萎縮性外陰腟炎	0	0	1 (<1)	1 (<1)	0
バルトリン腺炎	0	0	1 (<1)	1 (<1)	0
良性前立腺肥大症	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 42 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乳房分泌	0	0	1 (<1)	1 (<1)	0
乳房圧痛	0	0	1 (<1)	1 (<1)	0
子宮頚部の炎症	0	1 (<1)	0	1 (<1)	0
性交困難	0	0	1 (<1)	1 (<1)	0
射精障害	0	1 (<1)	0	1 (<1)	0
線維嚢胞性乳腺疾患	1 (<1)	0	1 (<1)	1 (<1)	0
乳汁漏出症	0	1 (<1)	0	1 (<1)	0
乳頭障害	0	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
骨盤痛	2 (<1)	1 (<1)	0	1 (<1)	0
多嚢胞性卵巣	0	0	1 (<1)	1 (<1)	0
閉経後出血	2 (<1)	0	1 (<1)	1 (<1)	0
早発閉経	0	1 (<1)	0	1 (<1)	0
前立腺腫大	0	0	1 (<1)	1 (<1)	1 (<1)
精巣障害	0	0	1 (<1)	1 (<1)	0
精巣痛	2 (<1)	1 (<1)	0	1 (<1)	0
子宮出血	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
子宮の炎症	0	1 (<1)	0	1 (<1)	0
子宮腟脱	0	1 (<1)	0	1 (<1)	0
外陰腟乾燥	0	0	1 (<1)	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0	0
乳房障害	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 43 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
乳房腫大	0	0	0	0	1 (<1)
乳房硬結	1 (<1)	0	0	0	0
子宮頚管ポリープ	0	0	0	0	1 (<1)
生殖器病変	1 (<1)	0	0	0	0
閉経期症状	1 (<1)	0	0	0	0
腟分泌物	1 (<1)	0	0	0	0
外陰腟痛	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
角膜ジストロフィー	0	0	1 (<1)	1 (<1)	0
異形成母斑症候群	0	1 (<1)	0	1 (<1)	0
先天性心臓疾患	0	1 (<1)	0	1 (<1)	0
陰嚢水瘤	0	0	1 (<1)	1 (<1)	0
ジルベール症候群	1 (<1)	0	0	0	0
過誤腫	0	0	0	0	1 (<1)
一般・全身障害および投与部位の状態	119 (26)	126 (22)	162 (28)	288 (25)	81 (34)
疲労	58 (13)	67 (12)	71 (12)	138 (12)	17 (7)
発熱	24 (5)	22 (4)	35 (6)	57 (5)	9 (4)
無力症	11 (2)	14 (2)	10 (2)	24 (2)	11 (5)
疼痛	7 (2)	12 (2)	11 (2)	23 (2)	3 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 44 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
熱感	1 (<1)	11 (2)	11 (2)	22 (2)	2 (<1)
胸痛	5 (1)	8 (1)	10 (2)	18 (2)	2 (<1)
インフルエンザ様疾患	7 (2)	6 (1)	10 (2)	16 (1)	1 (<1)
歩行障害	5 (1)	6 (1)	8 (1)	14 (1)	2 (<1)
末梢性浮腫	11 (2)	2 (<1)	10 (2)	12 (1)	3 (1)
悪寒	4 (<1)	3 (<1)	4 (<1)	7 (<1)	1 (<1)
非心臓性胸痛	2 (<1)	3 (<1)	4 (<1)	7 (<1)	1 (<1)
易刺激性	2 (<1)	3 (<1)	3 (<1)	6 (<1)	0
胸部不快感	4 (<1)	3 (<1)	2 (<1)	5 (<1)	0
倦怠感	1 (<1)	1 (<1)	4 (<1)	5 (<1)	2 (<1)
嚢胞	1 (<1)	0	4 (<1)	4 (<1)	0
顔面痛	1 (<1)	0	3 (<1)	3 (<1)	2 (<1)
高熱	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
浮腫	0	2 (<1)	1 (<1)	3 (<1)	1 (<1)
圧痛	0	0	3 (<1)	3 (<1)	0
冷感	1 (<1)	0	2 (<1)	2 (<1)	0
炎症	0	0	2 (<1)	2 (<1)	0
医療機器による疼痛	0	0	2 (<1)	2 (<1)	0
腫脹	0	1 (<1)	1 (<1)	2 (<1)	0
不快感	0	0	1 (<1)	1 (<1)	0
脂肪壊死	0	1 (<1)	0	1 (<1)	0
全身性浮腫	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 45 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
重力性浮腫	0	0	1 (<1)	1 (<1)	0
閉塞性ヘルニア	0	0	1 (<1)	1 (<1)	0
注入部位血腫	0	1 (<1)	0	1 (<1)	0
注射部位血腫	0	0	1 (<1)	1 (<1)	3 (1)
局所腫脹	0	1 (<1)	0	1 (<1)	0
足のもつれ	1 (<1)	1 (<1)	0	1 (<1)	0
粘膜乾燥	0	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	1 (<1)	0
不活発	0	0	1 (<1)	1 (<1)	0
口渇	1 (<1)	0	1 (<1)	1 (<1)	0
血管穿刺部位血腫	0	0	1 (<1)	1 (<1)	0
血管穿刺部位出血	0	1 (<1)	0	1 (<1)	0
血管穿刺部位疼痛	0	1 (<1)	0	1 (<1)	0
血管穿刺部位反応	0	1 (<1)	0	1 (<1)	0
異常感	0	0	0	0	1 (<1)
体温変動感	1 (<1)	0	0	0	0
全身症状	1 (<1)	0	0	0	0
空腹	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	3 (1)
注射部位変色	0	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	21 (9)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 46 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位血管外漏出	0	0	0	0	1 (<1)
注射部位出血	0	0	0	0	1 (<1)
注射部位過敏反応	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	1 (<1)
注射部位硬結	0	0	0	0	4 (2)
注射部位腫瘤	0	0	0	0	3 (1)
注射部位結節	0	0	0	0	1 (<1)
注射部位浮腫	0	0	0	0	3 (1)
注射部位疼痛	0	0	0	0	13 (5)
注射部位そう痒感	0	0	0	0	6 (3)
注射部位発疹	0	0	0	0	1 (<1)
注射部位反応	0	0	0	0	3 (1)
注射部位腫脹	0	0	0	0	6 (3)
注射部位蕁麻疹	0	0	0	0	1 (<1)
注射部位熱感	0	0	0	0	1 (<1)
微石症	0	0	0	0	1 (<1)
臨床検査	119 (26)	159 (28)	152 (26)	311 (27)	60 (25)
アラニン・アミノトランスフェラーゼ増加	21 (5)	35 (6)	36 (6)	71 (6)	14 (6)
尿中アルブミン陽性	17 (4)	36 (6)	27 (5)	63 (6)	8 (3)
アスパラギン酸アミノトランスフェラーゼ増加	11 (2)	25 (4)	22 (4)	47 (4)	10 (4)
尿中蛋白陽性	14 (3)	20 (4)	17 (3)	37 (3)	9 (4)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 47 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿中血陽性	5 (1)	12 (2)	12 (2)	24 (2)	1 (<1)
γ－グルタミルトランスフェラーゼ増加	12 (3)	15 (3)	8 (1)	23 (2)	5 (2)
尿中β２ミクログロブリン増加	6 (1)	9 (2)	12 (2)	21 (2)	5 (2)
血中ブドウ糖増加	5 (1)	6 (1)	15 (3)	21 (2)	5 (2)
白血球数減少	0	11 (2)	10 (2)	21 (2)	0
尿中白血球陽性	8 (2)	12 (2)	9 (2)	21 (2)	6 (3)
血中副甲状腺ホルモン増加	2 (<1)	8 (1)	12 (2)	20 (2)	1 (<1)
体重減少	1 (<1)	9 (2)	6 (1)	15 (1)	3 (1)
リンパ球数減少	0	8 (1)	6 (1)	14 (1)	0
尿中ケトン体陽性	2 (<1)	4 (<1)	10 (2)	14 (1)	2 (<1)
ヘモグロビン減少	3 (<1)	6 (1)	6 (1)	12 (1)	1 (<1)
β２ミクログロブリン増加	1 (<1)	3 (<1)	7 (1)	10 (<1)	0
肝酵素上昇	6 (1)	4 (<1)	5 (<1)	9 (<1)	2 (<1)
尿中赤血球陽性	4 (<1)	6 (1)	3 (<1)	9 (<1)	2 (<1)
血中トリグリセリド増加	2 (<1)	5 (<1)	3 (<1)	8 (<1)	1 (<1)
好中球数増加	7 (2)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
体重増加	7 (2)	2 (<1)	6 (1)	8 (<1)	2 (<1)
白血球数増加	10 (2)	4 (<1)	4 (<1)	8 (<1)	3 (1)
血中クレアチニン増加	4 (<1)	3 (<1)	4 (<1)	7 (<1)	4 (2)
血中カリウム増加	0	4 (<1)	3 (<1)	7 (<1)	0
ヘマトクリット減少	1 (<1)	4 (<1)	3 (<1)	7 (<1)	1 (<1)
赤血球数減少	2 (<1)	4 (<1)	2 (<1)	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 48 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ビタミンD減少	2 (<1)	4 (<1)	2 (<1)	6 (<1)	0
血中コレステロール増加	0	1 (<1)	4 (<1)	5 (<1)	0
体温上昇	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
尿中ブドウ糖陽性	2 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
好中球数減少	1 (<1)	4 (<1)	1 (<1)	5 (<1)	0
血中ビリルビン増加	5 (1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
血中乳酸脱水素酵素増加	3 (<1)	4 (<1)	0	4 (<1)	0
血中アルカリホスファターゼ増加	6 (1)	3 (<1)	0	3 (<1)	1 (<1)
血中クレアチン増加	0	2 (<1)	1 (<1)	3 (<1)	0
血圧上昇	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
血中ナトリウム増加	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
血中尿素増加	2 (<1)	0	3 (<1)	3 (<1)	0
血液学的検査異常	0	2 (<1)	1 (<1)	3 (<1)	0
肝機能検査異常	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
血小板数減少	2 (<1)	3 (<1)	0	3 (<1)	1 (<1)
ビタミンD増加	2 (<1)	0	3 (<1)	3 (<1)	0
細菌検査陽性	2 (<1)	0	2 (<1)	2 (<1)	0
血中クロール増加	0	0	2 (<1)	2 (<1)	0
血中葉酸減少	0	1 (<1)	1 (<1)	2 (<1)	0
尿中結晶陽性	5 (1)	1 (<1)	1 (<1)	2 (<1)	0
心電図異常	2 (<1)	0	2 (<1)	2 (<1)	0
心電図ＱＴ延長	5 (1)	0	2 (<1)	2 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 49 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心電図ＳＴ部分下降	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
好酸球数増加	2 (<1)	2 (<1)	0	2 (<1)	0
高比重リポ蛋白増加	0	0	2 (<1)	2 (<1)	0
低比重リポ蛋白増加	0	0	2 (<1)	2 (<1)	0
リンパ球形態異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
血小板数増加	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
赤血球数増加	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミンＢ１２減少	1 (<1)	2 (<1)	0	2 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)	0
アスパラギン酸アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)	0
血中アルカリホスファターゼ異常	0	1 (<1)	0	1 (<1)	0
血中重炭酸塩減少	0	1 (<1)	0	1 (<1)	0
血中重炭酸塩増加	0	1 (<1)	0	1 (<1)	0
血中カルシウム減少	0	1 (<1)	0	1 (<1)	1 (<1)
血中クレアチニン異常	0	1 (<1)	0	1 (<1)	0
血中鉄減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中ケトン体増加	0	1 (<1)	0	1 (<1)	0
血中副甲状腺ホルモン異常	0	0	1 (<1)	1 (<1)	0
血圧低下	1 (<1)	1 (<1)	0	1 (<1)	0
拡張期血圧上昇	0	0	1 (<1)	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	1 (<1)	0
血中甲状腺刺激ホルモン増加	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 50 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
体温低下	0	1 (<1)	0	1 (<1)	0
呼吸音異常	0	1 (<1)	0	1 (<1)	0
心雑音	1 (<1)	1 (<1)	0	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	1 (<1)	0
心筋虚血の心電図所見	0	1 (<1)	0	1 (<1)	0
心電図Ｔ波逆転	0	1 (<1)	0	1 (<1)	2 (<1)
好酸球数異常	0	0	1 (<1)	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	1 (<1)	0
大腸菌検査陽性	0	1 (<1)	0	1 (<1)	0
γ－グルタミルトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)	0
γ－グルタミルトランスフェラーゼ減少	0	1 (<1)	0	1 (<1)	0
心拍数増加	1 (<1)	1 (<1)	0	1 (<1)	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	1 (<1)	0
ヒステロスコピー	0	1 (<1)	0	1 (<1)	0
リンパ節触知	0	0	1 (<1)	1 (<1)	0
リンパ球百分率減少	0	1 (<1)	0	1 (<1)	0
単球数減少	0	0	1 (<1)	1 (<1)	1 (<1)
神経学的検査異常	0	1 (<1)	0	1 (<1)	0
好中球百分率増加	0	1 (<1)	0	1 (<1)	0
血小板数	0	1 (<1)	0	1 (<1)	0
ロンベルグ徴候陽性	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 51 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
残尿量増加	0	1 (<1)	0	1 (<1)	0
つぎ足歩行検査異常	0	1 (<1)	0	1 (<1)	0
尿円柱	0	0	1 (<1)	1 (<1)	0
抗甲状腺抗体陽性	1 (<1)	0	0	0	0
抗核抗体増加	1 (<1)	0	0	0	0
動脈雑音	1 (<1)	0	0	0	0
細菌検査	1 (<1)	0	0	0	0
血中カルシウム増加	2 (<1)	0	0	0	0
血中クロール減少	1 (<1)	0	0	0	0
血中ブドウ糖減少	1 (<1)	0	0	0	0
血中マグネシウム減少	1 (<1)	0	0	0	0
血中副甲状腺ホルモン減少	1 (<1)	0	0	0	0
血中リン増加	1 (<1)	0	0	0	0
血中カリウム減少	1 (<1)	0	0	0	0
収縮期血圧上昇	1 (<1)	0	0	0	0
血中尿酸増加	2 (<1)	0	0	0	1 (<1)
心電図ＰＲ延長	1 (<1)	0	0	0	0
心電図異常ＱＲＳ群	1 (<1)	0	0	0	0
心電図ＱＲＳ群延長	1 (<1)	0	0	0	0
心電図Ｔ波振幅減少	1 (<1)	0	0	0	0
心電図２相性Ｔ波	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 52 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
全血球数異常	1 (<1)	0	0	0	0
握力低下	0	0	0	0	2 (<1)
心音異常	1 (<1)	0	0	0	0
リンパ球数増加	1 (<1)	0	0	0	0
後骨髄球百分率増加	1 (<1)	0	0	0	0
骨髄球百分率増加	1 (<1)	0	0	0	0
脳核磁気共鳴画像異常	1 (<1)	0	0	0	0
便潜血陽性	0	0	0	0	1 (<1)
ＱＲＳ軸異常	1 (<1)	0	0	0	0
子宮頚部スミア異常	1 (<1)	0	0	0	0
膀胱超音波検査異常	1 (<1)	0	0	0	0
前庭機能検査異常	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	85 (19)	75 (13)	82 (14)	157 (14)	20 (8)
挫傷	9 (2)	12 (2)	17 (3)	29 (3)	2 (<1)
転倒	13 (3)	13 (2)	15 (3)	28 (2)	7 (3)
関節捻挫	9 (2)	8 (1)	8 (1)	16 (1)	2 (<1)
肉離れ	3 (<1)	5 (<1)	7 (1)	12 (1)	0
四肢損傷	4 (<1)	5 (<1)	5 (<1)	10 (<1)	0
処置による疼痛	3 (<1)	4 (<1)	6 (1)	10 (<1)	0
節足動物咬傷	7 (2)	3 (<1)	5 (<1)	8 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 53 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
足骨折	3 (<1)	5 (<1)	3 (<1)	8 (<1)	0
皮膚裂傷	5 (1)	5 (<1)	3 (<1)	8 (<1)	0
擦過傷	1 (<1)	2 (<1)	4 (<1)	6 (<1)	2 (<1)
半月板障害	1 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
交通事故	2 (<1)	3 (<1)	3 (<1)	6 (<1)	2 (<1)
靭帯断裂	3 (<1)	1 (<1)	4 (<1)	5 (<1)	0
歯牙破折	2 (<1)	3 (<1)	2 (<1)	5 (<1)	0
足関節部骨折	0	2 (<1)	2 (<1)	4 (<1)	1 (<1)
骨格損傷	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
熱傷	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
外傷性血腫	0	3 (<1)	1 (<1)	4 (<1)	0
節足動物刺傷	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
関節損傷	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
サンバーン	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
むち打ち損傷	1 (<1)	3 (<1)	0	3 (<1)	2 (<1)
脳振盪	0	2 (<1)	0	2 (<1)	1 (<1)
上顆炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
眼外傷	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
損傷	0	0	2 (<1)	2 (<1)	0
筋断裂	0	2 (<1)	0	2 (<1)	0
創傷	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
手首関節骨折	0	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 54 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
偶発的過量投与	0	1 (<1)	0	1 (<1)	0
アルコール中毒	0	0	1 (<1)	1 (<1)	0
動物咬傷	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
凍瘡	1 (<1)	1 (<1)	0	1 (<1)	0
眼瞼損傷	0	1 (<1)	0	1 (<1)	0
顔面損傷	0	1 (<1)	0	1 (<1)	0
顔面骨骨折	0	1 (<1)	0	1 (<1)	0
大腿骨骨折	0	1 (<1)	0	1 (<1)	0
尾骨骨折	0	0	1 (<1)	1 (<1)	0
手骨折	0	1 (<1)	0	1 (<1)	2 (<1)
腸脛靭帯症候群	0	0	1 (<1)	1 (<1)	0
切開部位痛	0	1 (<1)	0	1 (<1)	0
瘢痕ヘルニア	0	1 (<1)	0	1 (<1)	0
閉塞性瘢痕ヘルニア	0	0	1 (<1)	1 (<1)	0
靭帯捻挫	0	0	1 (<1)	1 (<1)	0
下肢骨折	0	0	1 (<1)	1 (<1)	0
頚部損傷	0	1 (<1)	0	1 (<1)	1 (<1)
処置後出血	0	1 (<1)	0	1 (<1)	0
処置後浮腫	0	0	1 (<1)	1 (<1)	0
処置による悪心	1 (<1)	1 (<1)	0	1 (<1)	0
処置による嘔吐	0	1 (<1)	0	1 (<1)	0
放射線皮膚損傷	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 55 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
橈骨骨折	1 (<1)	0	1 (<1)	1 (<1)	2 (<1)
反復性挫傷	0	1 (<1)	0	1 (<1)	0
網膜損傷	1 (<1)	1 (<1)	0	1 (<1)	0
肋骨骨折	0	0	1 (<1)	1 (<1)	0
引っかき傷	0	0	1 (<1)	1 (<1)	0
軟部組織損傷	0	1 (<1)	0	1 (<1)	0
脊椎圧迫骨折	0	1 (<1)	0	1 (<1)	0
滑膜断裂	0	0	1 (<1)	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
外傷性骨折	0	0	1 (<1)	1 (<1)	0
ワクチン接種合併症	1 (<1)	0	1 (<1)	1 (<1)	0
創し開	0	0	1 (<1)	1 (<1)	0
気圧性中耳炎	0	0	0	0	1 (<1)
眼部化学的損傷	1 (<1)	0	0	0	0
角膜擦過傷	1 (<1)	0	0	0	0
腓骨骨折	1 (<1)	0	0	0	0
眼内異物	1 (<1)	0	0	0	0
頭部損傷	0	0	0	0	1 (<1)
関節脱臼	1 (<1)	0	0	0	0
靭帯損傷	1 (<1)	0	0	0	0
口唇損傷	0	0	0	0	1 (<1)
筋損傷	2 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 56 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
処置後合併症	1 (<1)	0	0	0	1 (<1)
外傷後疼痛	2 (<1)	0	0	0	0
腱損傷	1 (<1)	0	0	0	0
腱断裂	2 (<1)	0	0	0	1 (<1)
治療薬毒性	1 (<1)	0	0	0	0
脛骨骨折	1 (<1)	0	0	0	0
有毒性刺傷	2 (<1)	0	0	0	0
第７神経損傷	0	0	0	0	1 (<1)
創傷出血	1 (<1)	0	0	0	0
外科および内科処置	1 (<1)	8 (1)	3 (<1)	11 (<1)	1 (<1)
抜歯	0	3 (<1)	0	3 (<1)	1 (<1)
子宮摘出	0	1 (<1)	1 (<1)	2 (<1)	0
乳房腫瘤摘除	0	1 (<1)	0	1 (<1)	0
女性不妊手術	0	1 (<1)	0	1 (<1)	0
ヘルニア修復	0	1 (<1)	0	1 (<1)	0
椎間板手術	0	0	1 (<1)	1 (<1)	0
治療食	0	1 (<1)	0	1 (<1)	0
静脈ステント挿入	0	0	1 (<1)	1 (<1)	0
色素性母斑切除	1 (<1)	0	0	0	0
社会環境	2 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Incidence of adverse events in subjects not treated with IV corticosteroids by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 57 of 57

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
閉経	0	1 (<1)	0	1 (<1)	0
元タバコ使用者	1 (<1)	0	0	0	0
職場でのストレス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVSTNO-A.SAS DATE: 02DEC2015

Table 289: Incidence of Adverse Events With Onset Within 28 Days of Initiation of IV Corticosteroids by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 1 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Number of subjects treated with IV corticosteroids	319 (100)	205 (100)	184 (100)	389 (100)	113 (100)
Number of subjects with an event	173 (54)	114 (56)	112 (61)	226 (58)	59 (52)
感染症および寄生虫症	34 (11)	20 (10)	26 (14)	46 (12)	10 (9)
尿路感染	5 (2)	7 (3)	3 (2)	10 (3)	3 (3)
鼻咽頭炎	5 (2)	2 (<1)	7 (4)	9 (2)	1 (<1)
副鼻腔炎	2 (<1)	1 (<1)	5 (3)	6 (2)	0
胃腸炎	1 (<1)	3 (1)	1 (<1)	4 (1)	0
気管支炎	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
蜂巣炎	0	0	2 (1)	2 (<1)	0
インフルエンザ	1 (<1)	0	2 (1)	2 (<1)	1 (<1)
ウイルス感染	1 (<1)	0	2 (1)	2 (<1)	0
細菌感染	0	1 (<1)	0	1 (<1)	0
膀胱炎	3 (<1)	0	1 (<1)	1 (<1)	0
性器カンジダ症	0	1 (<1)	0	1 (<1)	0
帯状疱疹	1 (<1)	0	1 (<1)	1 (<1)	0
爪真菌症	0	1 (<1)	0	1 (<1)	0
口腔カンジダ症	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 2 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
口腔ヘルペス	3 (<1)	0	1 (<1)	1 (<1)	0
中耳炎	0	1 (<1)	0	1 (<1)	0
咽頭炎	2 (<1)	1 (<1)	0	1 (<1)	0
鼻炎	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
足部白癬	0	0	1 (<1)	1 (<1)	0
上気道感染	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
細菌性膣炎	0	1 (<1)	0	1 (<1)	0
感染性下痢	1 (<1)	0	0	0	0
毛包炎	1 (<1)	0	0	0	0
下気道感染	0	0	0	0	1 (<1)
レンサ球菌性咽頭炎	0	0	0	0	1 (<1)
肺炎	0	0	0	0	1 (<1)
ライター症候群	1 (<1)	0	0	0	0
ウイルス性気道感染	1 (<1)	0	0	0	0
扁桃炎	1 (<1)	0	0	0	0
歯膿瘍	2 (<1)	0	0	0	0
気管炎	0	0	0	0	1 (<1)
ウイルス性上気道感染	1 (<1)	0	0	0	0
外陰膣真菌感染	2 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 3 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
子宮平滑筋腫	0	1 (<1)	0	1 (<1)	0
血液およびリンパ系障害	3 (<1)	3 (1)	3 (2)	6 (2)	2 (2)
貧血	1 (<1)	3 (1)	1 (<1)	4 (1)	0
白血球減少症	0	0	1 (<1)	1 (<1)	0
好中球増加症	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
小球性貧血	1 (<1)	0	0	0	0
血小板減少症	0	0	0	0	1 (<1)
免疫系障害	0	2 (<1)	2 (1)	4 (1)	1 (<1)
過敏症	0	1 (<1)	1 (<1)	2 (<1)	0
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
食物アレルギー	0	1 (<1)	0	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)
代謝および栄養障害	2 (<1)	4 (2)	1 (<1)	5 (1)	1 (<1)
脱水	0	1 (<1)	1 (<1)	2 (<1)	0
糖尿病	0	1 (<1)	0	1 (<1)	0
高血糖	0	1 (<1)	0	1 (<1)	0
低カリウム血症	0	1 (<1)	0	1 (<1)	0
ケトーシス	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 4 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
葉酸欠乏	1 (<1)	0	0	0	0
ビタミンD欠乏	0	0	0	0	1 (<1)
精神障害	9 (3)	11 (5)	10 (5)	21 (5)	4 (4)
不眠症	4 (1)	6 (3)	6 (3)	12 (3)	2 (2)
うつ病	2 (<1)	3 (1)	4 (2)	7 (2)	1 (<1)
不安	1 (<1)	0	2 (1)	2 (<1)	0
抑うつ気分	0	1 (<1)	0	1 (<1)	0
抑うつ症状	0	1 (<1)	0	1 (<1)	0
精神病性障害	0	0	1 (<1)	1 (<1)	0
感情不安定	0	0	0	0	1 (<1)
睡眠障害	2 (<1)	0	0	0	0
神経系障害	106 (33)	69 (34)	67 (36)	136 (35)	33 (29)
多発性硬化症再発	88 (28)	63 (31)	54 (29)	117 (30)	27 (24)
頭痛	8 (3)	3 (1)	5 (3)	8 (2)	2 (2)
浮動性めまい	0	1 (<1)	2 (1)	3 (<1)	0
灼熱感	0	1 (<1)	1 (<1)	2 (<1)	0
片頭痛	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
錯感覚	4 (1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
良性頭蓋内圧亢進	0	0	1 (<1)	1 (<1)	0
体位性めまい	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 5 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
構語障害	0	0	1 (<1)	1 (<1)	0
味覚異常	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
てんかん	0	0	1 (<1)	1 (<1)	0
感覚鈍麻	2 (<1)	0	1 (<1)	1 (<1)	2 (2)
思考散乱	0	0	1 (<1)	1 (<1)	0
意識消失	0	0	1 (<1)	1 (<1)	1 (<1)
前兆を伴う片頭痛	0	0	1 (<1)	1 (<1)	0
多発性硬化症	3 (<1)	0	1 (<1)	1 (<1)	0
筋痙直	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
後頭神経痛	0	0	1 (<1)	1 (<1)	0
視神経炎	0	0	1 (<1)	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
振戦	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
失語症	0	0	0	0	1 (<1)
運動失調	1 (<1)	0	0	0	0
小脳症候群	1 (<1)	0	0	0	0
痙攣	1 (<1)	0	0	0	0
頭部動揺	0	0	0	0	1 (<1)
感覚障害	1 (<1)	0	0	0	0
緊張性頭痛	1 (<1)	0	0	0	0
三叉神経痛	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 6 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼障害	4 (1)	1 (<1)	5 (3)	6 (2)	3 (3)
眼乾燥	0	0	2 (1)	2 (<1)	0
アレルギー性眼瞼炎	0	0	1 (<1)	1 (<1)	0
結膜炎	0	0	1 (<1)	1 (<1)	0
アレルギー性結膜炎	0	1 (<1)	0	1 (<1)	0
視力障害	1 (<1)	0	1 (<1)	1 (<1)	0
複視	0	0	0	0	2 (2)
遠視	1 (<1)	0	0	0	0
流涙増加	1 (<1)	0	0	0	0
眼充血	0	0	0	0	1 (<1)
視力低下	1 (<1)	0	0	0	1 (<1)
耳および迷路障害	1 (<1)	0	6 (3)	6 (2)	1 (<1)
回転性めまい	0	0	4 (2)	4 (1)	1 (<1)
耳鳴	0	0	1 (<1)	1 (<1)	0
頭位性回転性めまい	1 (<1)	0	1 (<1)	1 (<1)	0
心臓障害	1 (<1)	2 (<1)	2 (1)	4 (1)	2 (2)
徐脈	0	0	1 (<1)	1 (<1)	0
期外収縮	0	1 (<1)	0	1 (<1)	0
洞性頻脈	1 (<1)	0	1 (<1)	1 (<1)	0
上室性期外収縮	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 7 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
頻脈	0	1 (<1)	0	1 (<1)	1 (<1)
心室性期外収縮	0	1 (<1)	0	1 (<1)	0
心房細動	0	0	0	0	1 (<1)
心筋炎	0	0	0	0	1 (<1)
血管障害	5 (2)	5 (2)	3 (2)	8 (2)	3 (3)
潮紅	3 (<1)	3 (1)	1 (<1)	4 (1)	1 (<1)
高血圧	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	1 (<1)
血腫	0	0	0	0	1 (<1)
起立性低血圧	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (<1)	2 (<1)	4 (2)	6 (2)	4 (4)
口腔咽頭痛	0	1 (<1)	2 (1)	3 (<1)	1 (<1)
咳嗽	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	1 (<1)	0
喘息	0	1 (<1)	0	1 (<1)	0
呼吸困難	1 (<1)	0	0	0	0
喀血	1 (<1)	0	0	0	0
低換気	0	0	0	0	1 (<1)
鼻中隔穿孔	0	0	0	0	1 (<1)
ラ音	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 8 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
上気道うっ血	0	0	0	0	1 (<1)
胃腸障害	18 (6)	12 (6)	17 (9)	29 (7)	2 (2)
悪心	5 (2)	2 (<1)	3 (2)	5 (1)	1 (<1)
消化不良	0	1 (<1)	3 (2)	4 (1)	0
上腹部痛	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
下痢	5 (2)	1 (<1)	2 (1)	3 (<1)	1 (<1)
歯痛	0	1 (<1)	2 (1)	3 (<1)	0
嘔吐	1 (<1)	1 (<1)	2 (1)	3 (<1)	0
腹部不快感	0	2 (<1)	0	2 (<1)	0
便秘	4 (1)	2 (<1)	0	2 (<1)	1 (<1)
胃食道逆流性疾患	0	1 (<1)	1 (<1)	2 (<1)	0
腹痛	2 (<1)	0	1 (<1)	1 (<1)	0
口唇炎	0	1 (<1)	0	1 (<1)	0
胃炎	0	1 (<1)	0	1 (<1)	0
裂孔ヘルニア	0	1 (<1)	0	1 (<1)	0
嚥下痛	0	0	1 (<1)	1 (<1)	0
食道潰瘍	0	0	1 (<1)	1 (<1)	0
歯周炎	0	0	1 (<1)	1 (<1)	0
臍ヘルニア	0	0	1 (<1)	1 (<1)	0
鼓腸	1 (<1)	0	0	0	0
胃腸障害	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 9 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝胆道系障害	1 (<1)	0	0	0	0
肝炎	1 (<1)	0	0	0	0
皮膚および皮下組織障害	6 (2)	6 (3)	7 (4)	13 (3)	4 (4)
紅斑	0	0	2 (1)	2 (<1)	0
発疹	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
蕁麻疹	0	1 (<1)	1 (<1)	2 (<1)	0
脱毛症	0	1 (<1)	0	1 (<1)	1 (<1)
薬疹	0	0	1 (<1)	1 (<1)	0
全身紅斑	0	1 (<1)	0	1 (<1)	0
多汗症	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
掌蹠角化症	0	1 (<1)	0	1 (<1)	0
顔面感覚鈍麻	0	0	1 (<1)	1 (<1)	0
皮膚灼熱感	0	0	1 (<1)	1 (<1)	0
皮膚のつっぱり感	0	1 (<1)	0	1 (<1)	0
皮膚炎	1 (<1)	0	0	0	0
アレルギー性皮膚炎	2 (<1)	0	0	0	0
そう痒症	1 (<1)	0	0	0	0
皮膚色素過剰	0	0	0	0	1 (<1)
筋骨格系および結合組織障害	12 (4)	8 (4)	10 (5)	18 (5)	4 (4)
背部痛	1 (<1)	5 (2)	3 (2)	8 (2)	2 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 10 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
関節痛	2 (<1)	1 (<1)	2 (1)	3 (<1)	0
筋肉痛	1 (<1)	2 (<1)	0	2 (<1)	0
筋痙縮	1 (<1)	0	1 (<1)	1 (<1)	0
筋力低下	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
筋骨格痛	1 (<1)	0	1 (<1)	1 (<1)	0
筋骨格硬直	0	0	1 (<1)	1 (<1)	0
骨端症	0	0	1 (<1)	1 (<1)	0
関節周囲炎	0	1 (<1)	0	1 (<1)	0
腱鞘炎	0	0	1 (<1)	1 (<1)	0
外骨腫	0	0	0	0	1 (<1)
筋骨格系胸痛	1 (<1)	0	0	0	0
頚部痛	1 (<1)	0	0	0	0
変形性関節症	1 (<1)	0	0	0	0
四肢痛	2 (<1)	0	0	0	0
腱痛	1 (<1)	0	0	0	0
腱炎	1 (<1)	0	0	0	0
腎および尿路障害	9 (3)	7 (3)	10 (5)	17 (4)	3 (3)
蛋白尿	4 (1)	5 (2)	2 (1)	7 (2)	1 (<1)
血尿	3 (<1)	3 (1)	3 (2)	6 (2)	1 (<1)
ケトン尿	2 (<1)	0	2 (1)	2 (<1)	0
ミクロアルブミン尿	1 (<1)	0	2 (1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 11 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
排尿困難	0	0	1 (<1)	1 (<1)	0
尿閉	0	0	1 (<1)	1 (<1)	0
尿臭異常	0	0	1 (<1)	1 (<1)	0
糖尿	3 (<1)	0	0	0	0
夜間頻尿	0	0	0	0	1 (<1)
妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
自然流産	1 (<1)	0	0	0	0
生殖系および乳房障害	2 (<1)	1 (<1)	2 (1)	3 (<1)	2 (2)
月経困難症	0	0	1 (<1)	1 (<1)	0
勃起不全	0	0	1 (<1)	1 (<1)	0
月経障害	0	1 (<1)	0	1 (<1)	0
無月経	1 (<1)	0	0	0	1 (<1)
乳房障害	0	0	0	0	1 (<1)
希発月経	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (<1)	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	1 (<1)	0
一般・全身障害および投与部位の状態	11 (3)	8 (4)	7 (4)	15 (4)	10 (9)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 12 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
疲労	3 (<1)	4 (2)	3 (2)	7 (2)	2 (2)
疼痛	0	2 (<1)	1 (<1)	3 (<1)	1 (<1)
末梢性浮腫	2 (<1)	0	2 (1)	2 (<1)	0
無力症	0	0	1 (<1)	1 (<1)	0
歩行障害	1 (<1)	0	1 (<1)	1 (<1)	0
倦怠感	0	1 (<1)	0	1 (<1)	0
粘膜乾燥	0	1 (<1)	0	1 (<1)	0
発熱	4 (1)	1 (<1)	0	1 (<1)	2 (2)
顔面痛	1 (<1)	0	0	0	0
インフルエンザ様疾患	1 (<1)	0	0	0	0
注射部位紅斑	0	0	0	0	1 (<1)
注射部位疼痛	0	0	0	0	1 (<1)
注射部位発疹	0	0	0	0	1 (<1)
注射部位蕁麻疹	0	0	0	0	1 (<1)
易刺激性	0	0	0	0	1 (<1)
臨床検査	18 (6)	14 (7)	19 (10)	33 (8)	11 (10)
アラニン・アミノトランスフェラーゼ増加	1 (<1)	3 (1)	3 (2)	6 (2)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	3 (1)	1 (<1)	4 (1)	0
γ－グルタミルトランスフェラーゼ増加	1 (<1)	2 (<1)	2 (1)	4 (1)	0
尿中アルブミン陽性	0	2 (<1)	1 (<1)	3 (<1)	2 (2)
血中ブドウ糖増加	1 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 13 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中副甲状腺ホルモン増加	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
好中球数増加	3 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
白血球数増加	2 (<1)	1 (<1)	2 (1)	3 (<1)	1 (<1)
尿中血陽性	0	1 (<1)	1 (<1)	2 (<1)	0
肝酵素上昇	2 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (2)
リンパ球数増加	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
尿中蛋白陽性	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
アラニン・アミノトランスフェラーゼ異常	0	0	1 (<1)	1 (<1)	0
尿中β２ミクログロブリン増加	2 (<1)	0	1 (<1)	1 (<1)	0
血中カルシウム増加	0	0	1 (<1)	1 (<1)	1 (<1)
血中コレステロール増加	0	1 (<1)	0	1 (<1)	1 (<1)
血中クレアチニン増加	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
血中乳酸脱水素酵素増加	0	1 (<1)	0	1 (<1)	0
血中トリグリセリド増加	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
心電図ＱＴ延長	0	0	1 (<1)	1 (<1)	0
心電図Ｔ波振幅減少	0	0	1 (<1)	1 (<1)	0
γ－グルタミルトランスフェラーゼ異常	0	0	1 (<1)	1 (<1)	0
血液学的検査異常	1 (<1)	0	1 (<1)	1 (<1)	0
高比重リポ蛋白増加	0	0	1 (<1)	1 (<1)	0
低比重リポ蛋白増加	0	0	1 (<1)	1 (<1)	0
単球数増加	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 14 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿中赤血球陽性	1 (<1)	1 (<1)	0	1 (<1)	0
体重減少	0	1 (<1)	0	1 (<1)	0
体重増加	0	0	1 (<1)	1 (<1)	0
白血球数減少	0	1 (<1)	0	1 (<1)	0
尿中白血球陽性	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
血中ビリルビン増加	2 (<1)	0	0	0	0
血中クレアチン異常	1 (<1)	0	0	0	0
血中ケトン体増加	0	0	0	0	1 (<1)
血中尿素増加	0	0	0	0	1 (<1)
体温上昇	0	0	0	0	1 (<1)
尿中ブドウ糖陽性	0	0	0	0	1 (<1)
リンパ球数異常	0	0	0	0	1 (<1)
リンパ球百分率減少	1 (<1)	0	0	0	0
骨髄球数増加	1 (<1)	0	0	0	0
好中球数異常	0	0	0	0	1 (<1)
好中球百分率増加	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	1 (<1)	0	0	0	1 (<1)
白血球数異常	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	2 (<1)	2 (<1)	6 (3)	8 (2)	1 (<1)
挫傷	0	0	2 (1)	2 (<1)	0
関節捻挫	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Incidence of adverse events with onset within 28 days of initiation of IV corticosteroids
by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 15 of 15

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
造影剤反応	0	0	1 (<1)	1 (<1)	0
擦過傷	0	0	1 (<1)	1 (<1)	0
転倒	0	0	1 (<1)	1 (<1)	0
関節脱臼	0	1 (<1)	0	1 (<1)	0
肉離れ	0	0	1 (<1)	1 (<1)	0
サンバーン	0	0	1 (<1)	1 (<1)	0
術後創合併症	0	0	0	0	1 (<1)
熱傷	1 (<1)	0	0	0	0
外科および内科処置	0	0	0	0	1 (<1)
入院	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-IVST28D-A.SAS DATE: 02DEC2015

Table 290: Time on Study After Discontinuation of Study Treatment: Studies 109MS301 and 109MS302

Time on study after discontinuation of study treatment: Studies 109MS301 and 109MS302
Page 1 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Number of subjects who discontinued study treatment	272 (100)	232 (100)	223 (100)	455 (100)	86 (100)
Number of subjects with time on study after discontinuation of study treatment of (a)					
0 weeks	22 (8)	10 (4)	13 (6)	23 (5)	5 (6)
>0 to <12 weeks	117 (43)	119 (51)	125 (56)	244 (54)	39 (45)
>=12 to <24 weeks	23 (8)	30 (13)	17 (8)	47 (10)	10 (12)
>=24 to <36 weeks	24 (9)	12 (5)	15 (7)	27 (6)	6 (7)
>=36 to <48 weeks	25 (9)	12 (5)	12 (5)	24 (5)	4 (5)
>=48 to <60 weeks	29 (11)	14 (6)	13 (6)	27 (6)	8 (9)
>=60 to <72 weeks	10 (4)	13 (6)	4 (2)	17 (4)	3 (3)
>=72 to <84 weeks	14 (5)	9 (4)	5 (2)	14 (3)	4 (5)

NOTE: Numbers in parentheses are percentages.
(a) Time on study after discontinuation of study treatment in weeks is calculated as (last date on study - date of last exposure to study treatment + 1)/7.
(b) Time on study after discontinuation of study treatment in months is calculated as time on study after discontinuation of study treatment in weeks/4.
(c) Total number of subject-years for time on study after discontinuation of study treatment is calculated as the sum of number of days on study after discontinuation of study treatment/365.25.

SOURCE: BG12MS/JAPAN/ISS/T-STUTIME-DISCTRT-A.SAS DATE: 28SEP2015

Time on study after discontinuation of study treatment: Studies 109MS301 and 109MS302
Page 2 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
>=84 to <96 weeks	7 (3)	8 (3)	14 (6)	22 (5)	7 (8)
>=96 to <108 weeks	1 (<1)	5 (2)	5 (2)	10 (2)	0
>=12 weeks	133 (49)	103 (44)	85 (38)	188 (41)	42 (49)
>=24 weeks	110 (40)	73 (31)	68 (30)	141 (31)	32 (37)
>=36 weeks	86 (32)	61 (26)	53 (24)	114 (25)	26 (30)
>=48 weeks	61 (22)	49 (21)	41 (18)	90 (20)	22 (26)
>=60 weeks	32 (12)	35 (15)	28 (13)	63 (14)	14 (16)
>=72 weeks	22 (8)	22 (9)	24 (11)	46 (10)	11 (13)
>=84 weeks	8 (3)	13 (6)	19 (9)	32 (7)	7 (8)
>=96 weeks	1 (<1)	5 (2)	5 (2)	10 (2)	0

NOTE: Numbers in parentheses are percentages.
(a) Time on study after discontinuation of study treatment in weeks is calculated as (last date on study - date of last exposure to study treatment + 1)/7.
(b) Time on study after discontinuation of study treatment in months is calculated as time on study after discontinuation of study treatment in weeks/4.
(c) Total number of subject-years for time on study after discontinuation of study treatment is calculated as the sum of number of days on study after discontinuation of study treatment/365.25.

SOURCE: BG12MS/JAPAN/ISS/T-STUTIME-DISCTRT-A.SAS DATE: 28SEP2015

Time on study after discontinuation of study treatment: Studies 109MS301 and 109MS302
Page 3 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Time on study after discontinuation of study treatment (weeks)(a)					
n	272	232	223	455	86
Mean	23.98	22.65	21.39	22.04	25.54
SD	26.610	28.491	29.196	28.814	30.126
Median	9.86	8.00	4.86	6.43	9.14
Min, Max	0.0, 99.1	0.0, 98.4	0.0, 100.6	0.0, 100.6	0.0, 94.6
Time on study after discontinuation of study treatment (months)(b)					
n	272	232	223	455	86
Mean	6.00	5.66	5.35	5.51	6.38
SD	6.653	7.123	7.299	7.204	7.531
Median	2.46	2.00	1.21	1.61	2.29
Min, Max	0.0, 24.8	0.0, 24.6	0.0, 25.1	0.0, 25.1	0.0, 23.6

NOTE: Numbers in parentheses are percentages.
(a) Time on study after discontinuation of study treatment in weeks is calculated as (last date on study - date of last exposure to study treatment + 1)/7.
(b) Time on study after discontinuation of study treatment in months is calculated as time on study after discontinuation of study treatment in weeks/4.
(c) Total number of subject-years for time on study after discontinuation of study treatment is calculated as the sum of number of days on study after discontinuation of study treatment/365.25.

SOURCE: BG12MS/JAPAN/ISS/T-STUTIME-DISCTRT-A.SAS DATE: 28SEP2015

Time on study after discontinuation of study treatment: Studies 109MS301 and 109MS302
Page 4 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Total number of subject-years for time on study after discontinuation of study treatment (c)	125.03	100.73	91.43	192.15	42.09

NOTE: Numbers in parentheses are percentages.
(a) Time on study after discontinuation of study treatment in weeks is calculated as (last date on study - date of last exposure to study treatment + 1)/7.
(b) Time on study after discontinuation of study treatment in months is calculated as time on study after discontinuation of study treatment in weeks/4.
(c) Total number of subject-years for time on study after discontinuation of study treatment is calculated as the sum of number of days on study after discontinuation of study treatment/365.25.

SOURCE: BG12MS/JAPAN/ISS/T-STUTIME-DISCTRT-A.SAS DATE: 28SEP2015

Table 291: Incidence of Adverse Events Post-Study Treatment Discontinuation by System Organ Class and Preferred Term for Subjects Who Discontinued Study Treatment: Studies 109MS301 and 109MS302

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

Page 1 of 24

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Number of subjects who discontinued study treatment	272 (100)	232 (100)	223 (100)	455 (100)	86 (100)
Total number of subject-years for time on study after discontinuation of study treatment	125.03	100.73	91.43	192.15	42.09
Number of subjects with an event	121 (44)	92 (40)	89 (40)	181 (40)	37 (43)
感染症および寄生虫症	56 (21)	36 (16)	41 (18)	77 (17)	12 (14)
鼻咽頭炎	17 (6)	5 (2)	13 (6)	18 (4)	2 (2)
上気道感染	11 (4)	6 (3)	10 (4)	16 (4)	2 (2)
尿路感染	12 (4)	8 (3)	7 (3)	15 (3)	2 (2)
インフルエンザ	5 (2)	5 (2)	7 (3)	12 (3)	2 (2)
副鼻腔炎	2 (<1)	3 (1)	4 (2)	7 (2)	0
気管支炎	4 (1)	2 (<1)	4 (2)	6 (1)	1 (1)
耳感染	0	0	2 (<1)	2 (<1)	0
皮膚真菌感染	0	1 (<1)	1 (<1)	2 (<1)	0
胃腸炎	1 (<1)	0	2 (<1)	2 (<1)	0
細菌性性器感染	0	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
レンサ球菌性咽頭炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
肺炎	0	2 (<1)	0	2 (<1)	0
鼻炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
扁桃炎	0	1 (<1)	1 (<1)	2 (<1)	0
外陰腟真菌感染	3 (1)	2 (<1)	0	2 (<1)	0
無症候性細菌尿	0	0	1 (<1)	1 (<1)	0
細菌尿	0	1 (<1)	0	1 (<1)	0
気管支肺炎	0	1 (<1)	0	1 (<1)	0
蜂巣炎	0	0	1 (<1)	1 (<1)	0
感染性結膜炎	0	1 (<1)	0	1 (<1)	0
膀胱炎	2 (<1)	0	1 (<1)	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
真菌感染	0	1 (<1)	0	1 (<1)	0
サルモネラ菌性胃腸炎	0	1 (<1)	0	1 (<1)	0
ウイルス性胃腸炎	1 (<1)	1 (<1)	0	1 (<1)	0
ヘリコバクター感染	0	1 (<1)	0	1 (<1)	0
単純ヘルペス	0	1 (<1)	0	1 (<1)	0
帯状疱疹	0	0	1 (<1)	1 (<1)	0
感染性皮脂嚢腫	0	1 (<1)	0	1 (<1)	0
限局性感染	0	1 (<1)	0	1 (<1)	0
下気道感染	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
爪真菌症	0	1 (<1)	0	1 (<1)	0
口腔カンジダ症	0	1 (<1)	0	1 (<1)	0
口腔ヘルペス	2 (<1)	0	1 (<1)	1 (<1)	0
咽頭炎	3 (1)	1 (<1)	0	1 (<1)	0
歯髄炎	0	1 (<1)	0	1 (<1)	0
気道感染	2 (<1)	0	1 (<1)	1 (<1)	0
白癬感染	0	0	1 (<1)	1 (<1)	0
歯感染	0	0	1 (<1)	1 (<1)	0
ウイルス感染	3 (1)	1 (<1)	0	1 (<1)	0
ウイルス性迷路炎	0	0	1 (<1)	1 (<1)	0
ウイルス性上気道感染	0	1 (<1)	0	1 (<1)	1 (1)
子宮頚管炎	1 (<1)	0	0	0	0
デング熱	0	0	0	0	1 (1)
医療機器関連感染	1 (<1)	0	0	0	0
迷路炎	1 (<1)	0	0	0	0
喉頭炎	1 (<1)	0	0	0	0
リンパ管炎	1 (<1)	0	0	0	0
乳腺炎	1 (<1)	0	0	0	0
鼓膜炎	1 (<1)	0	0	0	0
外耳炎	1 (<1)	0	0	0	0
中耳炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
百日咳	0	0	0	0	1 (1)
ブドウ球菌感染	1 (<1)	0	0	0	0
歯膿瘍	0	0	0	0	1 (1)
細菌性腟炎	0	0	0	0	1 (1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	3 (1)	2 (<1)	0	2 (<1)	2 (2)
肝臓血管腫	0	1 (<1)	0	1 (<1)	0
外陰腟ヒト乳頭腫ウイルス感染	0	1 (<1)	0	1 (<1)	0
リンパ節の良性新生物	1 (<1)	0	0	0	0
子宮頚部の良性新生物	1 (<1)	0	0	0	0
乳房新生物	1 (<1)	0	0	0	0
子宮頚部癌	0	0	0	0	1 (1)
子宮平滑筋腫	0	0	0	0	1 (1)
血液およびリンパ系障害	4 (1)	2 (<1)	7 (3)	9 (2)	4 (5)
貧血	1 (<1)	0	4 (2)	4 (<1)	3 (3)
白血球増加症	0	1 (<1)	1 (<1)	2 (<1)	1 (1)
白血球減少症	0	0	2 (<1)	2 (<1)	0
リンパ球減少症	1 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
好中球減少症	0	0	2 (<1)	2 (<1)	0
好酸球増加症	0	0	1 (<1)	1 (<1)	0
赤血球増加症	0	0	1 (<1)	1 (<1)	0
血小板減少症	0	1 (<1)	0	1 (<1)	1 (1)
妊娠貧血	1 (<1)	0	0	0	0
骨髄球増加症	1 (<1)	0	0	0	0
好中球増加症	0	0	0	0	1 (1)
免疫系障害	0	1 (<1)	1 (<1)	2 (<1)	0
過敏症	0	1 (<1)	1 (<1)	2 (<1)	0
内分泌障害	0	0	1 (<1)	1 (<1)	2 (2)
甲状腺機能低下症	0	0	1 (<1)	1 (<1)	1 (1)
バセドウ病	0	0	0	0	1 (1)
代謝および栄養障害	4 (1)	2 (<1)	7 (3)	9 (2)	2 (2)
ビタミンD欠乏	0	1 (<1)	3 (1)	4 (<1)	0
耐糖能障害	0	1 (<1)	1 (<1)	2 (<1)	0
脱水	0	0	1 (<1)	1 (<1)	0
高コレステロール血症	0	0	1 (<1)	1 (<1)	0
低カリウム血症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
食欲減退	1 (<1)	0	0	0	0
妊娠糖尿病	1 (<1)	0	0	0	0
高トリグリセリド血症	1 (<1)	0	0	0	1 (1)
高尿酸血症	0	0	0	0	1 (1)
異食症	1 (<1)	0	0	0	0
精神障害	15 (6)	16 (7)	16 (7)	32 (7)	4 (5)
うつ病	7 (3)	8 (3)	3 (1)	11 (2)	3 (3)
不眠症	7 (3)	4 (2)	3 (1)	7 (2)	0
不安	1 (<1)	1 (<1)	4 (2)	5 (1)	0
抑うつ気分	1 (<1)	1 (<1)	3 (1)	4 (<1)	0
初期不眠症	0	0	2 (<1)	2 (<1)	0
気分動揺	0	0	2 (<1)	2 (<1)	0
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
情動障害	0	0	1 (<1)	1 (<1)	0
幻覚	0	1 (<1)	0	1 (<1)	0
リビド消失	0	1 (<1)	0	1 (<1)	0
身体表現性障害	1 (<1)	0	1 (<1)	1 (<1)	0
ストレス	0	1 (<1)	0	1 (<1)	0
自殺念慮	0	1 (<1)	0	1 (<1)	0
自殺企図	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
自殺既遂	0	0	0	0	1 (1)
睡眠障害	1 (<1)	0	0	0	0
神経系障害	65 (24)	41 (18)	39 (17)	80 (18)	19 (22)
多発性硬化症再発	46 (17)	27 (12)	24 (11)	51 (11)	14 (16)
頭痛	7 (3)	7 (3)	6 (3)	13 (3)	5 (6)
浮動性めまい	4 (1)	5 (2)	2 (<1)	7 (2)	1 (1)
感覚鈍麻	3 (1)	3 (1)	4 (2)	7 (2)	2 (2)
片頭痛	2 (<1)	4 (2)	3 (1)	7 (2)	0
筋痙直	3 (1)	4 (2)	2 (<1)	6 (1)	1 (1)
平衡障害	0	3 (1)	1 (<1)	4 (<1)	0
構語障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
錯感覚	1 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (3)
失神	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
灼熱感	3 (1)	2 (<1)	0	2 (<1)	0
注意力障害	0	1 (<1)	1 (<1)	2 (<1)	0
レルミット徴候	0	0	2 (<1)	2 (<1)	0
記憶障害	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (1)
意識変容状態	0	0	1 (<1)	1 (<1)	0
健忘	1 (<1)	1 (<1)	0	1 (<1)	0
失語症	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
失声症	0	0	1 (<1)	1 (<1)	0
運動失調	1 (<1)	0	1 (<1)	1 (<1)	0
帯状感	0	0	1 (<1)	1 (<1)	0
手根管症候群	0	1 (<1)	0	1 (<1)	0
小脳症候群	0	0	1 (<1)	1 (<1)	0
思考散乱	0	0	1 (<1)	1 (<1)	0
意識消失	0	0	1 (<1)	1 (<1)	0
多発性硬化症	4 (1)	1 (<1)	0	1 (<1)	0
ナルコレプシー	0	1 (<1)	0	1 (<1)	0
神経圧迫	0	0	1 (<1)	1 (<1)	0
神経痛	1 (<1)	1 (<1)	0	1 (<1)	1 (1)
下肢静止不能症候群	0	0	1 (<1)	1 (<1)	0
坐骨神経痛	0	0	1 (<1)	1 (<1)	0
感覚障害	0	0	1 (<1)	1 (<1)	0
振戦	0	1 (<1)	0	1 (<1)	0
ウートホフ現象	0	1 (<1)	0	1 (<1)	0
第７脳神経麻痺	0	1 (<1)	0	1 (<1)	0
視野欠損	0	1 (<1)	0	1 (<1)	0
脳浮腫	1 (<1)	0	0	0	0
中枢神経系病変	1 (<1)	0	0	0	0
頚髄神経根痛	0	0	0	0	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
昏睡	1 (<1)	0	0	0	0
大発作痙攣	1 (<1)	0	0	0	0
知覚過敏	0	0	0	0	1 (1)
反射亢進	1 (<1)	0	0	0	0
虚血性脳卒中	1 (<1)	0	0	0	0
不随意性筋収縮	0	0	0	0	1 (1)
二次性進行型多発性硬化症	2 (<1)	0	0	0	0
傾眠	1 (<1)	0	0	0	0
眼障害	4 (1)	5 (2)	8 (4)	13 (3)	6 (7)
眼痛	0	1 (<1)	2 (<1)	3 (<1)	1 (1)
霧視	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
眼瞼痙攣	0	0	1 (<1)	1 (<1)	0
アレルギー性結膜炎	0	1 (<1)	0	1 (<1)	0
複視	2 (<1)	0	1 (<1)	1 (<1)	0
眼乾燥	0	0	1 (<1)	1 (<1)	0
眼刺激	0	0	1 (<1)	1 (<1)	0
眼運動障害	0	0	1 (<1)	1 (<1)	0
緑内障	0	0	1 (<1)	1 (<1)	0
眼筋麻痺	0	0	1 (<1)	1 (<1)	0
光視症	0	1 (<1)	0	1 (<1)	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ブドウ膜炎	0	0	1 (<1)	1 (<1)	0
視力障害	0	1 (<1)	0	1 (<1)	0
白内障	0	0	0	0	1 (1)
眼出血	0	0	0	0	1 (1)
眼部腫脹	0	0	0	0	1 (1)
瞳孔反射障害	1 (<1)	0	0	0	0
視力低下	0	0	0	0	1 (1)
硝子体障害	0	0	0	0	1 (1)
耳および迷路障害	3 (1)	2 (<1)	4 (2)	6 (1)	2 (2)
回転性めまい	2 (<1)	1 (<1)	3 (1)	4 (<1)	2 (2)
耳鳴	2 (<1)	0	1 (<1)	1 (<1)	0
頭位性回転性めまい	0	1 (<1)	0	1 (<1)	0
心臓障害	2 (<1)	4 (2)	7 (3)	11 (2)	1 (1)
頻脈	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
動悸	0	1 (<1)	1 (<1)	2 (<1)	0
狭心症	0	0	1 (<1)	1 (<1)	0
心房頻脈	0	1 (<1)	0	1 (<1)	0
心不全	0	0	1 (<1)	1 (<1)	0
心筋症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
伝導障害	1 (<1)	1 (<1)	0	1 (<1)	0
冠動脈疾患	0	0	1 (<1)	1 (<1)	0
期外収縮	0	0	1 (<1)	1 (<1)	0
洞性徐脈	0	0	1 (<1)	1 (<1)	0
上室性期外収縮	0	0	1 (<1)	1 (<1)	0
発作性頻脈	0	0	1 (<1)	1 (<1)	0
心室性期外収縮	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	0	1 (1)
心筋炎	0	0	0	0	1 (1)
血管障害	4 (1)	5 (2)	6 (3)	11 (2)	3 (3)
高血圧	0	1 (<1)	4 (2)	5 (1)	1 (1)
ほてり	0	2 (<1)	1 (<1)	3 (<1)	1 (1)
潮紅	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
深部静脈血栓症	0	1 (<1)	0	1 (<1)	0
血腫	0	1 (<1)	0	1 (<1)	1 (1)
末梢性虚血	1 (<1)	0	0	0	0
レイノー現象	1 (<1)	0	0	0	0
静脈狭窄	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	13 (5)	4 (2)	10 (4)	14 (3)	2 (2)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
咳嗽	2 (<1)	3 (1)	2 (<1)	5 (1)	1 (1)
口腔咽頭痛	3 (1)	1 (<1)	1 (<1)	2 (<1)	0
呼吸困難	2 (<1)	0	1 (<1)	1 (<1)	1 (1)
肺気腫	0	0	1 (<1)	1 (<1)	0
鼻閉	0	0	1 (<1)	1 (<1)	0
咽頭腫瘤	0	0	1 (<1)	1 (<1)	0
胸膜炎	0	0	1 (<1)	1 (<1)	0
鼻漏	0	0	1 (<1)	1 (<1)	0
睡眠時無呼吸症候群	0	0	1 (<1)	1 (<1)	0
喘息	1 (<1)	0	0	0	0
鼻出血	0	0	0	0	1 (1)
口腔咽頭不快感	1 (<1)	0	0	0	0
湿性咳嗽	1 (<1)	0	0	0	0
アレルギー性鼻炎	1 (<1)	0	0	0	0
副鼻腔うっ血	1 (<1)	0	0	0	0
上気道うっ血	1 (<1)	0	0	0	0
胃腸障害	20 (7)	19 (8)	26 (12)	45 (10)	7 (8)
悪心	3 (1)	3 (1)	7 (3)	10 (2)	1 (1)
下痢	5 (2)	3 (1)	5 (2)	8 (2)	0
腹痛	5 (2)	3 (1)	4 (2)	7 (2)	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
便秘	3 (1)	3 (1)	4 (2)	7 (2)	1 (1)
嘔吐	4 (1)	2 (<1)	4 (2)	6 (1)	2 (2)
歯痛	1 (<1)	1 (<1)	4 (2)	5 (1)	0
下腹部痛	0	1 (<1)	2 (<1)	3 (<1)	0
腹部膨満	0	0	2 (<1)	2 (<1)	0
上腹部痛	0	1 (<1)	1 (<1)	2 (<1)	0
消化不良	0	1 (<1)	1 (<1)	2 (<1)	0
胃炎	1 (<1)	0	2 (<1)	2 (<1)	1 (1)
口の感覚鈍麻	0	1 (<1)	1 (<1)	2 (<1)	1 (1)
歯周炎	0	1 (<1)	1 (<1)	2 (<1)	0
腹部圧痛	0	0	1 (<1)	1 (<1)	0
裂肛	0	0	1 (<1)	1 (<1)	0
唾液欠乏	0	0	1 (<1)	1 (<1)	0
結腸ポリープ	0	0	1 (<1)	1 (<1)	0
齲歯	1 (<1)	1 (<1)	0	1 (<1)	0
口内乾燥	1 (<1)	1 (<1)	0	1 (<1)	0
出血性胃炎	0	1 (<1)	0	1 (<1)	0
胃腸障害	0	0	1 (<1)	1 (<1)	1 (1)
胃腸の炎症	0	0	1 (<1)	1 (<1)	0
胃食道逆流性疾患	1 (<1)	0	1 (<1)	1 (<1)	1 (1)
痔出血	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
痔核	0	0	1 (<1)	1 (<1)	0
裂孔ヘルニア	0	1 (<1)	0	1 (<1)	0
膵炎	0	1 (<1)	0	1 (<1)	0
歯の脱落	0	1 (<1)	0	1 (<1)	0
腹部不快感	2 (<1)	0	0	0	0
大腸炎	1 (<1)	0	0	0	0
潰瘍性大腸炎	1 (<1)	0	0	0	0
十二指腸潰瘍	1 (<1)	0	0	0	0
便失禁	0	0	0	0	1 (1)
歯肉痛	1 (<1)	0	0	0	0
胃酸過多	1 (<1)	0	0	0	1 (1)
歯の磨耗	1 (<1)	0	0	0	0
肝胆道系障害	4 (1)	2 (<1)	0	2 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
肝障害	1 (<1)	1 (<1)	0	1 (<1)	0
急性胆嚢炎	1 (<1)	0	0	0	0
胆石症	1 (<1)	0	0	0	0
肝炎	1 (<1)	0	0	0	0
黄疸	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚および皮下組織障害	11 (4)	11 (5)	11 (5)	22 (5)	6 (7)
発疹	0	7 (3)	2 (<1)	9 (2)	1 (1)
顔面感覚鈍麻	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
そう痒症	3 (1)	0	2 (<1)	2 (<1)	0
脱毛症	1 (<1)	0	1 (<1)	1 (<1)	0
皮膚乾燥	1 (<1)	1 (<1)	0	1 (<1)	0
湿疹	0	1 (<1)	0	1 (<1)	1 (1)
多汗症	0	1 (<1)	0	1 (<1)	1 (1)
寝汗	1 (<1)	0	1 (<1)	1 (<1)	0
光線過敏性反応	0	0	1 (<1)	1 (<1)	0
紫斑	0	1 (<1)	0	1 (<1)	0
全身性皮疹	0	0	1 (<1)	1 (<1)	0
皮膚病変	0	0	1 (<1)	1 (<1)	0
顔面腫脹	0	0	1 (<1)	1 (<1)	0
毛細血管拡張症	0	1 (<1)	0	1 (<1)	0
頭部粃糠疹	1 (<1)	0	0	0	1 (1)
褥瘡性潰瘍	0	0	0	0	1 (1)
皮膚炎	0	0	0	0	1 (1)
アレルギー性皮膚炎	1 (<1)	0	0	0	0
点状出血	1 (<1)	0	0	0	0
そう痒性皮疹	0	0	0	0	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
酒さ	1 (<1)	0	0	0	0
瘢痕	0	0	0	0	1 (1)
蕁麻疹	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	26 (10)	24 (10)	17 (8)	41 (9)	10 (12)
背部痛	7 (3)	5 (2)	9 (4)	14 (3)	2 (2)
四肢痛	5 (2)	4 (2)	5 (2)	9 (2)	2 (2)
関節痛	6 (2)	6 (3)	1 (<1)	7 (2)	3 (3)
筋力低下	7 (3)	2 (<1)	3 (1)	5 (1)	0
筋痙縮	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
頚部痛	3 (1)	1 (<1)	2 (<1)	3 (<1)	1 (1)
骨痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
筋骨格系胸痛	0	1 (<1)	1 (<1)	2 (<1)	0
筋骨格痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (1)
骨減少症	0	1 (<1)	1 (<1)	2 (<1)	0
重感	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
関節炎	0	1 (<1)	0	1 (<1)	0
滑液包炎	0	1 (<1)	0	1 (<1)	0
尾骨痛	0	0	1 (<1)	1 (<1)	0
筋攣縮	0	1 (<1)	0	1 (<1)	1 (1)
筋肉痛	1 (<1)	0	1 (<1)	1 (<1)	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
骨粗鬆症	0	1 (<1)	0	1 (<1)	0
関節腫脹	0	0	0	0	1 (1)
靭帯炎	1 (<1)	0	0	0	0
半月板変性	1 (<1)	0	0	0	0
筋拘縮	0	0	0	0	1 (1)
変形性関節症	1 (<1)	0	0	0	0
顎痛	0	0	0	0	1 (1)
上肢腫瘤	0	0	0	0	1 (1)
腎および尿路障害	15 (6)	8 (3)	14 (6)	22 (5)	6 (7)
血尿	2 (<1)	3 (1)	3 (1)	6 (1)	0
頻尿	1 (<1)	2 (<1)	3 (1)	5 (1)	0
蛋白尿	5 (2)	1 (<1)	3 (1)	4 (<1)	3 (3)
ミクロアルブミン尿	2 (<1)	2 (<1)	0	2 (<1)	2 (2)
尿閉	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
排尿困難	2 (<1)	0	1 (<1)	1 (<1)	0
糖尿	0	0	1 (<1)	1 (<1)	0
尿意切迫	2 (<1)	0	1 (<1)	1 (<1)	0
腎結石症	1 (<1)	0	1 (<1)	1 (<1)	0
膀胱機能障害	0	0	0	0	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
神経因性膀胱	0	0	0	0	1 (1)
尿失禁	1 (<1)	0	0	0	1 (1)
妊娠、産褥および周産期の状態	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
自然流産	0	0	1 (<1)	1 (<1)	0
妊娠	0	1 (<1)	0	1 (<1)	0
妊娠浮腫	1 (<1)	0	0	0	0
生殖系および乳房障害	3 (1)	5 (2)	4 (2)	9 (2)	3 (3)
不規則月経	1 (<1)	2 (<1)	0	2 (<1)	0
腟出血	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
無月経	0	0	1 (<1)	1 (<1)	1 (1)
良性前立腺肥大症	0	1 (<1)	0	1 (<1)	0
乳房痛	0	0	1 (<1)	1 (<1)	0
性交困難	0	0	1 (<1)	1 (<1)	0
不正子宮出血	0	0	1 (<1)	1 (<1)	0
卵巣嚢胞	0	1 (<1)	0	1 (<1)	2 (2)
骨盤痛	0	0	1 (<1)	1 (<1)	0
先天性、家族性および遺伝性障害	0	0	1 (<1)	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
一般・全身障害および投与部位の状態	32 (12)	23 (10)	28 (13)	51 (11)	10 (12)
疲労	6 (2)	9 (4)	10 (4)	19 (4)	2 (2)
インフルエンザ様疾患	15 (6)	5 (2)	9 (4)	14 (3)	3 (3)
発熱	7 (3)	4 (2)	10 (4)	14 (3)	0
注射部位紅斑	0	4 (2)	4 (2)	8 (2)	0
歩行障害	1 (<1)	3 (1)	4 (2)	7 (2)	1 (1)
疼痛	1 (<1)	3 (1)	3 (1)	6 (1)	0
末梢性浮腫	1 (<1)	3 (1)	2 (<1)	5 (1)	1 (1)
無力症	0	1 (<1)	3 (1)	4 (<1)	2 (2)
注射部位疼痛	1 (<1)	3 (1)	0	3 (<1)	1 (1)
胸痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
悪寒	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
易刺激性	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
非心臓性胸痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (1)
歩行不能	0	0	1 (<1)	1 (<1)	0
熱感	0	1 (<1)	0	1 (<1)	1 (1)
全身性浮腫	0	1 (<1)	0	1 (<1)	0
高熱	0	0	1 (<1)	1 (<1)	0
注射部位知覚消失	0	0	1 (<1)	1 (<1)	0
注射部位乾燥	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位血腫	1 (<1)	1 (<1)	0	1 (<1)	0
注射部位炎症	0	1 (<1)	0	1 (<1)	0
注射部位腫瘤	0	0	1 (<1)	1 (<1)	0
注射部位腫脹	1 (<1)	0	1 (<1)	1 (<1)	0
局所腫脹	0	1 (<1)	0	1 (<1)	0
腫脹	0	0	1 (<1)	1 (<1)	0
温度変化不耐症	0	1 (<1)	0	1 (<1)	0
嚢胞破裂	0	0	0	0	1 (1)
顔面痛	1 (<1)	0	0	0	0
異常感	1 (<1)	0	0	0	0
酩酊感	1 (<1)	0	0	0	0
全身症状	1 (<1)	0	0	0	0
注入に伴う反応	1 (<1)	0	0	0	0
臨床検査	27 (10)	23 (10)	20 (9)	43 (9)	9 (10)
尿中アルブミン陽性	5 (2)	5 (2)	4 (2)	9 (2)	0
血中副甲状腺ホルモン増加	0	2 (<1)	4 (2)	6 (1)	1 (1)
尿中蛋白陽性	1 (<1)	4 (2)	2 (<1)	6 (1)	0
アラニン・アミノトランスフェラーゼ増加	5 (2)	2 (<1)	2 (<1)	4 (<1)	1 (1)
尿中血陽性	0	2 (<1)	2 (<1)	4 (<1)	0
γ－グルタミルトランスフェラーゼ増加	1 (<1)	3 (1)	0	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
体重増加	0	2 (<1)	1 (<1)	3 (<1)	0
尿中白血球陽性	0	1 (<1)	2 (<1)	3 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (<1)	0	2 (<1)	2 (<1)	1 (1)
尿中β２ミクログロブリン増加	0	2 (<1)	0	2 (<1)	3 (3)
ヘモグロビン減少	1 (<1)	0	2 (<1)	2 (<1)	1 (1)
β２ミクログロブリン増加	0	0	1 (<1)	1 (<1)	0
血中アルカリホスファターゼ増加	1 (<1)	1 (<1)	0	1 (<1)	0
血中重炭酸塩減少	0	1 (<1)	0	1 (<1)	0
血中ビリルビン増加	0	0	1 (<1)	1 (<1)	0
血中コレステロール増加	0	0	1 (<1)	1 (<1)	0
血中クレアチニン増加	1 (<1)	0	1 (<1)	1 (<1)	1 (1)
血中ブドウ糖増加	2 (<1)	0	1 (<1)	1 (<1)	1 (1)
血中鉄減少	0	1 (<1)	0	1 (<1)	0
血中トリグリセリド増加	3 (1)	1 (<1)	0	1 (<1)	0
心電図異常	0	0	1 (<1)	1 (<1)	0
心電図Ｔ波振幅減少	0	0	1 (<1)	1 (<1)	0
好酸球数増加	0	0	1 (<1)	1 (<1)	0
心拍数増加	0	1 (<1)	0	1 (<1)	0
肝酵素上昇	2 (<1)	1 (<1)	0	1 (<1)	1 (1)
肝機能検査異常	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
医学的観察	0	0	1 (<1)	1 (<1)	0
好中球数増加	2 (<1)	0	1 (<1)	1 (<1)	0
尿中赤血球陽性	0	1 (<1)	0	1 (<1)	0
ビタミンD増加	0	0	1 (<1)	1 (<1)	0
体重減少	1 (<1)	1 (<1)	0	1 (<1)	0
白血球数増加	2 (<1)	0	1 (<1)	1 (<1)	0
血中ブドウ糖減少	1 (<1)	0	0	0	1 (1)
血中ケトン体減少	0	0	0	0	1 (1)
体温上昇	1 (<1)	0	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0	0
心電図ＱＴ延長	2 (<1)	0	0	0	0
心電図ＳＴ部分下降	1 (<1)	0	0	0	0
γ－グルタミルトランスフェラーゼ異常	1 (<1)	0	0	0	0
ヘマトクリット減少	0	0	0	0	1 (1)
高比重リポ蛋白減少	0	0	0	0	1 (1)
リンパ球数増加	1 (<1)	0	0	0	0
リンパ球形態異常	0	0	0	0	1 (1)
後骨髄球数増加	1 (<1)	0	0	0	0
単球数減少	0	0	0	0	1 (1)
骨髄球数減少	0	0	0	0	1 (1)
総蛋白減少	0	0	0	0	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
赤血球数減少	1 (<1)	0	0	0	0
膀胱超音波検査異常	1 (<1)	0	0	0	0
尿中シュウ酸塩	1 (<1)	0	0	0	0
尿中ウロビリノーゲン増加	1 (<1)	0	0	0	0
前庭機能検査異常	0	0	0	0	1 (1)
傷害、中毒および処置合併症	6 (2)	7 (3)	12 (5)	19 (4)	5 (6)
転倒	2 (<1)	1 (<1)	4 (2)	5 (1)	4 (5)
挫傷	1 (<1)	0	3 (1)	3 (<1)	2 (2)
半月板障害	0	2 (<1)	0	2 (<1)	0
アルコール中毒	0	0	1 (<1)	1 (<1)	0
動物咬傷	0	0	1 (<1)	1 (<1)	0
擦過傷	1 (<1)	0	1 (<1)	1 (<1)	0
足骨折	0	0	1 (<1)	1 (<1)	0
頭部損傷	2 (<1)	1 (<1)	0	1 (<1)	0
瘢痕ヘルニア	0	1 (<1)	0	1 (<1)	0
関節脱臼	0	1 (<1)	0	1 (<1)	0
関節捻挫	0	0	1 (<1)	1 (<1)	0
肉離れ	0	1 (<1)	0	1 (<1)	0
放射線皮膚損傷	0	0	1 (<1)	1 (<1)	0
交通事故	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Incidence of adverse events post-study treatment discontinuation by system organ class and preferred term for subjects who discontinued study treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚裂傷	0	0	1 (<1)	1 (<1)	0
脊椎圧迫骨折	0	1 (<1)	0	1 (<1)	0
熱傷	0	1 (<1)	0	1 (<1)	1 (1)
外傷性骨折	0	0	1 (<1)	1 (<1)	0
手骨折	0	0	0	0	1 (1)
上腕骨骨折	1 (<1)	0	0	0	0
術後創合併症	0	0	0	0	1 (1)
橈骨骨折	1 (<1)	0	0	0	0
尺骨骨折	1 (<1)	0	0	0	0
外科および内科処置	0	1 (<1)	1 (<1)	2 (<1)	2 (2)
虫垂切除	0	0	1 (<1)	1 (<1)	0
ヘルニア修復	0	1 (<1)	0	1 (<1)	0
股関節手術	0	0	0	0	1 (1)
入院	0	0	0	0	1 (1)

NOTE 1: Numbers in parentheses are percentages.
2: The table presents adverse events with onset after discontinuation of study treatment for subjects who discontinued study treatment.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-POST-DISC-A.SAS DATE: 02DEC2015

Table 292: Summary of Special Chemistry Laboratory Parameters - Actual Values by Visit: Studies 109MS301 and 109MS302

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 1 of 14
Lab test: Vitamin D (pmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Baseline					
n	657	654	642	1296	308
Mean	126.951	128.213	129.103	128.654	136.791
SD	60.0360	59.9293	58.3203	59.1165	55.9545
Median	115.000	118.150	119.000	119.000	126.000
Min, Max	6.50, 439.00	6.50, 434.00	31.00, 663.00	6.50, 663.00	13.00, 426.00
Week 48					
n	631	652	643	1295	306
Mean	128.034	111.570	104.704	108.161	120.195
SD	58.4335	50.9356	47.8213	49.5140	49.3420
Median	120.640	105.500	97.000	100.000	113.500
Min, Max	23.00, 439.00	6.50, 317.00	15.00, 291.00	6.50, 317.00	31.00, 334.00

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 2 of 14
Lab test: Vitamin D (pmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	466	503	485	988	252
Mean	109.652	99.847	93.404	96.684	108.681
SD	54.4501	51.4266	43.9869	48.0032	48.3008
Median	99.010	90.000	86.000	88.000	100.000
Min, Max	20.00, 376.00	13.00, 330.00	14.00, 280.80	13.00, 330.00	31.00, 288.08

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 3 of 14
Lab test: Parathyroid Hormone (ng/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Baseline					
n	676	661	656	1317	309
Mean	42.614	43.152	40.493	41.828	40.319
SD	27.7407	23.6034	18.0844	21.0702	17.7928
Median	38.178	39.996	38.178	39.087	37.269
Min, Max	5.00, 439.05	5.50, 345.42	5.00, 139.08	5.00, 345.42	5.00, 113.63
Week 48					
n	664	675	674	1349	309
Mean	41.886	49.527	50.381	49.954	44.224
SD	20.1139	24.0590	25.0498	24.5536	23.6191
Median	39.044	44.541	46.359	45.450	39.996
Min, Max	5.50, 239.00	10.00, 257.25	12.00, 328.15	10.00, 328.15	11.82, 192.71

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 4 of 14
Lab test: Parathyroid Hormone (ng/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	471	513	503	1016	252
Mean	45.491	53.524	54.508	54.011	47.920
SD	20.0539	23.4754	22.8363	23.1550	21.2768
Median	42.723	49.995	50.904	50.904	43.816
Min, Max	5.00, 149.99	5.00, 217.25	10.91, 186.35	5.00, 217.25	10.91, 146.35

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 5 of 14
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Baseline					
n	771	769	760	1529	351
Mean	1.462	1.467	1.471	1.469	1.492
SD	0.3902	0.3847	0.3840	0.3843	0.4244
Median	1.422	1.420	1.440	1.430	1.440
Min, Max	0.53, 3.00	0.56, 2.75	0.47, 3.06	0.47, 3.06	0.71, 2.95
Week 4					
n	751	736	730	1466	337
Mean	1.454	1.506	1.495	1.501	1.424
SD	0.3751	0.3885	0.3851	0.3867	0.3897
Median	1.420	1.470	1.460	1.460	1.370
Min, Max	0.51, 2.84	0.60, 2.93	0.52, 3.38	0.52, 3.38	0.72, 2.82

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 6 of 14
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 8					
n	726	704	682	1386	328
Mean	1.459	1.542	1.523	1.533	1.417
SD	0.3793	0.4061	0.3867	0.3966	0.3925
Median	1.426	1.490	1.490	1.490	1.375
Min, Max	0.49, 2.79	0.66, 3.00	0.54, 3.12	0.54, 3.12	0.69, 2.95
Week 12					
n	716	691	670	1361	327
Mean	1.455	1.557	1.543	1.550	1.427
SD	0.3816	0.4144	0.3884	0.4017	0.3935
Median	1.430	1.520	1.500	1.510	1.396
Min, Max	0.65, 2.84	0.67, 3.37	0.60, 3.07	0.60, 3.37	0.65, 2.84
Week 16					
n	700	666	650	1316	318
Mean	1.460	1.563	1.546	1.554	1.435
SD	0.3779	0.4225	0.3873	0.4054	0.3772
Median	1.422	1.520	1.520	1.520	1.398
Min, Max	0.53, 3.00	0.50, 3.37	0.68, 2.94	0.50, 3.37	0.66, 2.90

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 7 of 14
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 20					
n	691	651	636	1287	313
Mean	1.450	1.556	1.532	1.544	1.420
SD	0.3730	0.4131	0.3878	0.4008	0.3762
Median	1.410	1.520	1.500	1.500	1.390
Min, Max	0.54, 3.13	0.62, 3.71	0.61, 3.14	0.61, 3.71	0.65, 2.73
Week 24					
n	702	671	656	1327	320
Mean	1.439	1.564	1.533	1.549	1.412
SD	0.3818	0.4228	0.3816	0.4031	0.3987
Median	1.405	1.520	1.510	1.510	1.370
Min, Max	0.57, 2.88	0.67, 3.49	0.68, 3.39	0.67, 3.49	0.57, 3.31
Week 36					
n	666	644	631	1275	314
Mean	1.448	1.567	1.552	1.560	1.431
SD	0.3834	0.4229	0.3940	0.4087	0.3862
Median	1.415	1.530	1.526	1.526	1.398
Min, Max	0.61, 3.21	0.65, 3.49	0.73, 2.95	0.65, 3.49	0.72, 2.66

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 8 of 14
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 48					
n	616	625	616	1241	304
Mean	1.454	1.593	1.554	1.574	1.419
SD	0.3899	0.4517	0.4040	0.4289	0.3777
Median	1.430	1.550	1.526	1.530	1.371
Min, Max	0.57, 3.30	0.70, 3.13	0.61, 3.04	0.61, 3.13	0.73, 2.77
Week 60					
n	573	600	596	1196	291
Mean	1.450	1.579	1.571	1.575	1.419
SD	0.3785	0.4171	0.4045	0.4107	0.3917
Median	1.430	1.550	1.550	1.550	1.380
Min, Max	0.65, 3.12	0.57, 3.10	0.65, 3.26	0.57, 3.26	0.71, 3.07
Week 72					
n	538	587	574	1161	282
Mean	1.438	1.601	1.559	1.580	1.394
SD	0.3737	0.4483	0.4067	0.4285	0.3800
Median	1.410	1.550	1.540	1.540	1.342
Min, Max	0.59, 2.95	0.66, 3.60	0.71, 3.13	0.66, 3.60	0.75, 2.71

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 9 of 14
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 84					
n	527	570	563	1133	274
Mean	1.438	1.570	1.543	1.557	1.395
SD	0.3730	0.4293	0.3946	0.4125	0.3804
Median	1.430	1.510	1.526	1.520	1.375
Min, Max	0.65, 2.99	0.66, 3.30	0.75, 3.34	0.66, 3.34	0.65, 2.59
Week 96					
n	487	529	520	1049	262
Mean	1.443	1.600	1.571	1.586	1.458
SD	0.3813	0.4472	0.4041	0.4264	0.3887
Median	1.410	1.540	1.552	1.550	1.400
Min, Max	0.71, 3.21	0.57, 3.22	0.68, 3.13	0.57, 3.22	0.72, 2.71

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 10 of 14
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Baseline					
n	771	769	760	1529	351
Mean	3.078	3.080	3.064	3.072	3.117
SD	0.8982	0.8974	0.8780	0.8876	0.9110
Median	2.974	3.000	2.990	3.000	3.040
Min, Max	0.73, 10.38	0.82, 5.85	0.76, 7.30	0.76, 7.30	0.41, 6.91
Week 4					
n	756	738	735	1473	340
Mean	3.015	3.000	3.044	3.022	3.030
SD	0.8691	0.8292	0.8755	0.8526	0.8522
Median	2.910	2.926	2.990	2.950	2.926
Min, Max	0.64, 7.69	0.73, 6.44	1.03, 7.55	0.73, 7.55	1.03, 6.18

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 11 of 14
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 8					
n	735	708	682	1390	329
Mean	3.021	2.981	3.008	2.995	3.021
SD	0.8904	0.8434	0.8659	0.8543	0.8672
Median	2.920	2.842	2.950	2.900	2.922
Min, Max	0.70, 11.16	1.04, 6.44	1.12, 8.22	1.04, 8.22	0.91, 6.09
Week 12					
n	723	692	671	1363	328
Mean	3.035	3.004	3.143	3.072	3.004
SD	0.8570	0.8663	2.7714	2.0406	0.8449
Median	2.960	2.930	2.960	2.940	2.893
Min, Max	0.50, 9.75	1.04, 7.73	0.44, 71.00	0.44, 71.00	0.92, 5.64
Week 16					
n	707	668	652	1320	318
Mean	3.031	3.001	3.052	3.026	3.011
SD	0.8974	0.8766	0.8987	0.8876	0.8575
Median	2.900	2.910	2.950	2.926	2.920
Min, Max	0.44, 8.85	1.18, 6.02	1.20, 6.80	1.18, 6.80	0.90, 6.61

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 12 of 14
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 20					
n	699	659	639	1298	314
Mean	3.019	2.980	3.027	3.003	2.998
SD	0.8907	0.8784	0.8940	0.8860	0.8494
Median	2.922	2.860	2.900	2.871	2.896
Min, Max	0.57, 9.86	1.01, 6.48	1.09, 6.70	1.01, 6.70	1.01, 6.93
Week 24					
n	703	673	657	1330	321
Mean	3.026	2.989	3.048	3.018	3.034
SD	0.9181	0.8627	0.8823	0.8726	0.8790
Median	2.922	2.896	2.950	2.920	2.990
Min, Max	0.48, 8.60	0.98, 6.26	1.11, 6.86	0.98, 6.86	1.07, 6.29
Week 36					
n	669	648	633	1281	316
Mean	3.040	2.994	3.033	3.013	3.009
SD	0.8693	0.8914	0.8882	0.8897	0.8941
Median	2.974	2.920	2.950	2.940	2.890
Min, Max	0.34, 9.10	1.16, 6.47	0.75, 6.39	0.75, 6.47	0.51, 6.41

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 13 of 14
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 48					
n	618	625	619	1244	304
Mean	3.105	3.051	3.075	3.063	3.099
SD	0.9265	0.8878	0.8941	0.8907	0.9077
Median	3.010	2.974	2.970	2.970	3.023
Min, Max	0.61, 8.31	0.90, 6.36	1.14, 6.60	0.90, 6.60	1.16, 6.32
Week 60					
n	578	602	602	1204	294
Mean	3.084	3.020	3.102	3.061	3.090
SD	0.9101	0.8789	0.9235	0.9020	0.8680
Median	2.970	2.950	3.005	2.980	3.030
Min, Max	0.63, 8.60	1.08, 6.12	1.27, 10.13	1.08, 10.13	1.01, 6.01
Week 72					
n	537	589	573	1162	285
Mean	3.079	3.061	3.083	3.072	3.154
SD	0.8883	0.8984	0.8842	0.8911	0.8841
Median	2.970	2.970	2.970	2.970	3.040
Min, Max	1.17, 6.53	0.94, 6.32	0.83, 6.09	0.83, 6.32	1.24, 5.95

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - actual values by visit:
Studies 109MS301 and 109MS302
Page 14 of 14
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 84					
n	532	573	565	1138	279
Mean	3.150	3.090	3.076	3.083	3.146
SD	0.9473	0.8972	0.8927	0.8946	0.9591
Median	3.030	3.010	2.930	2.965	3.040
Min, Max	0.84, 6.28	1.15, 6.61	1.26, 6.33	1.15, 6.61	1.16, 9.04
Week 96					
n	493	534	523	1057	262
Mean	3.203	3.163	3.152	3.157	3.241
SD	0.9586	0.9479	0.9559	0.9514	0.9778
Median	3.100	3.030	2.970	3.020	3.195
Min, Max	0.76, 6.95	1.19, 8.08	1.30, 7.14	1.19, 8.08	1.01, 8.79

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-A.SAS DATE: 12DEC2011

Table 293: Summary of Special Chemistry Laboratory Parameters - Change From Baseline by Visit: Studies 109MS301 and 109MS302

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 1 of 12
Lab test: Vitamin D (pmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 48					
n	538	561	548	1109	270
Mean	0.58	-18.31	-24.69	-21.46	-18.12
SD	67.555	60.416	62.833	61.677	57.749
Median	1.65	-14.56	-23.50	-18.00	-14.00
Min, Max	-227.0, 252.0	-247.0, 190.0	-572.0, 158.1	-572.0, 190.0	-191.0, 153.0
Week 96					
n	404	433	413	846	219
Mean	-20.97	-31.92	-36.17	-33.99	-25.87
SD	71.032	65.236	55.094	60.500	61.789
Median	-15.17	-27.00	-32.50	-29.06	-23.00
Min, Max	-370.0, 319.0	-295.0, 199.7	-228.0, 114.9	-295.0, 199.7	-236.0, 132.0

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 2 of 12
Lab test: Parathyroid Hormone (ng/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 48					
n	581	587	582	1169	275
Mean	-0.96	7.97	10.40	9.18	3.11
SD	27.119	23.161	24.418	23.816	18.521
Median	1.82	6.36	8.00	7.00	2.73
Min, Max	-395.4, 201.0	-152.7, 234.5	-90.0, 289.1	-152.7, 289.1	-71.8, 112.7
Week 96					
n	415	452	441	893	223
Mean	3.07	12.02	15.40	13.69	7.43
SD	29.533	20.968	20.978	21.029	19.173
Median	4.55	10.45	13.64	11.82	7.27
Min, Max	-381.8, 70.9	-128.2, 103.6	-53.6, 96.4	-128.2, 103.6	-53.6, 63.6

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 3 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 4					
n	751	736	730	1466	337
Mean	-0.01	0.04	0.02	0.03	-0.07
SD	0.182	0.211	0.221	0.216	0.204
Median	0.00	0.05	0.03	0.04	-0.06
Min, Max	-0.7, 0.7	-0.7, 1.0	-1.1, 0.9	-1.1, 1.0	-1.4, 0.7
Week 8					
n	726	704	682	1386	328
Mean	-0.01	0.07	0.05	0.06	-0.07
SD	0.202	0.202	0.208	0.205	0.194
Median	0.00	0.07	0.05	0.06	-0.07
Min, Max	-0.7, 1.3	-1.1, 0.7	-0.8, 0.9	-1.1, 0.9	-0.9, 0.5

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 4 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 12					
n	716	691	670	1361	327
Mean	-0.01	0.09	0.07	0.08	-0.07
SD	0.205	0.218	0.213	0.216	0.200
Median	-0.01	0.08	0.06	0.07	-0.07
Min, Max	-0.9, 1.0	-1.4, 1.2	-0.8, 1.0	-1.4, 1.2	-0.7, 0.5
Week 16					
n	700	666	650	1316	318
Mean	-0.01	0.09	0.07	0.08	-0.06
SD	0.208	0.229	0.226	0.228	0.212
Median	-0.02	0.09	0.07	0.08	-0.05
Min, Max	-0.7, 1.6	-1.0, 1.1	-0.9, 1.5	-1.0, 1.5	-0.7, 0.6
Week 20					
n	691	651	636	1287	313
Mean	-0.02	0.09	0.05	0.07	-0.08
SD	0.208	0.225	0.219	0.223	0.219
Median	-0.02	0.09	0.05	0.07	-0.06
Min, Max	-0.7, 0.9	-0.8, 1.0	-1.2, 0.9	-1.2, 1.0	-0.9, 0.7

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 5 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 24					
n	702	671	656	1327	320
Mean	-0.03	0.10	0.06	0.08	-0.08
SD	0.212	0.229	0.231	0.231	0.220
Median	-0.03	0.10	0.06	0.08	-0.06
Min, Max	-1.0, 0.9	-0.7, 1.2	-0.9, 0.9	-0.9, 1.2	-1.0, 0.7
Week 36					
n	666	644	631	1275	314
Mean	-0.01	0.09	0.07	0.08	-0.07
SD	0.222	0.230	0.240	0.235	0.219
Median	-0.02	0.08	0.06	0.08	-0.06
Min, Max	-1.0, 1.4	-1.0, 0.9	-1.1, 1.0	-1.1, 1.0	-0.8, 0.7
Week 48					
n	616	625	616	1241	304
Mean	0.00	0.12	0.07	0.10	-0.07
SD	0.229	0.238	0.244	0.242	0.223
Median	0.00	0.11	0.07	0.08	-0.06
Min, Max	-1.0, 1.9	-0.7, 1.2	-0.8, 1.2	-0.8, 1.2	-0.7, 0.9

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 6 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 60					
n	573	600	596	1196	291
Mean	-0.01	0.10	0.09	0.10	-0.08
SD	0.235	0.226	0.242	0.234	0.217
Median	-0.03	0.10	0.08	0.08	-0.07
Min, Max	-0.9, 1.2	-0.5, 1.2	-0.7, 0.9	-0.7, 1.2	-0.7, 0.7
Week 72					
n	538	587	574	1161	282
Mean	-0.02	0.12	0.08	0.10	-0.10
SD	0.235	0.261	0.255	0.258	0.243
Median	-0.03	0.11	0.06	0.09	-0.08
Min, Max	-1.1, 1.0	-0.8, 1.5	-0.8, 1.1	-0.8, 1.5	-1.0, 0.7
Week 84					
n	527	570	563	1133	274
Mean	-0.01	0.09	0.06	0.08	-0.10
SD	0.230	0.241	0.247	0.244	0.249
Median	-0.01	0.08	0.06	0.07	-0.09
Min, Max	-1.1, 0.9	-0.7, 1.3	-0.8, 1.1	-0.8, 1.3	-0.9, 1.1

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 7 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	487	529	520	1049	262
Mean	-0.01	0.12	0.10	0.11	-0.03
SD	0.250	0.254	0.252	0.253	0.252
Median	-0.01	0.10	0.08	0.10	-0.03
Min, Max	-1.0, 1.1	-0.7, 1.1	-0.9, 1.1	-0.9, 1.1	-0.8, 0.9

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 8 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 4					
n	756	738	735	1473	340
Mean	-0.07	-0.09	-0.02	-0.06	-0.08
SD	0.582	0.544	0.567	0.556	0.501
Median	-0.08	-0.07	-0.04	-0.05	-0.12
Min, Max	-8.4, 3.2	-3.6, 2.2	-2.7, 4.2	-3.6, 4.2	-1.5, 3.3
Week 8					
n	735	708	682	1390	329
Mean	-0.06	-0.09	-0.04	-0.07	-0.10
SD	0.522	0.549	0.557	0.553	0.596
Median	-0.05	-0.07	-0.05	-0.06	-0.13
Min, Max	-3.2, 2.0	-2.9, 2.2	-2.4, 3.9	-2.9, 3.9	-3.2, 3.3

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 9 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 12					
n	723	692	671	1363	328
Mean	-0.05	-0.08	0.09	0.00	-0.13
SD	0.552	0.580	2.727	1.959	0.609
Median	-0.03	-0.05	-0.05	-0.05	-0.12
Min, Max	-4.7, 1.8	-3.5, 2.6	-2.6, 69.0	-3.5, 69.0	-3.4, 2.3
Week 16					
n	707	668	652	1320	318
Mean	-0.05	-0.09	-0.01	-0.05	-0.14
SD	0.567	0.592	0.624	0.609	0.595
Median	-0.07	-0.10	-0.05	-0.07	-0.15
Min, Max	-3.2, 2.0	-3.4, 2.2	-2.6, 4.3	-3.4, 4.3	-3.3, 2.6
Week 20					
n	699	659	639	1298	314
Mean	-0.05	-0.10	-0.03	-0.06	-0.13
SD	0.583	0.568	0.602	0.586	0.586
Median	-0.05	-0.08	-0.07	-0.07	-0.13
Min, Max	-3.0, 3.6	-2.8, 2.3	-1.7, 3.5	-2.8, 3.5	-2.8, 2.3

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 10 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 24					
n	703	673	657	1330	321
Mean	-0.04	-0.11	-0.02	-0.06	-0.10
SD	0.577	0.591	0.596	0.595	0.635
Median	-0.03	-0.11	-0.03	-0.08	-0.08
Min, Max	-2.9, 3.3	-3.2, 2.5	-2.0, 3.3	-3.2, 3.3	-2.2, 3.3
Week 36					
n	669	648	633	1281	316
Mean	-0.03	-0.09	-0.03	-0.06	-0.11
SD	0.587	0.568	0.617	0.593	0.609
Median	-0.01	-0.07	-0.03	-0.05	-0.10
Min, Max	-4.2, 2.7	-3.2, 1.8	-2.3, 4.0	-3.2, 4.0	-2.9, 2.6
Week 48					
n	618	625	619	1244	304
Mean	0.04	-0.04	0.01	-0.02	-0.03
SD	0.589	0.568	0.642	0.606	0.673
Median	0.04	-0.05	0.03	-0.02	0.00
Min, Max	-2.9, 3.6	-2.7, 2.4	-2.5, 3.6	-2.7, 3.6	-2.9, 2.7

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 11 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 60					
n	578	602	602	1204	294
Mean	0.02	-0.08	0.04	-0.02	-0.03
SD	0.601	0.611	0.656	0.637	0.615
Median	0.02	-0.05	0.02	-0.02	-0.04
Min, Max	-3.9, 4.2	-3.5, 2.4	-2.1, 3.9	-3.5, 3.9	-2.5, 2.4
Week 72					
n	537	589	573	1162	285
Mean	0.04	-0.03	0.03	0.00	0.01
SD	0.585	0.636	0.651	0.644	0.701
Median	0.03	-0.02	0.02	-0.01	0.02
Min, Max	-1.8, 3.1	-2.2, 2.6	-2.2, 3.6	-2.2, 3.6	-3.4, 3.4
Week 84					
n	532	573	565	1138	279
Mean	0.10	-0.01	0.02	0.00	0.03
SD	0.591	0.608	0.662	0.636	0.719
Median	0.05	0.01	0.02	0.01	0.00
Min, Max	-1.9, 3.0	-2.1, 2.0	-2.2, 3.5	-2.2, 3.5	-2.4, 3.5

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - change from baseline by visit:
Studies 109MS301 and 109MS302
Page 12 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	493	534	523	1057	262
Mean	0.16	0.04	0.09	0.07	0.10
SD	0.623	0.668	0.645	0.657	0.661
Median	0.13	0.05	0.10	0.07	0.07
Min, Max	-3.0, 4.4	-2.8, 2.8	-2.9, 2.7	-2.9, 2.8	-2.4, 3.5

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-CHG-A.SAS DATE: 12DEC2011

Table 294: Summary of Special Chemistry Laboratory Parameters - Percentage Change From Baseline by Visit: Studies 109MS301 and 109MS302

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 1 of 12
Lab test: Vitamin D (pmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 48					
n	538	561	548	1109	270
Mean	16.01	-1.06	-9.09	-5.03	-4.40
SD	68.702	61.985	48.556	55.875	47.085
Median	1.66	-13.25	-20.26	-16.80	-12.34
Min, Max	-84.0, 592.0	-90.0, 521.1	-86.3, 296.6	-90.0, 521.1	-75.6, 371.9
Week 96					
n	404	433	413	846	219
Mean	0.44	-13.25	-20.18	-16.63	-7.74
SD	79.024	54.167	42.450	48.894	63.645
Median	-14.59	-25.41	-28.21	-26.38	-19.05
Min, Max	-84.3, 884.6	-82.7, 361.3	-85.7, 167.4	-85.7, 361.3	-78.3, 646.2

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 2 of 12
Lab test: Parathyroid Hormone (ng/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 48					
n	581	587	582	1169	275
Mean	15.23	30.52	39.18	34.84	19.07
SD	67.726	72.098	72.238	72.267	59.175
Median	4.08	17.07	21.81	19.70	8.00
Min, Max	-90.1, 663.6	-75.0, 1032.0	-72.8, 739.5	-75.0, 1032.0	-63.9, 518.2
Week 96					
n	415	452	441	893	223
Mean	26.93	40.91	55.21	47.97	29.57
SD	80.094	58.094	78.614	69.326	54.685
Median	14.52	28.58	36.36	32.69	23.81
Min, Max	-87.0, 1118.2	-87.8, 360.0	-58.8, 564.7	-87.8, 564.7	-61.5, 318.2

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 3 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 4					
n	751	736	730	1466	337
Mean	0.07	3.52	2.50	3.01	-3.75
SD	12.813	14.783	15.026	14.908	12.997
Median	0.00	3.40	1.95	2.55	-4.31
Min, Max	-56.8, 68.4	-39.6, 70.6	-50.5, 64.2	-50.5, 70.6	-53.3, 57.1
Week 8					
n	726	704	682	1386	328
Mean	0.31	5.92	4.45	5.20	-4.00
SD	14.236	14.127	14.434	14.293	12.533
Median	0.00	5.02	3.25	4.08	-4.78
Min, Max	-50.0, 112.7	-45.6, 73.9	-41.5, 57.5	-45.6, 73.9	-32.0, 42.1

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 4 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 12					
n	716	691	670	1361	327
Mean	0.51	6.66	5.85	6.26	-3.60
SD	14.314	15.178	15.631	15.402	13.537
Median	-0.71	5.83	4.40	5.26	-4.84
Min, Max	-38.0, 106.3	-55.2, 79.5	-43.9, 91.4	-55.2, 91.4	-47.1, 57.1
Week 16					
n	700	666	650	1316	318
Mean	0.71	7.39	6.24	6.82	-2.86
SD	14.926	15.786	16.899	16.349	13.729
Median	-1.00	6.92	4.71	5.59	-3.91
Min, Max	-39.2, 132.5	-60.6, 87.2	-38.2, 164.5	-60.6, 164.5	-35.3, 48.9
Week 20					
n	691	651	636	1287	313
Mean	0.08	6.91	4.93	5.93	-3.55
SD	14.502	15.729	14.881	15.342	14.644
Median	-1.32	6.18	3.79	5.08	-4.20
Min, Max	-37.5, 98.8	-38.2, 68.0	-50.6, 77.8	-50.6, 77.8	-58.3, 70.1

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 5 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 24					
n	702	671	656	1327	320
Mean	-0.80	7.54	5.38	6.47	-4.20
SD	14.611	16.044	16.200	16.152	14.110
Median	-2.00	6.47	4.29	5.68	-4.27
Min, Max	-43.7, 83.0	-37.5, 78.2	-40.4, 73.3	-40.4, 78.2	-47.9, 51.9
Week 36					
n	666	644	631	1275	314
Mean	0.20	7.28	6.20	6.75	-2.97
SD	14.642	15.777	16.654	16.219	14.623
Median	-1.26	6.02	4.70	5.30	-4.07
Min, Max	-41.1, 72.6	-47.9, 80.9	-47.2, 78.5	-47.9, 80.9	-36.4, 78.0
Week 48					
n	616	625	616	1241	304
Mean	1.14	8.76	6.14	7.46	-3.46
SD	16.135	16.726	17.001	16.907	14.645
Median	0.00	7.14	4.78	6.09	-4.58
Min, Max	-36.5, 137.4	-46.9, 79.5	-38.3, 86.7	-46.9, 86.7	-41.2, 67.2

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 6 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 60					
n	573	600	596	1196	291
Mean	0.87	8.02	7.46	7.74	-3.69
SD	16.869	16.012	16.898	16.455	14.230
Median	-1.85	6.69	5.44	6.10	-4.65
Min, Max	-34.6, 90.2	-29.8, 109.4	-37.2, 87.7	-37.2, 109.4	-39.9, 52.6
Week 72					
n	538	587	574	1161	282
Mean	0.03	8.98	6.81	7.91	-5.03
SD	15.805	17.841	18.048	17.969	15.456
Median	-1.76	7.76	4.62	6.72	-6.37
Min, Max	-39.3, 70.5	-38.2, 101.8	-41.9, 105.9	-41.9, 105.9	-50.6, 54.8
Week 84					
n	527	570	563	1133	274
Mean	0.27	6.99	5.81	6.40	-4.96
SD	15.786	16.557	17.352	16.959	16.419
Median	-1.00	5.78	3.56	5.10	-6.72
Min, Max	-41.8, 89.0	-26.8, 98.3	-42.4, 89.2	-42.4, 98.3	-47.4, 80.9

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 7 of 12
Lab test: High-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	487	529	520	1049	262
Mean	0.55	9.07	7.96	8.52	-0.73
SD	16.988	17.655	18.061	17.858	16.353
Median	-0.81	7.50	5.95	6.67	-2.12
Min, Max	-36.0, 87.5	-36.7, 75.4	-45.5, 110.8	-45.5, 110.8	-41.2, 55.8

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 8 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771	769	760	1529	351
Week 4					
n	756	738	735	1473	340
Mean	-1.01	-0.46	1.42	0.48	0.17
SD	17.179	19.677	27.698	24.026	31.574
Median	-2.48	-2.18	-1.18	-1.85	-3.79
Min, Max	-80.8, 168.8	-64.1, 149.3	-57.0, 552.6	-64.1, 552.6	-36.8, 485.4
Week 8					
n	735	708	682	1390	329
Mean	-0.68	-0.74	0.63	-0.07	0.01
SD	16.841	19.602	26.980	23.515	34.734
Median	-1.52	-2.19	-2.06	-2.13	-4.56
Min, Max	-49.8, 102.7	-60.5, 146.6	-62.5, 507.9	-62.5, 507.9	-57.8, 524.4

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 9 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 12					
n	723	692	671	1363	328
Mean	-0.10	-0.49	6.74	3.07	-0.92
SD	17.637	20.092	134.551	95.517	31.022
Median	-0.97	-1.52	-1.77	-1.59	-4.52
Min, Max	-59.2, 107.7	-62.8, 150.7	-85.5, 3414.9	-85.5, 3414.9	-68.2, 436.6
Week 16					
n	707	668	652	1320	318
Mean	-0.45	-0.73	2.25	0.74	-1.20
SD	18.450	19.995	31.045	26.079	32.175
Median	-2.16	-3.23	-1.82	-2.39	-4.55
Min, Max	-71.4, 84.9	-61.1, 94.6	-62.5, 564.5	-62.5, 564.5	-65.6, 468.3
Week 20					
n	699	659	639	1298	314
Mean	-0.02	-1.24	1.52	0.11	-0.64
SD	19.523	20.168	27.963	24.350	36.336
Median	-1.68	-2.84	-2.33	-2.43	-4.24
Min, Max	-56.5, 142.8	-66.1, 158.1	-53.8, 461.8	-66.1, 461.8	-57.3, 548.8

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 10 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 24					
n	703	673	657	1330	321
Mean	0.01	-1.26	1.79	0.25	0.84
SD	19.172	20.635	26.305	23.647	42.891
Median	-0.90	-3.64	-1.04	-2.65	-2.79
Min, Max	-52.5, 150.0	-63.1, 168.2	-50.8, 431.6	-63.1, 431.6	-53.3, 668.3
Week 36					
n	669	648	633	1281	316
Mean	0.83	-0.92	1.51	0.28	-0.29
SD	19.799	19.760	29.333	24.974	35.989
Median	-0.38	-2.18	-0.90	-1.66	-3.23
Min, Max	-53.4, 120.7	-67.3, 127.1	-54.0, 522.4	-67.3, 522.4	-80.5, 531.7
Week 48					
n	618	625	619	1244	304
Mean	2.92	0.69	3.16	1.92	3.02
SD	20.755	20.357	28.971	25.037	41.771
Median	1.19	-1.80	0.68	-0.59	0.00
Min, Max	-51.0, 163.5	-56.6, 162.8	-59.2, 469.7	-59.2, 469.7	-57.8, 619.5

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 11 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 60					
n	578	602	602	1204	294
Mean	2.32	-0.47	4.26	1.90	3.02
SD	20.568	20.454	30.859	26.274	39.574
Median	0.53	-1.81	0.75	-0.59	-1.44
Min, Max	-69.3, 188.7	-67.2, 159.5	-50.2, 509.2	-67.2, 509.2	-59.8, 587.8
Week 72					
n	537	589	573	1162	285
Mean	2.75	1.22	3.81	2.50	4.67
SD	20.137	22.483	30.171	26.574	42.557
Median	1.09	-0.78	0.44	-0.26	0.50
Min, Max	-42.1, 118.3	-50.8, 157.4	-56.9, 475.0	-56.9, 475.0	-60.4, 619.5
Week 84					
n	532	573	565	1138	279
Mean	4.46	1.74	3.36	2.54	4.65
SD	20.340	20.745	29.868	25.684	36.752
Median	1.89	0.36	0.80	0.46	0.00
Min, Max	-42.3, 119.9	-43.9, 136.5	-56.2, 453.9	-56.2, 453.9	-46.8, 480.5

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Summary of special chemistry laboratory parameters - percentage change from baseline by visit:
Studies 109MS301 and 109MS302
Page 12 of 12
Lab test: Low-density lipoprotein (mmol/L)

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Week 96					
n	493	534	523	1057	262
Mean	6.43	3.70	5.03	4.36	7.44
SD	21.495	22.211	26.042	24.180	51.332
Median	4.38	1.70	3.59	2.36	2.27
Min, Max	-57.8, 176.9	-51.4, 111.9	-56.0, 303.9	-56.0, 303.9	-48.5, 763.4

NOTE: Data after subjects switched to alternative MS medications are excluded. Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-PCTCHG-A.SAS DATE: 12DEC2011

Table 295: Summary of Shifts From Baseline - Special Chemistry (Vitamin D, Parathyroid Hormone, and LDL): Studies 109MS301 and 109MS302

Summary of shifts from baseline - Special chemistry (vitamin D, parathyroid hormone, HDL, & LDL):
Studies 109MS301 and 109MS302
Page 1 of 2

	Placebo		BG00012 240 mg BID		BG00012 240 mg TID	
Laboratory Parameters	Shift to Low (a)	Shift to High (b)	Shift to Low (a)	Shift to High (b)	Shift to Low (a)	Shift to High (b)
Vitamin D	32/666(5)	118/557(21)	57/675(8)	74/568(13)	66/676 (10)	57/564 (10)
Parathyroid Hormone	2/676(<1)	52/637(8)	2/698(<1)	124/652(19)	0/691	149/663 (22)
HDL (high-density lipoprotein)	60/750(8)	81/714(11)	28/738(4)	136/707(19)	20/727 (3)	127/694 (18)
LDL (low-density lipoprotein)		231/532(43)		169/490(34)		197/488 (40)

NOTE 1: Data after subjects switched to alternative MS medications are excluded.
2: Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.
3: Entries are number low (or high)/number at risk. Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on number at risk.
(a) Shift to low includes normal to low, high to low, and unknown to low.
(b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-SHFT-A.SAS DATE: 07DEC2011

Summary of shifts from baseline - Special chemistry (vitamin D, parathyroid hormone, HDL, & LDL):
Studies 109MS301 and 109MS302
Page 2 of 2

Laboratory Parameters	Total BG00012 Shift to Low (a)	Total BG00012 Shift to High (b)	GA Shift to Low (a)	GA Shift to High (b)
Vitamin D	123/1351(9)	131/1132(12)	14/316(4)	46/264(17)
Parathyroid Hormone	2/1389(<1)	273/1315(21)	0/320	52/304(17)
HDL (high-density lipoprotein)	48/1465(3)	263/1401(19)	33/341(10)	29/313(9)
LDL (low-density lipoprotein)		366/978 (37)		80/220(36)

NOTE 1: Data after subjects switched to alternative MS medications are excluded.
2: Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.
3: Entries are number low (or high)/number at risk. Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on number at risk.
(a) Shift to low includes normal to low, high to low, and unknown to low.
(b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: BG12MS/ISS/CSR/T-LB-SPC-SHFT-A.SAS DATE: 07DEC2011

Table 296: Summary of Shifts From Baseline - Urinalysis: 24 Weeks of Studies 109MS301 and 109MS302

Summary of shifts from baseline - Urinalysis: 24 weeks of studies 109MS301 and 109MS302
Page 1 of 2

Laboratory Parameters	Placebo		BG00012 240 mg BID		BG00012 240 mg TID	
	Shift to Low (a)	Shift to High/Pos (b)	Shift to Low (a)	Shift to High/Pos (b)	Shift to Low (a)	Shift to High/Pos (b)
Urine Specific Gravity	2/765(<1)	8/764(1)	3/756(<1)	4/755(<1)	3/746(<1)	3/745(<1)
Urine pH	0/766	3/765(<1)	0/756	3/756(<1)	0/746	2/746(<1)
Urine Color		38/755(5)		52/742(7)		65/737(9)
Urine Blood		198/710(28)		162/689(24)		195/691(28)
Urine Glucose		34/756(4)		14/750(2)		21/733(3)
Urine Ketones		82/751(11)		305/737(41)		350/726(48)
Urine Protein		341/564(60)		325/546(60)		345/528(65)
Urine RBC		101/560(18)		104/564(18)		123/555(22)
Urine WBC		76/648(12)		76/631(12)		109/631(17)

NOTE 1: Data after subjects switched to alternative MS medications are excluded.
2: Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.
3: Numbers in parentheses are percentages based on numbers at risk. Number at risk for shift to low (or high/positive) are those subjects whose baseline value was not low (or high/positive) and who had at least one post-baseline value.
(a) Shift to low includes normal to low, high to low, and unknown to low.
(b) Shift to high/pos includes normal/unknown to high/positive or negative/unknown to high/positive.

SOURCE: BG12MS/JAPAN/ISS/T-LB-UR-SHFT-A-24W.SAS DATE: 16OCT2015

Summary of shifts from baseline - Urinalysis: 24 weeks of studies 109MS301 and 109MS302
Page 2 of 2


Laboratory Parameters	Total BG00012		GA	
	Shift to Low (a)	Shift to High/Pos (b)	Shift to Low (a)	Shift to High/Pos (b)
Urine Specific Gravity	6/1502(<1)	7/1500(<1)	0/347	1/346 (<1)
Urine pH	0/1502	5/1502(<1)	0/347	0/347
Urine Color		117/1479(8)		35/338 (10)
Urine Blood		357/1380(26)		61/318 (19)
Urine Glucose		35/1483(2)		10/343 (3)
Urine Ketones		655/1463(45)		32/340 (9)
Urine Protein		670/1074(62)		151/246 (61)
Urine RBC		227/1119(20)		41/243 (17)
Urine WBC		185/1262(15)		51/286 (18)

NOTE 1: Data after subjects switched to alternative MS medications are excluded.
2: Baseline is defined as the latest available value prior to or on the date of first exposure to study treatment.
3: Numbers in parentheses are percentages based on numbers at risk. Number at risk for shift to low (or high/positive) are those subjects whose baseline value was not low (or high/positive) and who had at least one post-baseline value.
(a) Shift to low includes normal to low, high to low, and unknown to low.
(b) Shift to high/pos includes normal/unknown to high/positive or negative/unknown to high/positive.

SOURCE: BG12MS/JAPAN/ISS/T-LB-UR-SHFT-A-24W.SAS DATE: 16OCT2015

LIST OF FIGURES

Figure 20: Hematology Parameters – Mean Values (±SE) Over Studies 109MS301 and 109MS302 Lab Test




NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Lymphocytes (x10^9/L)

Page 2 of 10



Number of Patients at Risk

Placebo	770	744	728	728	699	655	607	565	526	519	479
240 mg BID	767	731	694	699	665	636	611	596	574	564	527
240 mg TID	758	721	671	669	648	617	606	586	568	555	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Neutrophils (x10^9/L)

Page 3 of 10



Number of Patients at Risk

Placebo	770	744	728	728	699	655	607	565	526	519	479
240 mg BID	767	731	694	699	665	636	611	596	574	564	527
240 mg TID	758	721	671	669	648	617	606	586	568	555	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Monocytes (x10^9/L)

Page 4 of 10



Number of Patients at Risk

Placebo	770	744	728	728	699	655	607	565	526	519	479
240 mg BID	767	731	694	699	665	636	611	596	574	564	527
240 mg TID	758	721	671	669	648	617	606	586	568	555	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Eosinophils (x10^9/L)

Page 5 of 10



Number of Patients at Risk

Placebo	770	744	728	728	699	655	607	565	526	519	479
240 mg BID	767	731	694	699	665	636	611	596	574	564	527
240 mg TID	758	721	671	669	648	617	606	586	568	555	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Basophils (x10^9/L)

Page 6 of 10



Number of Patients at Risk

Placebo	770	744	728	728	699	655	607	565	526	519	479
240 mg BID	767	731	694	699	665	636	611	596	574	564	527
240 mg TID	758	721	671	669	648	617	606	586	568	555	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: RBC (x10^12/L)

Page 7 of 10



Number of Patients at Risk

Placebo	770	745	728	728	699	655	608	565	526	521	479
240 mg BID	767	732	694	699	665	636	611	596	575	564	527
240 mg TID	758	721	671	669	648	617	606	586	569	556	505
GA	350	333	329	325	316	307	299	287	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Hemoglobin (g/L)

Page 8 of 10



Number of Patients at Risk

Placebo	770	745	728	728	699	655	608	565	526	521	479
240 mg BID	767	732	694	699	665	634	610	594	574	564	527
240 mg TID	758	721	671	669	648	617	606	584	569	556	505
GA	350	333	329	325	316	307	298	285	280	264	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Hematocrit (%)

Page 9 of 10



Number of Patients at Risk

Placebo	767	738	723	720	693	648	601	559	519	518	475
240 mg BID	765	720	691	690	661	633	608	585	567	560	520
240 mg TID	757	716	669	664	645	613	604	581	564	553	500
GA	349	329	328	323	312	306	297	280	276	263	252

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.


SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015

Hematology parameters - mean values (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Platelets (x10^9/L)

Page 10 of 10



Number of Patients at Risk


Placebo	769	741	723	725	695	655	604	562	524	516	479
240 mg BID	765	720	690	694	658	631	608	592	572	563	525
240 mg TID	757	717	669	665	647	614	604	581	566	554	503
GA	350	329	325	322	315	303	295	286	279	261	249

NOTE : LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.

SOURCE: BG12MS/JAPAN/F-LB-HE-A

DATE: 02DEC2015


Figure 21: Hematology Parameters: Mean Values (±SE) Over Time – (Placebo-Controlled Period)



NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Lymphocytes (x10^9/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Neutrophils (x10^9/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Monocytes (x10^9/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Eosinophils (x10^9/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Basophils (x10^9/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: RBC (TI/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Hemoglobin (g/L)




Number of Patients at Risk

Placebo	113	112	111	110	110	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Hematocrit (%)




Number of Patients at Risk

Placebo	113	112	111	110	109	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: mean values(+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Platelets (x10^9/L)




Number of Patients at Risk

Placebo	112	112	111	110	109	108	107
240 mg BID	111	109	107	106	107	106	104

NOTE: LLN is lower limit in std unit. If there are multiple values of LLN for a given parameter, highest LLN is shown. SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HM-MEANSE.SAS

DATE: 25SEP2015


Figure 22: Hematology Parameters: Percentage Change From Baseline Values by Visit - (Placebo-Controlled Period)



NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Lymphocytes




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Neutrophils




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Monocytes




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Eosinophils




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Basophils




Number of Patients at Risk

Placebo	111	110	109	109	107	106
240 mg BID	108	106	105	106	105	103

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: RBC




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Hemoglobin




Number of Patients at Risk

Placebo	112	111	110	110	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Hematocrit




Number of Patients at Risk

Placebo	112	111	110	109	108	107
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015

Hematology parameters: percent change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Platelets




Number of Patients at Risk

Placebo	111	110	109	108	107	106
240 mg BID	109	107	106	107	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-HEM-PCHG-MEANSE.SAS

DATE: 25SEP2015


Figure 23: Hematology Parameters – Percent Change From Baseline (±SE) Over Time: Studies 109MS301 and 109MS302 - Lab Test: WBC (×10^9/L)



Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Lymphocytes (x10^9/L)

Page 2 of 10



Number of Patients at Risk

Placebo	744	727	727	698	654	607	565	526	519	479
240 mg BID	729	693	697	664	634	609	594	572	562	526
240 mg TID	719	669	667	646	615	604	584	567	553	503
GA	332	328	324	315	306	298	286	279	263	251


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Neutrophils (x10^9/L)

Page 3 of 10



Number of Patients at Risk

Placebo	744	727	727	698	654	607	565	526	519	479
240 mg BID	729	693	697	664	634	609	594	572	562	526
240 mg TID	719	669	667	646	615	604	584	567	553	503
GA	332	328	324	315	306	298	286	279	263	251


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Monocytes (x10^9/L)

Page 4 of 10



Number of Patients at Risk

Placebo	744	727	727	698	654	607	565	526	519	479
240 mg BID	729	693	697	664	634	609	594	572	562	526
240 mg TID	719	669	667	646	615	604	584	567	553	503
GA	332	328	324	315	306	298	286	279	263	251


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Eosinophils (x10^9/L)

Page 5 of 10



Number of Patients at Risk

Placebo	740	723	722	694	651	603	563	525	518	478
240 mg BID	724	688	692	660	630	605	590	568	558	523
240 mg TID	711	659	658	637	608	597	578	560	546	495
GA	329	325	321	312	303	295	283	276	260	249


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Basophils (x10^9/L)

Page 6 of 10



Number of Patients at Risk

Placebo	719	703	701	676	635	586	547	510	502	466
240 mg BID	710	674	679	647	620	595	580	558	548	514
240 mg TID	699	647	646	625	597	587	568	550	537	487
GA	325	321	317	309	300	291	279	272	257	245


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: RBC (x10^12/L)

Page 7 of 10



Number of Patients at Risk

Placebo	745	727	727	698	654	608	565	526	521	479
240 mg BID	730	693	697	664	634	609	594	573	562	526
240 mg TID	719	669	667	646	615	604	584	568	554	503
GA	332	328	324	315	306	298	286	279	263	251


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Hemoglobin (g/L)

Page 8 of 10



Number of Patients at Risk

Placebo	745	727	727	698	654	608	565	526	521	479
240 mg BID	730	693	697	664	632	608	592	572	562	526
240 mg TID	719	669	667	646	615	604	582	568	554	503
GA	332	328	324	315	306	297	284	279	263	251


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Hematocrit (%)

Page 9 of 10



Number of Patients at Risk

Placebo	735	719	716	689	645	598	557	517	515	473
240 mg BID	717	688	686	658	630	604	582	564	557	518
240 mg TID	714	666	661	642	610	601	578	562	551	497
GA	327	326	321	310	304	295	278	274	261	250


SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015

Hematology parameters - percentage change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Platelets (x10^9/L)

Page 10 of 10




Number of Patients at Risk

Placebo	740	721	723	693	654	603	561	523	515	478
240 mg BID	718	689	692	657	629	606	590	570	561	524
240 mg TID	714	666	662	644	611	601	578	564	551	500
GA	328	324	321	314	302	294	285	278	260	248

SOURCE: BG12MS/JAPAN/F-LB-HE-PCTCHG-A

DATE: 22OCT2015


Figure 24: Blood Chemistry Parameters: Mean Values (±SE) Over Time - (Placebo-Controlled Period)



NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: AST/SGOT (U/L)




Number of Patients at Risk

Placebo	113	112	111	109	111	107	107
240 mg BID	111	107	108	106	106	106	104

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Alkaline Phosphatase (ALP) (U/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	108
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Total Bilirubin (umol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: GGT (U/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	108
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: LDH (U/L)




Number of Patients at Risk

Placebo	113	111	111	107	107	105	104
240 mg BID	111	100	107	104	103	101	102

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: BUN/urea (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Creatinine (umol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Sodium (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Potassium (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	108	108
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Chloride (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Bicarbonate (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Calcium (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Magnesium (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Phosphorus (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	108
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Glucose (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Cholesterol (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Triglycerides (mmol/L)




Number of Patients at Risk

Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: mean values (+/- SE) over time
-Part I(placebo-controlled period)
Lab test: Uric Acid (umol/L)



Number of Patients at Risk


Placebo	113	113	112	109	111	110	109
240 mg BID	111	109	108	107	106	106	105

NOTE: ULN is upper limit in std unit. If there are multiple values of ULN for a given parameter, lowest ULN is shown. SE = standard error
SOURCE: BG12MS/109MS305/PART1/F-BC-MEANSE.SAS

DATE: 25SEP2015

Figure 25: Summary of High Values of Beta-2 Microglobulin by Categories and Visit: Studies 109MS301 and 109MS302


Summary of high values of beta-2 microglobulin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: Placebo
Page 1 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine beta-2 microglobulin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-SUM-A.SAS

DATE: 30NOV2011


Summary of high values of beta-2 microglobulin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID
Page 2 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine beta-2 microglobulin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-SUM-A.SAS

DATE: 30NOV2011


Summary of high values of beta-2 microglobulin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID
Page 3 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine beta-2 microglobulin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-SUM-A.SAS

DATE: 30NOV2011

Summary of high values of beta-2 microglobulin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: GA
Page 4 of 4




NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine beta-2 microglobulin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-SUM-A.SAS

DATE: 30NOV2011


Figure 26: Categorical Analysis of Beta-2 Microglobulin by Visit for Subjects with Two Consecutive High Values Post-Baseline: Studies 109MS301 and 109MS302

Categorical analysis of beta-2 microglobulin by visit for subjects with two consecutive high values
post-baseline: Studies 109MS301 and 109MS302
Treatment Group: Placebo (n=23)
Page 1 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-CATE-A.SAS DATE: 30NOV2011


Categorical analysis of beta-2 microglobulin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID (n=26)
Page 2 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-CATE-A.SAS

DATE: 30NOV2011


Categorical analysis of beta-2 microglobulin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID (n=15)
Page 3 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-CATE-A.SAS

DATE: 30NOV2011

Categorical analysis of beta-2 microglobulin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: GA (n=10)
Page 4 of 4




NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPB2MU-CATE-A.SAS

DATE: 30NOV2011

Figure 27: Summary of High Values of Microglobulin by Categories and Visit: Studies 109MS301 and 109MS302


Summary of high values of microalbumin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: Placebo
Page 1 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine microalbumin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-SUM-A.SAS

DATE: 30NOV2011


Summary of high values of microalbumin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID
Page 2 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine microalbumin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-SUM-A.SAS

DATE: 30NOV2011


Summary of high values of microalbumin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID
Page 3 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine microalbumin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-SUM-A.SAS

DATE: 30NOV2011


Summary of high values of microalbumin by categories and visit: Studies 109MS301 and 109MS302
Treatment Group: GA
Page 4 of 4



NOTE: Data after subjects switched to alternative MS medications are excluded. N=xx is the number of subjects with non-missing values for urine microalbumin at that visit.
(a) These cutoff values correspond to the ULN, the 50th and 90th percentile of the high values.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-SUM-A.SAS

DATE: 30NOV2011

Figure 28: Categorical Analysis of Microglobulin by Visit for Subjects with Two Consecutive High Values Post-Baseline: Studies 109MS301 and 109MS302




NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.

(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.

SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-CATE-A.SAS

DATE: 30NOV2011


Categorical analysis of microalbumin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID (n=93)
Page 2 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-CATE-A.SAS

DATE: 30NOV2011


Categorical analysis of microalbumin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID (n=90)
Page 3 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-CATE-A.SAS

DATE: 30NOV2011


Categorical analysis of microalbumin by visit for subjects with two consecutive high values post-baseline: Studies 109MS301 and 109MS302
Treatment Group: GA (n=53)
Page 4 of 4



NOTE: N=xx in the bottom of the graph indicates the denominator, which is the number of all subjects with non-missing values at that visit, including those with normal values.
(a) These ranges correspond to the <=ULN, >ULN-50th percentile, >50th percentile-90th percentile, and >90th percentile.
SOURCE: BG12MS/ISS/CSR/F-LB-SPMALBU-CATE-A.SAS

DATE: 30NOV2011

Figure 29: Blood Chemistry Parameters – Change From Baseline (±SE) Over Time: Studies 109MS301 and 109MS302 - Lab Test:




SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: AST/SGOT (U/L)

Page 2 of 19



Number of Patients at Risk

Placebo	746	723	712	702	685	677	657	633	645	623	602	593	553	557	553	533	521	517	502	502	507	494	480	482
240 mg BID	726	695	686	659	638	653	613	615	618	601	579	595	572	553	569	560	545	558	540	531	545	528	511	526
240 mg TID	722	675	666	645	624	620	595	599	612	593	587	599	570	559	579	544	544	559	543	530	550	528	513	513
GA	334	324	320	309	308	311	295	295	305	292	293	294	285	280	286	267	273	272	264	260	270	257	257	260


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Alkaline phosphatase (ALP) (U/L)

Page 3 of 19



Number of Patients at Risk

Placebo	754	732	722	708	692	682	667	647	653	631	609	605	566	570	562	542	525	522	511	508	516	503	489	490
240 mg BID	732	706	692	663	651	658	627	625	630	606	592	603	577	565	579	566	556	568	546	540	555	532	523	534
240 mg TID	732	683	672	651	637	637	609	604	619	601	595	608	576	569	588	559	552	567	547	533	556	534	523	522
GA	340	328	328	317	313	316	299	300	309	297	296	296	288	284	291	271	278	276	266	268	271	261	258	262


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Total bilirubin (umol/L)

Page 4 of 19



Number of Patients at Risk

Placebo	752	730	718	707	690	682	662	642	651	628	608	602	559	566	561	539	525	521	509	506	515	499	488	488
240 mg BID	732	701	690	661	644	655	625	624	627	605	584	600	575	559	577	564	554	565	544	535	552	531	519	532
240 mg TID	727	679	669	647	632	631	601	602	615	599	591	604	572	564	588	550	547	565	544	534	551	529	517	518
GA	335	327	322	314	311	315	297	299	306	295	295	296	286	282	287	267	276	275	266	265	271	260	257	261


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: GGT (U/L)

Page 5 of 19



Number of Patients at Risk

Placebo	754	732	722	708	692	682	667	647	653	631	609	605	566	570	562	542	525	522	510	508	516	503	489	490
240 mg BID	732	706	692	663	651	658	628	625	630	605	592	602	577	565	579	566	556	568	544	540	555	532	523	534
240 mg TID	732	683	672	651	637	637	609	604	619	601	595	608	576	569	588	559	552	567	547	533	556	534	523	522
GA	340	328	328	317	313	316	299	301	309	297	296	296	288	284	291	271	278	276	266	268	271	261	258	262


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: LDH (U/L)

Page 6 of 19



Number of Patients at Risk

Placebo	736	717	708	693	674	669	656	629	634	617	590	590	553	551	551	526	515	513	498	499	504	494	477	481
240 mg BID	718	691	680	653	636	646	604	608	615	593	582	588	567	551	564	552	543	558	535	530	545	524	512	522
240 mg TID	715	663	657	640	621	611	596	591	605	578	584	595	561	556	570	547	539	552	539	522	546	528	510	511
GA	334	323	324	312	310	306	296	293	306	290	292	293	285	277	287	268	271	267	262	260	265	256	255	255


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: BUN/urea (mmol/L)

Page 7 of 19



Number of Patients at Risk

Placebo	754	733	722	708	692	683	667	647	653	631	609	605	567	570	563	542	527	522	511	508	516	503	489	490
240 mg BID	734	706	692	664	651	658	627	627	630	606	592	604	577	564	579	567	558	569	546	541	556	532	524	534
240 mg TID	732	684	672	652	637	638	609	604	620	600	595	608	577	569	591	559	552	567	548	535	555	534	524	523
GA	340	329	328	318	314	317	299	302	309	297	296	296	288	284	291	271	278	276	267	268	271	262	258	263


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Creatinine (umol/L)

Page 8 of 19



Number of Patients at Risk

Placebo	754	733	722	708	692	683	667	647	653	631	609	605	567	570	563	542	527	522	511	508	516	503	489	490
240 mg BID	734	706	692	664	651	658	627	627	629	606	592	604	577	565	579	567	558	569	546	541	556	532	524	534
240 mg TID	732	684	672	652	637	638	610	604	619	600	595	608	577	569	591	559	552	567	548	535	555	535	524	523
GA	340	329	328	318	314	317	299	302	309	297	296	296	288	284	291	271	278	276	267	268	271	262	258	263


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Sodium (mmol/L)

Page 9 of 19



Number of Patients at Risk

Placebo	754	732	722	707	691	683	667	646	653	631	608	605	567	570	563	542	527	522	511	508	516	503	489	490
240 mg BID	734	705	692	664	651	658	628	626	629	606	589	604	577	564	579	567	558	568	544	541	556	532	523	533
240 mg TID	732	684	672	652	637	638	610	603	619	600	595	608	576	569	589	558	551	567	548	534	556	534	524	523
GA	339	329	328	317	314	316	299	302	309	297	296	296	288	284	291	271	278	276	265	268	271	262	258	263


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Potassium (mmol/L)

Page 10 of 19



Number of Patients at Risk

Placebo	752	730	722	707	689	680	665	645	652	631	605	600	561	568	561	539	524	522	509	507	514	502	487	486
240 mg BID	730	703	690	663	646	657	623	620	626	605	589	601	576	562	577	563	551	567	542	539	552	531	521	530
240 mg TID	729	682	670	649	635	634	609	603	618	595	593	606	573	566	586	555	550	564	546	529	555	534	523	522
GA	339	328	328	316	313	314	297	297	309	296	294	295	287	281	290	270	277	275	262	268	271	260	257	262


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Chloride (mmol/L)

Page 11 of 19



Number of Patients at Risk

Placebo	754	732	722	707	691	683	667	646	653	631	609	605	567	570	563	542	527	522	510	508	516	503	489	490
240 mg BID	734	705	692	664	651	658	628	626	629	606	590	604	577	564	579	567	558	568	544	541	556	532	523	533
240 mg TID	732	684	672	652	637	638	610	604	620	600	595	608	576	569	589	558	551	567	548	534	556	534	524	523
GA	339	329	328	317	314	316	299	302	309	297	296	296	288	284	291	271	278	276	265	268	271	262	258	263


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Bicarbonate (mmol/L)

Page 12 of 19



Number of Patients at Risk

Placebo	752	730	718	706	688	680	661	641	650	628	608	602	557	566	561	538	526	521	509	506	515	499	488	488
240 mg BID	731	701	689	659	643	654	622	623	626	605	583	600	574	558	577	562	554	564	544	533	551	531	519	531
240 mg TID	727	679	668	646	632	631	601	602	614	598	591	604	572	563	587	549	546	565	544	531	550	529	516	516
GA	335	327	322	313	311	315	297	297	306	295	295	296	286	282	287	267	276	275	266	265	269	259	257	259


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Calcium (mmol/L)

Page 13 of 19



Number of Patients at Risk

Placebo	726	707	695	682	669	659	646	624	630	608	588	586	550	550	544	523	509	502	492	489	497	485	471	477
240 mg BID	712	687	671	641	635	639	609	608	612	590	575	587	561	547	562	550	541	551	529	524	540	515	508	520
240 mg TID	711	666	654	634	621	620	592	587	603	583	578	591	561	552	573	542	537	552	534	521	541	522	512	512
GA	336	325	325	315	311	315	296	299	306	294	293	293	285	281	288	268	275	273	264	264	268	259	255	260


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Magnesium (mmol/L)

Page 14 of 19



Number of Patients at Risk

Placebo	726	707	695	682	668	659	646	624	630	609	587	586	550	551	544	524	508	502	491	489	497	485	471	477
240 mg BID	712	687	671	641	635	639	609	608	611	590	574	587	561	546	562	550	541	552	529	522	540	515	508	520
240 mg TID	712	666	654	634	621	620	592	586	603	583	578	591	561	552	574	542	537	552	534	520	542	522	512	512
GA	336	325	325	315	311	315	296	298	306	294	293	293	285	281	288	268	275	273	264	265	268	259	255	260


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Phosphorus (mmol/L)

Page 15 of 19



Number of Patients at Risk

Placebo	725	707	695	682	667	658	646	624	629	609	586	585	545	549	543	521	506	502	491	489	497	484	471	477
240 mg BID	711	687	670	641	634	638	607	606	611	589	574	585	560	548	562	547	537	552	528	523	538	514	507	518
240 mg TID	709	665	653	631	619	618	592	587	601	581	577	591	559	550	573	542	536	550	533	518	540	522	511	511
GA	336	325	325	315	310	314	295	295	306	294	291	293	284	278	288	267	275	273	262	265	268	257	254	260


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Glucose (mmol/L)

Page 16 of 19



Number of Patients at Risk

Placebo	723	704	691	680	665	656	641	618	627	606	585	581	538	545	542	519	507	501	490	487	495	480	470	474
240 mg BID	707	683	668	638	626	635	602	602	606	588	565	582	558	541	560	545	535	547	528	518	534	513	502	517
240 mg TID	704	659	649	626	614	611	584	585	597	579	574	587	554	545	571	532	531	548	529	517	536	517	506	506
GA	331	323	319	311	308	313	293	293	303	292	290	293	282	276	284	263	273	272	261	262	267	255	252	258


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Cholesterol (mmol/L)

Page 17 of 19



Number of Patients at Risk

Placebo	756	735	722	707	696	704		669		618		576		538		530		491						
240 mg BID	737	706	693	666	654	672		647		625		604		589		573		532						
240 mg TID	734	684	671	651	638	656		632		620		602		574		565		522						
GA	339	329	328	318	314	319		315		304		294		284		278		262						


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Triglycerides (mmol/L)

Page 18 of 19



Number of Patients at Risk

Placebo	756	735	722	707	696	704		669		618		576		538		530		491					
240 mg BID	737	706	693	666	654	672		647		625		604		589		573		532					
240 mg TID	734	684	671	651	638	656		632		620		602		574		565		522					
GA	339	329	328	318	314	319		315		304		294		284		278		262					


SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015

Blood chemistry parameters - change from baseline (+/- SE) over time: Studies 109MS301 and 109MS302

Lab test: Uric Acid (umol/L)

Page 19 of 19




Number of Patients at Risk

Placebo	726	707	695	681	669	659	646	624	630	609	588	586	550	551	544	524	509	502	492	489	497	485	471	477
240 mg BID	712	687	671	641	635	639	609	608	612	590	574	587	561	548	562	550	541	552	530	524	540	515	508	520
240 mg TID	712	666	654	634	621	620	593	587	603	583	578	591	561	552	574	542	537	552	534	521	541	522	512	512
GA	336	325	325	315	311	315	296	299	306	294	293	293	285	281	288	268	275	273	264	265	268	259	255	260

SOURCE: BG12MS/JAPAN/F-LB-BC-CHG-A

DATE: 22OCT2015


Figure 30: Blood Chemistry Parameters: Change From Baseline Values by Visit – (Placebo-Controlled Period) - Lab Test:



NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: AST/SGOT (U/L)




Number of Patients at Risk

Placebo	112	111	109	111	107	107
240 mg BID	107	108	106	106	106	104

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Alkaline Phosphatase (ALP) (U/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	108
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Total Bilirubin (umol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: GGT (U/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	108
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: LDH (U/L)




Number of Patients at Risk

Placebo	111	111	107	107	105	104
240 mg BID	100	107	104	103	101	102

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: BUN/urea (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Creatinine (umol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Sodium (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Potassium (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	108	108
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Chloride (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Bicarbonate (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Calcium (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Magnesium (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Phosphorus (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	108
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Glucose (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Cholesterol (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Triglycerides (mmol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Blood chemistry parameters: change from baseline values by visit
-Part I(placebo-controlled period)
Lab test: Uric Acid (umol/L)




Number of Patients at Risk

Placebo	113	112	109	111	110	109
240 mg BID	109	108	107	106	106	105

NOTE: SE=Standard Error.
SOURCE: BG12MS/109MS305/PART1/F-BC-CHG-MEANSE.SAS

DATE: 25SEP2015

Figure 31: Distribution of Total Bilirubin by Concurrent ALT: Studies 109MS301 and 109MS302




NOTE: For subjects without any ALT elevations >= 3xULN, the subject's total bilirubin at the time of maximum ALT (relative to ULN) and the maximum ALT value (relative to ULN) are plotted. For subjects with only 1 ALT elevation >= 3xULN, the total bilirubin and the ALT value at the time of this ALT elevation are plotted. For subjects with more than 1 ALT elevation >= 3xULN, the maximum total bilirubin among these ALT elevations and the concurrent ALT value are plotted. Values are plotted as log10(value/ULN).

SOURCE: bg12ms/japan/iss/f-lb-tbil-alt-a.sas

DATE: 05OCT2015


Figure 32: Distribution of Total Bilirubin by Concurrent ALT/AST: Studies 109MS301 and 109MS302



NOTE: For subjects without any ALT/AST elevations >= 3xULN, the subject's total bilirubin at the time of maximum ALT/AST (relative to ULN) and the maximum ALT/AST value (relative to ULN) are plotted. For subjects with only 1 ALT/AST elevation >= 3xULN, the total bilirubin and the ALT/AST value at the time of this ALT/AST elevation are plotted. For subjects with more than 1 ALT/AST elevation >= 3xULN, the maximum total bilirubin among these ALT/AST elevations and the concurrent ALT/AST value are plotted. Values are plotted as log10(value/ULN).

SOURCE: bg12ms/japan/iss/f-lb-tbil-at-a.sas DATE: 05OCT2015

Figure 33: Distribution of Total Bilirubin by Concurrent AST: Studies 109MS301 and 109MS302




NOTE: For subjects without any AST elevations >= 3xULN, the subject's total bilirubin at the time of maximum AST (relative to ULN) and the maximum AST value (relative to ULN) are plotted. For subjects with only 1 AST elevation >= 3xULN, the total bilirubin and the AST value at the time of this AST elevation are plotted. For subjects with more than 1 AST elevation >= 3xULN, the maximum total bilirubin among these AST elevations and the concurrent AST value are plotted. Values are plotted as log10(value/ULN).

SOURCE: bg12ms/japan/iss/f-lb-tbil-ast-a.sas

DATE: 05OCT2015

Figure 35: Categorical Analysis of Low Lymphocytes by Visit: Studies 109MS301 and 109MS302




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a non-missing lymphocyte value at that visit, including those with normal values.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYM-CATE-A

DATE: 22OCT2015

Categorical analysis of low lymphocytes by visit:
Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID (n=769)
Page 2 of 4




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a non-missing lymphocyte value at that visit, including those with normal values.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYM-CATE-A

DATE: 22OCT2015

Categorical analysis of low lymphocytes by visit:
Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID (n=760)
Page 3 of 4




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a non-missing lymphocyte value at that visit, including those with normal values.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYM-CATE-A

DATE: 22OCT2015

Categorical analysis of low lymphocytes by visit:
Studies 109MS301 and 109MS302
Treatment Group: GA (n=351)
Page 4 of 4




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a non-missing lymphocyte value at that visit, including those with normal values.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYM-CATE-A

DATE: 22OCT2015

Figure 36: Categorical Analyses of Lymphocytes by Visit for Subjects With a Post-Baseline Lymphocyte Count <0.5 × 10^9/L: Studies 109MS301 and 109MS302




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a post-baseline lymphocyte value < 0.5 x 10^9/L with a non-missing lymphocyte value at that visit.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYMPB-CATE-A

DATE: 22OCT2015

Categorical analysis of lymphocytes by visit for subjects with a post-baseline lymphocyte count < 0.5 x10^9/L:
Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg TID (n=24)
Page 2 of 3




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a post-baseline lymphocyte value < 0.5 x 10^9/L with a non-missing lymphocyte value at that visit.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYMPB-CATE-A

DATE: 22OCT2015

Categorical analysis of lymphocytes by visit for subjects with a post-baseline lymphocyte count < 0.5 x10^9/L:
Studies 109MS301 and 109MS302
Treatment Group: BG00012 240 mg BID and TID (n=67)
Page 3 of 3




NOTE 1: N=xxx at the bottom of the graph indicates the denominator, which is the number of subjects with a post-baseline lymphocyte value < 0.5 x 10^9/L with a non-missing lymphocyte value at that visit.
2: The percentage and the number of subjects are provided at the top of each bar.
3: The lower limit of normal (LLN) is 0.91 x10^9/L.
4: Data from after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/F-LB-LYMPB-CATE-A

DATE: 22OCT2015

Figure 37: Summary of Baseline and Worst Post- Baseline Values for Selected Laboratory Parameters – WBC - (Placebo-Controlled Period)




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 3, 2 : <3 - 2, 3 : <2 - 1, 4 : <1.

SOURCE: BG12MS/109MS305/PART1/F-LB-MAXSUMM-WBC.SAS

DATE: 25SEP2015

Figure 38: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters – Lymphocyte – (Placebo-Controlled Period)




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 0.8,2 : <0.8 - 0.5, 3 : <0.5 - 0.2, 4 : <0.2

SOURCE: BG12MS/109MS305/PART1/F-LB-MAXSUMM-LYM.SAS

DATE: 25SEP2015

Figure 39: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters - WBC - 24 Weeks of Studies 109MS301 and 109MS302




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 3.0x 10^9/L, 2 : <3.0 - 2.0x 10^9/L, 3 : <2.0 - 1.0x 10^9/L, 4 : <1.0x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-WBC-A-24W.SAS DATE: 22OCT2015

Summary of baseline and worst post-baseline values for selected laboratory parameters - WBC

24 weeks of studies 109MS301 and 109MS302: Worst post-baseline




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 3.0x 10^9/L, 2 : <3.0 - 2.0x 10^9/L, 3 : <2.0 - 1.0x 10^9/L, 4 : <1.0x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-WBC-A-24W.SAS

DATE: 22OCT2015

Figure 40: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters – WBC – Studies 109MS301 and 109MS302




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 3.0x 10^9/L, 2 : <3.0 - 2.0x 10^9/L, 3 : <2.0 - 1.0x 10^9/L, 4 : <1.0x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-WBC-A.SAS DATE: 22OCT2015

Summary of baseline and worst post-baseline values for selected laboratory parameters - WBC

Studies 109MS301 and 109MS302: Worst post-baseline




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 3.0x 10^9/L, 2 : <3.0 - 2.0x 10^9/L, 3 : <2.0 - 1.0x 10^9/L, 4 : <1.0x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-WBC-A.SAS

DATE: 22OCT2015

Figure 41: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters - Lymphocytes - Studies 109MS301 and 109MS302




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 0.8x 10^9/L, 2 : <0.8 - 0.5x 10^9/L, 3 : <0.5 - 0.2x 10^9/L, 4 : <0.2x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-LYM-A.SAS

DATE: 22OCT2015

Summary of baseline and worst post-baseline values for selected laboratory parameters - Lymphocytes

Studies 109MS301 and 109MS302: Worst post-baseline




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in x10^9/L units: 0 : >=LLN, 1 : <LLN - 0.8x 10^9/L, 2 : <0.8 - 0.5x 10^9/L, 3 : <0.5 - 0.2x 10^9/L, 4 : <0.2x 10^9/L.

SOURCE: BG12MS/JAPAN/F-LB-SUM-LYM-A.SAS

DATE: 22OCT2015

Figure 42: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters - ALT - (Placebo-Controlled Period)




NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in U/L units: 0 : <=1 xULN,1 : >1 - <3 xULN, 2 : >=3 - 5 xULN, 3 : >5 - 10 xULN, 4 : >10 - 20 xULN, 5: >20 xULN.

SOURCE: BG12MS/109MS305/PART1/F-LB-MAXSUMM-ALT.SAS

DATE: 25SEP2015

Figure 43: Summary of Baseline and Worst Post-Baseline Values for Selected Laboratory Parameters - AST - (Placebo-Controlled Period)



NOTE 1: Besides percentage, the number of subjects is also provided on the top of each bar.
2: Categories are in U/L units: 0 : <=1 xULN,1 : >1 - <3 xULN, 2 : >=3 - 5 xULN, 3 : >5 - 10 xULN, 4 : >10 - 20 xULN, 5: >20 xULN.

SOURCE: BG12MS/109MS305/PART1/F-LB-MAXSUMM-AST.SAS DATE: 25SEP2015